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Abstract 
Using death ligands to induce apoptosis is an attractive concept for the treatment of cancer. 
By triggering the extrinsic apoptosis pathway, death ligands are independent of intrinsic 
apoptosis induction, which is frequently impaired in tumor cells. Due to its unique selectivity 
properties, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been 
considered as an especially promising candidate to exploit this approach. Clinical trials, 
however, were largely disappointing, provoking the development of manifold second 
generation TRAIL-based therapeutics with improved efficacy. Extensive investigations 
revealed the particularly high potential of increased TRAIL valency and targeted delivery as 
improvement strategies. This study was performed to comparatively analyze different formats 
of scTRAIL fusion proteins employing the concepts of increased valency and tumor targeting 
to further guide therapeutic development. 
 
Based on an optimized single-chain version of TRAIL (scTRAIL), the investigated set of dimeric 
antibody-scTRAIL fusion proteins included the already described Db-scTRAIL and scFv-EHD2-
scTRAIL formats and was extended by a disulfide-stabilized version of the diabody molecule 
(dsDb-scTRAIL) and scFv-Fc-scTRAIL. These four formats were generated comprising targeting 
moieties directed against EGFR, HER2, HER3, and EpCAM. Additionally, non-targeted 
monomeric scTRAIL as well as non-targeted dimeric EHD2-scTRAIL and Fc-scTRAIL were 
included. Consistent with previous studies, dimeric EHD2-scTRAIL and Fc-scTRAIL exerted 
significantly increased cell death induction compared to scTRAIL. The different formats of 
dimeric antibody-scTRAIL fusion proteins were equipotent with respect to binding activities 
and in vitro cell death induction in two colorectal cancer cell lines. However, by displaying 
enhanced properties regarding production, thermal stability, reliable dimer formation, in vivo 
half-life, and pharmacodynamic effects, scFv-Fc-scTRAIL emerged as superior protein format. 
Comparative analysis of scFv-Fc-scTRAIL fusion proteins comprising different targeting 
moieties revealed major differences in binding activity and in vitro cell death induction. 
Interestingly, only three of the five analyzed antibody units improved the cytotoxic activity of 
the respective targeted molecule compared to Fc-scTRAIL in a partly cell line-dependent 
manner. Correlation of cell death induction with binding properties indicated the relevance of 
improved cell binding of scFv-Fc-scTRAIL compared to Fc-scTRAIL for targeting effects in vitro. 
This appeared to be determined by strong antigen binding of the antibody part and sufficient 
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antigen expression levels. Surprisingly, despite strong efficacy, the targeting effects observed 
for three scFv-Fc-scTRAIL molecules in vitro did not translate into an increased anti-tumor 
activity compared to non-targeted Fc-scTRAIL in a Colo205 xenograft model. Further 
investigations will therefore be required to identify the factors underlying the discrepancy of 
in vitro and in vivo data. In conclusion, this study demonstrated the potent activity of non-
targeted Fc-scTRAIL that further provides a platform for combination with tumor-targeting 
ligands as fusion partners, thereby offering the opportunity for tumor-tailored optimization. 
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Zusammenfassung 
Ein attraktiver Ansatz zur Behandlung von Krebs ist die Verwendung von Todesliganden. Diese 
induzieren Apoptose über den extrinsischen Weg und sind damit unabhängig von intrinsischer 
Apoptoseinduktion, welche in Tumorzellen häufig beeinträchtig ist. Aufgrund seiner 
Selektivität für Tumorzellen gilt TRAIL (Tumornekrosefaktor-verwandter Apoptose-
induzierender Ligand) als besonders vielversprechender Kandidat für die Umsetzung dieses 
Konzepts. Klinische Studien lieferten allerdings weitgehend enttäuschende Ergebnisse, was 
zur Weiterentwicklung TRAIL-basierter Therapeutika führte und eine Vielzahl verbesserter 
Varianten generierte. Besonders effektive Verbesserungsstrategien stellen dabei die 
Steigerung der Valenz von TRAIL sowie die Modifikation zur gezielten Tumorzellbindung 
(sogenanntes Targeting) dar. Ziel dieser Arbeit war die Untersuchung unterschiedlicher 
Formate von scTRAIL Fusionsproteinen, die auf den Konzepten der Valenzsteigerung und 
zielgerichteten Tumorzellbindung basierten und deren systematischer Vergleich der 
Unterstützung weiterer Entwicklungsschritte dienen sollte. 
 
Unter Verwendung einer optimierten TRAIL-Version, die alle TRAIL-Untereinheiten auf einer 
Polypeptidkette verbindet (sogenanntes single-chain TRAIL; scTRAIL), wurden verschiedene 
dimere Antikörper-scTRAIL Fusionsproteine hergestellt. Dazu zählten, neben den etablierten 
Formaten Db-scTRAIL und scFv-EHD2-scTRAIL, eine Disulfid-stabilisierte Form des Diabody-
Moleküls (dsDb-scTRAIL) sowie scFv-Fc-scTRAIL. Als zusätzliche Varianten ohne Targeting-
Einheiten wurden sowohl monomeres scTRAIL als auch dimere EHD2-scTRAIL und Fc-scTRAIL 
Fusionsproteine generiert. Verglichen mit scTRAIL zeigten EHD2-scTRAIL und Fc-scTRAIL in 
Übereinstimmung mit vorangegangenen Untersuchungen eine signifikant stärkere Induktion 
von Zelltod. Für die unterschiedlichen Formate der dimeren Antikörper-scTRAIL 
Fusionsproteine wurden vergleichbare Eigenschaften hinsichtlich der Bindungsaktivität sowie 
der Zelltodinduktion in zwei kolorektalen Tumorzelllinien bestimmt. Weitere Untersuchungen 
zeigten jedoch eine verbesserte Produktion, erhöhte thermische Stabilität, verlässlichere 
Ausbildung der dimeren Form, verlängerte in vivo Halbwertszeit sowie stärkere 
pharmakodynamische Effekte für scFv-Fc-scTRAIL. Dies verdeutlicht die überlegenen 
Eigenschaften dieses Formats. Deutliche Unterschiede in der Bindungsaktivität und Induktion 
von Zelltod ergaben sich für scFv-Fc-scTRAIL Fusionsproteine mit unterschiedlichen Targeting-
Einheiten. Nur drei der fünf eingesetzten Antikörper-Module verbesserten dabei die 
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zytotoxische Aktivität des jeweiligen scFv-Fc-scTRAIL Moleküls im Vergleich zu Fc-scTRAIL, zum 
Teil in Abhängigkeit von der Zelllinie. Die Korrelation von Zelltodinduktion mit 
Bindungseigenschaften deutete darauf hin, dass eine verstärkte Zellbindung von scFv-Fc-
scTRAIL verglichen mit Fc-scTRAIL notwendig ist, um Targeting-Effekte in vitro zu erzielen. Dies 
wiederum schien auf einer starken Antigenbindung durch den Antikörper und einer 
ausreichenden Antigenexpression zu beruhen. Ein Colo205 Xenotransplantat-Modell 
bestätigte die hohe Wirksamkeit der Proteine. Allerdings führten die in vitro Targeting-
Effekte, die für drei scFv-Fc-scTRAIL Moleküle gezeigt wurden, nicht zu einer Erhöhung der 
antitumoralen Aktivität im Vergleich zu Fc-scTRAIL in vivo. Weitere Untersuchungen sind 
daher erforderlich, um die Faktoren zu bestimmen, die dieser Diskrepanz von in vitro und in 
vivo Daten zu Grunde liegen. Zusammenfassend verdeutlichte diese Arbeit die hohe 
Wirksamkeit von Fc-scTRAIL, das zudem eine Plattform zur weiteren Verknüpfung mit Tumor 
bindenden Liganden als Fusionspartnern bietet und auf diese Weise eine dem jeweiligen 
Tumor angepasste Optimierung ermöglicht. 
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1 Introduction 
One hallmark of cancer development and progression is the dysregulation of a cell’s 
machinery to induce controlled death, a mechanism essential to determine cell fate upon 
severe damage. The mutations underlying this phenotypic alteration are diverse, but 
frequently affect the p53 status, thereby hampering the induction of the intrinsic apoptotic 
pathway (see 1.1). These modifications contribute to resistance towards classical treatment 
approaches, like chemo- and radiotherapy (reviewed by Ashkenazi, 2008; Cotter, 2009; 
Johnstone et al., 2002). Therefore, strategies inducing death of malignant cells independent 
of these alterations are promising therapeutic concepts. Using death ligands, in particular the 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), to exploit the extrinsic 
apoptotic pathway (see 1.1) for tumor cell killing is an attractive approach to circumvent the 
necessity of p53-dependent apoptosis induction (Galligan et al., 2005). Limitations of classical 
therapy do not only arise due to intrinsic or acquired resistance mechanisms and thus 
insufficient efficacy, but are also caused by the lack of selectivity for cancer cells often leading 
to severe side effects (reviewed by Ashkenazi, 2002). Besides benefitting from death ligand-
specific selectivity properties, the advances achieved in targeted cancer therapy offer great 
potential to further restrict the cytotoxic activity of death ligands to tumor cells. 
 
1.1 Apoptosis 
The sequence of programmed cell death, termed apoptosis, is crucial during development, in 
immune reactions, and for tissue homeostasis of multicellular organisms. The involvement in 
these processes already implicates the detrimental effects that can be caused by its 
dysregulation. Besides the afore-mentioned role in malignant cell transformation due to 
process-impairing alterations, also increased rates of programmed cell death contribute to the 
development of diseases, such as neurodegeneration. In general, two pathways, the intrinsic 
and the extrinsic apoptosis induction that are both characterized by sequential activation of 
caspases (cysteine-aspartic proteases) are distinguished (reviewed by Elmore, 2007; Tait and 
Green, 2010). The intrinsic or mitochondrial pathway is triggered upon deprivation of anti-
apoptotic stimuli or detection of severe damage (e.g. induced by chemotherapeutics or 
irradiation). Subsequently, regulation of BCL-2 family members by p53 results in mitochondrial 
outer membrane permeabilization (MOMP; Figure 1.2; reviewed by Hemann and Lowe, 2006; 
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Vaseva and Moll, 2009). The BCL-2 family comprises pro- as well as anti-apoptotic proteins. 
The pro-apoptotic members BAX and BAK promote MOMP and are negatively regulated by 
anti-apoptotic members, like BCL-2, BCL-XL, and MCL-1 that in turn are antagonized by BH3-
only members, including PUMA, NOXA, BIM, and BAD. This complex regulation is further 
extended by the capability of some BH3-only proteins to directly interact with and activate 
the effector proteins BAX and BAK (reviewed by Chipuk et al., 2010). MOMP via pore 
formation by BAX and BAK leads to the release of pro-apoptotic proteins from the 
intermembrane space (IMS) into the cytosol. Binding of released cytochrome c to APAF-1 
induces heptamerization and recruitment of procaspase-9. Formation of this platform, called 
apoptosome, enables proteolytic activation of initiator caspase-9 that subsequently activates 
executioner caspases. Release of other pro-apoptotic proteins, like SMAC/DIABLO further 
supports this activation cascade by antagonizing caspase-inhibiting XIAP (reviewed by Tait and 
Green, 2010). 
 
The extrinsic or death receptor pathway is activated by binding of death ligands, i.e. tumor 
necrosis factor superfamily (TNFSF) members TNF, FasL, and TRAIL, to the respective death 
receptors (DRs), i.e. TNF receptor superfamily (TNFRSF) members TNF-R1, CD95, TRAIL-R1 and 
-R2 (Figure 1.2; reviewed by Elmore, 2007). The triggered signaling cascade is characterized 
by homotypic interactions of protein domains. Upon ligand binding, the death receptors 
recruit the adaptor protein FADD via homotypic interactions of so-called death domains. This 
occurs either directly (CD95, TRAIL-R1, TRAIL-R2) or indirectly via TRADD and RIP1 that 
together with TRAF2 dissociate from the receptor to form a cytoplasmic platform (TNF-R1; 
Micheau and Tschopp, 2003). Mediated by homotypic interactions of death effector domains, 
FADD subsequently associates with procaspase-8 or -10 leading to the formation of the death-
inducing signaling complex (DISC). Homodimerization of procaspases-8 or -10 at the DISC 
provokes conformational changes that expose the active site to allow autocatalytic activation. 
Activated initiator caspases then cleave and activate further procaspase-8 and -10 molecules. 
In type I cells, activation of caspases-8 and -10 is sufficient to trigger apoptosis, whereas type II 
cells require an additional amplification loop that links the extrinsic to the intrinsic apoptotic 
pathway. Here, cleavage of the pro-apoptotic BH3-only BCL-2 family member BID by caspase-8 
generates truncated BID (tBID). TBID mediates the insertion of BAX and BAK into the 
mitochondrial outer membrane, inducing the release of cytochrome c and SMAC into the 
cytosol and thus activating caspase-9 (reviewed by de Miguel et al., 2016). 
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Both the intrinsic and extrinsic pathway share the same execution pathway, which starts with 
activation of executioner caspases-3, -6, and -7 by initiator caspases. Activated executioner 
caspases cleave various cellular substrates and thereby e.g. activate endonucleases and 
proteases. Morphological changes that characterize apoptotic cell death comprise cell 
shrinkage, chromatin condensation, membrane blebbing, and nuclear fragmentation 
concluding with the formation of apoptotic bodies that are rapidly removed by phagocytosis. 
Thus, a cell undergoing apoptosis stays intact during the whole process (reviewed by Elmore, 
2007). 
 
1.2 Structural and functional properties of TRAIL and TRAIL receptors 
TRAIL, also known as CD253, TNFSF10, and Apo2L, is expressed as a 281 amino acids long 
type II transmembrane protein, i.e. with an intracellular N-terminus and an extracellular C-
terminus connected via a single transmembrane domain (Wiley et al., 1995). As a member of 
the TNFSF, TRAIL comprises a conserved C-terminal domain, the so-called TNF homology 
domain (THD) that exhibits a jelly roll structure consisting of two anti-parallel β-sheets (Figure 
1.1A; Cha et al., 1999; Cha et al., 2000). The THD mediates homotrimeric assembly of the 
ligand into a bell-like shape and defines receptor binding properties (reviewed by Bodmer et 
al., 2002; Locksley et al., 2001). In contrast to other TNFSF members, homotrimerization of 
TRAIL requires coordination of a zinc ion by three unpaired cysteine residues (Cys230 of each 
monomer) at the trimer interface, which is essential for stability, solubility, and activity 
(Bodmer et al., 2000; Hymowitz et al., 2000). A stalk region links the transmembrane domain 
to the THD and can be subject to proteolytic processing of TRAIL into a soluble homotrimeric 
form. The receptor binding sites are located at the interface formed by two monomers, thus 
enabling simultaneous binding of three receptors (Figure 1.1B,C; Hymowitz et al., 1999; 
Ramamurthy et al., 2015). Physiologically, TRAIL is expressed on various tissues and on cells 
of the innate and adaptive immune system, like dendritic cells, monocytes, natural killer cells, 
and T cells, assigning TRAIL an important role in immune surveillance. This includes anti-viral 
and anti-tumoral activity as well as mediation of activation-induced cell death (AICD) to avoid 
autoimmune reactivity (reviewed by Almasan and Ashkenazi, 2003; de Miguel et al., 2016). 
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Figure 1.1: Crystal structure of TRAIL in complex with TRAIL-R2.  A) Secondary structure elements of the THD of 
homotrimeric TRAIL are represented as cartoon. B) Surface of homotrimeric TRAIL in complex with three TRAIL-
R2 chains is visualized. C) Surface and cartoon representation of the TRAIL3 – TRAIL-R23 complex is shown facing 
the C-terminal side of TRAIL-R2. Visualization of PDB 1DU3 (Cha et al., 2000) was performed using PyMOL. TRAIL 
monomers are shown in light gray, gray, and dark gray, while the TRAIL-R2 chains are colored in different shades 
of green. The zinc ion is represented as blue sphere coordinated by Cys230 of each TRAIL monomer highlighted 
as orange sticks. 
 
TRAIL is able to bind to five receptors of the TNFRSF. Generally, TNFRSF members are 
characterized by an elongated extracellular part composed of cysteine-rich domains (CRDs) 
that mediate ligand binding (reviewed by Ashkenazi, 2002; Holland, 2013; de Miguel et al., 
2016). TRAIL-R1 (DR4, TNFRSF10A) and TRAIL-R2 (DR5, TNFRSF10B, Apo2, KILLER, TRICK2) are 
type I transmembrane proteins that comprise a C-terminal cytoplasmic death domain 
equipping them with the capability to induce apoptosis (Pan et al., 1997a; Pan et al., 1997b). 
While TRAIL-R1 is activated upon ligation with membrane-bound as well as soluble TRAIL, 
TRAIL-R2 signaling requires higher order receptor clustering, which is only induced by the 
membrane-bound form (Figure 1.3A; Mühlenbeck et al., 2000; Wajant et al., 2001). TRAIL-R3 
(DcR1, TNFRSF10C) lacks a transmembrane and cytoplasmic domain and is linked to the cell 
surface via a glycosylphosphatidylinositol (GPI) anchor (Degli-Esposti et al., 1997a). In 
contrast, TRAIL-R4 (DcR2, TNFRSF10D) contains both a transmembrane and cytoplasmic death 
domain, the latter however in a truncated form, which precludes apoptotic signaling (Degli-
Esposti et al., 1997b; Pan et al., 1998). Both TRAIL-R3 and TRAIL-R4 are described to function 
as decoy receptors negatively regulating TRAIL-R1- and TRAIL-R2-mediated apoptosis by 
competing for ligand binding. Additionally, TRAIL-R4 is reported to trap TRAIL-R1 and TRAIL-
R2 in signaling-incompetent receptor complexes either in a TRAIL-dependent manner or 
independent of ligand binding by interactions of the pre-ligand assembly domains (PLADs) that 
are present in those receptors. Besides these inhibitory interactions, negative regulation of 
TRAIL-induced apoptosis has been proposed through non-apoptotic pro-survival signaling by 
TRAIL-R4. However, the physiological role of TRAIL-R3 and -R4 is far from being completely 
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understood and might furthermore vary for different cell types (Mérino et al., 2006; Neumann 
et al., 2014). Due to a low binding affinity at physiological temperatures, the relevance of the 
interaction of TRAIL with a fifth TNFRSF member, the soluble decoy receptor osteoprotegerin 
(OPG), is still unclear (Emery et al., 1998). Physiologically, TRAIL receptors are expressed on 
various tissues (Spierings et al., 2004). Besides their localization at the plasma membrane, in 
secretory vesicles, endosomes, and lysosomes, TRAIL receptors are furthermore found in the 
nucleus, in autophagosomes, as well as in a soluble cytosolic form. Elevated expression levels 
in these non-membranous intracellular compartments have been reported for cancer cells 
and associated with TRAIL resistance and higher malignancy (reviewed by Bertsch et al., 2014). 
 
1.3 TRAIL-mediated signaling and its regulation 
Being already implicated in its name, the canonical signaling pathway induced by TRAIL is 
apoptosis. Modulation of the afore-mentioned extrinsic or death receptor pathway (see 1.1) 
is possible and occurs on several levels (Figure 1.2; reviewed by Azijli et al., 2013; de Miguel 
et al., 2016). Besides the expression of decoy receptors that is able to regulate TRAIL signaling 
extracellularly (see 1.2), an important factor influencing intracellular signal transduction is 
cFLIP. CFLIP exists as three splice variants, cFLIPL, cFLIPS, and cFLIPR, all comprising two death 
effector domains structurally similar to those of procaspase-8 and -10. While cFLIPS and cFLIPR 
are dominant-negative inhibitors of caspase-8 and -10 activation by competing for binding to 
FADD, the effects of cFLIPL are more complex. Depending on the ratio to caspase-8, cFLIPL 
either exerts anti-apoptotic properties (at high cFLIPL levels) or exhibits substrate specificity-
modulating effects on caspase-8 (at lower cFLIPL levels). In the latter case, the caspase-8/cFLIPL 
heterodimer retains proteolytic activity that is even increased for certain substrates (Chang et 
al., 2002; Golks et al., 2005; Krueger et al., 2001; Micheau et al., 2002). Additional mechanisms 
that regulate apoptotic TRAIL signaling include the expression of XIAP (that inhibits caspases-
3, -7, and -9; Deveraux et al., 1997) and anti-apoptotic BCL-2 family members (Clohessy et al., 
2006; Hinz et al., 2000; Munshi et al., 2001), post-translational modifications of DISC proteins, 
like O-glycosylation (Wagner et al., 2007) and ubiquitination (Gonzalvez et al., 2012; Jin et al., 
2009), as well as endocytosis (Austin et al., 2006; Kohlhaas et al., 2007). Downregulation of 
pro- and upregulation of anti-apoptotic proteins is often found in TRAIL-resistant cancer cells. 
Commonly, resistance is not caused by a single alteration, but by simultaneous modifications 
of multiple factors (reviewed by Amarante-Mendes and Griffith, 2015). 
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Figure 1.2: Apoptosis, non-canonical TRAIL signaling, and possible levels of interference of bortezomib. 
Predominant signaling induced by TRAIL is the extrinsic apoptosis pathway that in type II cells is linked to intrinsic 
apoptotic signaling via cleavage of BID to tBID. Alternatively, TRAIL is able to induce necroptosis and non-cell 
death signaling pathways. Potential influence of bortezomib (BZB) treatment on TRAIL-mediated signaling is 
indicated. For a more detailed explanation of apoptosis, non-canonical TRAIL signaling pathways, and impact of 
BZB see 1.1, 1.3, and 1.4.3, respectively. Figure is modified based on Ashkenazi, 2008; Azijli et al., 2013; de Wilt 
et al., 2013. cyt c, cytochrome c. ‡, impact of BZB is dependent on rate of proteasomal degradation and influence 
on new synthesis. 
 
Besides classical signaling, TRAIL is able to induce non-canonical non-apoptotic signal 
transduction pathways in a cell type-dependent manner (Figure 1.2). Under circumstances of 
cell stress (e.g. acidic extracellular pH) combined with inhibition of caspases, TRAIL has been 
reported to induce necroptotic death in tumor cells. Necroptosis is an alternative form of 
programmed cell death phenotypically resembling necrosis, but being a strictly regulated 
process like apoptosis. This signaling pathway crucially involves the kinases RIP1 and RIP3. The 
contribution of necroptosis to TRAIL-induced anti-tumoral effects, however, is still unclear 
(Jouan-Lanhouet et al., 2012; Voigt et al., 2014). In addition to apoptosis and necroptosis 
induction, TRAIL is able to trigger non-cell death signaling that has been associated with 
conditions of blocked apoptosis and is thus observed in TRAIL-resistant tumor as well as non-
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transformed cells. Following DISC assembly, these non-canonical signal transductions are 
characterized by TRAIL-R clustering outside lipid rafts and the formation of a secondary 
complex containing FADD, caspase-8, RIP1, TRAF2, and NEMO. Various signaling pathways 
have been found to be activated upon assembly of this secondary complex, including NF-κB, 
MAPKs (JNKs, p38, ERKs, TAK1), PKC, PI3K/AKT, and SRC. Activation of these kinase cascades 
not only contributes to inhibition of TRAIL-induced apoptosis and therefore increased survival, 
but additionally promotes malignancy of tumor cells by enhancing proliferation, migration, 
invasion, and metastasis. Instead of leading to tumor cell killing, therapeutic application of 
TRAIL in TRAIL-resistant tumors may thus enforce malignant progression (reviewed by Azijli et 
al., 2013; Bertsch et al., 2014; de Miguel et al., 2016). 
 
1.4 TRAIL and its receptors in cancer therapy 
As outlined above, triggering the extrinsic apoptotic pathway is a promising strategy to kill 
tumor cells independent of their p53 status and intrinsic apoptosis induction. Various 
therapeutics based on this concept were thus developed and termed pro-apoptotic receptor 
agonists (PARAs; reviewed by Ashkenazi, 2015). Historically, first exploitation of this strategy 
occurred in 1891, when William Coley administered extracts of gram-negative bacteria to treat 
sarcoma patients (Coley, 1891). Almost a century later, the anti-tumoral effects of Coley’s 
toxins were attributed to LPS-induced TNF (Carswell et al., 1975). Systemic application of TNF 
for tumor therapy, however, led to severe toxicity (Kimura et al., 1987). Similarly, the 
observation of lethal hepatotoxic effects in mice upon triggering of the death receptor Fas 
(Ogasawara et al., 1993) hampered the translation of PARAs into the clinic. In contrast to TNF 
and FasL, TRAIL was found to selectively induce apoptosis in malignant cells without harming 
healthy tissue (Ashkenazi et al., 1999; Walczak et al., 1999). Due to this unique property, TRAIL 
has been extensively investigated and considered as a promising anti-cancer therapeutic. The 
mechanisms underlying the selectivity of TRAIL for tumor cells are still not completely 
understood, but might involve the protection of normal cells via high expression levels of 
decoy receptors (Marsters et al., 1997; Sheridan et al., 1997; see 1.2) as well as specific post-
translational modifications in cancer cells, e.g. clustering-promoting O-glycosylation of 
TRAIL-R1 and -R2 (Wagner et al., 2007). In addition to its tumor-selective activity, further 
factors encouraged the evaluation of TRAIL for tumor therapy. These include the possibility to 
exploit the complex TRAIL – TRAIL receptor system to design tumor-specific drugs, expression 
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of TRAIL-R1 and -R2 on various tumor types (Daniels et al., 2005), and most importantly the 
promising effects seen in preclinical models (Ashkenazi et al., 1999; Walczak et al., 1999). 
Besides a soluble form of recombinant human TRAIL (see 1.4.2), agonistic monoclonal 
antibodies targeting either TRAIL-R1 or TRAIL-R2 (see 1.4.1) have been developed and 
evaluated in clinical studies. Despite good tolerability of those therapies (Camidge et al., 2010; 
Herbst et al., 2010; Tolcher et al., 2007), the results were largely disappointing. Only few 
patients benefitted from treatment (reviewed by den Hollander et al., 2013). Apart from the 
observation that many human tumors are TRAIL-resistant (reviewed by Dimberg et al., 2013; 
Thorburn et al., 2008; Zhang and Fang, 2005), this limited success has been attributed to an 
insufficient activity of those first generation TRAIL receptor agonists. There are several 
properties of the TRAIL – TRAIL receptor system that partially underlie this low efficacy and 
challenge the translation into the clinic. On the one hand, these factors concern the ligand and 
include that it is naturally expressed as a transmembrane protein that exhibits a distinct 
activity profile compared to the soluble version, the short serum half-life of the soluble form 
and its limited capability to induce clustering of DRs. On the other hand, further challenges 
are linked to the receptors and concern the complexity of the receptor system, the expression 
of death receptors on healthy tissue, and the possible induction of non-cell death signaling 
potentially provoking antagonistic effects (reviewed by de Bruyn et al., 2013; de Miguel et al., 
2016; Wajant et al., 2013). Strategies that address these limitations include the development 
of agonists with improved activity (see 1.4.1, 1.4.2), combinatorial treatments to overcome 
TRAIL resistance (see 1.4.3), as well as careful selection of patients likely to benefit from the 
respective treatment (see 1.4.4). 
 
1.4.1 Agonistic TRAIL-R1- and TRAIL-R2-specific antibodies  
There is sound scientific rationale for the use of monoclonal antibodies (mAbs) to activate 
TRAIL-R1 and TRAIL-R2, despite the disadvantage of potentially inducing lower levels of 
apoptosis due to targeting of only one of the death receptors. Besides the vast experience 
concerning development, production, and approval of antibodies in general, agonistic TRAIL-
R1- or TRAIL-R2-specific antibodies benefit from several properties. These include the lack of 
binding to decoy receptors and the fact that in many tumors apoptosis is selectively triggered 
via either TRAIL-R1 or -R2 (Kelley et al., 2005; Lemke et al., 2010; MacFarlane et al., 2005a; 
MacFarlane et al., 2005b), which allows a tumor type-dependent adaptation of the antibody 
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specificity. Additionally, the use of mAbs circumvents the problem of low stability and short 
in vivo half-life of the homotrimeric ligand (reviewed by Lemke et al., 2014; Wajant, 2015). 
Therefore, clinical studies have been performed evaluating one anti-TRAIL-R1 antibody 
(mapatumumab) and several antibodies targeting TRAIL-R2 (lexatumumab, conatumumab, 
drozitumab, tigatuzumab, LBY135). These trials verified the extended half-life typically seen 
for antibodies ranging from 19 to 26 days for mapatumumab and 6 to 19 days for the TRAIL-
R2-specific antibodies (reviewed by den Hollander et al., 2013). As outlined above, apart from 
safety and good tolerability, the conducted clinical studies did not confirm the promising 
effects seen in preclinical models (Chuntharapai et al., 2001; Ichikawa et al., 2001; Kaplan-
Lefko et al., 2010). These findings encouraged further clinical studies analyzing these 
antibodies in combinatorial treatment approaches to enhance efficacy (see 1.4.3). 
 
Antibodies are bivalent and thus incapable of inducing receptor trimerization or even 
organization into supramolecular clusters. Investigations of antibodies targeting other TNFRSF 
members revealed the impact of antibody valency on agonistic activity. For example, 
pentameric IgM directed against TNFR1 or CD95 has been shown to exert superior agonistic 
properties compared to bivalent forms (Espevik et al., 1990; Fadeel et al., 1997). Likewise, a 
recent study on a TRAIL-R1-targeting antibody reported considerably enhanced apoptosis 
induction upon switching the isotype from IgG to IgM (Piao et al., 2016). Similar effects have 
been documented for secondary cross-linking of bivalent antibodies (Li et al., 2008; Natoni et 
al., 2007; Yada et al., 2008). These observations explain the low activity found in clinical trials, 
but fail to describe the discrepancy with the data obtained from preclinical models. Further 
studies have been performed to elucidate these differences and revealed that the efficacy 
seen in mouse models crucially depends on FcγR-mediated cross-linking of the antibodies. Via 
binding to the Fc part of the respective antibodies, FcγRs expressed on immune cells of the 
tumor microenvironment mediate clustering of TRAIL receptors and thereby enable efficient 
DISC formation and apoptotic signaling (Figure 1.3B; Haynes et al., 2010; Li and Ravetch, 2012; 
Li and Ravetch, 2013; Wilson et al., 2011). Since most preclinical studies were performed in 
athymic mice lacking significant levels of endogenous immunoglobulins, a sufficient amount 
of FcγRs is available to cross-link the applied antibodies. This is in sharp contrast to clinical 
trials, where treated patients exhibit high levels of endogenous IgG, strongly competing with 
the administered antibodies for FcγR binding. Additionally, varying infiltration of the tumor 
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with leukocytes as well as binding to FcγR-expressing cells in the circulation are factors that 
may influence in vivo activity. 
 
Figure 1.3: Requirements for efficient apoptosis induction. A) Physiologically, TRAIL is expressed as a 
transmembrane protein that can be cleaved into a soluble form. While TRAIL-R1 is activated by both forms, only 
membrane-bound TRAIL efficiently activates TRAIL-R2 (Wajant et al., 2001). B) Agonistic antibodies targeting 
TRAIL-R1 or -R2 are poor activators of apoptosis due to their bivalent nature. Via binding to the Fc part, FcγRs 
expressed on immune cells of the tumor microenvironment mediate efficient TRAIL receptor clustering and 
apoptosis induction (reviewed by Wajant, 2015). C) Activity of soluble TRAIL (here in a single-chain form) is 
considerably enhanced by combination with fusion partners that bind to membrane-attached structures or by 
increasing TRAIL valency (reviewed by de Miguel et al., 2016). 
 
The importance of receptor clustering for efficient apoptotic signaling was furthermore 
confirmed by studies demonstrating a strong synergism of soluble TRAIL and conatumumab 
that are both poorly active as single agents. Conatumumab is thought to cross-link 
homotrimeric TRAIL – TRAIL-R complexes, thereby promoting the formation of hexagonal 
honeycomb-like supramolecular structures. A prerequisite for this activity is that 
conatumumab and TRAIL bind to non-overlapping epitopes on TRAIL-R2, thus allowing 
simultaneous binding (Graves et al., 2014; Tuthill et al., 2015). Based on these studies, 
highlighting the insufficient capability of the investigated antibodies alone to induce receptor 
clustering, effort was made to develop new therapeutics overcoming this limitation. Besides 
defined oligomerization of TRAIL receptor-binding units (see 1.4.2), a TRAIL-R2-specific 
antibody (KMTR2) has been reported to induce superoligomerization independent of 
additional cross-linking. Investigations of the crystal structure of KMTR2 in complex with 
TRAIL-R2 suggested clustering of PLAD-mediated TRAIL-R2 homodimers via two paratopes of 
the antibody. Binding of KMTR2 to TRAIL-R2 is supposed to generate a second paratope 
allowing concomitant association with another antibody molecule to induce linear 
oligomerization (Tamada et al., 2015). Addressing the issue of targeting only one death 
receptor, a recent study described the generation of a pre-BCR-derived so-called Surrobody™ 
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exhibiting agonistic activity on TRAIL-R1 and -R2 (Milutinovic et al., 2016). Newest concepts 
employing TRAIL receptor-targeting antibodies make use of TAA (tumor-associated antigen) 
binding-dependent hyperclustering of especially TRAIL-R2. Bispecific antibodies incorporating 
binding units directed against MCSP or FAP in addition to TRAIL-R2-specific domains 
demonstrated efficient apoptosis induction without the necessity of secondary cross-linking 
(Brünker et al., 2016; He et al., 2016). 
 
1.4.2 Evolution of recombinant TRAIL therapeutics 
Concerning the development of therapeutics based on the natural homotrimeric ligand, 
mainly three strategies are pursued to overcome the limited success of soluble recombinant 
human TRAIL (dulanermin) seen in clinical trials (Herbst et al., 2010; Soria et al., 2011). These 
approaches comprise improving the stability, enhancing the valency, as well as targeted 
delivery. Based on the poor pharmacokinetic properties of dulanermin (Kelley et al., 2001) and 
supported by the observation that other TNFSF members (like TNF or GITRL) are inactivated 
due to dissociation of the homotrimer (Chattopadhyay et al., 2007; Corti et al., 1992), first 
improvements addressed the stability. Via fusion to protein sequences that enforce 
homotrimerization, including leucine zippers (Rozanov et al., 2015; Walczak et al., 1999), an 
isoleucine zipper (Ganten et al., 2006), and the trimerization domains of tenascin-C (Berg et 
al., 2007) or human adenovirus type 5 fiber protein (Yan et al., 2016), not only stability, but 
also activity of the respective variants have been enhanced. Compared to a half-life of only 3 
to 5 min in mice reported for dulanermin (Kelley et al., 2001), the leucine zipper-fused protein 
shows an elongated PK profile with a terminal half-life of 4.8 h (Walczak et al., 1999). Due to 
safety concerns however, the stabilized formulations did not enter clinical investigations. 
These concerns were raised by the toxicities experienced with TNF and FasL on the one hand 
(Kimura et al., 1987; Ogasawara et al., 1993), and by toxic effects observed for other TRAIL 
preparations on the other. Early forms of TRAIL were expressed containing a His- or FLAG-tag, 
mainly due to purification purposes. Unfortunately, His-tagged versions as well as cross-linked 
FLAG-TRAIL induced apoptosis not only in tumor cells, but also in hepatocytes. This 
hepatotoxicity was associated with the presence of aggregates either intentionally induced by 
cross-linking or caused by interference of the His-tag with proper zinc coordination and 
assembly (Ganten et al., 2006; Lawrence et al., 2001). This highlighted the importance of using 
stably assembled and non-aggregated forms of TRAIL. Based on studies of TNF (Krippner-
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Heidenreich et al., 2008), another strategy for increased stability was adopted. Fusion of the 
extracellular domains of three TRAIL monomers (via short peptide linkers) allowed the 
development of single-chain versions of TRAIL (Schneider et al., 2010; Spitzer et al., 2010). 
These single-chain formats show improved properties with respect to stability, aggregation 
propensity, PK, and activity without demonstrating toxicity. Additionally and in contrast to 
homotrimeric versions with limited options of fusion partners, conversion of TRAIL into a 
monomeric sequence permits a wide variety of possible combination types. Further 
optimization of the single-chain format was reported by a recent study comprehensively 
analyzing versions comprising variations in TRAIL and linker sequences (Siegemund et al., 
2016). Besides improvements of the intrinsic stability of TRAIL, additional strategies are 
applied to specifically extend pharmacokinetic properties. Classical approaches include 
PEGylation and fusion to long-circulating serum proteins, such as HSA. Both concepts have 
been employed successfully. Terminal half-lives of PEGylated forms range from 1 h up to 20 h 
depending on PEG size, conjugation chemistry and site, as well as TRAIL version (Chae et al., 
2010; Kim et al., 2011a; Pan et al., 2013). An HSA-TRAIL conjugate and an HSA-TNC-TRAIL 
fusion protein also exhibit elongated half-lives of 6.2 h and 15 h, respectively (Byeon et al., 
2014; Müller et al., 2010). Similarly, fusion of TRAIL to an albumin-binding domain prolonged 
the half-life to 14.1 h (Li et al., 2016). These extended pharmacokinetic properties in turn 
translated into improved therapeutic activity in vivo. 
 
Generally, targeting approaches are applied to enhance the bioactivity of a therapeutic by 
increasing its concentration at the tumor and to simultaneously decrease the exposure to 
healthy tissue, thereby reducing possible side effects. Respective strategies are categorized 
into passive and active targeting concepts. Passive targeting makes use of the improved half-
lives of macromolecular structures with sizes exceeding the threshold for renal filtration as 
well as the enhanced permeability and retention (EPR) effect. Due to leakiness of the tumor 
vasculature and impaired lymphatic drainage, macromolecular therapeutics are released and 
enriched at the tumor site (reviewed by Iyer et al., 2006). In order to exploit the EPR effect, 
TRAIL has been either encapsulated in or attached to the surface of nanoparticles. While 
encapsulation allows sustained release (Kim et al., 2011b; Kim et al., 2013; Lim et al., 2011), 
surface-attached TRAIL exerts increased bioactivity by mimicking the membrane-bound form, 
thus being capable of inducing higher order receptor clustering and activation of TRAIL-R2 (de 
Miguel et al., 2015; Nair et al., 2015; Perlstein et al., 2013). Various compounds have been 
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used as nanoparticulate carriers of TRAIL. Most extensively, liposomal formulations have been 
employed and additionally modified (reviewed by de Miguel et al., 2016). For example, 
liposomes loaded with chemotherapeutics are able to simultaneously deliver drugs enhancing 
the pro-apoptotic activity of TRAIL (Guo et al., 2011a; Guo et al., 2011b; Sun et al., 2012). 
Exploitation of active targeting by functionalization with scFvs directed against TAAs or with 
other ligands further increases tumor-specific enrichment or the cytotoxic activity of immune 
cells (Mitchell et al., 2014; Seifert et al., 2014b; Wayne et al., 2016). 
 
The observation that cross-linking of soluble versions of TRAIL readily converts these forms 
into highly active inducers of apoptosis highlighted the importance of spatial preorganization 
to efficiently cluster and activate TRAIL receptors (Mühlenbeck et al., 2000; Wiley et al., 1995). 
Physiologically, this is achieved by expression of a membrane-bound form of TRAIL. Thus, 
active targeting of TRAIL to membrane-bound structures not only determines its localization, 
but can be additionally used to confer properties of the membrane-expressed variant on 
soluble TRAIL (Figure 1.3C; Wajant et al., 2001). Furthermore, the fusion partner itself can be 
used to support anti-tumor effects, e.g. by activation or inhibition of signaling pathways 
triggered by the respective target structure. Most commonly, scFv molecules directed against 
various TAAs have been fused to TRAIL or scTRAIL, which allows killing of target-positive, but 
also target-negative tumor cells (bystander effect). Besides direct targeting of cancer cells, 
fusion partners binding to the tumor vasculature or immune cells are used to either disrupt 
tumor supply or to increase the cytotoxic potential of the respective immune cell (reviewed 
by de Bruyn et al., 2013; de Miguel et al., 2016; Holland, 2014). Additionally, receptor-specific 
mutants of TRAIL are used to optimize apoptosis induction by minimizing binding to decoy 
receptors (O’Leary et al., 2016) and specifically targeting the relevant death receptor of the 
corresponding tumor type (reviewed by Wajant et al., 2013). An overview of the broad variety 
of TRAIL fusion proteins exploiting active targeting is given in Table 1.1. 
 
The concept of improving TRAIL-based therapeutics by a stable and defined increase in valency 
(Figure 1.3C) is again inspired by the importance of efficient receptor clustering and 
furthermore supported by the observation that other TNFRSF members require cross-linking 
of two TNFSF trimers for optimal activation (Holler et al., 2003; Wyzgol et al., 2009). In fact, 
fusion of a single-chain version of TRAIL to dimerization modules (Gieffers et al., 2013; Seifert 
et al., 2014a; Siegemund et al., 2012) or combination of soluble TRAIL with an isoleucine zipper 
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hexamerization motif (Han et al., 2016) considerably enhanced apoptosis induction (Table 
1.1). Consistent with these data, oligomerization of TRAIL-R2-agonistic antibody fragments or 
scaffolds to an at least tetravalent form generated active therapeutics (Huet et al., 2014; Liu 
et al., 2015; Swers et al., 2013; Wang et al., 2013), while trimerization was sufficient for a 
TRAIL-R1-specific protein (Allen et al., 2012). 
 
Table 1.1: Variety of TRAIL fusion proteins exploiting active targeting and/or increased valency. Name of fusion 
protein, its format, target, and described effects are listed. Table is modified based on de Miguel et al., 2016. 
Fusion protein 
(Format) 
Target Main effects Reference 
Targeting of tumor cells and tumor vasculature – trivalent TRAIL forms 
anti-CD47:TRAIL 
(scFv-sTRAIL) 
CD47 active targeting, increased bioactivity, 
blocking of “don’t eat me” signal 
Wiersma et al., 2014 
anti-MCSP:TRAIL 
(scFv-sTRAIL) 
MCSP active targeting, increased bioactivity, 
inhibition of MCSP signaling, no side 
effects in vivo 
de Bruyn et al., 2010 
anti-PD-L1:TRAIL 
(scFv-sTRAIL) 
PD-L1 active targeting, increased bioactivity, 
enhanced T cell activation, conversion 
of suppressive myeloid cells into pro-
apoptotic effector cells 
Hendriks et al., 2016 
CD19L-sTRAIL 
(ligand-sTRAIL) 
CD19 active targeting, increased bioactivity, 
no side effects in vivo 
Uckun et al., 2015 
CD40ed-TRAILed 
(receptor-sTRAIL) 
CD40L active targeting, increased bioactivity Assohou-Luty et al., 
2006 
F8-TRAIL 
(scFv-sTRAIL) 
EDA active targeting Hemmerle et al., 
2014 
Fn14•TRAIL 
(receptor-sTRAIL) 
TWEAK increased bioactivity, no side effects in 
vivo 
Aronin et al., 2013 
MBOS4-TRAIL 
(scFv-CH3-sTRAIL) 
FAP active targeting, increased bioactivity Wajant et al., 2001 
MSC.scFvCD20-sTRAIL 
(scFv-sTRAIL delivered 
by HUMSCs) 
CD20 active targeting, increased bioactivity, 
no side effects in vivo 
Yan et al., 2013 
RGD-L-TRAIL 
(peptide-sTRAIL) 
Integrins active targeting, increased bioactivity, 
no side effects in vivo 
Cao et al., 2008 
scFv425:sTRAIL 
(scFv-sTRAIL, wt, TRAIL-
R1- + -R2-specific) 
EGFR active targeting, increased bioactivity, 
reduced EGFR activation 
Bremer et al., 2005a, 
Bremer et al., 2008a 
scFvαEGFR-scTRAIL 
(scFv-scTRAIL) 
EGFR active targeting, increased bioactivity, 
no side effects in vivo 
Siegemund et al., 
2012 
scFvαErbB2-scTRAIL 
(scFv-scTRAIL) 
HER2 active targeting, increased bioactivity, 
no side effects in vivo 
Schneider et al., 2010 
scFvC54:sTRAIL 
(scFv-sTRAIL) 
EpCAM active targeting, increased bioactivity Bremer et al., 2004a; 
Bremer et al., 2004b 
scFvCD7:sTRAIL 
(scFv-scTRAIL) 
CD7 active targeting, increased bioactivity Bremer et al., 2005b 
scFvCD19:sTRAIL 
(scFv-sTRAIL) 
CD19 active targeting, increased bioactivity, 
no side effects in vivo 
Stieglmaier et al., 
2008 
scFvCD33:sTRAIL 
(scFv-sTRAIL) 
CD33 active targeting, increased bioactivity ten Cate et al., 2009 
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Fusion protein 
(Format) 
Target Main effects Reference 
Targeting of tumor cells and tumor vasculature – trivalent TRAIL forms 
scFv:lαhCD70-TNC-TRAIL 
(scFv-TNC-TRAIL, wt, 
TRAIL-R1-, -R2-specific) 
CD70 active targeting, increased bioactivity, 
inhibition of immunosuppressive 
effects of CD70 
Trebing et al., 2014 
SS-TR3 
(scFv-scTRAIL) 
Mesothelin active targeting, increased bioactivity Tatzel et al., 2016 
sTRAIL-TMTP1 
(sTRAIL-peptide) 
highly 
metastatic 
tumor cells 
active targeting, increased bioactivity, 
no side effects in vivo 
Liu et al., 2014 
Tf-PEG-TRAIL 
(ligand-PEG-sTRAIL, 
conjugate) 
Tf receptor active targeting, increased bioactivity, 
no side effects in vivo 
Kim et al., 2012 
Modulation of immune cells – trivalent TRAIL forms 
Anti-CD3:TRAIL 
(scFv-sTRAIL) 
CD3 active targeting, increased bioactivity, 
enhanced cytotoxic activity of T cells, 
no side effects in vivo 
de Bruyn et al., 2011 
CLL1:TRAIL 
(scFv-sTRAIL) 
CLL1 active targeting, increased bioactivity, 
enhanced cytotoxic activity of 
granulocytes 
Wiersma et al., 2015 
K12:TRAIL 
(ligand-sTRAIL) 
CD7 active targeting, increased bioactivity, 
enhanced cytotoxic activity of T cells, 
no side effects in vivo 
de Bruyn et al., 2011 
scFv:G28-TRAILmutRs 
(scFv-TNC-TRAIL, wt, 
TRAIL-R1-, -R2-specific) 
CD40 active targeting, increased bioactivity, 
maturation of dendritic cells 
El-Mesery et al., 2013 
scFvRBC-TR3 
(scFv-scTRAIL) 
glycophorin A on 
mouse RBC 
active targeting, increased bioactivity, 
no side effects in vivo 
Spitzer et al., 2010 
Increased valency – hexavalent TRAIL forms 
EHD2-scTRAIL 
(EHD2-scTRAIL) 
- increased bioactivity, no side effects in 
vivo 
Seifert et al., 2014a 
ILz(6):TRAIL 
(hexameric ILZ-TRAIL) 
- increased bioactivity Han et al., 2016 
scTRAIL-RBD-IgG1-Fc 
(scTRAIL-Fc) 
- increased bioactivity, no side effects in 
vivo 
Gieffers et al., 2013 
Targeting of tumor cells combined with increased valency – hexavalent TRAIL forms 
DbαEGFR-scTRAIL 
(Db-scTRAIL) 
EGFR active targeting, increased bioactivity, 
reduced EGFR activation, no side 
effects in vivo 
Siegemund et al., 
2012; Siegemund et 
al., 2016 
scFvαEGFR-EHD2-scTRAIL 
(scFv-EHD2-scTRAIL) 
EGFR active targeting, increased bioactivity, 
no side effects in vivo 
Seifert et al., 2014a  
CLL1, C-type lectin-like molecule-1; EDA, alternatively-spliced EDA domain of fibronectin; HUMSCs, human 
umbilical cord derived mesenchymal stem cells; ILZ, isoleucine zipper; RBC, red blood cell; RBD, receptor-binding 
domain; Tf, transferrin; TMTP1, tumor molecular targeted peptide 1; TNC, trimerization domain of tenascin-C. 
 
Furthermore, alternative approaches, like adenoviral expression (Bremer et al., 2008b; Griffith 
and Broghammer, 2001; Liu et al., 2011) and delivery of TRAIL molecules by mesenchymal 
stem cells (reviewed by Attar et al., 2014) were developed. Besides the outlined strategies, 
especially concepts combining tumor targeting and increased TRAIL valency (Table 1.1) seem 
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to be promising to overcome the limitations of first generation TRAIL therapeutics. Two 
concepts employing targeted delivery and increased valency have been reported previously. 
In a first study, these properties were realized by fusion of scTRAIL to a diabody (Db; 
Siegemund et al., 2012). While a diabody combines tumor targeting and non-covalent dimeric 
assembly in one molecule, another study described the use of separate targeting and 
dimerization modules. Applying an scFv for targeting and the IgE heavy chain domain 2 (EHD2) 
for covalent homodimerization, targeted dimeric scFv-EHD2-scTRAIL fusion proteins were 
generated (Seifert et al., 2014a). Both Db-scTRAIL and scFv-EHD2-scTRAIL exerted remarkable 
activity in vitro and in vivo, showing half-lives of 3.5 h and 7.2 h (Seifert, 2014), respectively. 
 
In order to exploit the promising effects of tumor-targeted TRAIL fusion proteins, an important 
step in the generation of the respective therapeutics is the selection of a suitable tumor-
associated antigen. The TAAs targeted by the antibody-scTRAIL fusion proteins evaluated in 
this study are EGFR, HER2, HER3 (see 1.4.2.1), and EpCAM (see 1.4.2.2) and have been partly 
employed in similar constructs (Table 1.1). 
 
1.4.2.1 HER family members as targets in antibody-based tumor therapy 
The human epidermal growth factor receptor family comprises four members, EGFR (HER1, 
ERBB1), HER2 (NEU, ERBB2), HER3 (ERBB3), and HER4 (ERBB4). All receptors consist of an 
extracellular part, a transmembrane domain, and a cytoplasmic region. The extracellular part 
is composed of four domains that are responsible for ligand binding. The ligand-unbound 
receptor adopts a closed (or tethered) conformation that is characterized by the interaction 
of domains II and IV. Upon ligand binding, which is mediated by domains I and III, the 
dimerization interface of domain II is exposed (open or extended conformation) allowing 
receptor homo- and heterodimerization and activation of the tyrosine-kinase domain in the 
cytoplasmic region. Recruitment of proteins to phosphorylated tyrosine residues in the 
cytoplasmic tail finally leads to activation of downstream signaling, including MAPK and 
PI3K/AKT pathways. Physiologically, HER family members are expressed on epithelial, 
mesenchymal, and neuronal cells, and their activation is tightly controlled by a temporally and 
spatially restricted expression of the respective ligands. However, extensive HER signaling as 
a result of receptor or ligand overexpression or activating mutations has been found in various 
human tumors and associated with tumor development and progression (reviewed by Hynes 
and Lane, 2005; Roskoski, 2014). EGFR is overexpressed on a broad range of tumor types and 
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represents an established target molecule for antibody-based therapeutic approaches 
(reviewed by Ciardiello and Tortora, 2003; Seshacharyulu et al., 2012). The EGFR-targeting 
antibody domains used in this study are derived from cetuximab. Cetuximab is a chimeric 
human-mouse IgG1 antibody that binds to domain III of EGFR in the closed conformation, 
thereby inhibiting ligand binding and adoption of the open conformation (Li et al., 2005). 
Cetuximab is approved for the treatment of metastatic colorectal carcinoma and squamous 
cell carcinoma of the head and neck (reviewed by Arteaga and Engelman, 2014). HER2 differs 
from other family members, since it does not bind to a ligand, but permanently adopts an 
open conformation due to a lacking interaction of domains II and IV. Therefore, HER2 is the 
preferred heterodimerization partner of other family members. Although present in an open 
conformation, HER2 is only constitutively active when overexpressed. HER2 has been 
extensively evaluated as target structure, especially for the treatment of breast cancer, but 
high expression levels are also found for other tumor types, like gastric, ovarian, and prostate 
cancer (reviewed by Roskoski, 2014; Tai et al., 2010). In this study, the variable domains of the 
HER2-targeting humanized IgG1 antibody trastuzumab are employed in different molecules. 
Trastuzumab binds to domain IV of HER2, reduces its signaling activity, and is approved for 
the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic 
gastric or gastroesophageal junction adenocarcinoma (reviewed by Arteaga and Engelman, 
2014). For decades, HER3 has not been considered as a target structure for tumor therapy due 
to its impaired tyrosine kinase activity. Recently, it has been found, however, that HER3 has 
an important role in cancer progression and mediating resistance towards EGFR- and HER2-
targeting approaches by heterodimerization with these family members (reviewed by Hsieh 
and Moasser, 2007; Kol et al., 2014). Some of the HER3-binding molecules generated in this 
study are based on the HER3-targeting fully human IgG2 antibody MM-121 (seribantumab). 
Via binding to domain I of HER3, MM-121 inhibits ligand-dependent activation (Schoeberl et 
al., 2009; Schoeberl et al., 2010). MM-121 has already been analyzed in several clinical trials 
with promising results and is currently assessed in a phase II study in combinatorial treatment 
approaches of non-small cell lung cancer (http://www.clinicaltrials.gov, status September 
2016). Compared to the other family members, the role of HER4, which is not used as target 
in this study, in tumor development and progression is more complex. Further investigations 
of the influence of different isoforms and mutations will help to evaluate its potential as target 
for tumor therapy (reviewed by Arteaga and Engelman, 2014; Veikkolainen et al., 2011). 
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1.4.2.2 EpCAM as target in antibody-based tumor therapy 
Epithelial cell adhesion molecule (EpCAM, CD326) is a glycosylated type I transmembrane 
protein consisting of 314 amino acids. Its extracellular region (EpEX) constitutes the major part 
of the protein and consists of an EGF-like and thyroglobulin repeat domain, while the 
intracellular domain (EpICD) comprises only 26 amino acids. As implicated by its name, EpCAM 
is expressed on various epithelial tissues, where it is involved in the formation of homotypic 
cell-cell contacts. With respect to expression on malignant tissue, EpCAM is one of the most 
frequently and strongly expressed TAAs showing high levels on almost all adenocarcinomas, 
but also on squamous cell carcinoma, retinoblastoma, and hepatocellular carcinoma. 
Additionally, normal stem cells as well as cancer stem cells express EpCAM. In contrast to the 
homogeneous distribution of EpCAM on the surface of tumor cells, the accessibility of EpCAM 
on normal cells is limited, representing a favorable characteristic for the use as target in 
antibody-based therapies (reviewed by Baeuerle and Gires, 2007; Patriarca et al., 2012). 
Besides mediating cell adhesion, EpCAM has been found to induce mitogenic signaling. Upon 
activation, regulated intramembrane proteolysis releases EpEX and EpICD. While EpEX serves 
as soluble agonist for EpCAM-positive cells, EpICD becomes part of a multiprotein complex 
and transcriptionally regulates genes involved in cell growth, cell cycle, proliferation, and cell 
death (Maaser et al., 2008; Maetzel et al., 2009). This signaling activity has been discovered 
to be important for the phenotypic characteristics of normal and cancer stem cells. Thus, 
EpCAM is a promising target not only due to its strong expression on a wide range of tumor 
types, but also because of its presence on cancer stem cells potentially allowing selective 
eradication of the tumor cell subpopulation responsible for disease relapse. Additionally, 
blocking of EpCAM’s mitogenic signaling activity may support treatment efficacy (reviewed by 
Munz et al., 2009). The EpCAM-binding antibody domains used in this study are based on the 
mouse monoclonal IgG1 antibody 323/A3 that has been shown to exert anti-tumoral activity 
in preclinical mouse models (Edwards et al., 1986; Velders et al., 1995). Currently, only one 
EpCAM-targeting antibody (anti-EpCAMxCD3, catumaxomab; Seimetz et al., 2010) is approved 
in Europe (reviewed by Ecker et al., 2015). 
 
1.4.3 TRAIL and sensitizers 
The combination of TRAIL with sensitizing agents aims at improving several shortcomings of 
TRAIL-R-targeting therapies. These include the in general low activity, resistance, and the 
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potential induction of anti-apoptotic signaling. Exploitation of the cross-talk between extrinsic 
and intrinsic apoptosis induction by combination with various conventional 
chemotherapeutics induces synergistic effects and sensitizes tumor cells in preclinical settings. 
Based on these observations, combinatorial treatment approaches with dulanermin and 
TRAIL-R1/-R2-targeting antibodies have been analyzed in clinical studies, comprising 
combinations with single cytotoxic agents, multiple cytotoxic agents, targeted therapeutics, 
as well as mixtures of cytotoxic and targeted agents. However, no beneficial effects of TRAIL-
R-targeting therapeutics could be demonstrated. In general, the lacking efficacy of these 
combinatorial approaches is supposed to result from insufficient activity of either TRAIL-R-
targeting agents, sensitizers, or both. Further analysis of various sensitizers and their 
molecular effects indicated the requirement of simultaneous modulation of multiple levels of 
TRAIL signaling to overcome resistance (reviewed by den Hollander et al., 2013; Newsom-
Davis et al., 2009). An example for a potent and meanwhile extensively evaluated sensitizer is 
bortezomib, a proteasome inhibitor that reversibly binds to the β5 subunit of the 26S 
proteasome, thereby blocking its chymotrypsin-like proteolytic activity. Bortezomib 
(VELCADE, PS-341) is approved both as single agent and as combination therapy for the 
treatment of multiple myeloma and mantle cell lymphoma. Via inhibition of the proteasome, 
bortezomib affects various factors of the TRAIL pathway (Figure 1.2), on the one hand directly 
enhancing apoptosis, while on the other hand suppressing anti-apoptotic TRAIL signaling. The 
explicit mechanisms that are involved in sensitization depend on the respective tumor type, 
but include enhanced cell surface expression of TRAIL-R1 and -R2, increased activation of 
caspase-8, modulation of cFLIP levels, suppression of NF-κB activation, inhibition of NF-κB-
dependent XIAP, BCL-2, and BCL-XL expression, increased levels of pro-apoptotic BCL-2 family 
members, p53, p21, and p27, as well as inhibition of PKC and AKT signaling (reviewed by Chen 
et al., 2011; de Wilt et al., 2013). Investigations on potential toxicity revealed that co-
treatment with TRAIL and high concentrations of bortezomib kills primary human 
hepatocytes, yet with clearly lower sensitivity than the examined cancer cell lines, thus 
providing a therapeutic window for combinatorial application (Ganten et al., 2005; Koschny et 
al., 2007a). Despite the potent activity of TRAIL-R-targeting agents and bortezomib in mouse 
models and on primary tumor cells, a phase II randomized-controlled trial of mapatumumab 
and bortezomib failed to confirm superior effects of the combination (Belch et al., 2010). 
However, the lacking efficacy might again result from the insufficient activity of the applied 
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TRAIL-R-agonistic therapeutic. In order to develop more sensitizers with high potency and 
specificity, effort has been made to unravel the mechanisms underlying TRAIL resistance (see 
1.3). Counteracting high levels of XIAP or anti-apoptotic BCL-2 family members, molecules 
mimicking the antagonizing activity of SMAC and BH3-only proteins have been developed and 
shown to sensitize cancer cells to TRAIL-induced apoptosis. Several other strategies have been 
successfully applied, including inhibition of histone deacetylases, cyclin-dependent kinase 9, 
or the molecular chaperone Hsp90, as well as induction of ER stress (reviewed by Lemke et al., 
2014; Stolfi et al., 2012). 
 
1.4.4 Prognostic value of expression levels 
Independent of sensitivity towards TRAIL-R-targeting therapies, TRAIL and TRAIL receptor 
expression levels have been evaluated as potential prognostic markers for disease 
progression. Several studies have been published reporting a correlation between high TRAIL 
receptor expression and poor prognosis (reviewed by Bertsch et al., 2014). For instance, TRAIL-
R1 expression was associated with higher tumor grade in breast cancer (Sanlioglu et al., 2007), 
while TRAIL-R2 was identified as negative prognostic marker in several tumor entities, also 
including breast cancer (Ganten et al., 2009). In contrast, TRAIL receptor expression levels 
were also found to be associated with better prognosis in other tumor types, e.g. high TRAIL-
R1 expression in colorectal carcinoma (Sträter et al., 2002), high TRAIL-R2 levels in melanoma 
(Zhuang et al., 2006), and high levels of both death receptors in bladder cancer (Li et al., 2012). 
Other studies, however, could not identify any correlation, e.g. for cervical cancer (Maduro et 
al., 2009). Mostly, overall TRAIL receptor expression has been determined without 
differentiating distinct localizations. With respect to the different roles depending on 
localization, strictly compartment-specific determination of TRAIL receptor expression seems 
to be important to appropriately evaluate their potential as prognostic markers (reviewed by 
Bertsch et al., 2014). Additional studies were performed analyzing the predictive value of 
decoy receptor levels. In colon carcinomas for example, expression of neither TRAIL-R3 nor 
TRAIL-R4 showed prognostic relevance (Sträter et al., 2002). Further investigations aimed at 
evaluating the potential prognostic significance of TRAIL itself or molecules of the signaling 
pathway. High levels of TRAIL were identified as negative prognostic marker, e.g. in colorectal 
cancer (McLornan et al., 2010). In gastric carcinoma, no significant correlation was found for 
full-length TRAIL. However, high expression of its truncated non-apoptotic splice variant 
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TRAIL-γ was demonstrated to be predictive for improved survival (Krieg et al., 2013). An 
example of a signaling-involved molecule as prognostic marker is cFLIP that has been shown 
to be associated with a decrease in relapse-free survival in colorectal cancer (McLornan et al., 
2010). These studies clearly illustrate the tumor type dependence of the prognostic impact of 
molecules involved in TRAIL signaling and the importance of specific, e.g. localization- or 
variant-defined, determinations. 
 
As outlined above, clinical studies of dulanermin and TRAIL-R1/-R2-targeting antibodies both 
alone and in combination with sensitizers were disappointing. However, promising effects 
were seen for few individual patients, even in the absence of additional cytotoxic agents 
(reviewed by den Hollander et al., 2013). These observations underline the importance of 
unraveling factors that determine responsiveness to TRAIL-R-targeting therapies to allow 
selection of patients likely to benefit. Since O-glycosylation of TRAIL-R2 promotes DISC 
formation and apoptosis induction, the O-glycosylation enzyme GALNT14 has been analyzed 
as potential biomarker for TRAIL sensitivity. While a predictive value of GALNT14 expression 
for TRAIL sensitivity was demonstrated for several cancer cell lines and primary tumor samples 
(Wagner et al., 2007), a clinical study failed to identify a significant correlation of GALNT14 
expression and effects of dulanermin (Soria et al., 2011). In addition to the analysis of potential 
biomarkers, imaging studies using labeled TRAIL receptor-targeting antibodies provide helpful 
data on the bioavailability of the therapeutic at the tumor (Ciprotti et al., 2015; Oldenhuis et 
al., 2009). Recent approaches achieved promising results in predicting TRAIL sensitivity of 
tumor cell lines by using models that integrate the expression levels of a panel of genes (Chen 
et al., 2012; O’Reilly et al., 2014) or proteins (Passante et al., 2013; Weyhenmeyer et al., 2016). 
Further evaluation of these models on primary tumor cells and in vivo, however, is required 
to finally confirm their predictive capacity. Based on the progress in the field of high-
throughput technologies, determination of gene and protein expression profiles of individual 
patients may help guiding TRAIL-R-targeting therapies in terms of selecting appropriate 
patients as well as suitable sensitizers. 
 
1.5 Aim of the study 
Recent advances in improving TRAIL-based therapeutics highlight the superior activity induced 
via tumor targeting and increased valency. These observations enforced the development of 
a meanwhile long list of promising second generation TRAIL molecules (Table 1.1). However, 
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no comprehensive study has been performed yet to comparatively analyze those diverse 
forms of fusion proteins. Therefore, this study focuses on different versions of scTRAIL-based 
molecules that incorporate the most efficient improvement approaches – tumor targeting and 
increased valency – and aims at systematically comparing the generated fusion proteins, 
thereby ideally revealing the characteristics crucial for optimization. Initially, four different 
dimeric recombinant antibody formats were generated and evaluated for the potential use as 
fusion partners of scTRAIL. Besides the diabody (Db) and scFv-EHD2 that have been previously 
combined with scTRAIL (Seifert et al., 2014a; Siegemund et al., 2012), two other formats were 
selected to create a more diverse spectrum. Attempting to further stabilize the non-covalently 
associated chains of a diabody, cysteine residues were introduced to covalently connect the 
two chains yielding a disulfide-stabilized diabody (dsDb). Additionally, scFv-Fc was included 
representing a format that is able to exploit FcRn-mediated recycling. Further differences in 
the format properties comprise flexibility and size. While altered flexibilities are especially 
assumed between the diabody molecules and the formats containing separate targeting and 
dimerization modules connected by a flexible linker, size is a factor influencing PK properties. 
The various formats were directed against four therapeutically relevant tumor-associated 
antigens (EGFR, HER2, HER3, and EpCAM) and characterized in terms of thermal stability, 
binding properties, and effects on cell viability. The established dimeric recombinant antibody 
formats were subsequently employed to generate the respective sets of dimeric antibody-
scTRAIL fusion proteins (Db-scTRAIL, dsDb-scTRAIL, scFv-EHD2-scTRAIL, scFv-Fc-scTRAIL). 
Analysis of those molecules together with non-targeted monomeric and dimeric forms of 
scTRAIL was performed with respect to product quality, stability, binding properties, cell 
death-inducing activity in vitro, pharmacokinetics, and in vivo anti-tumor activity. Using these 
data, comparison of different formats directed against the same TAA and of a selected format 
comprising different targeting moieties allows conclusions about the impact of i) the protein 
format and ii) the targeting moieties on these properties, respectively. Finally, aiming at 
further improvement of dimeric antibody-scTRAIL fusion proteins, a new format was 
developed enabling simultaneous targeting of two different tumor-associated antigens. Four 
combinations of the above mentioned TAAs (EGFRxHER3, EpCAMxEGFR, HER2xEGFR, 
HER2xHER3) were realized and characterized regarding potential improvements. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 General consumables 
Laboratory plastics were purchased from Greiner Bio-One (Frickenhausen, Germany). 
Chemicals were obtained from Carl Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), 
Sigma-Aldrich (St. Louis, MO, USA), or Roche (Basel, Switzerland). Consumables purchased 
from any different source are explicitly specified. 
 
2.1.2 Antibodies and sera 
Antibodies and sera were obtained from Santa Cruz Biotechnology (Dallas, TX, USA), Sigma-
Aldrich (St. Louis, MO, USA), Miltenyi Biotec (Bergisch Gladbach, Germany), BioLegend (San 
Diego, CA, USA), R&D Systems (Minneapolis, MN, USA), Pineda Antikörper-Service (Berlin, 
Germany), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP; Stuttgart, 
Germany), and ImmunoTools (Friesoythe, Germany) (Table 2.1). 
 
Table 2.1: Antibodies and sera used in ELISA, flow cytometry, blocking studies, and PK. 
Antibody or serum Isotype Application Source 
Anti-DYKDDDDK-PE Monoclonal Flow cytometry (1:200) Miltenyi Biotec 
Anti-EGFR-PE Mouse IgG2b Flow cytometry (1:100) Santa Cruz Biotechnology 
Anti-FLAG® M2-HRP Mouse IgG1 ELISA (1:15,000) Sigma-Aldrich 
Anti-HER2-PE Mouse IgG1 Flow cytometry (1:100) Santa Cruz Biotechnology 
Anti-HER3-PE Mouse IgG2a, κ Flow cytometry (1:100) BioLegend 
Anti-HER4-PE Mouse IgG2a Flow cytometry (1:100) R&D Systems 
Anti-His-PE Mouse IgG1 Flow cytometry (1:200) Miltenyi Biotec 
Anti-human CD326 (EpCAM)-PE Mouse IgG2b, κ Flow cytometry (1:100) BioLegend 
Anti-human IgG (Fc specific)-
Peroxidase 
Goat polyclonal ELISA (1:5,000) Sigma-Aldrich 
Anti-human IgG (γ-chain 
specific) R-PE 
Goat polyclonal Flow cytometry (1:500) Sigma-Aldrich 
Anti-human TRAIL-R1 Mouse IgG1 Flow cytometry (1:100) R&D Systems 
Anti-human TRAIL-R2 Mouse IgG2b Flow cytometry (1:100) R&D Systems 
Anti-human TRAIL-R3 Mouse IgG1 Flow cytometry (1:100) R&D Systems 
Anti-human TRAIL-R4 Mouse IgG1 Flow cytometry (1:100) R&D Systems 
Anti-mouse IgG (whole 
molecule) R-PE 
Goat polyclonal Flow cytometry (1:100) Sigma-Aldrich 
Anti-rabbit IgG (whole 
molecule)-Peroxidase 
Goat polyclonal ELISA (1:5,000) Sigma-Aldrich 
Anti-scDbCEAxCD3-PEG Rabbit polyclonal ELISA (1:1,000) Pineda Antikörper-Service 
Cetuximab Human IgG1, κ Blocking studies, PK IKP 
His-probe (H-3) HRP Mouse IgG1 ELISA (1:1,000) Santa Cruz Biotechnology 
Mouse IgG1 control PE Mouse IgG1 Flow cytometry (1:100) ImmunoTools 
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Antibody or serum Isotype Application Source 
Mouse IgG2a control PE Mouse IgG2a Flow cytometry (1:100) ImmunoTools 
PE Mouse IgG2b, κ Isotype Ctrl Mouse IgG2b, κ Flow cytometry (1:100) BioLegend 
Trastuzumab Human IgG1, κ Blocking studies IKP 
 
2.1.3 Buffers and solutions 
If not stated otherwise, all components were dissolved in water. 
Bradford reagent (5x) Bio-Rad protein assay (Bio-Rad, Munich, Germany)  
Coomassie staining solution 0.008 % (w/v) Coomassie Brilliant Blue G-250 (SERVA 
Electrophoresis, Heidelberg, Germany), 35 mM HCl 
Crystal violet staining solution 0.5 % (w/v) crystal violet, 20 % (v/v) methanol 
DNA loading dye (6x) 10 mM Tris-HCl pH 7.6, 0.03 % (w/v) xylene cyanol FF, 
0.03 % (w/v) bromophenol blue, 60 mM EDTA, 60 % (v/v) 
glycerol (Thermo Fisher Scientific, Waltham, MA, USA) 
DPBS (1x) GIBCO® Dulbecco’s phosphate-buffered saline (Thermo 
Fisher Scientific, Waltham, MA, USA) 
ELISA blocking buffer (MPBS) 2 % (w/v) non-fat dry milk powder in 1x PBS 
ELISA substrate solution 100 mM sodium acetate pH 6.0, 0.1 mg/ml TMB, 0.006 % 
(v/v) H2O2 
ELISA wash buffer (PBST) 0.005 % (v/v) TWEEN 20 in 1x PBS 
HPLC running buffer 0.1 M Na2HPO4/NaH2PO4, 0.1 M Na2SO4, pH 6.7 
IMAC elution buffer 250 mM imidazole in 1x sodium phosphate buffer 
IMAC wash buffer 25 mM imidazole in 1x sodium phosphate buffer 
Laemmli loading buffer (5x) non-reducing: 25 % (v/v) glycerol, 10 % (w/v) SDS, 0.05 % 
(w/v) bromophenol blue in 312.5 mM Tris-HCl pH 6.8; 
reducing: non-reducing, 12.5 % (v/v) β-mercaptoethanol 
PBA 2 % (v/v) FBS, 0.02 % (w/v) NaN3 in 1x PBS 
PBS (10x) 80.6 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M NaCl, 
26.7 mM KCl; used as 1x PBS pH 7.5 
Periplasmic preparation buffer 30 mM Tris-HCl pH 8.0, 20 % (w/v) sucrose, 1 mM EDTA 
Protein A elution buffer 100 mM glycine-HCl pH 3.0 
Protein A wash buffer 100 mM Tris-HCl pH 7.5 
SDS-PAGE running buffer 192 mM glycine, 25 mM Tris, 0.1 % (w/v) SDS, pH 8.3 
Sodium phosphate buffer (5x,  
250 mM) 
210 mM Na2HPO4, 40 mM NaH2PO4, 1.25 M NaCl, pH 7.5 
TAE buffer (50x) 2 M Tris, 1 M glacial acetic acid, 50 mM EDTA, pH 8.0 
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2.1.4 Enzymes and other proteins 
Receptor-Fc fusion proteins kindly provided by Sina Fellermeier and Lisa Marquardt (both 
Institute of Cell Biology and Immunology, University of Stuttgart, Germany) are indicated. 
EGFR-Fc extracellular domain (aa 25-645) fused to the human Fcγ1 
chain (Seifert et al., 2012) 
FastAP Thermosensitive Alkaline  
Phosphatase 
1 U/µl (Thermo Fisher Scientific, Waltham, MA, USA) 
HER2-Fc extracellular domain (aa 23-652) fused to the human Fcγ1 
chain (Seifert et al., 2012) 
HER3-Fc extracellular domain (aa 20-643) fused to the human Fcγ1 
chain (Seifert et al., 2012); kindly provided by Sina 
Fellermeier 
Human OPG-Fc extracellular domain (aa 22-186) fused to the human Fcγ1 
chain; kindly provided by Lisa Marquardt 
Human TRAIL-R1-Fc extracellular domain (aa 24-239) fused to the human Fcγ1 
chain (Seifert et al., 2014a); kindly provided by Lisa 
Marquardt 
Human TRAIL-R2-Fc extracellular domain (aa 52-212) fused to the human Fcγ1 
chain (Seifert et al., 2014a); kindly provided by Lisa 
Marquardt 
Human TRAIL-R3-Fc extracellular domain (aa 25-240) fused to the human Fcγ1 
chain (Seifert et al., 2014a); kindly provided by Lisa 
Marquardt 
Human TRAIL-R4-Fc extracellular domain (aa 56-212) fused to the human Fcγ1 
chain (Seifert et al., 2014a); kindly provided by Lisa 
Marquardt 
Lysozyme Muramidase from hen egg white (Roche Diagnostics, 
Mannheim, Germany) 
Mouse DcTRAIL-R1-Fc extracellular domain (aa 32-158) fused to the human Fcγ1 
chain; kindly provided by Lisa Marquardt 
Mouse DcTRAIL-R2-Fc extracellular domain (aa 42-168) fused to the human Fcγ1 
chain; kindly provided by Lisa Marquardt 
Mouse OPG-Fc extracellular domain (aa 22-186) fused to the human Fcγ1 
chain; kindly provided by Lisa Marquardt 
Mouse TRAIL-R2-Fc extracellular domain (aa 53-180) fused to the human Fcγ1 
chain; kindly provided by Lisa Marquardt 
Mouse TRAIL-R2-Fc-His extracellular domain (aa 1-177) fused to a C-terminally 
polyhistidine-tagged human Fcγ1 chain (Sino Biological, 
Beijing, China) 
Pfu DNA Polymerase (native) 2.5 U/µl (Thermo Fisher Scientific, Waltham, MA, USA) 
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Protein L-HRP used in ELISA as 1:1,000 dilution (Genscript, Piscataway, 
NJ, USA) 
Restriction enzymes AgeI, ApaI, BamHI, BspEI, EcoRI, KpnI, NotI, SfiI, SgsI, XbaI, 
XhoI: 10 U/µl (Thermo Fisher Scientific, Waltham, MA, 
USA) 
PspXI: 5 U/µl (New England Biolabs, Ipswich, MA, USA) 
sEpCAM extracellular domain (aa 24-265) fused to a FLAG-tag 
(Seifert et al., 2012); kindly provided by Sina Fellermeier 
T4 DNA Ligase 5 U/µl (Thermo Fisher Scientific, Waltham, MA, USA) 
 
2.1.5 Markers and kits 
Alanine Transaminase Activity  
Assay kit 
(abcam, Cambridge, UK) 
Amylase Assay kit (abcam, Cambridge, UK) 
BD OptEIA™ human TRAIL ELISA 
Set 
(BD Biosciences, San Diego, CA, USA) 
Caspase-Glo® 3/7 Assay (Promega, Madison, WI, USA) 
Caspase-Glo® 8 Assay (Promega, Madison, WI, USA) 
GeneRuler™ DNA Ladder Mix  (Thermo Fisher Scientific, Waltham, MA, USA) 
NucleoBond® Xtra Midi (Macherey-Nagel, Düren, Germany) 
NucleoSpin® Gel & PCR Clean-up (Macherey-Nagel, Düren, Germany) 
NucleoSpin® Plasmid (Macherey-Nagel, Düren, Germany) 
PageRuler™ Prestained Protein Ladder (Thermo Fisher Scientific, 
Waltham, MA, USA) 
 
2.1.6 Special implements 
Anti-FLAG® M2 affinity gel (Sigma-Aldrich, St. Louis, MO, USA) 
Bortezomib in vitro studies (UBPBio, Aurora, USA); 
in vivo studies: VELCADE® (Dr. Margarete Fischer-Bosch-
Institute of Clinical Pharmacology, Stuttgart, Germany) 
Bottle Top Filter CA Low Protein binding, 500 ml, 0.2 µm/0.45 µm (Corning 
Incorporated, Tewksbury, MA, USA) 
Centrifuge tubes 13 ml, PP (Sarstedt, Nümbrecht , Germany) 
Chromatography columns Poly-Prep® (Bio-Rad, Munich, Germany) 
Counting chamber Neubauer improved (Marienfeld Superior, Paul Marienfeld 
GmbH & Co. KG, Lauda-Königshofen, Germany) 
Cuvette 12 mm O.D. square glass cell with cap (Malvern 
Instruments, Malvern, Worcestershire, UK) 
Dialysis membrane High retention seamless cellulose tubing, 23 mm, MWCO 
12,400 (Sigma-Aldrich, St. Louis, MO, USA) 
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Dialysis membrane ZelluTrans, MWCO 6,000-8,000, 40 mm; ZelluTrans, 
MWCO 3,500, 46 mm (Carl Roth, Karlsruhe, Germany) 
FLAG peptide 5 mg/ml (peptides&elephants, Potsdam, Germany) 
FPLC column Superdex 200 10/300 GL (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) 
HPLC column Yarra™ 3 µm SEC-2000, Yarra™ 3 µm SEC-3000 
(Phenomenex, Torrance, CA, USA) 
Human plasma from healthy donors (blood bank, Klinikum Stuttgart, 
Germany) 
Protein A affinity resin TOYOPEARL® AF-rProtein A-650F (Tosoh Bioscience, 
Griesheim, Germany) 
Reaction tubes 1.5 ml, 2 ml Safe-Lock (Eppendorf AG, Hamburg, Germany) 
REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-Aldrich, St. Louis, MO, USA) 
Syringe filter Acrodisc® 13 mm, 0.2 µm, HT Tuffryn® Membrane (Pall 
Corporation, Port Washington, NY, USA) 
TripleFlask™ 500 cm², Nunclon™ Delta Surface (Thermo Fisher 
Scientific, Waltham, MA, USA) 
Ultrafiltration spin columns Vivaspin 500, 30,000 MWCO PES (Sartorius, Göttingen, 
Germany) 
 
2.1.7 Prokaryotic and eukaryotic cell lines 
Escherichia coli TG1 Genotype: supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK- 
mK-) [F’ traD36 proAB lacIqZΔM15] (Stratagene, La Jolla, 
CA, USA) 
HEK293T Human embryonic kidney 
A-431 Human epidermoid carcinoma 
SKBR3 Human breast adenocarcinoma 
MCF7 Human breast adenocarcinoma 
Colo205 Human colorectal adenocarcinoma 
HCT116 Human colorectal carcinoma 
 
2.1.8 Media and supplements for prokaryotic and eukaryotic cell culture 
2xTY medium 1.6 % (w/v) peptone, 1 % (w/v) yeast extract, 0.5 % (w/v) 
NaCl in H2O 
Ampicillin (1000x) 100 mg/ml in H2O 
Cryopreservation solution 10 % (v/v) dimethyl sulfoxide in FBS 
Eosin staining solution 0.4 % (w/v) eosin G, 0.02 % (w/v) NaN3 in 1x PBS pH 7.4 
FBS FBS Premium (PAN Biotech, Aidenbach, Germany) 
IPTG (1000x) 1 M isopropyl β-D-1-thiogalactopyranoside in H2O 
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LBamp,glc agar plates LB medium, 2 % (w/v) agar; after autoclaving: addition of 
1 % (w/v) D-glucose and 100 µg/ml ampicillin 
LB medium 1 % (w/v) peptone, 0.5 % (w/v) yeast extract, 0.5 % (w/v) 
NaCl in H2O 
Lipofectamine® 2000 (Thermo Fisher Scientific, Waltham, MA, USA) 
Opti-MEM® Reduced Serum Medium (Thermo Fisher Scientific, 
Waltham, MA, USA) 
Penicillin-Streptomycin (100x) 10,000 U/ml penicillin, 10,000 µg/ml streptomycin 
(Thermo Fisher Scientific, Waltham, MA, USA) 
Puromycin (Sigma-Aldrich, St. Louis, MO, USA) 
RPMI Medium 1640 (1x) + L-Glutamine (Thermo Fisher Scientific, Waltham, MA, 
USA) 
Trypsin-EDTA (10x) 0.5 % Trypsin-EDTA, diluted to 1x in sterile PBS (Thermo 
Fisher Scientific, Waltham, MA, USA) 
Zeocin™ Selection Reagent 100 mg/ml (Thermo Fisher Scientific, Waltham, MA, USA) 
ZnCl2 100 mM in H2O, sterile filtered 
 
2.1.9 Mice 
CD-1® Crl:CD1 (ICR) (Charles River, Wilmington, MA, USA) 
NMRI nude Crl:NMRI-Foxn1nu (Charles River, Wilmington, MA, USA) 
 
2.1.10 Plasmids 
Plasmids developed at the Institute of Cell Biology and Immunology (University of Stuttgart, 
Germany) are indicated. 
pAB1 Vector for prokaryotic protein expression and secretion 
into the periplasm of E. coli (Kontermann et al., 1997) 
pAB1-scFv323/A3hu3 (Sina Fellermeier, 2012, Institute of Cell Biology and 
Immunology) 
pAB1-scFvhu225 (Anja Nusser, 2008, Institute of Cell Biology and 
Immunology) 
pAB1-scFvMM-6 (Sina Fellermeier, 2011, Institute of Cell Biology and 
Immunology) 
pAB1-scFvMOC31hu2 (Sina Fellermeier, 2012, Institute of Cell Biology and 
Immunology) 
pIRESpuro3 Bicistronic mammalian expression vector (Clontech 
Laboratories, Mountain View, CA, USA) 
pIRESpuro-L-F-scTRAIL281-G-118 (Martin Siegemund, 2013, Institute of Cell Biology and 
Immunology) 
  MATERIALS AND METHODS   
  41   
pSecTagA Vector for eukaryotic protein expression and secretion 
(Thermo Fisher Scientific, Waltham, MA, USA) 
pSecTagAHis Modification of pSecTagA lacking the myc epitope 
(Gerhard Trunk, 2005, Institute of Cell Biology and 
Immunology) 
pSecTagAHis-Db4D5-HPR (Heike Lill, 2009, Institute of Cell Biology and Immunology) 
pSecTagAHis-Dbhu225-HPR (Heike Lill, 2009, Institute of Cell Biology and Immunology) 
pSecTagAHis-scDb4D5xhu225 (Aline Plappert, 2011, Institute of Cell Biology and 
Immunology) 
pSecTagAHis-scDbhu225xCD3 (Sina Fellermeier, 2010, Institute of Cell Biology and 
Immunology) 
pSecTagAHis-scDbMocBxhu225 (Aline Plappert, 2011, Institute of Cell Biology and 
Immunology) 
pSecTagAHis-scFv4D5 (Heike Lill, 2009, Institute of Cell Biology and Immunology) 
pSecTagAL1 Modification of pSecTagAHis with an additional AgeI 
restriction site in the Igκ chain leader sequence (Julia 
Seitter, 2007, Institute of Cell Biology and Immunology) 
 
2.1.11 Primers 
Primers used for DNA sequencing, colony screening, and cloning were synthesized by Sigma-
Aldrich (St. Louis, MO, USA). Primers were dissolved in water to a concentration of 50 µM and 
stored at -20 °C. 
 
Table 2.2: Primers used for cloning, PCR screening, and sequencing. 
# Name Sequence (5’3’) Application 
61 LMB4 GCAAGGCGATTAAGTTGG Reverse primer for pAB1 
88 LMB3 CAGGAAACAGCTATGACC Forward primer for pAB1 
89 pET-Seq1 TAATACGACTCACTATAGG Forward primer for pSecTagA 
91 pSec-Seq2 TAGAAGGCACAGTCGAGG Reverse primer for pSecTagA 
910 AgeI-scFvhu225-back AAAACCGGTGAAGTGCAGCTGGTTGAAA Cloning: (ds)Dbhu225 
911 AgeI-VH4D5-back AAAACCGGTGAAGTGCAGCTCGTCGAA Cloning: scFv4D5, (ds)Db4D5 
912 BamHI-VH4D5-for AAAGGATCCTCCGCCTCCTGAGCCAC Cloning: scFv4D5 
913 BamHI-VL4D5-back AAAGGATCCGACATCCAGATGACCCAG Cloning: scFv4D5 
942 AgeI-scFvMM-6-back AAAACCGGTGAAGTGCAGCTGCTGGAA Cloning: scFv3M6, dsDb3M6 
944 KpnI-VHhu225-back AAAGGTACCGAAGTGCAGCTGGTTGAAA Cloning: hu225 scTRAIL 
molecules 
945 KpnI-VH4D5-back AAAGGTACCGAAGTGCAGCTCGTCGAA Cloning: 4D5 scTRAIL molecules 
947 KpnI-VH3M6-back AAAGGTACCGAAGTGCAGCTGCTGGAA Cloning: 3M6 scTRAIL molecules 
953 NotI-VLMM-6-Ser-for AAATGCGGCCGCCAGCACGGTCACTTTGGTGCCAC
CTCCGAAGATCACGAAGATGCTGCTGCCGGCGTAG
CTGGAGCAGTAGTAGTCGGCCTC 
Cloning: scFv3M6 
954 VHhu225-Cys44-for CCCAGCCATTCCAGACATTTGCCCGGTGCCTGAC Cloning: dsDbhu225 
955 VHhu225-Cys44-back AGGCACCGGGCAAATGTCTGGAATGGCTGGGCGT Cloning: dsDbhu225 
956 BamHI-GGGGS-
VHhu255-for 
AAAGGATCCACCGCCACCG Cloning: dsDbhu225 
  MATERIALS AND METHODS   
  42   
# Name Sequence (5’3’) Application 
957 BamHI-VLhu225-
back 
AAAGGATCCGATATTCAGCTGA Cloning: dsDbhu225 
958 NotI-VLhu225-
Cys100-for 
AAAGGCGGCCGCACGTTTAATTTCCAGTTTGGTGCC
GCAACCAAAGGTGGTCGGCC 
Cloning: dsDbhu225 
959 VH4D5-Cys44-for GCGACCCACTCCAAACACTTTCCAGGAGCTTGCCT Cloning: dsDb4D5 
960 VH4D5-Cys44-back AAGCTCCTGGAAAGTGTTTGGAGTGGGTCGCTAGG Cloning: dsDb4D5 
961 BspEI-VH4D5-for AAATCCGGAACTGACGGTCAC Cloning: dsDb4D5 
962 BspEI-VL4D5-back AAATCCGGAGGAGGGGGTAG Cloning: dsDb4D5 
963 NotI-VL4D5-Cys100-
for 
AAATGCGGCCGCACGCTTGATCTCGACCTTCGTTCC
GCAACCGAAGGTTGGAGGAGT 
Cloning: dsDb4D5 
986 ApaI-scTRAIL118-for AAAGGGCCCTCTAGACGTACGTCAACCC Cloning: pSecTagFLAG-linker-
EHD2-scTRAIL 
987 XhoI-linker-
scTRAIL118-back 
AAAGCCTCGAGCGGCGGCGGCCCCCAG Cloning: pSecTagFLAG-linker-
EHD2-scTRAIL 
992 BamHI-linker-
VH3M6-for 
AAAGGATCCGCCTCCCCCACTCGAGACTGTGACCAG Cloning: Db3M6 
1015 NotI-linker-
scTRAIL118-back 
ATAAGAATGCGGCCGCCGGGGGAAGCGGCGGCGG
CCCCCAG 
Cloning: pSecTagFLAG-linker-
scTRAIL 
1016 EcoRI-scTRAIL118-for CCGGAATTCTCTAGACGTACGTCAACCC Cloning: scTRAIL vectors 
1019 XhoI-linker-
scTRAIL118-back 
CCGGCCTCGAGCGGCGGCGGCCCCCAG Cloning: pSecTagFLAG-EHD2-
scTRAIL 
1050 VH3M6-Cys44-for GACACCCATTCCAGACACTTGCCAGGGGCCTGTC Cloning: dsDb3M6 
1051 VH3M6-Cys44-back AGGCCCCTGGCAAGTGTCTGGAATGGGTGTCCAGC Cloning: dsDb3M6 
1052 BamHI-GGGGS-
VH3M6-for 
AAAGGATCCGCCTCCCCCA Cloning: dsDb3M6 
1053 BamHI-VL3M6-back AAAGGATCCCAGTCTGCCCT Cloning: dsDb3M6 
1054 NotI-VL3M6-Cys100-
for 
AAAGGCGGCCGCCAGCACGGTCACTTTGGTGCCGC
ATCCGAAGATCACGAAGATG 
Cloning: dsDb3M6 
1081 XhoI-G-Fc(Q)-for AAAGCTCGAGCCACCGCCGCTTCCCCCCTGACCCGG
AGACAGGGAG 
Cloning: optimized Fc-linker for 
scTRAIL molecules 
1210 KpnI-Fc(Q)-back AAAGGTACCGACAAAACTCACACATGCC Cloning: Fc-scTRAIL 
1212 BamHI-VL323A3hu3-
back 
AAAGGATCCGAGATCGTGCTGACACAG Cloning: Db323/A3hu3 
1213 KpnI-VH323A3hu3-
back 
AAAGGTACCCAAGTGCAGCTGGTGCAG Cloning: 323/A3hu3 scTRAIL 
molecules 
1214 XhoI-linker-VL3M6-
back 
AAACTCGAGTGGCGGTGGCGGATCGCAGTCTGCCC
TGACACAG 
Cloning: scDbhu225x3M6 
1215 SgsI-linker-VL3M6-
for 
AAAGGCGCGCCCACCGCTGCCACCGCCTCCCAGCAC
GGTCACTTTGGT 
Cloning: scDbhu225x3M6 
1216 SgsI-linker-VH3M6-
back 
AAAGGCGCGCCTCGGGCGGAGGTGGCTCAGAAGT
GCAGCTGCTGGAA 
Cloning: scDbhu225x3M6 
1217 BamHI-linker-
VH3M6-for 
AAAGGATCCCCCGCCTCCACTCGAGACTGTGACCAG Cloning: scDbhu225x3M6 
1245 AgeI-VH3-43-back AAAACCGGTCAGGTGCAGCTGCAGCA Cloning: Db3-43 
1246 BamHI-GGGGS-VL3-
43-for 
AAAGGATCCGCCTCCCCCTGAAGAGACGGTGACCA
TT 
Cloning: Db3-43 
1247 BamHI-VL3-43-back AAAGGATCCCAGGCTGGGCTGACTCA Cloning: Db3-43 
1248 NotI-VL3-43-for AAAGGCGGCCGCTAGGACGGTCAGCTTGGT Cloning: Db3-43 
1249 KpnI-VH3-43-back AAAGGTACCCAAGTGCAGCTGCAGCAG Cloning: 3-43 scTRAIL molecules 
1306 BamHI-(GGGGS)3-
VH3-43-for 
AAAGGATCCACCGCCGCCACTTCCACCTCCCCCAGA
TCCTCCCCCGCCAGAGGACACTGTGACCAT 
Cloning: scFv3-43 
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2.1.12 Instruments 
Centrifuges Centrifuges 5415D, 5810R (Eppendorf, Hamburg, 
Germany); Rotanta 460 RF (Hettich Zentrifugen, 
Tuttlingen, Germany); J2-MC and Avanti® J-30I with rotors 
JA-10, JA-14, JA-20, JA-30.50 Ti; Avanti® J-26XP with rotor 
JLA-8.1000 (Beckman Coulter, Krefeld, Germany) 
CO2 incubator for cell culture Varocell 140 (varolab GmbH, Giesen, Germany) 
Electrophoresis systems Mini-PROTEAN® Tetra Cell, Mini-Sub® Cell GT, PowerPac™ 
Basic and HC power supply (Bio-Rad, Munich, Germany) 
Flow cytometer MACSQuant® Analyzer 10, MACSQuant® VYB (Miltenyi 
Biotec, Bergisch Gladbach, Germany) 
FPLC ÄKTApurifier (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) 
Gel documentation Transilluminator, ImageSystem Felix® (biostep, Jahnsdorf, 
Germany) 
HPLC Waters 2695 Separations Module, Waters 2489 UV/Visible 
Detector (Waters Corporation, Milford, MA, USA) 
Incubator for bacteria Infors HT Multitron (Infors AG, Bottmingen, Switzerland) 
Laminar flow cabinet Variolab Mobilien W90 Sicherheitswerkbank (Waldner 
Laboreinrichtungen, Wangen, Germany) 
Microplate reader Infinite M200 (Tecan Group, Männedorf, Switzerland) 
PCR cycler RoboCycler® 96 (Stratagene, La Jolla, CA, USA) 
Spectrophotometer NanoDrop™ ND-1000 (Thermo Fisher Scientific, Waltham, 
MA, USA) 
Zetasizer Zetasizer Nano ZS (Malvern Instruments, Malvern, 
Worcestershire, UK) 
 
2.1.13 Software and online tools 
Antibody sequence numbering Abnum (http://www.bioinf.org.uk/abs/abnum/) 
IMGT (http://www.imgt.org/IMGTScientificChart/ 
Numbering/Hu_IGHGnber.html) 
Cleavage site analysis ExPASy PeptideCutter 
(http://web.expasy.org/peptide_cutter/) 
Data evaluation GraphPad Prism® 5.00 for Windows (GraphPad Software, 
La Jolla, CA, USA); Microsoft Excel 2013 (Microsoft, 
Redmond, WA, USA) 
Flow cytometry  MACSQuantify 2.6 (Miltenyi Biotec, Bergisch Gladbach, 
Germany); FlowJo 7.6.5 (Tree Star Inc., Ashland, OR, USA) 
Molecular biology software SerialCloner 2.6.1 
(http://serialbasics.free.fr/Serial_Cloner.html) 
Molecular visualization PyMOL™ v0.99 (DeLano Scientific, San Francisco, CA, USA) 
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Protein databases UniProt (http://www.uniprot.org/) 
PDB (http://www.rcsb.org/pdb/home/home.do) 
Protein parameter determination ExPASy ProtParam (http://web.expasy.org/protparam/) 
Sequence alignment BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
 
2.2 Cloning techniques 
2.2.1 Polymerase chain reaction 
PCR was performed to specifically modify existing DNA sequences. 1 µl of forward and 1 µl of 
reverse primer (both 10 µM) were mixed with 1 µl of template DNA (10 ng/µl to 5 µg/µl), 
2.5 µl of dNTP mix (5 mM each), 5 µl 10x Pfu buffer containing MgSO4, 1 µl Pfu DNA 
polymerase, and 38.5 µl nuclease-free water. DNA fragments were amplified using a standard 
PCR protocol, composed of an initial denaturation phase (94 °C, 5 min), followed by 30 cycles 
of denaturation (94 °C, 1 min), annealing (temperature depending on the melting point of the 
primers, 1 min) and elongation (72 °C, time adjusted to the length of the amplified fragment). 
PCR was completed with a final elongation step (72 °C, 5 min). The elongation time in the PCR 
cycles was adapted based on the synthesis rate of the Pfu DNA polymerase of 500 nucleotides 
per min and the length of the expected fragment. Amplified DNA fragments were subjected 
to agarose gel electrophoresis and subsequent gel extraction (see 2.2.2). 
 
In order to introduce mutations that are not located near to restrictions sites, fusion-PCR was 
used. Initially, two separate polymerase chain reactions were performed based on the 
standard protocol described above to amplify two overlapping fragments containing the 
desired mutation. These DNA fragments were purified by preparative gel electrophoresis, and 
extracted DNA was eluted in 30 µl nuclease-free water (see 2.2.2). 15 µl of each PCR product 
were mixed, and 2.5 µl of dNTP mix (5 mM each), 5 µl 10x Pfu buffer containing MgSO4, 1 µl 
Pfu DNA polymerase, and 11.5 µl nuclease-free water were added. The fusion-PCR protocol 
consisted of an initial denaturation phase (94 °C, 5 min) and 5 cycles of denaturation (94 °C, 
0.5 min), annealing (50 °C, 0.5 min) and elongation (72 °C, 1 min). After the last elongation 
step, the PCR sample was held at 94 °C and directly transferred on ice. After 3 min, 1 µl of 
forward and 1 µl of reverse primer (both 10 µM) as well as 2.5 µl of dNTP mix (5 mM each) 
were added, and a final standard PCR was run to amplify the fused fragment. 
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2.2.2 Agarose gel electrophoresis and gel extraction 
PCR products and DNA fragments generated by restriction digestion were analyzed by 
horizontal agarose gel electrophoresis (80 V according to 1 V/cm, 40 min). 1 % (w/v) agarose 
was dissolved in 1x TAE buffer by heating, and ethidium bromide was added to a final 
concentration of 1 µg/ml to visualize DNA bands by exposure to UV light. DNA samples 
containing 1x DNA loading dye were analyzed together with GeneRuler™ DNA Ladder Mix. 
DNA fragments desired for further cloning were excised, and DNA was extracted using 
NucleoSpin® Gel & PCR Clean-up kit according to the manufacturer’s instructions. 
 
2.2.3 Restriction digestion and ligation 
Plasmid DNA or purified PCR products were digested by preparing a reaction mixture of DNA 
(10 µg or complete amount of PCR product), 1 µl restriction enzyme, and the corresponding 
buffer at the indicated concentration. Sample volume was adjusted to 50 µl with water. 
Digestion was done at the working temperature of the respective enzyme for at least 2 h. Prior 
to digestion with the second enzyme, buffer was exchanged using NucleoSpin® Gel & PCR 
Clean-up kit. Double digest was only performed, when recommended by the manufacturer. 
To prevent religation, vector DNA was dephosphorylated by adding 1 µl FastAP and incubation 
at 37 °C for at least 1 h. Agarose gel electrophoresis was run and desired DNA fragments were 
extracted using NucleoSpin® Gel & PCR Clean-up kit (see 2.2.2). Ligation was prepared with 
purified insert and vector DNA (100 ng to 200 ng vector DNA, typically in molar ratios of 3:1 
and 5:1 of insert to vector), 2 µl ligase buffer, and 1 µl T4 DNA ligase. Sample volume was 
adjusted to 20 µl with water. Ligation was performed at room temperature for at least 1 h. 
 
2.2.4 Transformation 
E. coli TG1 were transformed with purified plasmid DNA (100 ng) or ligation preparations 
(20 µl) by heat shock. Chemically competent bacteria were thawed on ice, mixed with DNA, 
and incubated on ice for 15 min. Heat shock was performed for 1 min at 42 °C. Bacteria were 
transferred back on ice for 1 min, and LB medium (1 ml) was added. Bacteria were incubated 
shaking at 37°C for 1 h and subsequently plated on LBamp,glc agar plates for overnight culture 
at 37 °C. 
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2.2.5 Colony Screening 
Transformed bacteria colonies were screened for positive clones by PCR. The reaction mix 
consisted of 50 % (v/v) REDTaq® ReadyMix™, 0.2 µM of forward and 0.2 µM of reverse primer 
in water. Samples of 20 µl reaction mix were inoculated with single picked colonies that were 
subsequently plated on LBamp,glc agar plates and incubated at 37 °C for at least 6 h. DNA 
fragments were amplified by PCR (see 2.2.1) and analyzed on agarose gels (see 2.2.2) to 
identify clones showing bands of the desired size. 
 
2.2.6 Plasmid DNA preparation 
LB medium containing 1 % (w/v) glucose and 100 µg/ml ampicillin was inoculated with 
transformed bacteria and incubated shaking overnight at 37 °C. Plasmid DNA was prepared 
using NucleoSpin® Plasmid (Mini-preparation, 6 ml overnight culture) and NucleoBond® Xtra 
Midi kits (Midi-preparation, 150 ml overnight culture) according to the manufacturer’s 
protocol. 
 
2.2.7 Determination of DNA concentration and sequence analysis 
DNA concentration was determined by measuring the absorbance at 260 nm using 
NanoDrop™ ND-1000. DNA mixed with the respective primer at the recommended 
concentrations was sent to GATC (Constance, Germany) for sequence analysis. BLAST was 
used to compare the sequencing result with the virtually cloned DNA sequence. 
 
2.3 Cloning strategies 
2.3.1 Cloning of scFv 
ScFvhu225 was generated by humanization of the anti-EGFR antibody C225 (Goldstein et al., 
1995) by complementarity-determining region grafting (Seifert et al., 2012). ScFv4D5, 
scFvMM-6, and scFv323/A3 were derived from previously published data (Carter et al., 1992; 
Schoeberl et al., 2009; Edwards et al., 1986 and Roovers et al., 1998). Humanization of 
scFv323/A3 required sequential analysis of several humanized forms finally developing 
scFv323/A3hu3 (Fellermeier et al., 2016). ScFv3-43 was selected from a human scFv phage 
display library using HER3-Fc as target structure (Stefan Dübel, Technical University of 
Braunschweig, Germany). VH and VL sequences of 3-43 codon-optimized for eukaryotic 
expression were ordered from GeneArt® Gene Synthesis (Thermo Fisher Scientific GENEART 
  MATERIALS AND METHODS   
  47   
GmbH, Regensburg, Germany). ScFv sequences were cloned into pAB1 for periplasmic 
expression in E. coli. Sequences of scFvhu225, scFvMM-6, and scFv323/A3hu3 in pAB1 were 
already available. The sequence of scFv4D5 containing an alternative linker was modified to 
generate an scFv with the standard (GGGGS)3 linker. AgeI-VH4D5-linker-BamHI and BamHI-
VL4D5-NotI fragments were amplified by PCR (primers #911/912 and #913/91, Table 2.2), 
followed by digestion with the respective restriction enzymes and substitution of the scFv in 
pAB1-scFvMOC31hu2. ScFvMM-6 was modified by mutation of the cysteine residue at 
position 89 (Kabat numbering scheme) in the CDR-L3 loop to serine generating scFv3M6 
(mutated MM-6). The C89S mutation was introduced by PCR generating an AgeI-scFv3M6-
NotI fragment (primers #942/953, Table 2.2) and subsequent transfer into pAB1. ScFv3-43 was 
cloned based on Db3-43 (see 2.3.2) by PCR amplification of an AgeI-VH3-43-linker-BamHI 
fragment containing a (GGGGS)3 linker (primers #89/1306, Table 2.2) and substitution of the 
VH-linker part of the diabody via AgeI/BamHI digestion. 
 
2.3.2 Cloning of Db 
All diabody sequences were cloned into pSecTagAL1 for eukaryotic expression. Dbhu225 was 
amplified by PCR from pSecTagAHis-Dbhu225-HPR adding an AgeI restriction site (primers 
#910/91, Table 2.2) and transferred to pSecTagAL1 via AgeI/NotI digestion. Generation of 
pSecTagAL1-Db4D5 was performed according to the Dbhu225 construct using pSecTagAHis-
Db4D5-HPR as template in PCR (primers #911/91, Table 2.2). Db3M6 was generated based on 
scFv3M6 by substituting the VH-linker part with PCR amplified AgeI-VH3M6-linker-BamHI 
containing a GGGGS linker (primers #89/992, Table 2.2). pSecTagAL1-Db323/A3hu3 was 
constructed by substitution of the VH of pSecTagAL1-Dbhu225 with the VH of pAB1-
scFv323/A3hu3 via AgeI/XhoI prior to replacing the VL with PCR amplified BamHI-
VL323/A3hu3-NotI (primers #1212/61, Table 2.2). Db3-43 was cloned by generating AgeI-VH3-
43-linker-BamHI and BamHI-VL3-43-NotI fragments using the sequence synthesized by 
GeneArt® as template in PCR (primers #1245/1246 and #1247/1248, Table 2.2) and 
subsequent transfer into pSecTagAL1. 
 
2.3.3 Cloning of dsDb 
Disulfide-stabilized versions of the diabodies were cloned into pSecTagAL1 for eukaryotic 
expression. One amino acid in the VH domain and one amino acid in the VL domain located at 
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positions allowing the formation of interchain disulfide bonds were specifically mutated to 
cysteines (reviewed by Reiter et al., 1996). One cysteine residue was introduced at position 
44 in the VH domain (Kabat numbering scheme) by fusion-PCR (primers #910/954 and 
#955/956 for hu225, #911/959 and #960/961 for 4D5, #942/1050 and #1051/1052 for 3M6, 
Table 2.2). Another cysteine residue was introduced in the VL domain at position 100 (Kabat 
numbering scheme) by standard PCR (primers #957/958 for hu225, #962/963 for 4D5, 
#1053/1054 for 3M6, Table 2.2). VH and VL domains of the diabodies were sequentially 
substituted with the corresponding mutated domains via AgeI/BamHI and BamHI/NotI 
(hu225, 3M6) or AgeI/BspEI and BspEI/NotI (4D5) digestion, respectively. 
 
2.3.4 Cloning of scFv-EHD2 and scFv-Fc 
ScFv-EHD2 and scFv-Fc fusion proteins were constructed by generation of vectors enabling the 
subsequent insertion of scFv sequences (Figure 2.1). PSecTagAL1 vectors containing 
appropriate restriction sites, linkers, and the respective dimerization modules were 
constructed by PCR, restriction digestion, and ligation steps. ScFv-EHD2 and scFv-Fc molecules 
were generated via transfer of the corresponding scFv as AgeI/NotI fragment into pSecTagAL1-
linker-EHD2-His and pSecTagAL1-linker-Fc, respectively. 
 
Figure 2.1: Schematic representation of relevant vector parts for cloning of scFv-EHD2 and scFv-Fc molecules. 
A) pSecTagAL1-linker-EHD2-His was constructed for generation of scFv-EHD2 fusion proteins. B) pSecTagAL1-
linker-Fc allows generation of scFv-Fc molecules. Amino acid sequences of linkers are shown. Residues originating 
from restriction sites used for cloning are highlighted, and respective restriction enzymes are indicated. L, Igκ 
chain leader sequence. 
 
2.3.5 Cloning of Db-scTRAIL and dsDb-scTRAIL 
All scTRAIL molecules generated in this study contain a single-chain version of TRAIL consisting 
of amino acids 118 to 281 with linkers of a single glycine connecting the TRAIL subunits 
(scTRAIL281-G-118). ScTRAIL was expressed using a pIRESpuro vector that was already available, 
while all other scTRAIL molecules were cloned into pSecTagAL1. For the generation of Db-
scTRAIL and dsDb-scTRAIL fusion proteins, the vector pSecTagFLAG-linker-scTRAIL was 
A) pSecTagAL1-linker-EHD2-His L AAAGGSGG GGSGGASSEHD2 H
is
6
AgeI NotI XhoI
B)  pSecTagAL1-linker-Fc L AAAGGSGG huIgG1 Fc
AgeI NotI
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constructed allowing insertion of Db or dsDb modules (Figure 2.2). The vector was developed 
based on pSecTagFLAG-linker-EHD2-linker (Figure 2.3A) via NotI/EcoRI digestion and ligation 
with PCR amplified NotI-linker-scTRAIL281-G-118-EcoRI (pIRESpuro-L-F-scTRAIL281-G-118 as 
template, primers #1015/1016, Table 2.2). Diabodies and disulfide-stabilized diabodies were 
inserted into pSecTagFLAG-linker-scTRAIL as KpnI/NotI fragments generated by PCR (primers 
#944/91 for hu225, #945/91 for 4D5, #947/91 for 3M6, #1213/91 for 323/A3hu3, #1249/91 
for 3-43, Table 2.2). 
 
Figure 2.2: Schematic representation of the relevant vector part for cloning of Db- and dsDb-scTRAIL molecules. 
Amino acid sequences of the linkers of pSecTagFLAG-linker-scTRAIL are shown. Residues generated by restriction 
sites used for cloning and the respective restriction enzymes are indicated. L, Igκ chain leader sequence. 
 
2.3.6 Cloning of EHD2- and Fc-containing scTRAIL fusion proteins 
Modular vector systems for sequential insertion of scFv and scTRAIL moieties were generated 
for cloning of scFv-EHD2-scTRAIL and scFv-Fc-scTRAIL molecules and their corresponding non-
targeted variants.  
 
Figure 2.3: Schematic representation of relevant vector parts for cloning of EHD2-containing scTRAIL fusion 
proteins. A) pSecTagFLAG-linker-EHD2-linker was used to generate pSecTagFLAG-linker-EHD2-scTRAIL (B) 
allowing the construction of scFv-EHD2-scTRAIL fusion proteins. C) pSecTagFLAG-EHD2-linker was created for 
cloning of pSecTagFLAG-EHD2-scTRAIL (D) to express non-targeting EHD2-scTRAIL. Amino acid sequences of 
linkers are shown. Restriction enzymes and amino acids generated by their corresponding restriction sites are 
highlighted. L, Igκ chain leader sequence. 
 
pSecTagFLAG-linker-scTRAIL L GGGGSGTAAAGGSGG scTRAIL281-G-118
AgeI NotI
FL
A
G
KpnI
L GGGGSGTAAAGGSGG
AgeI NotI
FL
A
G
KpnI
A) pSecTagFLAG-linker-EHD2-linker GGSGGASSEFKLGP
XhoI
EHD2
HindIII
ApaI
EcoRI
L GGGGSGTAAAGGSGG
AgeI NotI
FL
A
G
KpnI
B) pSecTagFLAG-linker-EHD2-scTRAIL GGSGGASSGG
XhoI
EHD2
ApaI
scTRAIL281-G-118
L AAAGGSGG
AgeI NotI
FL
A
G
C) pSecTagFLAG-EHD2-linker GGSGGASSEFKLGP
XhoI
EHD2
HindIII
ApaI
EcoRI
L AAAGGSGG
AgeI NotI
FL
A
G
D) pSecTagFLAG-EHD2-scTRAIL GGSGGASSGG
XhoI
EHD2
EcoRI
scTRAIL281-G-118
  MATERIALS AND METHODS   
  50   
In order to generate scFv-EHD2-scTRAIL fusion proteins, the vector pSecTagFLAG-linker-EHD2-
scTRAIL was constructed based on pSecTagFLAG-linker-EHD2-linker (Figure 2.3B and A) by 
insertion of the PCR fragment XhoI-scTRAIL281-G-118-ApaI (pIRESpuro-L-F-scTRAIL281-G-118 as 
template, primers #987/986, Table 2.2) after digestion with XhoI and partial digestion with 
ApaI. KpnI-scFv-NotI fragments generated by PCR (primers #944/91 for hu225, #945/91 for 
4D5, #947/91 for 3M6, #1213/61 for 323/A3hu3, Table 2.2) were cloned into pSecTagFLAG-
linker-EHD2-scTRAIL. Non-targeted EHD2-scTRAIL was expressed using pSecTagFLAG-EHD2-
scTRAIL that was developed from pSecTagFLAG-EHD2-linker (Figure 2.2D and C) by ligation 
with the PCR-amplified XhoI/EcoRI fragment of scTRAIL281-G-118 (pIRESpuro-L-F-scTRAIL281-G-118 
as template, primers #1019/1016, Table 2.2). 
 
The Fc part used in scTRAIL fusion proteins was derived from human IgG1. Several versions of 
Fc-containing scTRAIL molecules were analyzed before developing the final format. 
PSecTagAL1-linker-Fc-linker (Figure 2.4A) was constructed for insertion of scTRAIL as 
XhoI/ApaI PCR fragment (pIRESpuro-L-F-scTRAIL281-G-118 as template, primers #987/986, Table 
2.2) after digestion with XhoI and partial digestion with ApaI. First versions of scFv-Fc-scTRAIL 
were expressed without a FLAG-tag using pSecTagAL1-linker-Fc-scTRAIL-v1 (Figure 2.4B) after 
ligation with AgeI-scFv-NotI fragments. Characterization of these fusion proteins, however, 
revealed cleavage products. An analysis of potential protease cleavage sites identified several 
candidates in the sequence connecting the Fc part and scTRAIL. Therefore, the sequence was 
optimized by mutation of K447 of the Fc part (EU numbering scheme) to Q and A in the XhoI 
restriction site to G, which removed all potential protease cleavage sites in this sequence part 
(Figure 2.4C). Mutations were introduced by PCR (primers #89/1081, Table 2.2) and 
replacement of the old with the new Fc-linker version by NotI/XhoI digestion. Since 
neutralization of scFv-Fc-scTRAIL fusion proteins after acidic elution from protein A beads led 
to strong precipitation of the protein, the final versions were expressed containing a FLAG-
tag. These FLAG-tagged scFv-Fc-scTRAIL molecules were generated by transferring FLAG-scFv 
fragments of previously generated pSecTagFLAG-scFv-EHD2-scTRAIL sequences to 
pSecTagAL1-linker-Fc-scTRAIL by AgeI/NotI digestion. The final version of non-targeted Fc-
scTRAIL containing a FLAG-tag and the K to Q and A to G mutations (Figure 2.4D) was 
constructed based on pSecTagFLAG-scFv4D5-Fc-scTRAIL by PCR (primers #1210/91, Table 2.2) 
and replacing of scFv4D5-Fc with KpnI-Fc by KpnI/PspXI digestion. 
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Figure 2.4: Schematic representation of relevant vector parts for cloning of Fc-containing scTRAIL molecules. 
A) pSecTagAL1-linker-Fc-linker was generated to develop pSecTagAL1-linker-Fc-scTRAIL-v1 (B). C) pSecTagAL1-
linker-Fc-scTRAIL contains mutations (K to Q and A to G) to remove potential protease cleavage sites. D) 
pSecTagFLAG-Fc-scTRAIL was used to express non-targeted Fc-scTRAIL. Amino acid sequences of linkers are 
represented, and residues generated by restriction sites and their respective enzymes are highlighted. L, Igκ chain 
leader sequence. *, mutation of K447 (EU numbering scheme) of the Fc part to Q. 
 
2.3.7 Cloning of scDb-EHD2-scTRAIL 
Single-chain diabodies (scDbs) combining the selected targeting moieties were generated 
based on existing scDbs by replacing unrequired domains with the desired ones. PSecTagAHis-
scDbhu225x3M6 was constructed using pSecTagAHis-scDbhu225xCD3 by exchanging the anti-
CD3 domains with XhoI-linker-VL3M6-linker-SgsI and SgsI-linker-VH3M6-linker-BamHI 
(pSecTagAL1-Db3M6 as template, primers #1214/1215 and #1216/1217, respectively, Table 
2.2). PSecTagAHis-scDb4D5xhu225 was already available and furthermore used to generate 
pSecTagAHis-scDb4D5x3M6 by replacing the hu225 moieties with the 3M6 PCR fragments 
described above. Sfi/XhoI and BamHI/NotI digestions were used to exchange VH and VL MocB 
domains of pSecTagAHis-scDbMocBxhu225 with the domains derived from pAB1-
scFv323/A3hu3 to construct pSecTagAHis-scDb323/A3hu3xhu225. Single-chain diabodies 
were transferred from pSecTagAHis to pSecTagFLAG-linker-EHD2-scTRAIL (Figure 2.3B) as 
KpnI/NotI fragments adding the KpnI restriction site by PCR (primers #944/91 for hu225x3M6, 
#945/91 for 4D5xhu225 and 4D5x3M6, #1213/91 for 323/A3hu3xhu225, Table 2.2). 
 
2.4 Prokaryotic protein production 
ScFvs were expressed in the periplasm of E. coli TG1. 20 ml 2xTY medium containing 1 % (w/v) 
glucose and 100 µg/ml ampicillin were inoculated with pAB1-scFv transformed bacteria and 
A)  pSecTagAL1-linker-Fc-linker L AAAGGSGG
AgeI NotI
B) pSecTagAL1-linker-Fc-scTRAIL-v1
C) pSecTagAL1-linker-Fc-scTRAIL
GGSGGASSGP
XhoI ApaI
huIgG1 Fc
L AAAGGSGG
AgeI NotI
GGSGGASSGG
XhoI
huIgG1 Fc
ApaI
scTRAIL281-G-118
L AAAGGSGG
AgeI NotI
GGSGGGSSGG
XhoI
huIgG1 Fc*
ApaI
scTRAIL281-G-118
L GGGGSGT
AgeI KpnI
FL
A
G
D) pSecTagFLAG-Fc-scTRAIL GGSGGGSSGG
PspXI ApaI
scTRAIL281-G-118huIgG1 Fc
*
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incubated shaking at 37 °C. The next day, 10 ml of the overnight culture were added to 1 l 
2xTY supplemented with 0.1 % (w/v) glucose and 100 µg/ml ampicillin and incubated shaking 
at 37 °C until the optical density measured at 600 nm reached 0.8 to 1.0 (exponential growth 
phase). After addition of IPTG to a final concentration of 1 mM to induce periplasmic protein 
expression, incubation was continued shaking at room temperature for 3 h. Cells were 
harvested by centrifugation (6,200 g, 10 min) and resuspended in 50 ml PPB. Lysozyme 
(50 µg/ml) was used to hydrolyze the bacterial cell wall. The cell suspension was incubated on 
ice for 30 min, followed by addition of MgSO4 (10 mM) to stabilize the spheroblasts and 
another centrifugation step (9,820 g, 10 min). The protein-containing supernatant was 
dialyzed against 5 l 1xPBS at 4 °C overnight. After centrifugation (9,820 g, 10 min), proteins 
were purified from the dialyzed supernatant via IMAC (see 2.6.1). 
 
2.5 Cell culture 
2.5.1 General cultivation techniques 
All cells were cultivated in a humidified atmosphere containing 5 % CO2 at 37 °C. HEK293T cells 
were grown in RPMI 1640 medium (+ L-glutamine) with 5 % FBS, while all other cell lines were 
cultivated in RPMI 1640 medium (+L-glutamine) supplemented with 10 % FBS. Cell passaging 
was typically performed every two to three days depending on the confluence. Prior to 
detachment of the cells by addition of 1x Trypsin-EDTA (37 °C, up to 5 min depending on the 
cell line), cells were washed with DPBS. Detached cells were resuspended in medium and 
harvested by centrifugation (500 g, 5 min). In order to count the cells using a Neubauer 
chamber, the cell suspension was mixed 1:2 with eosin staining solution to discriminate viable 
and dead cells. Cells were stored in FBS containing 10 % (v/v) dimethyl sulfoxide at -80 °C after 
gentle cooling in an isopropanol-filled cryobox. Frozen cells were thawed at 37 °C, 
resuspended in medium, centrifuged (500 g, 5 min), and cultivated in appropriate medium. 
 
2.5.2 Transfection and selection of stably transfected clones 
Eukaryotic protein expression with transfected HEK293T cells was used for production of all 
recombinant antibodies and fusion proteins, except for scFvs. 1∙106 cells per well were seeded 
into 6-well plates in 2 ml culture medium. The next day, medium was replaced by 1.7 ml Opti-
MEM®. Transfection solutions A (6.7 µl Lipofectamine® 2000, 166 µl Opti-MEM®) and B (2.7 µg 
DNA, 166 µl Opti-MEM®) were prepared, mixed, incubated for 20 min at room temperature, 
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and added drop by drop to the cells. After cultivation for 6 h up to overnight, transfection 
medium was removed and cells were transferred to 25 cm2 cell culture flasks containing 
culture medium. Before adding Zeocin™ (300 µg/ml) or Puromycin (10 µg/ml) to select for 
stably transfected clones, cells were cultivated for at least 6 h. Medium was regularly replaced 
until untransfected cells had died and transfected cells started to grow. Cells were stepwise 
expanded for protein production and storage of a fraction of the cells at -80 °C. Cell pools 
expressing EGFR-targeting scTRAIL fusion proteins, EHD2-scTRAIL, and Fc-scTRAIL were 
furthermore subjected to limiting dilution cloning. Suspensions of the cell pools were serially 
diluted to concentrations of 25 cells/ml and 50 cells/ml. Cell suspensions of each 
concentration were seeded into 96-well plates (200 µl/well, 1 plate/concentration). Cells 
were cultivated until clones started to grow. Supernatants of grown clones were analyzed for 
protein expression in ELISA (see 2.8) and clones were stepwise expanded. Up to 8 clones per 
protein were selected for further analysis. 1∙106 cells of each clone were seeded per well into 
6-well plates. After 24 h, culture medium was replaced by production medium and cells were 
cultivated for another 24 h. Supernatants were analyzed in ELISA for the amount of expressed 
protein. The two most promising clones of each construct were selected and expanded to one 
TripleFlask™ for protein production, purification and determination of the protein yield. Final 
protein production was performed with the clone showing best production properties. 
 
2.5.3 Eukaryotic protein production 
Stably transfected HEK293T cells were expanded to a number of 175 cm2 cell culture flasks or 
TripleFlasks™ depending on the required protein amount (at least six 175 cm2 cell culture 
flasks or two TripleFlasks™). During expansion, concentrations of 50 µg/ml Zeocin™ and 
10 µg/ml Puromycin were used. After reaching approximately 80 % confluence, medium was 
removed, cells were washed with DPBS, and production medium was added (30 ml per 
175 cm2 cell culture flask, 100 ml per TripleFlask™). Opti-MEM® was used for production of 
recombinant antibodies. Expression of scTRAIL fusion proteins required Opti-MEM® 
supplemented with 50 µM ZnCl2. Production medium was replaced every two to four days up 
to five times. Collected supernatant was cleared from cells by centrifugation (500 g, 5 min) 
and stored at 4 °C. Depending on their amount, detached cells were transferred back to the 
cell culture flasks. To reduce the volume of the collected supernatant, ammonium sulfate 
(390 g/l) was added stepwise to the filtered supernatant to precipitate the proteins, while 
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stirring at 4 °C. Precipitated proteins were pelleted by centrifugation (11,250 g, 1 h, 4 °C), 
resuspended in at least 10 ml DPBS (depending on the supernatant volume), and optionally 
dialyzed against 5 l PBS overnight at 4 °C. Proteins were then purified via IMAC, protein A or 
FLAG affinity chromatography (see 2.6.1, 2.6.2, and 2.6.3, respectively). 
 
2.6 Purification of recombinant proteins 
2.6.1 Immobilized metal ion affinity chromatography 
His-tagged proteins were purified from dialyzed periplasmic preparations or resuspended 
precipitates of cell culture supernatants via immobilized metal ion affinity chromatography 
(IMAC). 0.5 ml of equilibrated Ni-NTA agarose was added to the protein solution and 
incubated rolling for at least 3 h at 4 °C. The suspension was then transferred to a 
chromatography column to separate protein-loaded Ni-NTA agarose from the flow-through. 
Unspecifically bound proteins were removed using IMAC wash buffer, and washing progress 
was monitored qualitatively by Bradford assay (10 µl sample, 90 µl 1x Bradford solution). Ni-
NTA agarose-bound protein was eluted in 500 µl fractions with IMAC elution buffer. The 
protein concentration of the eluted fractions was analyzed by Bradford assay as described 
above. Protein-containing fractions were pooled and dialyzed against 5 l PBS overnight at 4 °C. 
 
2.6.2 Protein A affinity chromatography 
Antibody- and receptor-Fc fusion proteins were purified via protein A affinity 
chromatography. 0.25 ml protein A affinity resin were added to the resuspended precipitate 
of a cell culture supernatant and incubated rolling overnight at 4 C. The resin was collected in 
chromatography columns and washed with protein A wash buffer to remove unbound 
proteins. Qualitative Bradford assay was used to determine the protein amount in wash and 
elution fractions as described above (see 2.6.1). Elution was performed in 500 µl fractions 
using protein A elution buffer. Protein-rich fractions were pooled and dialyzed against 5 l PBS 
overnight at 4 °C. 
 
2.6.3 FLAG affinity chromatography 
All scTRAIL molecules were purified via FLAG affinity chromatography. Depending on the 
volume of collected cell culture supernatant, 1.5 ml to 4 ml anti-FLAG® M2 affinity resin were 
used. Prior to addition to the resuspended cell culture supernatant precipitate, the affinity gel 
  MATERIALS AND METHODS   
  55   
was equilibrated by three sequential washing steps with 100 mM glycin HCl, pH 3.5 and 
another five washing rounds with DPBS. To capture the target protein, protein solution and 
affinity resin were incubated rolling at 4 °C for at least 2 h up to overnight. The resin was 
collected by centrifugation (1,000 g, 5 min) and subsequent transfer to a chromatography 
column. Washing was performed using DPBS as wash buffer. Wash and elution steps were 
analyzed by qualitative Bradford assay as described above (see 2.6.1). Resin-bound protein 
was eluted with DPBS containing 100 µg/ml FLAG peptide. The elution progress was 
continuously monitored to collect the complete protein-containing eluate, which was dialyzed 
against 5 l PBS overnight at 4 °C. To recycle the affinity gel, equilibration was repeated, and 
resin was stored in 50 % (v/v) glycerol in PBS containing 0.02 % sodium azide at 4 °C. 
 
2.6.4 Preparative size exclusion chromatography 
Purified proteins were analyzed by size exclusion HPLC (see 2.7.3). Protein eluates containing 
considerable amounts of aggregates, fractions with wrong oligomerization status, or cleavage 
products were further purified by size exclusion FPLC. Concentrated protein was applied on a 
Superdex 200 10/300 GL column using PBS as mobile phase and a flow rate of 0.5 ml/min. 
Protein was collected in 100 µl to 250 µl fractions. Fractions containing the desired protein 
configuration were pooled. Preparative size exclusion chromatography was performed by 
Doris Göttsch (Institute of Cell Biology and Immunology, University of Stuttgart, Germany). 
 
2.7 Biochemical characterization of recombinant proteins 
2.7.1 Protein concentration 
Protein concentration (𝑐 in mg/ml) was determined by measuring the absorption at 280 nm 
(𝐴) with a NanoDrop™ ND-1000 spectrophotometer and using the molecular mass (𝑀 in 
mg/µmol) and extinction coefficient (𝜀 in ml/(µmol∙cm)) of the respective protein in the Beer-
Lambert equation (𝑐 =
𝐴∙𝑀
𝜀∙𝑑
 with 𝑑 being the path length in cm). The molecular weight and the 
extinction coefficient were calculated with the ExPASy ProtParam tool. Optionally, protein 
solutions were concentrated using Vivaspin 500, 30,000 MWCO PES centrifugal filters. 
 
2.7.2 SDS polyacrylamide gel electrophoresis 
Protein purity and integrity was analyzed by SDS polyacrylamide gel electrophoresis (SDS-
PAGE). Depending on the expected molecular weight of the protein, 8 %, 10 %, or 12 % 
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polyacrylamide (PAA)-containing gels were prepared (Table 2.3). Protein samples (2 µg 
protein) were mixed with Laemmli loading buffer (reducing or non-reducing, final 
concentration 1x) and incubated for 5 min at 95 °C, prior to loading on the gel together with 
PageRuler™ prestained protein ladder. Electrophoresis was performed with SDS-PAGE running 
buffer and a constant current of 40 mA/gel. After three rounds of boiling in demineralized 
water, gels were incubated in Coomassie staining solution for at least 1 h at room 
temperature. Excess staining was removed by incubation in demineralized water. 
 
Table 2.3: Composition of SDS polyacrylamide gels. Described volumes are sufficient for two gels. 
Component Stacking gel Separating gel   
 5 % PAA 8 % PAA 10 % PAA 12 % PAA 
ddH2O 4.1 ml 6.9 5.9 ml 4.9 ml 
30 % acrylamide mix 1.0 ml 4 ml 5.0 ml 6.0 ml 
1.5 M Tris-HCl pH 8.0 – 3.8 ml 3.8 ml 3.8 ml 
1 M Tris-HCl pH 6.8 0.75 ml – – – 
10 % SDS 0.06 ml 0.15 ml 0.15 ml 0.15 ml 
10 % APS 0.06 ml 0.15 ml 0.15 ml 0.15 ml 
TEMED 0.006 ml 0.009 ml 0.006 ml 0.006 ml 
 
2.7.3 Analytical size exclusion chromatography 
Measuring the hydrodynamic radius by size exclusion HPLC, protein purity, integrity, and the 
oligomerization status were analyzed under native conditions. 20 µl protein sample 
(0.1 mg/ml to 0.5 mg/ml) were injected onto a Yarra™ 3 µm SEC-2000 or -3000 HPLC column 
using a Waters 2695 Separations Module and a Waters 2489 UV/Visible Detector. Size 
exclusion HPLC was performed with 0.1 M Na2HPO4/NaH2PO4, 0.1 M Na2SO4, pH 6.7 as mobile 
phase at a flow rate of 0.5 ml/min. Thyroglobulin (669 kDa, 8.5 nm), β-amylase (200 kDa, 
5.4 nM), bovine serum albumin (67 kDa, 3.55 nm), carbonic anhydrase (29 kDa, 2.35 nm), and 
FLAG peptide (1 kDa) were used as reference molecules. Alternatively, a mixture of 
thyroglobulin (669 kDa, 8.5 nm), apoferritin (443 kDa, 6.1 nM), alcohol dehydrogenase 
(150 kDa), bovine serum albumin (67 kDa, 3.55 nm), carbonic anhydrase (29 kDa, 2.35 nm), 
and FLAG peptide (1 kDa) was applied. 
 
2.7.4 Thermal stability 
Thermal stability of the proteins was analyzed by dynamic light scattering using a Zetasizer 
Nano ZS. 100 µg protein in 1 ml PBS were sterile filtered into a glass cuvette before measuring 
the particle size in a temperature range of 35 °C to 90 °C in 1 °C intervals. Measurements were 
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performed twice at each temperature after equilibration of the sample for 2 min. The melting 
point was defined as the temperature showing a clear increase in the detected mean count 
rate. 
 
2.8 Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) was used to analyze binding of recombinant 
antibodies and fusions proteins to their respective antigens and target receptors. 
Furthermore, protein concentrations in cell culture supernatants, in plasma and in serum 
samples were measured by ELISA to determine high-producer clones, plasma stability and 
pharmacokinetics, respectively. Soluble antigen or receptor-Fc fusion proteins (200 ng/well or 
300 ng/well in 100 µl, as indicated) were coated overnight at 4 °C. After washing with PBS, 
remaining binding sites were blocked with 2 % MPBS (200 µl/well) for at least 1 h at room 
temperature. After another washing step with PBS, samples diluted in 2 % MPBS were added 
in duplicates (100 µl/well) and incubated for at least 1 h at room temperature. Depending on 
the analyzed protein, anti-His-HRP, anti-scDbCEAxCD3-PEG and anti-rabbit-POD, protein L-
HRP, or anti-FLAG-HRP were used for detection (for dilutions, see Table 2.1). Two washing 
steps with PBST (0.005 % TWEEN 20) and one with PBS were performed before adding 
detection antibody diluted in 2 % MPBS (100 µl/well, incubation for at least 1 h at room 
temperature). The before-mentioned washing procedure with PBST (0.005 % TWEEN 20) and 
PBS was repeated and 100 µl/well substrate solution (100 mM sodium acetate pH 6.0, 
0.1 mg/ml TMB, 0.006 % (v/v) H2O2) were added. Using anti-scDbCEAxCD3-PEG and anti-
rabbit-POD as detection system, another washing and incubation step were performed prior 
to detection. Reaction was stopped with 50 µl/well 1 M H2SO4. Optical density at 450 nm was 
measured using an Infinite M200 microplate reader. 
 
2.9 Flow cytometry 
2.9.1 Determination of expression levels 
Relative expression levels were determined by flow cytometry. 250,000 cells/well were 
seeded in 96-well U-bottom plates and incubated with 100 µl detection antibody diluted in 
PBA for 1 h at 4 °C. Detection of TAAs and TRAIL receptors was done either with directly 
labeled antibodies or using unlabeled primary antibodies, followed by a washing step and 
incubation with a labeled secondary antibody (for dilutions, see Table 2.1). Respective controls 
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were included, and all samples were investigated in duplicates. Washing was performed by 
centrifugation (500 g, 5 min) and resuspension of the cell pellet in 150 µl PBA two times. 
Finally, washed and pelleted cells were analyzed in 150 µl PBA using MACSQuant® Analyzer 
10 (approximately 15,000 cells/gate). 
 
2.9.2 Binding studies 
Binding of recombinant antibodies and fusion proteins to antigen- and TRAIL receptor-
expressing cells was evaluated by flow cytometry. 250,000 cells/well were seeded in 96-well 
U-bottom plates. Dilutions of the proteins in PBA were titrated on the cells in duplicates and 
incubated for 1 h at 4 °C. Prior to addition of detection antibody diluted in PBA (100 µl/well), 
washing was performed as described above (see 2.9.1). Depending on the analyzed protein, 
anti-His-PE, anti-human IgG γ-chain specific-PE, or anti-FLAG-PE were used for detection of 
bound proteins and respective controls (for dilutions, see Table 2.1). After another washing 
step, cells were analyzed in 150 µl PBA using MACSQuant® Analyzer 10 or MACSQuant® VYB 
(approximately 15,000 cells/gate). ScTRAIL molecules were furthermore investigated, while 
binding of the antibody part was blocked. Before adding 25 µl of the scTRAIL molecule (20 nM 
scTRAIL units final concentration, 1 h, 4 °C), cells were preincubated with 75 µl of blocking 
antibody (200-fold molar excess final concentration) or PBA for comparison with unblocked 
binding (30 min, 4 °C). Bound scTRAIL molecules were detected via their FLAG-tag. Relative 
median fluorescence intensities (𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑀𝐹𝐼) were calculated based on the MFI of cells 
incubated with analyzed protein and detection system (𝑀𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒), the MFI of cells treated 
only with detection system (𝑀𝐹𝐼𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑦𝑠𝑡𝑒𝑚), and the MFI of cells alone (𝑀𝐹𝐼𝑐𝑒𝑙𝑙𝑠): 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑀𝐹𝐼 =
𝑀𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒 − (𝑀𝐹𝐼𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑦𝑠𝑡𝑒𝑚 − 𝑀𝐹𝐼𝑐𝑒𝑙𝑙𝑠)
𝑀𝐹𝐼𝑐𝑒𝑙𝑙𝑠
 
 
2.10 Cell death induction analysis 
Effects of recombinant antibodies and scTRAIL molecules on Colo205 and HCT116 cells were 
analyzed by crystal violet staining. 50,000 Colo205 cells/well or 15,000 HCT116 cells/well were 
seeded in 100 µl medium (RPMI 1640, 10 % FBS, P/S) in 96-well F-bottom plates and incubated 
for 24 h at 37 °C, 5 % CO2. After preincubation of the cells with 50 µl/well of medium or 
bortezomib (250 ng/ml final concentration corresponding to 650 nM) for 30 min at 37 °C, 5 % 
CO2, serial dilutions of the proteins in medium (50 µl/well) were added in duplicates or 
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triplicates. Control wells were treated with 50 µl Triton X-100 (0.25 % final concentration). 
Cells were incubated for 16 h at 37 °C, 5 % CO2, prior to detection of viable cells with crystal 
violet staining solution (50 µl/well, 20 min, room temperature). Excess staining was removed 
by washing with demineralized water. Dried staining was dissolved in 50 µl/well methanol by 
shaking for 30 min at room temperature. Viable cells were quantified by measuring the optical 
density at 550 nm and normalization to medium- or bortezomib-treated controls. 
Recombinant antibodies were only investigated on Colo205 cells in the absence of 
bortezomib. In order to examine the targeting effects of the antibody moiety, the scTRAIL 
molecules were furthermore analyzed in the presence of a blocking antibody. Cells were 
preincubated with a 200-fold molar excess of blocking antibody (final concentration) in 
medium or medium additionally containing bortezomib (250 ng/ml final conectration, 
50 µl/well, 30 min, 37 °C, 5 % CO2). Subsequent treatment with scTRAIL constructs and 
determination of viable cells was done as described above. Experiments performed with 
varying incubation times and bortezomib concentrations are indicated. 
 
2.11 Caspase activity assay 
15,000 Colo205 cells/well were seeded in 100 µl medium (RPMI 1640, 10 % FBS, P/S) in white-
walled 96-well F-bottom plates and cultivated for 24 h at 37 °C, 5 % CO2. Medium was 
removed and cells were preincubated with 60 µl medium or bortezomib (250 ng/ml final 
concentration) for 30 min at 37 °C, 5 % CO2, prior to addition of scTRAIL molecules (20 µl) in 
duplicates. After varying incubation times, caspase-8 and -3/7 activities were determined 
using Caspase-Glo® 8 Assay and Caspase-Glo® 3/7 Assay according to the manufacturer’s 
instructions. The measured luminescence signal is proportional to the amount of caspase 
activity. Luminescence signals detected 60 min and 30 min after addition of the reagent were 
used for data evaluation of caspase-8 and -3/7 activity, respectively. 
 
2.12 Protein stability 
2.12.1 In vitro plasma stability 
Stability in human plasma was analyzed for EGFR-targeting and non-targeted scTRAIL 
molecules. Proteins were diluted to a final concentration of 100 nM scTRAIL units in 50 % 
human plasma and either directly stored at -20 °C (0 d value) or incubated at 37 °C for 1 d, 3 d, 
and 7 d prior to storage at -20 °C. Levels of intact protein were determined by binding of the 
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C-terminal scTRAIL moiety to TRAIL-R2 and detection via the N-terminal FLAG-tag in ELISA. 
200 ng TRAIL-R2-Fc were coated per well and ELISA was performed as already described (see 
2.8). Different dilutions of the construct-containing plasma samples were analyzed 
simultaneously to a serial dilution of the purified protein. Protein concentrations in the plasma 
samples were determined by interpolation from the standard curve and under consideration 
of the dilution factor. For final evaluation, concentrations were normalized to the 0 d value. 
 
2.12.2 In vivo pharmacokinetics 
Animal care and all pharmacokinetic experiments were in accordance with federal and 
European guidelines and have been approved by university and state authorities. In vivo 
pharmacokinetics were analyzed for EGFR-targeting and non-targeted scTRAIL molecules, as 
well as scFvhu225-Fc and cetuximab. 25 µg or 50 µg protein (in 150 µl PBS) were injected into 
the tail vein of female CD-1® mice (8 to16 weeks old, 25 g to 35 g, 3 or 6 mice per molecule). 
Blood samples (50 µl) were taken from the tail (3 min, 30 min, 1 h, 2 h, 6 h, 1 d, 3 d, and 7 d 
after injection or alternatively after 3 min, 30 min, 2 h, 6 h, 12 h, 1 d, 3 d, 7 d) and incubated 
on ice for 30 min, prior to centrifugation (13,000 g, 30 min, 4 °C). Serum samples were stored 
at -20 °C. Serum concentrations of scTRAIL constructs were determined using BD OptEIA™ 
human TRAIL ELISA Set as recommended by the manufacturer. Serum samples of scFvhu225-
Fc and cetuximab were analyzed by binding to EGFR-Fc (300 ng/well) in ELISA as already 
described (see 2.8). ScFvhu225-Fc was detected with anti-scDbCEAxCD3-PEG serum and anti-
rabbit IgG-POD, while detection of cetuximab was performed using HRP-conjugated protein L 
(for dilutions, see Table 2.1). Serum concentrations of all proteins were interpolated from a 
standard curve of the purified protein and normalized to the 3 min value. Initial and terminal 
half-lives (t1/2α, t1/2β) and AUC were calculated with Microsoft Excel. Initial half-lives were 
calculated over the time interval of 3 min to 2 h. Terminal half-lives were calculated starting 
with the serum concentration at 6 h. 
 
2.13 Pharmacodynamics and toxicity 
Animal care and all pharmacodynamic experiments were in accordance with federal and 
European guidelines and have been approved by university and state authorities. 
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2.13.1 Colo205 xenograft model 
A Colo205 xenograft model was used in all experimental settings to analyze the in vivo 
therapeutic activity of the scTRAIL fusion proteins. 3∙106 Colo205 cells (in 100 µl DPBS) were 
injected subcutaneously into the left and right flank of female NMRI nude mice. Tumor growth 
was monitored by measuring the length (𝑎) and width (𝑏) of the tumors with a caliper to 
calculate the tumor volume (𝑉 = 𝑎 ∙ 𝑏2 2⁄ ). Upon reaching a size of approximately 100 cm3, 
treatment was started. Bortezomib (in 150 µl DPBS) was injected intraperitoneally, whereas 
injections of fusion proteins (in 150 µl DPBS) were done intravenously. Control animals 
received respective injections of 150 µl DPBS. 
 
A first experiment was performed to analyze the anti-tumor activity of bortezomib. Mice 
(8 weeks old, 4 mice for PBS, 5 mice for bortezomib) received six injections of either DPBS or 
5 µg bortezomib every other day starting at day 12 (days 12, 14, 16, 18, 20, 22). In a second 
experiment, different formats of EGFR-targeting scTRAIL fusion proteins and Fc-scTRAIL were 
compared under simultaneous application of bortezomib. Mice (10 weeks old, 6 mice per 
group) received six treatments with 5 µg bortezomib and 0.5 nmol protein (1 nmol scTRAIL 
units). After three treatments every other day (starting at day 13), treatment intervals were 
gradually increased by one day (days 13, 15, 17, 20, 24, 29). Blood samples were taken 3 min, 
4 h, 24 h, and 48 h after the first and last treatment, and serum levels of the proteins were 
determined as already described (see 2.12.2). Blood samples taken 4 h and 24 h after the first 
and the last treatment were furthermore analyzed for alanine transaminase (ALT) and amylase 
activity (see 2.13.2 and 2.13.3, respectively). A third experiment was performed to further 
compare scFvhu225-Fc-scTRAIL and Fc-scTRAIL, both in co-treatment with bortezomib. 
Treatment of the mice (10 weeks old, 6 mice per group) with 5 µg bortezomib and 0.3 nmol 
or 0.1 nmol protein (0.6 nmol or 0.2 nmol scTRAIL units) started at day 14 and was repeated 
twice a week (corresponding to every fourth and third day, respectively) for three weeks (days 
14, 18, 21, 25, 28, 32). Blood samples were collected 3 min, 4 h, and 24 h after the first 
treatment to determine the serum concentrations of the proteins (see 2.12.2). In a final 
experiment, several formats of EGFR-targeting scTRAIL fusion proteins, scFv-Fc-scTRAIL 
molecules with different targeting moieties, and Fc-scTRAIL were compared without 
simultaneous application of bortezomib. Mice (9 or 11 weeks old, 6 mice per group) were 
treated with 0.2 nmol protein (0.4 nmol scTRAIL units) twice a week for three weeks (days 14, 
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18, 21, 25, 28, 32). Blood samples were taken 4 h and 24 h after the last treatment to analyze 
protein and ALT levels (see 2.12.2 and 2.13.2, respectively). 
 
2.13.2 Alanine transaminase activity assay 
Serum levels of alanine transaminase (ALT) were analyzed to detect potential liver toxicity. 
Blood samples taken during the pharmacodynamic experiments (see 2.13.1) were incubated 
on ice for 30 min prior to centrifugation (13,000 g, 30 min, 4 °C) and storage of the serum at 
4 °C. ALT levels were determined using Alanine Transaminase Activity Assay kit according to 
the manufacturer’s instructions. 5 µl or 10 µl of serum were applied. 
 
2.13.3 Amylase activity assay 
Potential induction of pancreatic and renal toxicity was evaluated by determination of 
amylase levels in the serum. Blood samples were collected and treated as already described 
(see 2.13.2). Amylase activity in the serum was detected using Amylase Assay kit as 
recommended by the manufacturer. 5 µl of serum were analyzed. 
 
2.14 Statistics 
Data are represented as mean ± standard deviation of at least three independent 
experiments, except for tumor volumes that are shown as mean ± 95 % confidence interval. 
Pairwise and multiple comparisons were performed by GraphPad Prism® implemented 
unpaired t test (two-tailed) and One-Way ANOVA, followed by Tukey’s post hoc test, 
respectively. A P value of <0.05 was considered statistically significant (*P<0.05; **P<0.01; 
***P<0.001; ns, P>0.05). 
 
Block shift was only applied when compensation of variabilities, e.g. in optical densities due 
to differences in ELISA developing times, was necessary and is clearly indicated. The corrected 
value of the experiment n (𝑋𝑛
′ ) was calculated from the measured value of experiment n (𝑋𝑛), 
the duplicate average of experiment n (𝑌𝑛), and the average of all measured values of all 
experiments (?̅?) using the equation 𝑋𝑛
′ = 𝑋𝑛 − (𝑌𝑛 − ?̅?).  
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3 Results 
3.1 Generation and characterization of dimeric recombinant antibody 
formats 
As outlined before, previous studies have shown that antibody-targeted scTRAIL fusion 
proteins (Schneider et al., 2010) and especially dimeric formats (Siegemund et al., 2012; 
Seifert et al., 2014a) possess a considerably higher activity than untargeted monomeric 
scTRAIL versions. Thus, the first part of this study was subjected to the generation and 
characterization of different recombinant antibody formats suitable as fusion partner for 
scTRAIL. Based on the monomeric scFv, two concepts for the formation of dimeric antibodies 
were used. On the one hand, an scFv can be forced into a non-covalent assembly of two chains 
by reducing the linker length from 15 to 5 amino acid residues ((GGGGS)3 to GGGGS) 
generating a diabody (Db; Holliger et al., 1993). On the other hand, dimeric assembly can be 
achieved by fusion of an scFv to a dimerization module (Figure 3.1). Further stabilization of 
the non-covalently associated chains in the diabody can be achieved by mutation of the amino 
acid residues at position 44 in the VH and position 100 in the VL (Kabat numbering scheme) to 
cysteines (reviewed by Reiter et al., 1996). Located at these positions, the cysteine residues 
have an appropriate distance and orientation enabling the formation of interchain disulfide 
bonds to covalently connect the two chains creating a disulfide-stabilized diabody (dsDb). As 
dimerization modules, the domain 2 of the heavy chain of IgE (EHD2) and a human IgG1 Fc 
part were used. Fusion of an scFv to the N-terminus of these modules generated scFv-EHD2 
and scFv-Fc fusion proteins. Characterization of the different antibody formats, i.e. scFv, Db, 
dsDb, scFv-EHD2, and scFv-Fc, was performed for several targeting moieties including variants 
directed against EGFR, HER2, HER3, and EpCAM. The scFv molecules were analyzed as 
monomeric reference and produced in the periplasm of E. coli TG1, while all other formats 
were produced with stably transfected HEK293T cells and secreted into the supernatant. All 
proteins were expressed comprising a C-terminal His-tag for purification via immobilized 
metal ion affinity chromatography (IMAC), except for the scFv-Fc molecules that were 
expressed tagless and purified by protein A affinity chromatography. 
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Figure 3.1: Overview of different recombinant antibody formats.  A) Composition and B) schematic assembly of 
scFv, Db, dsDb, scFv-EHD2, and scFv-Fc. The concepts for the generation of dimeric antibody formats based on 
the monomeric scFv are illustrated. L, pelB leader sequence (scFv) or Igκ chain leader sequence (Db, dsDb, scFv-
EHD2, scFv-Fc). L1, (GGGGS)3 linker. L2, GGGGS linker. L3, AAAGGSGG linker. L4, GGSGGASS linker. 
 
3.1.1 EGFR-targeting recombinant antibodies 
The targeting moiety hu225 used to generate antibodies directed against EGFR was derived 
from cetuximab (antibody C225, Goldstein et al., 1995) and humanized by CDR grafting (Seifert 
et al., 2012). The different formats of EGFR-targeting antibodies were produced with yields of 
1.4 (scFvhu225, dsDbhu225) up to 6.5 mg protein (scFvhu225-Fc) per liter bacterial culture or 
cell culture supernatant, respectively (Table 3.1). Purity and integrity of the molecules was 
verified by SDS-PAGE. Under reducing conditions, all proteins migrated according to their 
monomeric molecular masses as single bands, except for scFvhu225-EHD2 that showed two 
bands of similar size (Figure 3.2A). As demonstrated by previous studies, these differences 
arise from variations in the glycosylation status (Seifert, 2014). Under non-reducing 
conditions, the expected disulfide-linked dimers were observed for the dsDb, scFv-EHD2, and 
scFv-Fc formats (Figure 3.2B). Additionally, some high molecular weight species were found 
for dsDbhu225, and a small amount of the monomeric form was seen for scFvhu225-EHD2 
that was even lower for scFvhu225-Fc. The thermal stability of the different formats was 
analyzed by dynamic light scattering revealing a melting point of 64 °C for scFvhu225 (Figure 
3.2C, Table 3.1), whereas the diabody exhibited decreased stability (57 °C) that was improved 
by disulfide-stabilization (61 °C). A melting point of 64 °C was detected for scFvhu225-EHD2, 
while fusion to the Fc part further stabilized the protein (66 °C). 
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Figure 3.2: Biochemical characterization of EGFR-targeting recombinant antibodies. SDS-PAGE analysis (12 % 
PAA) of scFvhu225 (1), Dbhu225 (2), dsDbhu225 (3), scFvhu225-EHD2 (4), and scFvhu225-Fc (5) was performed 
under reducing (A) and non-reducing conditions (B). 2 µg of each protein were analyzed per lane and stained 
with Coomassie Brilliant Blue. M, protein marker. C) Thermal stability was determined by dynamic light 
scattering. Melting points [°C] are indicated with dotted lines. Measurements were performed once for each 
protein. Melting curves of Dbhu225 (black) and dsDbhu225 (gray) are shown in one graph. 
 
Evaluation of the binding properties of the different formats was done by ELISA (Figure 3.3A). 
All molecules showed concentration-dependent binding to EGFR with EC50 values in the 
subnanomolar range (Table 3.1). EC50 values refer to the concentration of functional binding 
sites. Further investigations of binding were performed with EGFR-expressing A-431 cells via 
flow cytometry (Figure 3.3B). Comparable binding curves were determined for all formats 
revealing half-maximal binding at concentrations of 0.9 nM to 1.9 nM (Table 3.1). Since 
Colo205 cells were used for in vitro and in vivo characterization of the corresponding antibody-
scTRAIL fusion proteins, effects of the recombinant antibodies on this cell line were examined. 
In a concentration range of 1 pM to 10 nM, no influence on cell viability was seen (Figure 3.3C). 
In summary, these data confirm the suitability of all formats for targeting of EGFR. 
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Figure 3.3: Binding analysis of EGFR-targeting recombinant antibodies and effects on Colo205 cells. A) Binding 
to EGFR-Fc (200 ng/well) was investigated by ELISA. Bound molecules were detected via anti-His-HRP. Optical 
densities (at 450 nm) were normalized to the value determined for the highest concentration. B) Binding to EGFR-
expressing A-431 cells was analyzed by flow cytometry, detecting cell-bound proteins with an anti-His-PE or anti-
human IgG (γ-chain specific)-PE. C) Colo205 cells (50,000/well) were treated with serial dilutions of the proteins 
for 16 h. Viable cells were stained with crystal violet. Concentrations refer to functional binding sites. 
 
Table 3.1: Biochemical and binding properties of EGFR-targeting recombinant antibodies. The molecular 
masses (M) were calculated based on the amino acid sequences. Yields are expressed as mg protein per l bacterial 
culture or cell culture supernatant. Binding to EGFR-Fc and A-431 cells was determined by ELISA and flow 
cytometry, respectively. EC50 values refer to concentrations of functional binding sites. 
Protein M [kDa] Yield [mg/l] TM [°C] EC50 EGFR [nM] EC50 A-431 [nM] 
scFvhu225 28 1.4 64 0.8 ± 0.2 1.9 ± 0.2 
Dbhu225 52 1.7 57 0.5 ± 0.1 1.1 ± 0.1 
dsDbhu225 53 1.4 61 0.3 ± 0.05 1.0 ± 0.04 
scFvhu225-EHD2 79 2.3 64 0.7 ± 0.1 0.9 ± 0.1 
scFvhu225-Fc 104 6.5 66 n.d. 1.3 ± 0.1 
n.d., not determined. 
 
3.1.2 HER2-targeting recombinant antibodies 
Recombinant antibodies directed against HER2 were generated using the trastuzumab-
derived targeting moiety 4D5 (Carter et al., 1992). The different HER2-targeting antibody 
formats were produced with yields ranging from 0.7 (scFv4D5) to 9.3 mg protein (scFv4D5-
EHD2) per liter bacterial culture or cell culture supernatant (Table 3.2). Purity and integrity 
analysis was performed by SDS-PAGE. Under reducing (Figure 3.4A) as well as under non-
reducing conditions (Figure 3.4B), the sizes of the detected protein bands were in good 
agreement with the molecular masses calculated based on the amino acid sequences. Under 
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non-reducing conditions, formation of disulfide-linked dimers was confirmed for dsDb4D5, 
scFv4D5-EHD2, and scFv4D5-Fc. High molecular weight species were additionally identified for 
dsDb4D5 in the absence of a reducing agent, while scFv4D5-EHD2 was found in the monomeric 
beside the major dimeric form. As outlined before, the appearance of scFv4D5-EHD2 as double 
band is caused by differential glycosylation of the EHD2 (Seifert, 2014). Good thermal stability 
with a melting point of 69 °C was determined for scFv4D5 (Figure 3.4C, Table 3.2). As already 
observed for the EGFR-targeting antibodies, converting the scFv into the diabody format led 
to a decrease in thermal stability (64 °C) that was again improved for the disulfide-stabilized 
diabody (67 °C). Melting points of 67 °C and 69 °C were measured for scFv4D5-EHD2 and 
scFv4D5-Fc, respectively. 
 
Figure 3.4: Biochemical characterization of recombinant antibodies directed against HER2. ScFv4D5 (1), Db4D5 
(2), dsDb4D5 (3), scFv4D5-EHD2 (4), and scFv4D5-Fc (5) were analyzed by SDS-PAGE (12 % PAA) under reducing 
(A) and non-reducing conditions (B). 2 µg protein were loaded per lane and stained with Coomassie Brilliant Blue. 
M, protein marker. C) Dynamic light scattering was performed to determine the thermal stability. Melting 
points [°C] are indicated with dotted lines. Melting curves of Db4D5 (black) and dsDb4D5 (gray) are represented 
in one graph. Thermal stability was analyzed once for each protein. 
 
The binding properties of the HER2-targeting recombinant antibodies were evaluated by ELISA 
(Figure 3.5A) and flow cytometry (Figure 3.5B) using a HER2-Fc fusion protein and HER2-
expressing SKBR3 cells, respectively. The EC50 values determined in ELISA were in the range of 
2.7 nM to 3.6 nM (concentrations referring to functional binding sites), except for the diabody 
that showed weaker binding (Table 3.2). Flow cytometric studies revealed half-maximal 
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binding at concentrations of 4.8 nM to 8.7 nM for scFv4D5, scFv4D5-EHD2, and scFv4D5-Fc. 
Higher EC50 values of 16.4 nM and 19.5 nM were detected for the diabody formats. Treatment 
of Colo205 cells with the recombinant antibodies was performed to assess potential effects 
that might be exerted by the antibody parts of the respective scTRAIL fusion proteins (Figure 
3.5C). Incubation of the cells with the different formats of HER2-targeting antibodies did not 
identify an influence on cell viability in the analyzed concentration range. Similar to the results 
obtained for the EGFR-targeting recombinant antibodies, no clear differences were found for 
the investigated formats, apart from weaker binding of the diabody constructs. 
 
Figure 3.5: Binding analysis of HER2-targeting recombinant antibodies and effects on Colo205 cells. A) Binding 
to HER2-Fc (200 ng/well) was investigated in ELISA by detection of bound proteins using an HRP-conjugated anti-
His-tag antibody. Optical density measured at 450 nm was normalized to the value determined for the highest 
concentration analyzed. B) Binding to HER2-expressing SKBR3 cells was evaluated by flow cytometry detecting 
bound molecules with a PE-conjugated anti-His-tag antibody or anti-human IgG (γ-chain specific)-PE. C) Effects 
on Colo205 cells (50,000 cells/well) were determined after treatment with serial dilutions of the proteins for 
16 h. Viable cells were visualized with crystal violet. Concentrations refer to functional binding sites. 
 
Table 3.2: Biochemical and binding properties of HER2-targeting recombinant antibodies. Molecular masses 
(M) were calculated based on the amino acid sequence. Yields are expressed as mg protein per liter bacterial 
culture or cell culture supernatant. EC50 values [nM of functional binding sites] for binding to HER2-Fc and SKBR3 
cells were determined by ELISA and flow cytometry, respectively.  
Protein M [kDa] Yield [mg/l] TM [°C] EC50 HER2 [nM] EC50 SKBR3 [nM] 
scFv4D5 28 0.7 69 2.7 ± 0.6 8.7 ± 1.7 
Db4D5 53 7.2 64 8.2 ± 0.8 19.5 ± 2.7 
dsDb4D5 53 6.6 67 3.6 ± 0.4 16.4 ± 4.3 
scFv4D5-EHD2 79 9.3 67 3.3 ± 0.3 4.8 ± 1.3 
scFv4D5-Fc 104 5.4 69 n.d. 8.5 ± 3.2 
n.d., not determined. 
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3.1.3 HER3-targeting recombinant antibodies 
Recombinant antibodies directed against HER3 were based on the targeting moiety 3M6. 3M6 
was developed as a modified version of MM-6 (MM-121, Ab #6, Schoeberl et al., 2009). Since 
the MM-6 binding moiety contained a cysteine residue at position 89 (Kabat numbering 
scheme) in the CDR-L3 loop that might lead to uncontrolled formation of disulfide-linked 
dimers, 3M6 was generated by mutating this cysteine to serine (3M6, mutated MM-6). 
 
Figure 3.6: Biochemical characterization of 3M6-based recombinant antibodies. SDS-PAGE (12 % PAA) of 
scFv3M6 (1), Db3M6 (2), dsDb3M6 (3), scFv3M6-EHD2 (4), and scFv3M6-Fc (5) was performed under reducing (A) 
and non-reducing conditions (B). 2 µg protein were analyzed per lane and stained with Coomassie Brilliant Blue. 
M, protein marker. C) Thermal stability was determined by dynamic light scattering. Melting points [°C] are 
indicated with dotted lines. Measurement was performed once for each protein. Melting curves of Db3M6 (black) 
and dsDb3M6 (gray) are shown in one graph. 
 
The 3M6-based antibody formats were produced with yields of 0.4 (scFv3M6) to 6.9 mg 
protein (Db3M6) per liter bacterial culture or cell culture supernatant (Table 3.3). SDS-PAGE 
analysis of the constructs confirmed their purity, while integrity was not observed for all 
proteins (Figure 3.6A,B). About half of the dsDb3M6 molecule migrated as a band of smaller 
size that was only visible under non-reducing conditions. Disulfide-linked dimers were 
detected for dsDb3M6, scFv3M6-EHD2, and scFv3M6-Fc under non-reducing conditions, but 
approximately half of scFv3M6-EHD2 remained in its monomeric form. As already seen for the 
EGFR- and HER2-targeting proteins, scFv3M6-EHD2 appeared as two bands of similar size due 
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to differences in glycosylation (Seifert, 2014). Thermal stability of the different formats was 
analyzed by dynamic light scattering (Figure 3.6C). ScFv3M6 showed a melting point of 70 °C 
that was reduced to 63°C for the diabody format and again somewhat improved to 65 °C for 
the disulfide-stabilized form (Table 3.3). This resembles the data of the corresponding anti-
EGFR and anti-HER2 formats. Melting points of 67 °C and 72 °C were measured for scFv3M6-
EHD2 and -Fc, respectively. 
 
Figure 3.7: Binding analysis of 3M6-based recombinant antibodies and effects on Colo205 cells. A) Binding to 
HER3-Fc (200 ng/well) was investigated by ELISA. Bound molecules were detected with an anti-His-HRP. Optical 
density measured at 450 nm was normalized to the value determined for the highest concentration. B) Binding 
to HER3-expressing MCF7 cells was analyzed by flow cytometry. Detection of bound proteins was performed 
using a PE-conjugated anti-His-tag antibody or anti-human IgG (γ-chain specific)-PE. Binding curve of scFv3M6-
Fc is represented from two independent experiments. C) Colo205 cells (50,000/well) were incubated overnight 
and treated with serial dilutions of the proteins for 16 h. Cell viability was determined by crystal violet staining. 
Concentrations refer to functional binding units. 
 
Further characterization of the different 3M6-based formats was done by ELISA and flow 
cytometry (Figure 3.7A,B). All molecules showed concentration-dependent binding to HER3 
with EC50 values of 5.5 nM to 9.5 nM (Table 3.3). Binding to cell surface-expressed HER3 was 
confirmed using MCF7 cells. Half-maximal binding was detected at concentrations ranging 
from 1.1 nM (dsDb3M6) to 7.4 nM (scFv3M6-Fc). Effects of the different recombinant 
antibody formats on Colo205 cells were analyzed to evaluate the contribution of the antibody 
part of the corresponding antibody-scTRAIL fusion proteins (Figure 3.7C). In a concentration 
range of 1 pM to 10 nM, none of the 3M6-based molecules had an impact on the cell viability. 
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Table 3.3: Biochemical and binding properties of recombinant antibodies directed against HER3. Molecular 
masses (M) were calculated based on the amino acid sequence. Yields are expressed as mg protein per liter 
bacterial culture or cell culture supernatant. Binding to HER3-Fc and HER3+ cells (MCF7 for 3M6, Colo205 for 3-
43) was analyzed by ELISA and flow cytometry, respectively. EC50 values refer to functional binding sites. 
Protein M [kDa] Yield [mg/l] TM [°C] EC50 HER3 [nM] EC50 cells [nM] 
scFv3M6 28 0.4 70 8.0 ± 1.1 5.4 ± 1.2 
Db3M6 52 6.9 63 4.3 ± 1.2 1.1 ± 0.1 
dsDb3M6 52 1.9 65 9.5 ± 1.4 1.9 ± 0.4 
scFv3M6-EHD2 78 4.1 67 5.5 ± 0.3 3.6 ± 1.0 
scFv3M6-Fc 103 6.6 72 n.d. 7.4 ± 1.6 
scFv3-43-Fc 104 13.5 58 n.d. 0.2 ± 0.001 
n.d., not determined. 
 
Summing up the presented data of EGFR-, HER2-, and HER3-targeting recombinant antibodies, 
all formats were functional in terms of binding to the respective antigen in ELISA and flow 
cytometry. Thus, characterization of further antibody moieties was done only for the scFv-Fc 
fusion protein. 
 
The above represented data confirmed full functionality of the 3M6-based recombinant 
antibodies concerning HER3 targeting, albeit with medium binding activity. Thus, another 
HER3 binding moiety (3-43) was analyzed in addition to the 3M6 constructs. ScFv3-43 was 
selected from a human scFv phage display library and was shown to exhibit considerably 
stronger binding to HER3 as well as a different binding site compared to scFv3M6. While 3M6 
binds to domain I of HER3, parts of domains III and IV are involved in binding of 3-43 (Schmitt 
et al., in preparation). The scFv3-43-Fc molecule was expressed with a yield of 13.5 mg protein 
per liter cell culture supernatant (Table 3.3). SDS-PAGE analysis revealed pure and intact 
protein migrating according to its calculated molecular mass and dimer formation under non-
reducing conditions (Figure 3.8A). Thermal stability was measured by dynamic light scattering 
detecting a melting point of 58 °C (Figure 3.8B, Table 3.3). Considering the results of the 3M6-
based molecules, binding of scFv3-43-Fc to cell-surface expressed HER3 was clearly stronger 
reaching half-maximal binding at a concentration of 0.2 nM (Figure 3.8C, Table 3.3). In contrast 
to all other investigated recombinant antibodies, scFv-3-43-Fc seemed to exert inhibitory 
effects on Colo205 cells leading to a concentration-dependent reduction of the amount of 
viable cells. Thus, 3-43 was included as alternative HER3-targeting scTRAIL fusion partner 
additionally to 3M6. 
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Figure 3.8: Characterization of scFv3-43-Fc. A) SDS-PAGE (12 % PAA) of scFv3-43-Fc was performed under 
reducing (1) and non-reducing (2) conditions. 2 µg protein were loaded per lane and stained with Coomassie 
Brilliant Blue. M, protein marker. B) Thermal stability was determined by dynamic light scattering. The melting 
point [°C] is indicated with a dotted line. Measurement was performed once. C) Binding to HER3-expressing 
Colo205 cells was analyzed by flow cytometry. Bound protein was detected with an anti-human IgG (γ-chain 
specific)-PE. D) Effects on Colo205 cells (50,000/well) were determined after treatment for 16 h. Viable cells were 
stained with crystal violet. Concentrations refer to functional binding sites. 
 
3.1.4 EpCAM-targeting recombinant antibody 
The scFv-Fc fusion protein directed against EpCAM was generated based on a humanized 
version (Fellermeier et al., 2016) of the mouse antibody 323/A3 (Edwards et al., 1986; Roovers 
et al., 1998). The scFv323/A3hu3-Fc fusion protein was produced with a yield 9.7 mg protein 
per liter cell culture supernatant (Table 3.4). Purity and integrity of the molecule were 
confirmed by SDS-PAGE detecting bands of sizes corresponding to the calculated molecular 
masses of the monomer and dimer under reducing and non-reducing conditions, respectively 
(Figure 3.8A). A melting point of 54 °C was determined by dynamic light scattering (Figure 
3.8B, Table 3.4). Flow cytometry was performed to investigate the binding properties (Figure 
3.8C). Half-maximal binding to EpCAM-expressing Colo205 cells was observed at a 
concentration of 3.4 nM (Table 3.4). Similar to the recombinant antibodies based on hu225, 
4D5, and 3M6, scFv323/A3hu3-Fc did not influence viability of Colo205 cells after treatment 
with a serial dilution for 16 h (Figure 3.8D). 
40 50 60 70 80
0
2000
4000
6000
8000
10000
58
Temperature [°C]
M
e
a
n
 c
o
u
n
t 
ra
te
 [
k
c
p
s
]
0
25
50
75
100
125
10 -3 10 -2 10 -1 100 1010
Binding sites [nM]
V
ia
b
il
it
y
 [
%
]
10 -3 10 -2 10 -1 100 101 102 103
0
2
4
6
8
Binding sites [nM]
re
la
ti
v
e
 M
F
I
kDa 1 M 2A)
B)
170 -
130 -
100 -
70 -
55 -
40 -
35 -
25 -
15 -
C)
D)
  RESULTS   
  73   
 
Figure 3.9: Characterization of scFv323/A3hu3-Fc. A) ScFv323/A3hu3-Fc was analyzed by SDS-PAGE (12 % PAA) 
under reducing (1) and non-reducing conditions (2). 2 µg protein were loaded per lane and stained with 
Coomassie Brilliant Blue. M, protein marker. B) Dynamic light scattering was performed to investigate thermal 
stability. The melting point [°C] is indicated with a dotted line. Thermal stability was measured once. C) Binding 
to EpCAM-expressing Colo205 cells was determined by flow cytometry. Detection of bound protein was 
performed using an anti-human IgG (γ-chain specific)-PE. D) Colo205 cells (50,000/well) were incubated 
overnight and treated for 16 h. Viable cells were stained with crystal violet. Concentrations refer to functional 
binding sites. 
 
Table 3.4: Biochemical and binding properties of scFv323/A3hu3-Fc. Molecular mass (M) was calculated based 
on the amino acid sequence. Yield is expressed as mg protein per liter cell culture supernatant. EC50 value 
(concentration referring to functional binding sites) for binding to Colo205 cells was determined by flow 
cytometry. 
Protein M [kDa] Yield [mg/l] TM [°C] EC50 Colo205 [nM] 
scFv323/A3hu3-Fc 105 9.7 54 3.4 ± 0.1 
 
In conclusion, all analyzed antibody formats and all targeting moieties exhibited full 
functionality concerning binding to their respective target structure. This allows generation of 
the corresponding set of different formats of dimeric antibody-scTRAIL fusion proteins with 
specificities for EGFR, HER2, HER3, and EpCAM using the hu225, 4D5, 3M6 and 3-43, and 
323/A3hu3 targeting moieties, respectively. 
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3.2 Comparison of different formats of scTRAIL fusion proteins 
As outlined above, the concept of generating improved TRAIL therapeutics was built on 
previous studies demonstrating considerably higher activity of dimeric and targeted dimeric 
versions of scTRAIL compared to its monomeric form (Gieffers et al., 2013; Seifert et al., 2014a; 
Siegemund et al., 2012). The first level of improvements consisted in the development of new 
single-chain variants of human TRAIL optimized for production, stability, and activity 
(Siegemund et al., 2016). The scTRAIL version used in this study comprises the amino acid 
residues 118 to 281 and linkers of a single glycine to connect the subunits. Fusion of scTRAIL 
to the C-terminus of the dimerization modules EHD2 and the human IgG1 Fc part allowed 
generation of two non-targeted dimeric formats (Figure 3.10A,C). The resulting EHD2-scTRAIL 
and Fc-scTRAIL molecules possess six TRAIL receptor binding sites, while the monomeric 
scTRAIL is able to bind to three TRAIL receptors. Employing the dimeric recombinant antibody 
formats described above (see 3.1), a set of four different targeted dimeric scTRAIL fusion 
proteins was furthermore developed. According to the non-targeted versions, scTRAIL was 
fused to the C-terminus of the recombinant antibodies creating Db-scTRAIL, dsDb-scTRAIL, 
scFv-EHD2-scTRAIL, and scFv-Fc-scTRAIL. Additionally to six TRAIL receptor binding sites, all 
these molecules exhibit two antigen binding sites. Despite this common composition, 
variations in activity may arise due to differences in e.g. flexibility or pharmacokinetics. 
Depending on the degree of flexibility (Tatzel et al., 2016), the molecules are thought to be 
able to simultaneously bind to antigens and TRAIL receptors either expressed on different 
tumor cells or also on the same cell (Figure 3.10B). Based on the already described targeting 
moieties, the different formats of targeted dimeric scTRAIL fusion proteins were developed 
with specificities for EGFR, HER2, HER3, and EpCAM. All molecules were expressed in stably 
transfected HEK293T cells comprising a FLAG-tag at the N-terminus for purification of the 
secreted protein from the supernatant via FLAG affinity chromatography. Since preparations 
of the initial versions of scFv-Fc-scTRAIL and Fc-scTRAIL contained considerable amounts of 
cleavage products, an analysis on potential protease cleavage sites was performed and 
identified several candidates in the sequence connecting the Fc part and scTRAIL. In order to 
improve the product quality of those fusion proteins, K447 (EU numbering scheme) of the Fc 
part was mutated to a glutamine residue and an alanine of the linker sequence was replaced 
by a glycine to remove all predicted protease cleavage sites in this sequence part. 
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Figure 3.10: Overview of scTRAIL molecules of different formats. A) Composition of targeted and non-targeted 
scTRAIL versions. L, VH (scTRAIL) or Igκ chain leader sequence (EHD2-, Fc-scTRAIL, and all targeted formats). L1, 
EFGG linker. L2, AAAGGSGG linker. L3, GGSGGASSGG linker. L4, GGGGSGT linker. L5, GGSGGGSSGG linker. L6, 
GGGGS linker. L7, (GGGGS)3 linker. TRAIL subunits consist of aa 118-281 and are connected by a glycine residue. 
B) Concept of a targeted dimeric scTRAIL fusion protein binding to antigen- and receptor-expressing tumor cells. 
C) Schematic assembly of scTRAIL molecules. Different categories are highlighted. 
 
3.2.1 EGFR-targeting and non-targeted scTRAIL fusion proteins 
3.2.1.1 Biochemical characterization 
Antibody-scTRAIL fusion proteins directed against EGFR comprise the above analyzed 
targeting moiety hu225 (see 3.1.1) and were directly compared to monomeric scTRAIL and its 
non-targeted dimeric variants EHD2-scTRAIL and Fc-scTRAIL. The product yields ranged from 
0.7 mg protein per liter supernatant for scTRAIL to 10.4 mg protein per liter supernatant for 
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scFvhu225-Fc-scTRAIL (Table 3.5). In general, higher yields were achieved for all fusion 
proteins than for scTRAIL itself with the Fc-containing molecules showing best production 
properties. SDS-PAGE revealed pure and intact proteins migrating according to their 
calculated molecular masses (Figure 3.11A, Table 3.5). Under non-reducing conditions, the 
expected disulfide-linked dimers were observed. However, a fraction of scFvhu225-EHD2-
scTRAIL remained in its monomeric form and high molecular weight species were found for all 
other molecules. 
 
Figure 3.11: Biochemical characterization of EGFR- and non-targeted scTRAIL molecules.  A) SDS-PAGE (8 % 
PAA) of Dbhu225-scTRAIL (1), dsDbhu225-scTRAIL (2), scFvhu225-EHD2-scTRAIL (3), scFvhu225-Fc-scTRAIL (4), 
scTRAIL (5), EHD2-scTRAIL (6), and Fc-scTRAIL (7) was performed under reducing (R) and non-reducing conditions 
(NR). 2 µg protein were analyzed per lane and proteins were stained with Coomassie Brilliant Blue. M, protein 
marker. B) Size exclusion HPLC was used to investigate the proteins under native conditions. Elution times of 
standard proteins and their corresponding molecular masses [kDa] are indicated. 
 
In size exclusion chromatography, all proteins eluted as one major peak corresponding to the 
expected protein form (Figure 3.11B). A Stokes radius of 3.4 nm was determined for scTRAIL 
and increased sizes of 5.5 nm to 6.4 nm were measured for its fusion proteins (Table 3.5). The 
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elution profile of Dbhu225-scTRAIL additionally showed a minor fraction of smaller size, 
whereas a peak of high molecular weight species was observed for dsDbhu225-scTRAIL, 
scTRAIL, and EHD2-scTRAIL. This is of importance for the further evaluation of these proteins, 
as such multimers have been demonstrated to possess increased activity (reviewed by 
Koschny et al., 2007b). First studies on stability were performed by dynamic light scattering 
detecting a melting point of 52 °C for scTRAIL and even increased temperatures for all other 
molecules (Table 3.5). This indicates stabilization of the proteins by fusion to an antibody and 
dimerization moiety. With melting points of 58 °C, the EHD2 and Fc part conferred best 
thermal stability on the respective fusion proteins. 
 
Table 3.5: Biochemical properties of EGFR- and non-targeted scTRAIL molecules. Molecular masses (M) were 
calculated based on the amino acid sequence. Yields are expressed as mg protein per l cell culture supernatant. 
Stokes radii (Sr) and melting points (TM) were determined by size exclusion HPLC and dynamic light scattering, 
respectively. 
Protein M [kDa] Yield [mg/l] Sr [nm] TM [°C] 
Dbhu225-scTRAIL 168 3.3 5.5 55 
dsDbhu225-scTRAIL 168 1.0 5.7 55 
scFvhu225-EHD2-scTRAIL 194 3.8 6.0 58 
scFvhu225-Fc-scTRAIL 222 10.4 6.4 58 
scTRAIL 58 0.7 3.4 52 
EHD2-scTRAIL 141 2.3 5.6 58 
Fc-scTRAIL 169 6.9 6.0 58 
 
3.2.1.2 Evaluation of binding properties 
Since targeted scTRAIL molecules are multifunctional proteins, binding properties of the 
antibody as well as the scTRAIL moieties were examined. In ELISA, all formats of EGFR-
targeting scTRAIL fusion proteins efficiently bound to EGFR with EC50 values in the sub- to low 
nanomolar range (Figure 3.12A, Table 3.6) similar to those identified for the respective 
recombinant antibodies (Table 3.1). This confirms that binding of the antibody part is not 
affected by fusion to scTRAIL. Half-maximal binding of targeted and non-targeted scTRAIL 
molecules to TRAIL receptors was exemplarily determined for human and mouse TRAIL-R2 
revealing concentrations in the range of 0.8 nM to 2.5 nM for huTRAIL-R2 and slightly higher 
values for the mouse receptor (Figure 3.12A, Table 3.6). For direct comparison of dimeric 
scTRAIL constructs with monomeric scTRAIL, all protein concentrations refer to scTRAIL units. 
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Figure 3.12: Binding of EGFR- and non-targeted scTRAIL molecules to target proteins in ELISA. Proteins were 
analyzed in serial dilutions (A) or at a concentration of 40 nM scTRAIL units (B). Receptor-Fc fusion proteins 
(300 ng/well EGFR-Fc, 200 ng/well TRAIL-R-Fc) were coated. Bound molecules were detected with an anti-FLAG-
HRP. Concentrations refer to scTRAIL units. OD450nm was normalized to the value of the highest concentration (A) 
or expressed as relative OD450nm (B; OD of investigated protein divided by OD of coating control detected via anti-
huIgG (Fc spec.)-POD). Block shift was performed for analysis of 40 nM scTRAIL units on human TRAIL receptors. 
 
To further investigate TRAIL receptor binding properties, binding of the molecules to all 
human and mouse TRAIL receptors was analyzed at a concentration of 40 nM scTRAIL units 
(Figure 3.12B). All proteins were capable of binding to all human TRAIL receptors. However, 
only low binding to huTRAIL-R3 and huTRAIL-R4 was detected for scTRAIL. In contrast to the 
results obtained for the human receptors, the scTRAIL molecules were not able to bind to all 
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mouse TRAIL-R. No binding was observed for moDcTRAIL-R1, which is consistent with data 
previously published by Bossen et al. (2006) already revealing the incapability of human TRAIL 
to bind to this mouse receptor. These data confirm the designated target specificities of EGFR-
targeting and non-targeted scTRAIL molecules. 
 
Figure 3.13: Binding of EGFR- and non-targeted scTRAIL molecules to cell surface-expressed receptors. Flow 
cytometry was performed to determine binding to Colo205 and HCT116 cells. Either serial dilutions or a 
concentration of 20 nM scTRAIL units were analyzed and bound proteins were detected using a PE-conjugated 
anti-FLAG antibody. To block binding of the antibody moiety to EGFR, cells were preincubated with a 200-fold 
molar excess of cetuximab, prior to addition of the scTRAIL molecules. Concentrations refer to scTRAIL units. 
 
Binding was further analyzed on the cell lines that were also used to investigate cell death 
induction. Targeted as well as non-targeted scTRAIL constructs bound to Colo205 and HCT116 
cells in a concentration-dependent manner (Figure 3.13). While strong binding with EC50 
values of 0.4 nm to 1.7 nm (Table 3.6) was detected for the targeted fusion proteins, EHD2-
scTRAIL and Fc-scTRAIL did not reach saturation levels for concentrations up to 3 µM. To 
analyze the contribution of the antibody and scTRAIL moieties on binding, blocking studies 
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were performed by incubating Colo205 and HCT116 cells with a 200-fold molar excess of 
cetuximab, prior to addition of the molecules (20 nM scTRAIL units). In the presence of 
cetuximab, binding of all targeted fusion proteins was reduced to the level observed for the 
non-targeted variants that was completely unaffected by blocking of EGFR. This demonstrates 
that binding of antibody-targeted scTRAIL molecules to Colo205 and HCT116 cells is mediated 
via both EGFR and TRAIL receptors. Statistical analysis of the EC50 values of the ELISA and flow 
cytometry studies revealed significantly reduced EGFR binding of scFvhu225-EHD2-scTRAIL 
compared to e.g. Dbhu225-scTRAIL in ELISA (P<0.001), while no significant differences were 
observed for binding to Colo205 cells (P>0.05) and even significantly increased binding of 
scFvhu225-EHD2-scTRAIL compared to Dbhu225-scTRAIL was seen for HCT116 cells (P<0.05). 
This illustrates that there are no consistent differences in the binding activity due to the 
format. Summing up the results of the binding studies, all molecules showed the expected 
behavior, i.e. comparable binding properties of targeted and non-targeted proteins for TRAIL 
receptors and improved cell binding of the targeted constructs mediated by the EGFR-binding 
antibody moiety. Furthermore, no consistent differences were identified for the different 
formats of EGFR-targeting scTRAIL fusion proteins. 
 
Table 3.6: Binding properties of EGFR- and non-targeted scTRAIL molecules. EC50 values are represented as nM 
scTRAIL units and were determined by ELISA (EGFR-, huTRAIL-R2-, moTRAIL-R2-Fc) and flow cytometry (Colo205, 
HCT116 cells). 
Protein EGFR huTRAIL-R2 moTRAIL-R2 Colo205 HCT116 
Dbhu225-scTRAIL 0.8 ± 0.1 0.8 ± 0.1 3.9 ± 1.2 0.9 ± 0.3 0.6 ± 0.03 
dsDbhu225-scTRAIL 0.9 ± 0.03 1.3 ± 0.4 3.0 ± 0.6 0.9 ± 0.1 0.5 ± 0.1 
scFvhu225-EHD2-scTRAIL 1.2 ± 0.1 2.1 ± 0.7 3.8 ± 0.8 0.6 ± 0.1 0.4 ± 0.02 
scFvhu225-Fc-scTRAIL 0.9 ± 0.01 1.6 ± 0.4 3.5 ± 0.7 1.7 ± 1.1 0.5 ± 0.1 
scTRAIL n.d. 1.8 ± 0.4 3.3 ± 0.2 6.7 ± 1.4 2.2 ± 0.2 
EHD2-scTRAIL n.d. 2.0 ± 0.2 2.0 ± 0.3 (>100)‡ (>100)‡ 
Fc-scTRAIL n.d. 2.5 ± 0.3 4.1 ± 1.0 (>100)‡ (>100)‡ 
n.d., not determined. ‡, no saturation reached. 
 
3.2.1.3 Induction of cell death and caspase activity in vitro 
The mechanism of anti-tumoral activity of the investigated molecules consists in the induction 
of apoptosis leading to cell death. Thus, the proteins were evaluated for their capability to 
induce cell death on the colorectal carcinoma cell lines Colo205 and HCT116 either alone or in 
combination with the proteasome inhibitor bortezomib (BZB) that is able to sensitize cells for 
TRAIL-induced apoptosis (reviewed by de Wilt et al., 2013). All EGFR- and non-targeting 
molecules induced concentration-dependent cell death on Colo205 cells in the absence as well 
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as in the presence of bortezomib after treatment for 16 h (Figure 3.14). Without sensitizer, 
the different targeted formats exhibited EC50 values ranging from 12.6 pM to 40.9 pM scTRAIL 
units (Table 3.7), whereas the non-targeted versions scTRAIL and Fc-scTRAIL required 
significantly higher concentrations (P<0.01) to induce 50 % cell death indicating beneficial 
effects of EGFR targeting. Furthermore, the 5-fold lower EC50 value of Fc-scTRAIL compared to 
scTRAIL (P<0.01) and the remaining level of approximately 40 % living cells for scTRAIL 
highlight the superiority of the dimeric over the monomeric scTRAIL form, which is in 
accordance with previous studies (Siegemund et al., 2012; Seifert et al., 2014a). Referring to 
the results of the SEC analysis, the considerable amount of high molecular weight species may 
explain the high activity of EHD2-scTRAIL. After preincubation with bortezomib, 5- to 20-fold 
lower EC50 values (P<0.01) were detected confirming the sensitizing effect. Similar to the 
results obtained without bortezomib, all EGFR-targeting fusion proteins exerted significantly 
better activity than Fc-scTRAIL (P<0.001) that in turn was superior to scTRAIL (P<0.001; Figure 
3.14, Table 3.7). 
 
Figure 3.14: Cell death induction of EGFR- and non-targeted scTRAIL molecules on Colo205 cells. 50,000 cells 
per well were incubated overnight and treated with serial dilutions of the proteins for 16 h after preincubation 
with medium or bortezomib (BZB, 250 ng/ml) for 30 min. Viable cells were stained with crystal violet. 
Concentrations refer to scTRAIL units. 
 
The data of EGFR- and non-targeting scTRAIL molecules described above already indicate a 
beneficial impact of EGFR targeting of the fusion proteins, although no influence was found 
for the recombinant antibodies alone (Figure 3.3C). To further analyze the contribution of the 
antibody moieties in the fusion proteins to cell death induction, binding to EGFR was blocked 
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by preincubation of Colo205 cells with a 200-fold molar excess of cetuximab (Figure 3.15). In 
the presence of cetuximab, all targeted and non-targeted constructs were still able to induce 
cell death treating the cells with protein alone as well as in combination with bortezomib. 
However, a shift in the activity profile was observed. Blocking of EGFR binding significantly 
increased the EC50 values of the targeted molecules by factors of 2 to 6 in the absence of 
bortezomib (P<0.01) and 3 to 4 in the presence of bortezomib (P<0.05; Table 3.7). 
Interestingly, also the non-targeted variants showed decreased effects after preincubation of 
the cells with cetuximab, although with increases of the EC50 values of 1.3-fold without 
bortezomib and 2-fold when combined with bortezomib to a lesser extent. These data further 
confirm a contribution of targeting EGFR to cell death induction. 
 
Figure 3.15: Cell death induction of EGFR- and non-targeted scTRAIL molecules on Colo205 cells in the presence 
of cetuximab. 50,000 cells per well were incubated overnight. To block binding of the molecules to EGFR, cells 
were preincubated with a 200-fold molar excess of cetuximab in medium or medium containing BZB (250 ng/ml) 
for 30 min. After treatment of the cells with the proteins for 16 h, viable cells were stained with crystal violet. 
Concentrations refer to scTRAIL units. 
 
In order to validate the cell death-inducing effects demonstrated for Colo205 cells, further 
studies were performed using HCT116 cells, a colorectal carcinoma cell line like Colo205, but 
with activating mutations in KRAS and PIK3CA instead of BRAF. Confirming their activity on 
Colo205 cells, all EGFR- and non-targeting molecules induced cell death on HCT116 cells 
(Figure 3.16). In the absence of bortezomib, EC50 values of 11.3 pM to 34.9 pM scTRAIL units 
were determined for the targeted proteins, while 165.7 pM and 1122.7 pM were necessary to 
kill 50 % of the cells by Fc-scTRAIL and scTRAIL, respectively (Table 3.7). This corresponds to a 
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significant increase in the EC50 values of these non-targeted compared to the EGFR-targeted 
constructs (P<0.01). With EC50 values decreased by factors of 16 to 136 (P<0.01), bortezomib 
exhibited an even more intense sensitizing effect on HCT116 cells than that observed for 
Colo205 cells. In agreement with the data obtained for Colo205 cells, strongest cell death 
induction was identified for the targeted scTRAIL fusion proteins, followed by Fc-scTRAIL, and 
finally scTRAIL alone as well as in combination with bortezomib. Again, EHD2-scTRAIL was 
more active than Fc-scTRAIL (P<0.05), which is supposed to result from the presence of 
multimeric forms exerting higher activity.  
 
Figure 3.16: Cell death induction of EGFR- and non-targeted scTRAIL molecules on HCT116 cells. 15,000 cells 
were seeded per well. After preincubation with medium or bortezomib (250 ng/ml) for 30 min, cells were treated 
with the proteins for 16 h. Cell viability was analyzed by crystal violet staining. Concentrations refer to scTRAIL 
units. 
 
Statistical analysis of all possible comparisons is beyond the scope of this study. However, 
major differences are illustrated. Attempting to make a conclusion about possible variations 
in the cell death-inducing activity of the different EGFR-targeted formats, comparison of the 
EC50 values on Colo205 or HCT116 cells in the absence or presence of bortezomib only 
revealed significantly lower activity for Dbhu225-scTRAIL under all conditions (P<0.05). With 
respect to the presence of protein fractions with smaller size (Figure 3.11B), this decreased 
activity may be related to heterogeneity of the protein preparation rather than to lower 
activity of the format itself. 
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Table 3.7: EC50 values of cell death induction of EGFR- and non-targeted scTRAIL molecules. EC50 values [pM 
scTRAIL units] were determined for Colo205 and HCT116 cells treated for 16 h with protein after preincubation 
with medium or BZB (250 ng/ml). To block binding to EGFR, cells were preincubated with cetuximab (200-fold 
molar excess) in medium or medium containing BZB (250 ng/ml). 
Protein Colo205 HCT116 
without cetuximab with cetuximab without cetuximab 
without BZB with BZB without BZB with BZB without BZB with BZB 
Dbhu225-
scTRAIL 
40.9 ± 3.0 3.7 ± 0.4 100.6 ± 12.0 14.1 ± 2.1 34.9 ± 2.4 1.7 ± 0.8 
dsDbhu225-
scTRAIL 
21.5 ± 3.4 2.4 ± 0.5 41.9 ± 4.1 7.3 ± 0.7 25.2 ± 4.0 0.8 ± 0.2 
scFvhu225-
EHD2-scTRAIL 
12.6 ± 2.6 1.8 ± 0.4 69.3 ± 11.6 6.8 ± 0.9 11.3 ± 1.7 0.7 ± 0.3 
scFvhu225-Fc-
scTRAIL 
12.8 ± 1.6 2.3 ± 0.5 66.0 ± 12.2 6.0 ± 2.1 12.5 ± 4.7 0.5 ± 0.1 
scTRAIL 474.7 ± 139.3 22.4 ± 2.3 – 36.0 ± 9.6 1122.7 ± 353.1 8.2 ± 1.5 
EHD2-scTRAIL 34.5 ± 6.8 2.9 ± 0.4 44.6 ± 8.4 6.0 ± 2.2 75.0 ± 13.5 1.3 ± 0.4 
Fc-scTRAIL 90.7 ± 3.5 7.0 ± 0.2 118.1 ± 8.7 14.1 ± 4.0 165.7 ± 25.6 3.6 ± 1.5 
–, less than 50 % of cells dead. 
 
 
Figure 3.17: Effects of treatment length on cell death induction of Dbhu225-scTRAIL on Colo205 cells. After 
preincubation with medium or bortezomib (250 ng/ml), Colo205 cells (50,000/well) were treated with serial 
dilutions of Dbhu225-scTRAIL for 16 h, 24 h, 48 h, and 72 h. Viable cells were stained with crystal violet and 
quantified by measuring the OD at 550 nm. EC50 values [pM scTRAIL units] are indicated with dotted lines. 
 
Besides analyzing cell death induction on different cell lines and the impact of combination 
with bortezomib or blocking of EGFR binding, further studies were performed to evaluate the 
influence of the treatment length. Effects of Dbhu225-scTRAIL on Colo205 cells were 
investigated in the absence and presence of bortezomib for treatment intervals of 16 h, 24 h, 
48 h, and 72 h (Figure 3.17). In accordance with the data described above (Table 3.7), 50 % 
cell death was detected at concentrations of 43.1 (± 10.8) pM and 4.4 (± 1.1) pM scTRAIL units 
after treatment for 16 h without and with bortezomib, respectively. With EC50 values of 
37.2 (± 5.2) pM and 1.4 (± 0.5) pM, an increase in the treatment length to 24 h induced a 
significant difference (P<0.05) only in combination with bortezomib. Further extending the 
treatments to 48 h and 72 h killed all cells treated with bortezomib, while similar EC50 values 
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were observed for cells treated with protein alone. Thus, extension of the treatment length 
did not alter the activity of Dbhu225-scTRAIL, but led to a more distinct switch between 
concentrations inducing cell death or not. 
 
Since previous studies and the above represented data already describe a considerable 
difference in the capability of monomeric, dimeric, and targeted dimeric scTRAIL versions to 
induce cell death, further experiments were performed to investigate these variabilities on 
the level of caspase-8 and -3/7 activity. To especially gain insight into variations in the kinetics 
of cell death induction, time-dependent activation of caspases by scFvhu225-Fc-scTRAIL, Fc-
scTRAIL, and scTRAIL was analyzed in Colo205 cells either alone or in combination with 
bortezomib. In a first experiment, levels of active caspase-8 induced by 10 pM of the proteins 
(corresponding to scTRAIL units) in combination with bortezomib were determined. 
Treatment with bortezomib alone, but also together with scTRAIL or Fc-scTRAIL did not or only 
marginally increase caspase-8 activity compared to cells incubated in medium. Only 
scFvhu225-Fc-scTRAIL was able to trigger activation of caspase-8 at the examined treatment 
interval of 8 h (Figure 3.18). 
 
Figure 3.18: Induction of caspase-8 activity in Colo205 cells. Colo205 cells (15,000/well) were preincubated with 
BZB (250 ng/ml) for 30 min and treated with 10 pM protein (scTRAIL units) for different intervals. Caspase-8 
activity was determined using Caspase-Glo® 8 Assay and measuring the luminescence signal (proportional to the 
amount of caspase-8 activity). RLU, relative light units. 
 
Since the investigated concentration of 10 pM corresponds to the EC50 value of scFvhu225-Fc-
scTRAIL that is clearly lower than those of the other proteins (Table 3.7), additional studies 
were performed with increased protein concentrations and extended treatment lengths. 
Besides the initiator caspase (Figure 3.19A), also executioner caspases-3/7 (Figure 3.19B) were 
analyzed in these settings. Similar to the results obtained for an incubation time of 8 h, 
treatment with bortezomib for 20 h did not or only marginally increase caspase-8 and -3/7 
activity. At a concentration of 100 pM scTRAIL units in combination with bortezomib, scTRAIL 
was able to induce caspase-8 and -3/7 activation, albeit requiring a treatment interval of 20 h. 
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In contrast, activation triggered by Fc-scTRAIL was clearly accelerated with marked caspase-8 
and -3/7 activity already seen after 8 h. The targeted dimeric scFvhu225-Fc-scTRAIL showed 
an even faster and stronger activation that was already detectable after 2 h and reached 
clearly higher levels than the other proteins. Further increasing the protein concentration to 
1 nM scTRAIL units in the presence of bortezomib accelerated the kinetics of activating 
initiator as well as executioner caspases of all molecules. Similar activation profiles were 
determined for both Fc fusion proteins inducing comparable levels of active caspases, though 
slightly delayed for the non-targeted construct. Despite a clearly faster activation kinetic with 
maximum activity measured already after 8 h, scTRAIL was not capable of reaching levels as 
high as those induced by the dimeric molecules. Application of the proteins at a concentration 
of 1 nM in the absence of bortezomib did not alter their activation profiles, but led to a slight 
reduction in the overall activity levels, especially for caspase-3/7 as compared to the 
combination with bortezomib. This is in agreement with data reporting that bortezomib 
treatment can also affect the level of XIAP that exerts inhibitory effects on caspase-3/7 
(reviewed by de Wilt et al., 2013). With reference to these results of caspase activities and 
those obtained for induction of cell death, all EGFR-targeting formats possess superior 
properties compared to those of Fc-scTRAIL that outperformed the monomeric scTRAIL. 
 
Figure 3.19: Induction of caspase-8 and -3/7 activity in Colo205 cells. Colo205 cells (15,000/well) were treated 
with the indicated concentrations of protein for different treatment intervals after preincubation with either BZB 
(250 ng/ml) or medium. Caspase-8 (A) and -3/7 (B) activities were determined using Caspase-Glo® 8 Assay and 
Caspase-Glo® 3/7 Assay, respectively. Measured luminescence signal is proportional to the amount of caspase 
activity. Data are represented as mean ± SD of two independent experiments. RLU, relative light units. 
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3.2.1.4 Plasma stability and in vivo pharmacokinetics 
Stability and serum half-lives of proteins are of great importance for therapeutic applications, 
as they determine their bioavailability and are thus factors limiting their potential to induce 
therapeutic effects. 
 
Figure 3.20: Plasma stability and in vivo pharmacokinetics of EGFR- and non-targeted scTRAIL molecules. 
A) 100 nM scTRAIL units were incubated in 50 % human plasma at 37 °C for 1 d, 3 d, and 7 d or directly frozen. 
Levels of intact protein were measured in ELISA by binding to human TRAIL-R2-Fc and detection with an anti-
FLAG-HRP. Data were normalized to the concentration of the sample directly frozen. B) Pharmacokinetic profiles 
were determined in female CD-1® mice (3 or 6 mice per molecule) after injection of 25 µg or 50 µg protein into 
the tail vein. Blood samples were collected after the indicated time intervals. Serum concentrations were 
analyzed by ELISA and normalized to the level detected after 3 min. 
 
First, the stability of all EGFR- and non-targeting fusion proteins was evaluated in human 
plasma (Figure 3.20A). The molecules were diluted in 50 % plasma and either directly frozen 
or incubated at 37 °C for 1 d, 3 d, and 7 d. Levels of intact protein were analyzed in ELISA by 
binding of the C-terminal scTRAIL to human TRAIL-R2 and detection via the N-terminal FLAG-
tag. All molecules showed a time-dependent decrease in the measured protein concentration 
reaching approximately 50 % or higher levels after 7 d. Deviations between different 
experiments were rather large for some proteins and thus do not allow clear conclusions 
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about differences in the stabilities of the proteins. Despite these variabilities, scTRAIL, Fc-
scTRAIL, and dsDbhu225-scTRAIL still seem to be slightly more stable. The increased stability 
of dsDbhu225-scTRAIL may indicate a positive influence of the introduction of disulfide bonds 
for the diabody construct. 
 
In vivo half-lives of the proteins were determined in tumor-free CD-1® mice after i.v. injection 
of 25 µg or 50 µg protein (Figure 3.20B). Blood samples were collected after different time 
intervals and serum concentrations of the molecules were analyzed by ELISA. With the 
shortest initial and terminal half-lives (Table 3.8), scTRAIL was only detectable for 24 h after 
injection. Similar pharmacokinetic properties were obtained for Dbhu225-scTRAIL and its 
disulfide-stabilized form revealing only a marginal improvement compared to scTRAIL. In 
contrast to that, the EHD2-containing fusion proteins showed with 6.5 h (scFvhu225-EHD2-
scTRAIL) and 8.7 h (EHD2-scTRAIL) significantly prolonged terminal half-lives (P<0.01 and 
P<0.001, respectively). As expected, best pharmacokinetic properties were observed for 
scFvhu225-Fc-scTRAIL and Fc-scTRAIL exhibiting terminal half-lives of 17.8 h and 14.5 h that 
represent a significant increase compared to the EHD2 constructs (P<0.001). These differences 
also translated into the corresponding areas under the curve (AUC). With an AUC of 603 %∙h, 
scFvhu225-Fc-scTRAIL possessed a more than 2-fold higher systemic exposure than the 
diabody molecules. Despite these superior properties, comparison with scFvhu225-Fc and 
cetuximab demonstrated 6- to 15-fold reduced half-lives of the Fc-containing scTRAIL fusion 
proteins (P<0.001) indicating a role of additional processes in the elimination of scTRAIL 
molecules. 
 
Table 3.8: Pharmacokinetic properties. PK was evaluated in female CD-1® mice (3 or 6 mice per molecule) 
injecting 25 µg or 50 µg protein into the tail vein. Initial half-lives (t1/2α) were calculated for the time interval of 
3 min to 2 h. The terminal half-life (t1/2β) was determined starting with the serum concentration at 6 h. 
Protein t1/2α [h] t1/2β [h] AUC [%∙h] 
Dbhu225-scTRAIL 1.2 ± 0.3 2.6 ± 0.2 235 ± 48 
dsDbhu225-scTRAIL 1.3 ± 0.2 2.3 ±0.1 292 ± 21 
scFvhu225-EHD2-scTRAIL 1.5 ± 0.1 6.5 ± 0.2 402 ± 51 
scFvhu225-Fc-scTRAIL 1.9 ± 0.3 17.8 ± 2.3 603 ± 101 
scTRAIL 0.7 ± 0.03 2.2 ± 0.1 118 ± 12 
EHD2-scTRAIL 1.4 ± 0.04 8.7 ± 0.4 422 ± 22 
Fc-scTRAIL 3.1 ± 0.1 14.5 ± 0.8 592 ± 23 
scFvhu225-Fc 2.7 ± 0.8 111.9 ± 23.3 3257 ± 562 
Cetuximab 4.8 ± 1.9 218.4 ± 27.0 6129 ± 682 
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3.2.1.5 In vivo activity of different formats of scTRAIL fusion proteins 
Final studies on the functionality and differences of the alternative formats of scTRAIL 
molecules were performed by investigating the in vivo therapeutic activity. In all experimental 
settings, a Colo205 xenograft model was established in NMRI nude mice by subcutaneous 
injections of 3∙106 cells into the left and right flank. Treatment was started after tumors 
reached a volume of approximately 100 mm3. A first experiment was arranged to evaluate the 
effects of bortezomib treatment alone (Figure 3.21). Mice received six intraperitoneal 
injections of bortezomib (5 µg) or PBS every other day. After an observation time of 27 d, no 
differences in tumor growth were induced by treatment with bortezomib. Based on these 
data, experiments analyzing combinations of protein and bortezomib only included a control 
group treated with bortezomib. 
 
Figure 3.21: Effects of bortezomib in vivo. A Colo205 xenograft model was established in NMRI nude mice (4 
mice for PBS, 5 mice for BZB). Upon reaching a tumor size of approximately 100 mm3, mice received six i.p. 
injections of bortezomib (5 µg) or PBS as control (days 12, 14, 16, 18, 20, 22). Treatments are indicated with a 
dotted line. 
 
In a second experiment, the therapeutic activities of the different EGFR-targeting scTRAIL 
formats and the non-targeted Fc-scTRAIL were compared in combination with bortezomib 
(Figure 3.22). Since in vitro and PK studies did not identify relevant differences in the 
properties of Dbhu225-scTRAIL and dsDbhu225-scTRAIL and high molecular weight species 
were found for the disulfide-stabilized form, only the unmodified diabody construct was 
analyzed resulting in five groups, i.e. BZB alone and combined with either Dbhu225-scTRAIL, 
scFvhu225-EHD2-scTRAIL, scFvhu225-Fc-scTRAIL, or Fc-scTRAIL. Mice received six 
combinatorial treatments of 5 µg bortezomib (i.p.) and 0.5 nmol protein (corresponding to 
1 nmol scTRAIL units; i.v.). After three treatments every other day, treatment intervals were 
gradually increased by one day. Already a single treatment with protein and bortezomib 
induced extensive tumor regression that continued until almost complete and persistent 
tumor remission was observed (Figure 3.22A). 
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Figure 3.22: In vivo activity and PK of different EGFR-targeting scTRAIL formats and Fc-scTRAIL in combination 
with bortezomib. A) NMRI nude mice (6 mice per group) bearing Colo205 tumors with a size of approximately 
100 mm3 received six combinatorial treatments of bortezomib (5 µg; i.p.) and protein (0.5 nmol protein 
corresponding to 1 nmol scTRAIL units; i.v.). Dotted lines indicate days of treatment (days 13, 15, 17, 20, 24, 29). 
B) Tumor volumes of groups I to V at day 38 are represented (numbering of groups according to A). Statistical 
analysis was performed by One-Way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001; 
ns, P>0.05). C) Serum concentrations of samples taken 3 min, 4 h, 24 h, and 48 h after the first (day 13) and last 
treatment (day 29) were determined by ELISA. D) Potential toxicity of the treatments was evaluated by measuring 
ALT and amylase activity in serum samples collected 4 h and 24 h after the first and the last treatment. 
 
Even after more than 100 d, only single tumors in the groups treated with Dbhu225-scTRAIL 
and scFvhu225-EHD2-scTRAIL slowly started to regrow. Except for these observations, no 
differences in the effects exerted by the different proteins were seen. Statistical analysis of 
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the tumor volumes at day 38 revealed a significant reduction in all protein-treated groups 
compared to mice only receiving bortezomib injections (Figure 3.22B). In order to confirm the 
PK data already described in tumor-free mice (see 3.2.1.4), serum concentrations of the 
proteins were examined after the first and last treatment (Figure 3.22C). Since the detected 
PK profiles of all proteins were in perfect accordance with those measured in CD-1® mice, the 
presence of Colo205 tumors and the application of clearly higher doses (84 µg to 111 µg 
protein instead of 25 µg or 50 µg) did not affect the in vivo half-lives of the proteins. 
Furthermore, no accumulation of the proteins due to multiple injections was observed as 
demonstrated by comparable serum concentrations determined after the first and last 
treatment. The potential induction of toxicity by the treatments was examined 4 h and 24 h 
after the first and the last injections (Figure 3.22D). Effects on the liver were assessed by 
measuring levels of alanine transaminase (ALT) in the serum, whereas pancreatic and renal 
toxicity was evaluated by determination of amylase activity. Compared to untreated mice, 
neither bortezomib alone nor combinations with any protein induced elevated levels of ALT 
or amylase at any analyzed point confirming safety of the treatments. 
 
In contrast to the in vitro data, no beneficial impact of targeting EGFR was observed in vivo in 
the above represented experiment. Since all proteins induced complete tumor regression, 
another study was performed using lower doses of scFvhu225-Fc-scTRAIL and Fc-scTRAIL to 
investigate potential targeting effects in more detail. The treatment comprised six 
administrations of 5 µg bortezomib (i.p.) and 0.3 nmol or 0.1 nmol protein (corresponding to 
0.6 nmol and 0.2 nmol scTRAIL units; i.v.) twice a week. Application of the higher doses again 
induced almost complete and persisting tumor remission for both proteins (Figure 3.23A), but 
only partial remission and regrowth were observed for treatment with a dose of 0.1 nmol. 
After 67 days, tumor volumes of mice treated with 0.1 nmol scFvhu225-Fc-scTRAIL were 
higher than those of mice receiving 0.1 nmol Fc-scTRAIL, but significant differences were only 
detected between treatment with 0.1 nmol scFvhu225-Fc-scTRAIL and the higher dose of both 
proteins (Figure 3.23B). The analyzed serum concentrations of the constructs were consistent 
with the previously described data and reflected the respective doses (Figure 3.23C). 
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Figure 3.23: Anti-tumor effects and PK of scFvhu225-Fc-scTRAIL and Fc-scTRAIL in combination with 
bortezomib. A) NMRI nude mice (6 mice per group) with established Colo205 tumors were treated with BZB 
(5 µg; i.p.) and protein (0.3 nmol or 0.1 nmol protein corresponding to 0.6 nmol or 0.2 nmol scTRAIL units, 
respectively; i.v.) twice a week for three weeks (days 14, 18, 21, 25, 28, 32). Treatments are indicated with dotted 
lines. B) Tumor volumes of groups II to V at day 67 are shown (numbering of groups according to A). Statistical 
analysis was performed by One-Way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001; 
ns, P>0.05). C) PK was analyzed by determination of the serum concentrations 3 min, 4 h, and 24 h after the first 
treatment (day 14) by ELISA. 
 
Since no favorable effects of targeting EGFR, but also no variations due to differences in the 
PK of the molecules were observed in the previous experiments, a final study was performed 
investigating Dbhu225-scTRAIL, scFvhu225-EHD2-scTRAIL, scFvhu225-Fc-scTRAIL, and Fc-
scTRAIL in the absence of bortezomib. Mice received six i.v. injections of 0.2 nmol protein 
(corresponding to 0.4 nmol scTRAIL units) twice a week. While treatment with both Fc 
constructs resulted in almost complete tumor remission, only a retardation of tumor growth 
was seen for Dbhu225- and scFvhu225-EHD2-scTRAIL (Figure 3.24A). Compared to control 
mice, tumor volumes of all protein-treated groups were significantly reduced at day 47 (Figure 
3.24B). Yet, significant differences between the different proteins were only obtained for Fc-
scTRAIL versus Dbhu225-scTRAIL and scFvhu225-EHD2-scTRAIL. Serum concentrations of the 
molecules fitted the PK data determined before (Figure 3.24C). Again, no liver toxicity was 
induced as examined by measuring ALT levels (Figure 3.24D). Thus, this final PD experiment 
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demonstrated higher activity of the longer-circulating Fc constructs, but no favorable 
influence of fusion to an antibody moiety was found. 
 
Figure 3.24: In vivo effects and PK of different formats of EGFR-targeting scTRAIL fusion proteins and Fc-scTRAIL 
in the absence of bortezomib. A) NMRI nude mice bearing Colo205 tumors (6 mice per group) received six i.v. 
treatments with 0.2 nmol protein (corresponding to 0.4 nmol scTRAIL units) or PBS as control. Dotted lines 
indicate the days of treatment (days 14, 18, 21, 25, 28, 32). B) Statistical analysis of tumor volumes of groups I to 
IV (numbering of groups according to A) at day 47 was done by One-Way ANOVA, followed by Tukey’s post hoc 
test (*P<0.05; **P<0.01; ***P<0.001; ns, P>0.05). C) Serum concentrations 4 h and 24 h after the last treatment 
(day 32) were determined by ELISA. D) To measure potential toxic effects, ALT activity was analyzed 4 h and 24 h 
after the last treatment. 
 
Summing up all data generated for the EGFR- and non-targeting scTRAIL fusion proteins, all 
targeted formats exerted better in vitro effects than the non-targeted dimeric molecule that 
in turn was superior to scTRAIL. Furthermore, highest yields were achieved for the Fc fusion 
proteins. In vivo PK studies revealed longest half-lives for the Fc constructs that probably 
translated into enhanced therapeutic activity at a dose of 0.2 nmol protein in the absence of 
bortezomib. However, the analyzed settings failed to confirm the beneficial impact of 
targeting in vivo. 
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3.2.2 HER2-targeting scTRAIL fusion proteins 
3.2.2.1 Biochemical characterization 
As outlined before, further validation of the different targeted dimeric scTRAIL formats, i.e. 
Db-scTRAIL, dsDb-scTRAIL, scFv-EHD2-scTRAIL, and scFv-Fc-scTRAIL, was done by exchanging 
the targeting moieties. Fusion proteins directed against HER2 were based on recombinant 
antibodies containing the 4D5 targeting moiety (see 3.1.2). All molecules were produced with 
yields in the range of 1.8 to 12.7 mg protein per liter cell culture supernatant (Table 3.9) 
confirming considerably better production properties of the Fc construct. SDS-PAGE verified 
purity and integrity of all proteins, but also identified bands of higher molecular masses under 
non-reducing conditions (Figure 3.25A). Size exclusion HPLC was performed to investigate the 
proteins under native conditions. All molecules eluted as one predominant peak of the 
expected size (Figure 3.25B) with a small amount of high molecular weight species detected 
for scFv4D5-Fc-scTRAIL, and even higher amounts observed for scFv4D5-EHD2-scTRAIL and 
dsDb4D5-scTRAIL. Hydrodynamic radii ranged from 5.3 nm to 6.7 nm (Table 3.9) and were 
thus comparable to those of the corresponding EGFR-targeting formats (Table 3.5). Dynamic 
light scattering revealed melting points of 54 °C to 63  C again indicating better thermal 
stability of the EHD2 and Fc constructs than of the diabody molecules (Table 3.9). 
 
Figure 3.25: Biochemical characterization of HER2-targeting scTRAIL fusion proteins. A) Db4D5-scTRAIL (1), 
dsDb4D5-scTRAIL (2), scFv4D5-EHD2-scTRAIL (3), and scFv4D5-Fc-scTRAIL (4) were analyzed in SDS-PAGE (8 % 
PAA) under reducing (R) and non-reducing conditions (NR). 2 µg of protein were loaded per lane and stained with 
Coomassie Brilliant Blue. M, protein marker. B) Proteins were separated depending on their sizes by HPLC. Elution 
points of standard proteins and their respective molecular masses [kDa] are indicated with dotted lines. 
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3.2.2.2 Evaluation of binding properties 
The binding capacities provided by the antibody and scTRAIL moieties were validated by 
investigating binding to HER2 as well as to human TRAIL-R2 in ELISA (Figure 3.26). All proteins 
bound in a concentration-dependent manner to both target proteins. HER2 binding properties 
were with EC50 values of 4.3 nM to 9.3 nM scTRAIL units (Table 3.9) similar to those of the 
respective recombinant antibodies (Table 3.2), and binding to huTRAIL-R2 was comparable to 
that detected for the EGFR- and non-targeting molecules (Table 3.6). Further binding studies 
were performed by flow cytometry (Figure 3.26) measuring half-maximal binding to Colo205 
cells at concentrations of 14.9 nM to 28.2 nM scTRAIL units (Table 3.9). Statistical analysis of 
the EC50 values of the ELISA and flow cytometry studies identified significantly reduced binding 
of Db4D5-scTRAIL to HER2 (P<0.05), whereas significantly increased binding of this molecule 
compared to scFv4D5-Fc-scTRAIL was detected on Colo205 cells (P<0.05), and no significant 
differences were observed for human TRAIL-R2 binding (P>0.05). Hence, there are no 
consistent differences in the binding properties of the HER2-targeting scTRAIL formats. 
 
Figure 3.26: Binding studies of HER2-targeting scTRAIL molecules. Binding to receptor-Fc fusion proteins was 
evaluated by ELISA. 300 ng HER2-Fc or 200 ng huTRAIL-R2-Fc were coated per well. Bound proteins were 
detected with an anti-FLAG-HRP conjugate. Optical densities measured at 450 nm were normalized to the value 
determined for the highest concentration analyzed. Binding to Colo205 cells was investigated by flow cytometry 
detecting bound proteins using a PE-conjugated anti-FLAG antibody. Concentrations refer to scTRAIL units. 
 
Table 3.9: Biochemical and binding properties of HER2-targeting scTRAIL fusion proteins. Molecular masses (M) 
were calculated based on the amino acid sequence. Yields are expressed as mg protein per liter cell culture 
supernatant. Stokes radii (Sr) and melting points (TM) were determined by size exclusion HPLC and dynamic light 
scattering, respectively. Half-maximal binding was analyzed by ELISA (HER2-, huTRAIL-R2-Fc) and flow cytometry 
(Colo205 cells) and is represented as nM of scTRAIL units. 
Protein M 
[kDa] 
Yield 
[mg/l] 
Sr 
[nm] 
TM 
[°C] 
EC50 HER2 
[nM] 
EC50 huTRAIL-
R2 [nM] 
EC50 Colo205 
[nM] 
Db4D5-scTRAIL 168 1.8 5.3 54 9.3 ± 2.9 1.5 ± 0.2 18.3 ± 3.1 
dsDb4D5-scTRAIL 168 2.3 5.3 56 4.7 ± 1.0 2.2 ± 1.6 23.3 ± 3.7 
scFv4D5-EHD2-scTRAIL 194 2.1 5.9 57 5.1 ± 1.3 2.4 ± 0.7 14.9 ± 3.7 
scFv4D5-Fc-scTRAIL 222 12.7 6.7 63 4.3 ± 0.6 0.7 ± 0.04 28.2 ± 3.0 
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3.2.2.3 Induction of cell death in vitro 
Bioactivity of the molecules was determined by investigating their potential to induce cell 
death on two colorectal carcinoma cell lines. All proteins were capable of inducing cell death 
on Colo205 cells alone or in combination with bortezomib (Figure 3.27A). Compared to 
dsDb4D5-scTRAIL and scFv4D5-Fc-scTRAIL that elicited 50 % cell death at concentrations of 
40.5 pM and 58.6 pM in the absence of bortezomib, lower activity was observed for Db4D5-
scTRAIL and scFv4D5-EHD2-scTRAIL (P<0.001; Table 3.10). Since high molecular weight species 
were not only detected for dsDb4D5-scTRAIL and scFv4D5-Fc-scTRAIL, but also for scFv4D5-
EHD2-scTRAIL (Figure 3.25), the SEC results are only partially able to explain the differences in 
cell death induction. Preincubation with bortezomib showed the desired sensitization 
(significant decrease in EC50 values with P<0.001) with similar variations in the activity profiles 
of the different formats. 
 
Figure 3.27: Cell death induction of HER2-targeting scTRAIL molecules on Colo205 cells. A) Colo205 cells 
(50,000/well) were cultivated overnight. After preincubation with medium or BZB (250 ng/ml) for 30 min, cells 
were treated with serial dilutions of the proteins for 16 h. Viable cells were stained with crystal violet. B) In order 
to analyze the effects of targeting HER2, cells were pretreated with a 200-fold molar excess of trastuzumab in 
medium or medium containing BZB (250 ng/ml). All other steps were performed as described in A. 
Concentrations refer to scTRAIL units. 
 
Although the HER2-targeting recombinant antibodies alone did not exert any effects on 
Colo205 cells (Figure 3.5C), further studies were performed after pretreatment with a 200-
fold molar excess of trastuzumab to analyze the potential contribution of targeting HER2 of 
the scTRAIL molecules (Figure 3.27B). In contrast to the results of the EGFR-targeting fusion 
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proteins, no significant alterations in cell death induction (P>0.05) were measured for the 
scTRAIL constructs directed against HER2 under blocking conditions, except for scFv4D5-Fc-
scTRAIL in the absence of bortezomib (P<0.05). This indicates that the HER2-targeting 4D5 
antibody moieties have no effect on cell death induction of the respective fusion proteins 
(Table 3.10). 
 
Figure 3.28: Cell death induction of HER2-targeting scTRAIL molecules on HCT116 cells. Prior to treatment of 
HCT116 cells (15,000/well) with serial dilutions of the proteins for 16 h, cells were preincubated with medium or 
BZB (250 ng/ml) for 30 min. Viable cells were visualized by crystal violet staining. Concentrations refer to scTRAIL 
units. 
 
The activity of the HER2-targeting scTRAIL molecules demonstrated for Colo205 cells was 
confirmed using HCT116 cells (Figure 3.28). Similar to the results obtained for Colo205 cells, 
dsDb4D5-scTRAIL and scFv4D5-Fc-scTRAIL showed with EC50 values of 66.4 pM and 125.1 pM 
in the absence of bortezomib better effects than the other two formats (P<0.05; Table 3.10). 
Preincubation with bortezomib strongly sensitized the cells for treatment with the HER2-
targeting scTRAIL molecules as illustrated by 25- to 57-fold lower EC50 values (P<0.01). 
 
Table 3.10: EC50 values of cell death induction of HER2-targeting scTRAIL molecules. Effects on Colo205 and 
HCT116 cells were analyzed after preincubation with medium or BZB (250 ng/ml) and treatment with the 
proteins for 16 h. Additional studies were performed in the presence of a 200-fold molar excess of trastuzumab 
to block binding of the molecules to HER2. EC50 values are represented as pM scTRAIL units. 
Protein Colo205 HCT116 
without trastuzumab with trastuzumab without trastuzumab 
without BZB with BZB without BZB with BZB without BZB with BZB 
Db4D5-
scTRAIL 
319.9 ± 27.4 27.9 ± 4.9 270.1 ± 51.4 30.3 ± 4.6 227.8 ± 33.1 9.1 ± 1.6 
dsDb4D5-
scTRAIL 
40.5 ± 7.9 4.5 ± 0.6 37.6 ± 7.8 6.0 ± 1.5 66.4 ± 18.2 2.0 ± 0.6 
scFv4D5-
EHD2-scTRAIL 
224.0 ± 22.1 19.1 ± 1.9 281.7 ± 37.5 18.2 ± 2.9 297.1 ± 42.7 5.2 ± 1.2 
scFv4D5-Fc-
scTRAIL 
58.6 ± 5.3 8.4 ± 1.2 103.1 ± 21.2 9.1 ± 1.2 125.1 ±31.6 3.3 ± 0.2 
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In summary, comparable binding properties were determined for all HER2-targeting formats, 
while the highest production yield and best thermal stability was found for the Fc construct. 
Further differences were detected in cell death induction, but are supposed to be caused by 
heterogeneities of the protein preparations. 
 
3.2.3 HER3-targeting scTRAIL fusion proteins 
3.2.3.1 Biochemical characterization 
The third set of targeted dimeric scTRAIL formats was generated using the HER3-targeting 
moiety 3M6. Additionally, the Db-scTRAIL and scFv-Fc-scTRAIL formats were constructed 
comprising the 3-43 targeting moiety that already showed better binding properties than the 
corresponding 3M6-based recombinant antibody (see 3.1.3). 
 
Yields ranged from 1.7 to 8.8 mg protein per liter cell culture supernatant and again confirmed 
best production properties of the Fc constructs for both targeting moieties (Table 3.11). Purity 
and integrity of the proteins was verified by SDS-PAGE analysis, however identifying 
considerable amounts of the monomeric form of dsDb3M6-scTRAIL and scFv3M6-EHD2-
scTRAIL under non-reducing conditions (Figure 3.29A). Investigation of the proteins under 
native conditions by size exclusion HPLC revealed major peaks of the expected size only for 
the Fc constructs (Figure 3.29B). While approximately half of the protein of Db3-43-scTRAIL 
remained in its monomeric form, even higher amounts of monomer were detected for 
scFv3M6-EHD2-scTRAIL and the 3M6-based diabody molecules that were almost completely 
found as monomers. The hydrodynamic radii determined for the dimeric forms of 5.4 nm to 
6.7 nm (Table 3.11) reflected the sizes of the EGFR- and HER2-targeting molecules (Table 3.5, 
Table 3.9). Dynamic light scattering identified melting points of 57 °C and 61 °C for scFv3M6-
Fc-scTRAIL and scFv3-43-Fc-scTRAIL confirming better stability compared to the other formats 
(Table 3.11). 
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Figure 3.29: Biochemical characterization of HER3-targeting scTRAIL fusion proteins. A) SDS-PAGE (8 % PAA) of 
Db3M6-scTRAIL (1), dsDb3M6-scTRAIL (2), scFv3M6-EHD2-scTRAIL (3), scFv3M6-Fc-scTRAIL (4), Db3-43-scTRAIL 
(5), and scFv3-43-Fc-scTRAIL (6) was performed under reducing (R) and non-reducing conditions (NR). 2 µg 
protein were analyzed per lane. Proteins were stained with Coomassie Brilliant Blue. M, protein marker. B) Size 
exclusion HPLC was used to investigate proteins under native conditions. Elution times of standard proteins and 
the corresponding molecular masses [kDa] are indicated. 
 
3.2.3.2 Evaluation of binding properties 
Binding studies were performed by ELISA and flow cytometry analyzing binding to HER3, 
human TRAIL-R2, and Colo205 cells (Figure 3.30). In agreement with the data obtained for the 
corresponding recombinant antibodies (Table 3.3), the 3M6-based scTRAIL molecules bound 
to HER3 with EC50 values of 3.3 nM to 6.6 nM, whereas half-maximal binding of Db3-43-
scTRAIL and scFv3-43-Fc-scTRAIL was detected at significantly lower concentrations of 0.6 nM 
and 0.3 nM (P<0.01), respectively (Table 3.11). Binding to huTRAIL-R2 reflected with EC50 
values ranging from 2.1 nM to 3.4 nM that determined for the EGFR-, HER2- and non-targeted 
scTRAIL constructs (Table 3.6, Table 3.9). At low concentrations, both 3-43 molecules 
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exhibited stronger binding to Colo205 cells than the 3M6-based formats, though no saturation 
was reached for the Fc constructs for concentrations up to 1 µM.  
 
Figure 3.30: Binding studies of HER3-targeting scTRAIL molecules. Binding to receptor-Fc fusion proteins 
(200 ng/well) was analyzed by ELISA detecting bound proteins with an anti-FLAG-HRP. Optical densities 
measured at 450 nm were normalized to the value determined for the highest concentration. Binding to Colo205 
cells was investigated by flow cytometry. A PE-conjugated anti-FLAG antibody was used for detection of bound 
proteins. Concentrations refer to scTRAIL units. 
 
Table 3.11: Biochemical and binding properties of HER3-targeting scTRAIL molecules. Molecular masses (M) 
were calculated based on the amino acid sequence. Yields are expressed as mg protein per liter cell culture 
supernatant. Size exclusion HPLC and dynamic light scattering were performed to determine Stokes radii (Sr) and 
melting points (TM), respectively. Half-maximal binding was analyzed by ELISA (HER3-, huTRAIL-R2-Fc) and flow 
cytometry (Colo205 cells). Concentrations refer to scTRAIL units. 
Protein M 
[kDa] 
Yield 
[mg/l] 
Sr 
[nm] 
TM 
[°C] 
EC50 HER3 
[nM] 
EC50 huTRAIL-
R2 [nM] 
EC50 Colo205 
[nM] 
Db3M6-scTRAIL 167 1.9 5.4 52 5.6 ± 1.0 2.7 ± 0.4 20.4 ± 1.8 
dsDb3M6-scTRAIL 167 1.7 5.6 52 6.6 ± 0.9 3.4 ± 0.3 29.1 ± 1.6 
scFv3M6-EHD2-scTRAIL 193 1.9 5.9 55 5.7 ± 1.3 2.1 ± 0.2 44.4 ± 0.7 
scFv3M6-Fc-scTRAIL 221 3.8 6.6 57 3.3 ± 0.3 2.6 ± 0.1 (112.0 ± 17.9)‡ 
Db3-43-scTRAIL 169 1.9 5.8 52 0.6 ± 0.03 2.5 ± 0.7 3.1 ±0.5  
scFv3-43-Fc-scTRAIL 222 8.8 6.7 61 0.3 ± 0.01 2.9 ± 0.3 (68.0 ± 9.4)‡ 
‡, no saturation reached. 
 
3.2.3.3 Induction of cell death in vitro 
Bioactivity of the molecules was assessed by investigation of their potential to induce cell 
death on Colo205 and HCT116 cells. All HER3-targeting fusion proteins showed concentration-
dependent induction of cell death on Colo205 cells in the absence and presence of bortezomib 
(Figure 3.31A). Significant differences in the activities of different formats comprising the 
same antibody moieties were found, but are supposed to result from the substantial 
heterogeneities of the protein preparations (Figure 3.29B). Comparison of the homogeneously 
formed scFv3M6-Fc-scTRAIL and scFv3-43-Fc-scTRAIL molecules revealed significantly 
stronger effects of the 3-43-based fusion protein (P<0.001). These differences were found for 
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pretreatment with medium as well as with bortezomib that sensitized the cells as indicated 
by significantly lower EC50 values (P<0.001; Table 3.12). 
 
Figure 3.31: Cell death induction of HER3-targeting scTRAIL molecules on Colo205 cells. A) Colo205 cells 
(50,000/well) were preincubated with medium or BZB (250 ng/ml) for 30 min and treated with serial dilutions of 
the proteins. After 16 h, viable cells were stained with crystal violet. B) Binding of the molecules to HER3 was 
blocked by pretreatment of the cells with a 200-fold molar excess of scFv3M6-Fc or scFv3-43-Fc in medium or 
medium containing BZB (250 ng/ml). Remaining experimental set-up is described in A. Concentrations refer to 
scTRAIL units. 
 
Further studies were performed to analyze the impact of HER3 targeting by the different 
targeting moieties (Figure 3.31B). Experiments with the recombinant antibodies already 
demonstrated no influence for the 3M6 molecules, while scFv3-43-Fc seemed to exert 
inhibitory effects on Colo205 cells (Figure 3.7C, Figure 3.8D). The EC50 values obtained for the 
3M6-based fusion proteins after pretreatment with a 200-fold molar excess of scFv3M6-Fc did 
either not differ significantly from those observed in the absence of the blocking antibody or 
were even significantly reduced (P<0.05) instead of increased. However, preincubation with 
excess amounts of scFv3-43-Fc led to a 4- to 5-fold increase in the EC50 values of Db3-43-
scTRAIL and scFv3-43-Fc-scTRAIL in the absence and presence of bortezomib (P<0.01) 
corresponding to activity levels similar to those of the 3M6 constructs (Table 3.12). This 
indicates that targeting HER3 via the 3M6 moiety is not able to improve the properties of the 
respective scTRAIL fusion proteins. In contrast, the 3-43-based molecules that exhibit better 
binding to HER3 show clearly enhanced induction of cell death. 
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Figure 3.32: Cell death induction of HER3-targeting scTRAIL molecules on HCT116 cells. After preincubation 
with medium or BZB (250 ng/well) for 30 min, cells (15,000/well) were treated with serial dilutions of the proteins 
for 16 h. Cell viability was determined by crystal violet staining. Concentrations refer to scTRAIL units. 
 
The activities of the HER3-targeting molecules were further validated on HCT116 cells (Figure 
3.32). All fusion proteins were able to induce cell death in the absence and presence of 
bortezomib. Differing from the data obtained for Colo205 cells, similar effects were observed 
for all 3M6- and 3-43-based molecules with EC50 values ranging from 272.8 pM to 593.2 pM 
in the absence of bortezomib (P>0.05). Preincubation with bortezomib strongly sensitized the 
cells reducing the EC50 values by factors of 81 to 168 (P<0.05; Table 3.12). 
 
Table 3.12: EC50 values of cell death induction of HER3-targeting scTRAIL molecules. After preincubation with 
medium or BZB (250 ng/ml), Colo205 or HCT116 cells were treated with the proteins for 16 h. Further studies 
were performed adding a 200-fold molar excess of scFv3M6-Fc or scFv3-43-Fc to the preincubation medium. EC50 
values are represented as pM scTRAIL units. 
Protein Colo205 HCT116 
without blocking antibody with blocking antibody without blocking antibody 
without BZB with BZB without BZB with BZB without BZB with BZB 
Db3M6-
scTRAIL 
264.1 ± 21.1 43.0 ± 2.2 209.5 ± 6.0 46.6 ± 3.4 593.2 ± 289.6 6.7 ± 0.8 
dsDb3M6-
scTRAIL 
119.8 ± 9.5 27.3 ± 2.9 88.7 ± 4.4 28.0 ± 3.2 319.8 ± 173.4 3.4 ± 0.9 
scFv3M6-
EHD2-scTRAIL 
402.0 ± 16.8 51.1 ±5.3  204.1 ± 49.0 44.0 ± 4.7 446.2 ± 100.1 5.5 ± 0.6 
scFv3M6-Fc-
scTRAIL 
251.3 ± 12.2 34.1 ± 3.0 132.3 ± 6.3 25.8 ± 6.4 370.2 ± 83.0 3.5 ± 1.4 
Db3-43-
scTRAIL 
50.6 ± 1.6 8.9 ± 1.1 226.7 ± 11.4 40.1 ± 6.1 348.1 ± 99.9 2.2 ± 1.1 
scFv3-43-Fc-
scTRAIL 
32.1 ± 3.2 5.1 ± 0.6 163.9 ± 31.2 27.8 ± 8.4 272.8 ± 144.3 1.6 ± 0.8 
 
In conclusion, the 3-43 scTRAIL molecules showed improved HER3-binding activity compared 
to the 3M6-based fusion proteins. Furthermore, superior properties were identified for both 
Fc constructs with respect to production yield, stability, and reliable formation of the dimer. 
Variations in the capability of different formats comprising the same targeting moiety to 
induce cell death were attributed to heterogeneities of the protein preparations, but 
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beneficial effects of the 3-43-based fusion proteins were found, yet only on Colo205 cells, 
indicating a role of binding strength on cell death induction. 
 
3.2.4 EpCAM-targeting scTRAIL fusion proteins 
3.2.4.1 Biochemical characterization 
To finally validate the different formats of targeted dimeric scTRAIL molecules, Db-scTRAIL, 
scFv-EHD2-scTRAIL, and scFv-Fc-scTRAIL fusion proteins were generated containing the 
EpCAM-targeting moiety 323/A3hu3 (see 3.1.4). With 5.2 mg protein per liter cell culture 
supernatant, a 6- to 7-fold higher yield was achieved for scFv323/A3hu3-Fc-scTRAIL compared 
to the other formats (Table 3.13). SDS-PAGE analysis confirmed purity and integrity of all 
proteins under denaturing reducing and non-reducing conditions (Figure 3.33A).  
 
Figure 3.33: Biochemical characterization of EpCAM-targeting scTRAIL fusion proteins. A) Db323/A3hu3-
scTRAIL (1), scFv323/A3hu3-EHD2-scTRAIL (2), and scFv323/A3hu3-Fc-scTRAIL (3) were analyzed in SDS-PAGE 
(8 % PAA) under reducing (R) and non-reducing conditions (NR). 2 µg protein were loaded per lane and proteins 
were stained with Coomassie Brilliant Blue. M, protein marker. B) Size exclusion HPLC was performed to 
investigate proteins under native conditions. Elution times of standard proteins and their respective molecular 
masses [kDa] are indicated with dotted lines. 
 
Under native conditions examined by size exclusion HPLC, scFv323/A3hu3-EHD2-scTRAIL and 
scFv323/A3hu3-Fc-scTRAIL eluted as one major peak corresponding to the expected size 
(Figure 3.33B), whereas only a small amount of the correctly assembled dimer was detected 
for the diabody fusion protein. The considerable peak of FLAG peptide seen for the latter 
molecule becomes apparent due to the low concentration of the fusion protein itself. Protein 
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fractions of smaller size were additionally found for the EHD2 and Fc constructs. The 
hydrodynamic radii were determined for the dimeric forms of the proteins and ranged from 
5.7 nm to 6.7 nm (Table 3.13), which resembles the above described data. Thermal stability 
was measured by dynamic light scattering identifying a melting point of 60 °C for the Fc 
molecule that is 7 °C and 4 °C higher than those of Db323/A3hu3-scTRAIL and scFv323/A3hu3-
EHD2-scTRAIL, respectively (Table 3.13). 
 
3.2.4.2 Evaluation of binding properties 
Binding properties of the EpCAM-targeting scTRAIL molecules were evaluated by ELISA and 
flow cytometry by determination of binding to EpCAM, human TRAIL-R2, and Colo205 cells 
(Figure 3.34). ScFv323/A3hu3-EHD2-scTRAIL and scFv323/A3hu3-Fc-scTRAIL bound to EpCAM 
with similar EC50 values of 2.7 nM and 2.5 nM (P>0.05; Table 3.13), while the diabody 
construct exhibited significantly weaker binding (P<0.001) and did not reach saturation levels 
for concentrations up to 300 nM. Similarly, half-maximal binding of the EHD2 and Fc molecules 
to human TRAIL-R2 was detected at a concentration of 1.5 nM, whereas Db323/A3hu3-
scTRAIL required a significantly higher concentration of 2.7 nM (P<0.01; Table 3.13). This 
indicates that antigen and TRAIL-R2 binding are affected by the insufficient dimer formation 
of Db323/A3hu3-scTRAIL (Figure 3.33B). With an EC50 value of 85.6 nM for binding to Colo205 
cells, the diabody construct again showed lower binding activity (P<0.001) compared to 
15.1 nM and 9.8 nM measured for scFv323/A3hu3-EHD2-scTRAIL and scFv323/A3hu3-Fc-
scTRAIL, respectively (Table 3.13). 
 
Figure 3.34: Binding studies of EpCAM-targeting scTRAIL molecules. Binding to sEpCAM and huTRAIL-R2-Fc 
(each 200 ng/well) was analyzed by ELISA detecting bound proteins with an anti-FLAG-HRP. OD was measured at 
450 nm. Flow cytometry was performed to investigate binding to Colo205 cells. A PE-conjugated anti-FLAG 
antibody was used for detection. Data were normalized to the value determined for the highest concentration. 
Concentrations refer to scTRAIL units. 
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Table 3.13: Biochemical and binding properties of EpCAM-targeting scTRAIL molecules. Molecular masses (M) 
were calculated based on the amino acid sequence. Yields are expressed as mg protein per liter cell culture 
supernatant. Stokes radii (Sr) and melting points (TM) were determined by size exclusion HPLC and dynamic light 
scattering, respectively. EC50 values of binding to sEpCAM and huTRAIL-R2-Fc (ELISA), as well as to Colo205 cells 
(flow cytometry) are represented as nM scTRAIL units. 
Protein M 
[kDa] 
Yield 
[mg/l] 
Sr 
[nm] 
TM 
[°C] 
EC50 EpCAM 
[nM] 
EC50 huTRAIL-
R2 [nM] 
EC50 Colo205 
[nM] 
Db323/A3hu3-scTRAIL 169 0.7 5.7 53 (118.0 ± 33.7)‡ 2.7 ± 0.4 85.6 ± 17.7 
scFv323/A3hu3-EHD2-
scTRAIL 
195 0.9 6.2 56 2.7 ± 0.4 1.5 ± 0.1 15.1 ± 2.3 
scFv323/A3hu3-Fc-
scTRAIL 
223 5.2 6.7 60 2.5 ± 0.5 1.5 ± 0.2 9.8 ± 1.9 
‡, no saturation reached. 
 
3.2.4.3 Induction of cell death in vitro 
As already described above, bioactivity of the molecules was investigated by analyzing cell 
death induction on Colo205 and HCT116 cells. In the absence and presence of bortezomib, all 
EpCAM-targeting molecules were capable of inducing cell death on Colo205 cells (Figure 
3.35A). Resembling the Colo205 binding data (Table 3.13), the EHD2 and Fc constructs exerted 
with EC50 values of 85.5 pM und 57.2 pM in the absence of bortezomib similar effects (P>0.05) 
that were 7- to 10-fold stronger than the activity observed for Db323/A3hu3-scTRAIL (P<0.05; 
Table 3.14). Comparable differences between the formats were found in the presence of 
bortezomib that significantly increased cell death induction (P<0.05).  
 
Experiments with scFv323/A3hu3-Fc did not reveal an influence of the recombinant antibody 
alone on Colo205 cells (Figure 3.9D). Evaluation of a potential contribution of the EpCAM-
targeting antibody moiety on cell death induction of the scTRAIL molecules was performed by 
preincubation of the cells with a 200-fold molar excess of scFv323/A3hu3-Fc (Figure 3.35B). 
This induced an increase in the EC50 values of Db323/A3hu3-scTRAIL by factors of 4 and 2 in 
the absence (P<0.05) and presence of bortezomib (P<0.01), respectively. Interestingly, similar 
(P>0.05) or even significantly lower values (P<0.05) were detected for the EHD2 and Fc 
constructs under blocking conditions (Table 3.14). 
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Figure 3.35: Cell death induction of EpCAM-targeting scTRAIL molecules on Colo205 cells. A) Cells (50,000/well) 
were treated with serial dilutions of the proteins for 16 h after preincubation with medium or BZB (250 ng/ml) 
for 30 min. Viable cells were stained with crystal violet. B) A 200-fold molar excess of scFv323/A3hu3-Fc was 
added during preincubation, while all other steps were performed as described in A. Concentrations refer to 
scTRAIL units. 
 
Experiments using HCT116 cells confirmed the capability of the EpCAM-targeting scTRAIL 
fusion proteins to induce cell death (Figure 3.36). Reflecting the results obtained for Colo205 
cells, the EHD2 and Fc molecules elicited similar (P>0.05) and considerably stronger effects 
compared to Db323/A3hu3-scTRAIL (P<0.05) in the absence as well as in presence of 
bortezomib (Table 3.14). 
 
Figure 3.36: Cell death induction of EpCAM-targeting scTRAIL molecules on HCT116 cells. HCT116 cells 
(15,000/well) were preincubated with medium or BZB (250 ng/ml) for 30 min and treated with serial dilutions of 
the proteins for 16 h. Viable cells were visualized by crystal violet staining. Concentrations refer to scTRAIL units. 
 
 
 
 
A)
B)
without BZB
0
25
50
75
100
125
10 -3 10 -2 10 -1 100 1010
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
0
25
50
75
100
125
10 -4 10 -3 10 -2 10 -1 1000
Db323/A3hu3-scTRAIL
scFv323/A3hu3-EHD2-scTRAIL
scFv323/A3hu3-Fc-scTRAIL
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
0
25
50
75
100
125
10 -3 10 -2 10 -1 100 1010
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
250 ng/ml BZB
0
25
50
75
100
125
10 -4 10 -3 10 -2 10 -1 1000
Db323/A3hu3-scTRAIL
scFv323/A3hu3-EHD2-scTRAIL
scFv323/A3hu3-Fc-scTRAIL
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
250 ng/ml BZB
0
25
50
75
100
125
10 -4 10 -3 10 -2 10 -1 1000
Db323/A3hu3-scTRAIL
scFv323/A3hu3-EHD2-scTRAIL
scFv323/A3hu3-Fc-scTRAIL
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
without BZB
0
25
50
75
100
125
10 -3 10 -2 10 -1 100 1010
scTRAIL units [nM]
V
ia
b
il
it
y
 [
%
]
  RESULTS   
  107   
Table 3.14: EC50 values of cell death induction of EpCAM-targeting scTRAIL molecules. Half-maximal effective 
concentrations are represented as pM scTRAIL units for Colo205 and HCT116 cells preincubated with medium or 
BZB (250 ng/ml). Additional experiments were performed in the presence of a 200-fold molar excess of 
scFv323/A3hu3-Fc during the preincubation step. 
Protein Colo205 HCT116 
without scFv323/A3hu3-Fc with scFv323/A3hu3-Fc without scFv323/A3hu3-Fc 
without BZB with BZB without BZB with BZB without BZB with BZB 
Db323/A3hu3-
scTRAIL 
569.7 ± 275.7 63.3 ± 8.9 2294.5 ± 838.3 127.8 ± 15.2 410.8 ± 190.5 11.7 ± 5.2 
scFv323/A3hu3-
EHD2-scTRAIL 
85.5 ± 22.6 13.3 ± 4.4 40.9 ± 6.2 7.7 ± 1.0 32.5 ± 14.4 1.4 ± 0.6 
scFv323/A3hu3-
Fc-scTRAIL 
57.2 ± 21.5 11.2 ± 2.7 34.0 ± 0.7 4.4 ± 0.8 24.8 ± 8.5 1.3 ± 0.2 
 
Consequently, the data of the EpCAM-targeting scTRAIL fusion proteins confirm the 
observations already described for the other targeted scTRAIL molecules. In summary, the 
results of all these sets of targeted dimeric scTRAIL fusion proteins allow several conclusions 
about the different formats: i) The format has no consistent influence on the binding activity. 
ii) Differences in the capability to induce cell death in vitro are supposed to solely result from 
heterogeneities of the protein preparations. iii) Superior properties were detected for the Fc 
constructs with respect to production yield, thermal stability, reliable dimer formation, 
pharmacokinetics, and in vivo therapeutic activity. iv) Targeting effects were only identified in 
vitro and only for molecules comprising the hu225 and 3-43 moieties, thus requiring further 
analysis of scTRAIL constructs of different targeting moieties to unravel the determinants of 
in vitro targeting effects and also to provide a deeper understanding of in vivo activities. 
Concerning the non-targeted formats, better activity was observed for the dimeric compared 
to the monomeric form. 
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3.3 Comparison of scTRAIL fusion proteins with different targeting moieties 
Based on the above mentioned results that demonstrate superior properties of scFv-Fc-
scTRAIL compared to the other targeted dimeric formats, further studies of scFv-Fc-scTRAIL 
molecules and Fc-scTRAIL were performed to evaluate variations due to different targeting 
moieties. Attention was in particular focused on gaining insight into factors influencing 
targeting effects in vitro as well as in vivo. To allow reliable comparison, several experiments 
were repeated analyzing the scFv-Fc-scTRAIL molecules of different targeting moieties 
simultaneously in the same experimental setting. Referring to the biochemical properties 
described above, the targeting moiety seems to have an influence of on the production yields 
ranging from 3.8 (3M6) to 12.7 mg (4D5) protein per liter cell culture supernatant as well as 
on the thermal stability with melting points differing by 6 °C. 
 
3.3.1 Binding properties 
Binding to target proteins and tumor cell lines was investigated as the first level to determine 
differences in the activities of the scFv-Fc-scTRAIL molecules. Evaluation of binding to the 
respective antigens in ELISA revealed strong binding of the hu225- and 3-43-based fusion 
proteins with EC50 values of 0.9 nM and 0.3 nM that were 3- to 14-fold lower (P<0.01) than 
the concentrations detected for the other constructs (Table 3.15). Consistent with the above 
represented data, EC50 values of binding to human TRAIL-R2 were in the low nanomolar range 
for all molecules. Further ELISA studies were performed to verify antigen specificities (Figure 
3.37A) and binding to human and mouse TRAIL receptors (Figure 3.37B,C). All molecules 
bound to their designated target antigens, and no binding to EGFR, HER2, HER3, or EpCAM 
was identified for Fc-scTRAIL. In accordance with the data obtained for the different formats 
of EGFR-targeting scTRAIL fusion proteins (Figure 3.12), all scFv-Fc-scTRAIL constructs and Fc-
scTRAIL were capable of binding to all human and mouse TRAIL receptors, except for mouse 
DcTRAIL-R1. 
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Figure 3.37: Binding of scFv-Fc-scTRAIL molecules and Fc-scTRAIL to target proteins in ELISA. A) 20 nM protein 
(scTRAIL units) were analyzed for binding to receptor-Fc fusion proteins or sEpCAM (300 ng/well). Bound 
molecules were detected with an anti-FLAG-HRP or anti-human IgG (Fc specific)-POD. B) Binding of the molecules 
to Fc fusion proteins of human and C) mouse TRAIL receptors (200 ng/well) was investigated at a concentration 
of 40 nM scTRAIL units. Bound molecules were detected with an anti-FLAG-HRP. relative OD450nm, OD of sample 
measured at 450 nm divided by OD of coating control (detection of coated protein via anti-human IgG (Fc 
specific)-POD or anti-FLAG-HRP). Block shift was performed for binding to human TRAIL receptors. 
 
To further characterize the two colorectal carcinoma cell lines Colo205 and HCT116, relative 
expression levels of EGFR, HER2, HER3, HER4, EpCAM, and all TRAIL receptors were 
determined by flow cytometry (Figure 3.38A). While HER2 and HER3 were expressed in higher 
levels on Colo205 compared to HCT116 cells, no differences in the expression levels of EGFR 
and EpCAM were observed between the two cell lines. Likewise, TRAIL receptor expression 
levels were comparable for both cell lines, except for TRAIL-R1 that was more strongly 
expressed on HCT116 cells. Binding studies of the scFv-Fc-scTRAIL molecules and Fc-scTRAIL 
on Colo205 cells confirmed the data already obtained (see 3.1) and were further verified on 
HCT116 cells (Figure 3.38B). Differing from the ELISA data, strongest binding to both cell lines 
was identified for the construct comprising the hu225 targeting moiety, followed by 
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323/A3hu3, 4D5, and the HER3-targeting molecules that did not reach saturation levels for 
concentrations up to 1 µM (Table 3.15). Of note, binding levels of the 4D5 and especially 3-43 
constructs on Colo205 cells were higher than those of Fc-scTRAIL already for low protein 
concentrations. In contrast, on HCT116 cells, increased binding of these proteins compared to 
Fc-scTRAIL was only observed for high concentrations indicating an impact of receptor 
expression levels on binding activities.  
 
Figure 3.38: Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells. 
A) Relative EGFR, HER2, HER3, HER4, EpCAM, and TRAIL-R expression levels were investigated. B) Serial dilutions 
of the molecules were analyzed. Concentrations refer to scTRAIL units. C) Binding of 20 nM scTRAIL units to 
Colo205 and HCT116 cells was determined after preincubation with PBA or a 200-fold molar excess of the 
respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies 
separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were 
detected via anti-FLAG-PE. 
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The contribution of the antibody moieties to cell binding was further investigated by blocking 
experiments (Figure 3.38C). After preincubation of Colo205 cells with a 200-fold molar excess 
of the respective blocking antibody, binding of the hu225, 4D5, 3-43, and 323/A3hu3 
constructs was reduced to a level similar to that of the non-targeted Fc-scTRAIL that was not 
influenced by the presence of blocking antibodies. In constrast, binding of scFv3M6-Fc-scTRAIL 
was not decreased by excess amounts of scFv3M6-Fc, but rather increased binding levels were 
detected. On HCT116 cells, only binding of scFvhu225-Fc-scTRAIL and scFv323/A3hu3-Fc-
scTRAIL was affected by blocking with the respective antibody, whereas all other targeted 
scTRAIL molecules already showed binding levels similar to Fc-scTRAIL without blocking. 
Consequently, comparison of the binding properties revealed strongest antigen binding for 
scFvhu225-Fc-scTRAIL and scFv3-43-Fc-scTRAIL in ELISA. Enhanced binding to Colo205 cells 
was confirmed for molecules comprising the hu225, 4D5, 3-43, and 323/A3hu3 moieties. 
However, only the hu225 and 323/A3hu3 antibody units improved binding of the respective 
scTRAIL molecules on HCT116 cells. 
 
Table 3.15: Binding properties of scFv-Fc-scTRAIL molecules and Fc-scTRAIL. EC50 values are expressed as nM 
scTRAIL units and were determined by ELISA (EGFR-, HER2-, HER3-, huTRAIL-R2-Fc, sEpCAM) and flow cytometry 
(Colo205, HCT116 cells). 
Protein Antigen huTRAIL-R2 Colo205 HCT116 
scFvhu225-Fc-scTRAIL 0.9 ± 0.01 1.0 ± 0.02 1.4 ± 1.1 0.4 ± 0.1 
scFv4D5-Fc-scTRAIL 4.3 ± 0.6 1.2 ± 0.1 32.5 ± 7.9 (34.8 ± 6.8)‡ 
scFv3M6-Fc-scTRAIL 3.3 ± 0.3 1.6 ± 0.2 (>100)‡ (26.3 ± 0.9)‡ 
scFv3-43-Fc-scTRAIL 0.3 ± 0.01 1.2 ± 0.1 (>100)‡ (>100)‡ 
scFv323/A3hu3-Fc-scTRAIL 2.5 ± 0.5 1.4 ± 0.1 7.2 ± 0.4 4.8 ± 0.3 
Fc-scTRAIL n.d. 1.4 ± 0.1 (>100)‡ (20.9 ± 2.1)‡ 
n.d., not determined. ‡, no saturation reached. 
 
3.3.2 Induction of cell death in vitro 
To reliably compare induction of cell death by the different scFv-Fc-scTRAIL molecules and Fc-
scTRAIL, experiments analyzing Colo205 and HCT116 cells in the absence and presence of 
bortezomib were repeated. In addition to Colo205 cells, blocking studies were furthermore 
performed using HCT116 cells. Overall, these data were in good agreement with the results 
already described (Table 3.16). In the absence of bortezomib, strongest effects on Colo205 
cells were observed for scFvhu225-Fc-scTRAIL and scFv3-43-Fc-scTRAIL (significantly reduced 
EC50 values compared to 4D5, 3M6, 323/A3hu3, and non-targeted constructs with P<0.05), 
followed by the EpCAM-targeting molecule (significantly reduced EC50 value compared to 4D5, 
3M6, and non-targeted constructs with P<0.01), while the remaining fusion proteins exhibited 
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similar or even decreased activity compared to Fc-scTRAIL. In the presence of bortezomib, 
only the hu225 and 3-43 constructs showed significantly improved properties in comparison 
to the non-targeted fusion protein (P<0.01). HCT116 cells were most effectively killed by the 
EGFR- and EpCAM-targeting scTRAIL molecules without and with bortezomib (P<0.05), and no 
beneficial contribution was identified for the other targeting moieties. Preincubation with the 
respective blocking antibody increased the EC50 values of the hu225 and 3-43 constructs on 
Colo205 cells in the absence and presence of bortezomib (P<0.01) to the level of the non-
targeted fusion protein or even higher. However, blocking of EpCAM binding did not reduce 
cell death induction of scFv323/A3hu3-Fc-scTRAIL. On HCT116 cells, blocking significantly 
increased the EC50 values of the hu225 molecule (P<0.01), while the activity of scFv323/A3hu3-
Fc-scTRAIL was not influenced to a similar extent. 
 
Table 3.16: EC50 values of cell death induction of scFv-Fc-scTRAIL molecules and Fc-scTRAIL. EC50 values [pM 
scTRAIL units] were determined after 16 h of treatment of Colo205 and HCT116 cells in the absence or presence 
of BZB (250 ng/ml). To analyze potential targeting effects, cells were preincubated with a 200-fold molar excess 
of the respective blocking antibody (Ab) in medium or medium containing BZB (250 ng/ml). Fc-scTRAIL was 
investigated in the presence of a mixture of all blocking antibodies. 
Protein Colo205 HCT116 
without blocking Ab with blocking Ab without blocking Ab with blocking Ab 
without 
BZB 
with 
BZB 
without 
BZB 
with 
BZB 
without 
BZB 
with 
BZB 
without 
BZB 
with 
BZB 
scFvhu225-Fc-
scTRAIL 
22.6 ± 
3.4 
7.9 ± 1.7 106.9 ± 
9.0 
18.5 ± 
3.6 
12.9 ± 
3.9 
1.3 ± 0.2 103.2 ± 
22.7 
4.0 ± 0.6 
scFv4D5-Fc-
scTRAIL 
104.4 ± 
6.0 
29.7 ± 
3.5 
163.3 ± 
9.4 
35.6 ± 
3.1 
109.5 ± 
10.7 
5.0 ± 1.4 79.2 ± 
17.7 
4.9 ± 1.6 
scFv3M6-Fc-
scTRAIL 
247.8 ± 
8.8 
39.5 ± 
5.7 
143.8 ± 
10.1 
26.4 ± 
2.9 
173.1 ± 
27.2 
5.7 ± 0.4 125.0 ± 
15.3 
5.4 ± 1.5 
scFv3-43-Fc-
scTRAIL 
31.1 ± 
3.5 
6.8 ± 0.9 217.3 ± 
6.5 
33.1 ± 
5.7 
131.1 ± 
7.1 
3.0 ± 0.8 148.4 ± 
31.2 
7.1 ± 1.1 
scFv323/A3hu3-
Fc-scTRAIL 
58.0 ± 
12.1 
17.7 ± 
2.9 
31.5 ± 
5.7 
9.7 ± 1.9 13.5 ± 
0.8 
1.3 ± 0.3 31.1 ± 
6.9 
1.0 ± 0.1 
Fc-scTRAIL 96.4 ± 
11.5 
21.7 ± 
3.5 
130.0 ± 
10.6 
35.7 ± 
9.7 
98.9 ± 
22.0 
3.2 ± 0.3 75.1 ± 
17.3 
4.9 ± 0.7 
 
Since a 200-fold molar excess of blocking antibody did not reduce the activity of 
scFv323/A3hu3-Fc-scTRAIL to the level of Fc-scTRAIL, additional blocking experiments were 
performed investigating the effects of the EpCAM-targeting fusion protein and the non-
targeted construct after increasing the molar excess of scFv323/A3hu3-Fc to 500-fold (Figure 
3.39). Even in the presence of these considerable amounts of blocking antibody, 
scFv323/A3hu3-Fc-scTRAIL induced cell death 2- to 3.4-fold more strongly than Fc-scTRAIL 
(P<0.05) on Colo205 and HCT116 cells in the absence as well as in presence of bortezomib. 
Thus, the beneficial properties of scFv323/A3hu3-Fc-scTRAIL were not impaired by blocking of 
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EpCAM binding and require further studies to elucidate the factors provoking this superior 
activity. With respect to the more than 16- and 9-fold higher relative MFIs of the EpCAM-
targeting molecule on Colo205 and HCT116 cells compared to all other fusion proteins (Figure 
3.38B), the lacking effects of blocking EpCAM binding on cell death induction may be related 
to high EpCAM expression levels. 
 
Figure 3.39: Blocking studies of scFv323/A3hu3-Fc-scTRAIL-induced cell death. Colo205 (50,000/well) and 
HCT116 cells (15,000/well) were treated with serial dilutions of scFv323/A3hu3-Fc-scTRAIL and Fc-scTRAIL for 
16 h after preincubation with a 500-fold molar excess of scFv323/A3hu3-Fc in medium or medium containing 
BZB (250 ng/ml). Viable cells were stained with crystal violet. Concentrations refer to scTRAIL units. EC50 values 
[pM scTRAIL units] are indicated with dotted lines. 
 
Additional studies of cell death induction were designed to analyze a potential influence of 
bortezomib on targeting. The hu225 and 3-43 constructs that exhibited strong targeting 
effects on Colo205 cells were compared to Fc-scTRAIL after preincubation of Colo205 cells 
with increasing concentrations of bortezomib (Figure 3.40). Investigations of the differences 
in the EC50 values of scFvhu225-Fc-scTRAIL and Fc-scTRAIL revealed a decrease from factor 
9.7 (± 1.4) over 5.0 (± 1.7) and 4.6 (± 0.6) to 4.1 (± 0.7) in the presence of medium, 250 ng/ml, 
750 ng/ml, and 1250 ng/ml bortezomib, respectively. This corresponds to a significant 
reduction (P<0.01) of targeting effects with each increase in the bortezomib concentration. 
Differing from these data, the impact of augmented bortezomib concentrations on targeting 
effects of scFv3-43-Fc-scTRAIL was with differences of factors 6.5 (± 0.5), 5.6 (± 0.8), 
5.9 (± 0.8), and 6.0 (± 0.6) compared to Fc-scTRAIL not significant (P>0.05). Hence, there is no 
distinct influence of bortezomib on targeting and impacts seem to be construct-dependent. 
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Figure 3.40: Effects of varying bortezomib concentrations on cell death induction on Colo205 cells. After 
preincubation with medium or increasing concentrations of BZB (250 ng/ml, 750 ng/ml, 1250 ng/ml) for 30 min, 
Colo205 cells (50,000/well) were treated with serial dilutions of the molecules for 16 h. Cell viability was 
determined by crystal violet staining. Concentrations refer to scTRAIL units. Differences between the EC50 values 
of the targeted molecules and Fc-scTRAIL are indicated. 
 
As an attempt to unravel potential determinants of targeting effects in vitro, EC50 values of 
cell death induction in the absence and presence of blocking antibody were correlated with 
the EC50 values of antigen binding in ELISA. The results obtained for Colo205 cells 
demonstrated that the two molecules (hu225, 3-43) showing strong cell death induction that 
can be reduced to the level of Fc-scTRAIL by the respective blocking antibodies possess strong 
binding to their corresponding antigen (Figure 3.41A). Here, the EC50 values of antigen binding 
were lower than those of binding to TRAIL-R2. These relationships were found in the absence 
and presence of bortezomib. This indicates that binding of the antibody part to the antigen 
needs to be stronger than binding of the scTRAIL moiety to the receptors to obtain targeting 
effects in vitro. However, the results determined for HCT116 cells are not able to confirm this 
correlation (Figure 3.41B). In accordance with the data observed on Colo205 cells, the hu225 
construct showed strong antigen binding and cell death induction that is reduced by 
cetuximab. In contrast to Colo205 cells, scFv3-43-Fc-scTRAIL did not exert higher activity than 
Fc-scTRAIL on HCT116 cells. Again, the observations were similar in the absence and presence 
of bortezomib. Additionally considering the binding properties for Colo205 and HCT116 cells 
(Figure 3.38) allows further explanation of these results. While the hu225 and 3-43 molecules 
both exhibit better binding than Fc-scTRAIL on Colo205 cells, superior binding on HCT116 cells 
was only seen for scFvhu225-Fc-scTRAIL, especially at the low concentrations applied for cell 
death induction. Consistent with these observations, scFv323/A3hu3-Fc-scTRAIL shows 
improved binding and cell death induction compared to Fc-scTRAIL on both cell lines. Thus, 
strong binding of the antibody part to the purified antigen seems to be necessary, but also 
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needs to translate into effective binding to the respective cells, which may be influenced by 
receptor expression levels. 
 
Figure 3.41: Analysis of potential correlation of cell death induction and antigen binding. EC50 values of cell 
death induction in the absence and presence of excess amounts of the respective blocking antibody (Table 3.16) 
were plotted against the EC50 value of binding to the corresponding antigen (Table 3.15). Plots were prepared 
for data determined in the absence and presence of BZB (250 ng/ml) for Colo205 (A) and HCT116 cells (B). EC50 
values of Fc-scTRAIL for binding to huTRAIL-R2 and cell death induction are indicated with dotted lines. 
 
In summary, these data identified superior cell death induction of the hu225, 3-43, and 
323/A3hu3 constructs on Colo205 cells, and of hu225 and 323/A3hu3 fusion proteins on 
HCT116 cells. Blocking of antigen binding of the hu225 and 3-43 moieties led to a reduction of 
this increased activity that was not obtained for scFv323/A3hu3-Fc-scTRAIL. Correlation with 
the binding properties indicated an importance of strong antigen and cell binding (better than 
Fc-scTRAIL in particular at low protein concentrations) for targeting effects in vitro. 
 
3.3.3 In vivo activity of scTRAIL fusion proteins with different targeting moieties 
The in vivo studies of EGFR-targeting scTRAIL formats and Fc-scTRAIL (see 3.2.1.5) were not 
able to confirm the beneficial impact of targeting observed in vitro. Thus, another in vivo 
experiment was performed evaluating scFv-Fc-scTRAIL molecules comprising the 3-43 and 
323/A3hu3 targeting moieties in addition to scFvhu225-Fc-scTRAIL and Fc-scTRAIL in the 
absence of bortezomib. NMRI nude mice with established Colo205 tumors received i.v. 
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injections of 0.2 nmol protein (corresponding to 0.4 nmol scTRAIL units) twice a week for three 
weeks. Treatments with the EGFR-, HER3-, and non-targeted molecules resulted in almost 
complete tumor remission, whereas only limited tumor regression and fast regrowth were 
observed for scFv323/A3hu3-Fc-scTRAIL (Figure 3.42A). Stable tumor remission over the 
monitoring period of almost 100 d was seen for scFv3-43-Fc-scTRAIL and only marginal 
regrowth was detected for Fc-scTRAIL at the end of the experiment. Differing from these data, 
considerably stronger regrowth of tumors treated with scFvhu225-Fc-scTRAIL was measured. 
Statistical analysis of the tumor volumes at day 69 revealed significant differences only 
between scFv323/A3hu3-Fc-scTRAIL compared to the HER3- and non-targeted molecules 
(Figure 3.42B). 
 
Figure 3.42: In vivo activity and PK of scFv-Fc-scTRAIL molecules and Fc-scTRAIL. A) NMRI nude mice (6 mice per 
group) with established Colo205 tumors were treated with 0.2 nmol protein (corresponding to 0.4 nmol scTRAIL 
units; i.v.) or PBS twice a week for three weeks (days 14, 18, 21, 25, 28, 32). Treatments are indicated with dotted 
lines. B) Statistical analysis of tumor volumes of groups II to V (numbering according to A) at day 69 was 
performed by One-Way ANOVA, followed by Tukey’s post hoc test (*P<0.05; **P<0.01; ***P<0.001; ns, P>0.05). 
C) Serum concentrations of the molecules and D) ALT were determined 4 h and 24 h after the last treatment (day 
32). 
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Serum concentrations of the proteins were determined 4 h and 24 h after the last treatment 
(Figure 3.42C) and resembled the PK data of scFvhu225-Fc-scTRAIL and Fc-scTRAIL described 
previously. Since serum levels of all molecules were comparable, no differences in in vivo half-
lives were induced by the different targeting moieties, although cross-reactivity with the 
corresponding mouse receptor was demonstrated for 3-43 (Schmitt et al., in preparation). 
Similar to the data generated before, none of the molecules induced toxic effects on the liver 
as measured by ALT levels in the serum 4 h and 24 h after the last treatment (Figure 3.42D). 
 
Consequently, major differences in the binding properties and cell death induction capabilities 
of the scFv-Fc-scTRAIL fusion proteins due to the different targeting moieties were detected. 
The hu225, 3-43, and 323/A3hu3 constructs were identified as superior candidates on Colo205 
cells, while highest activity on HCT116 cells was shown for the EGFR- and EpCAM-targeting 
proteins. Analyzing a potential correlation of cell death induction and binding properties 
indicated improved cell binding of the targeted compared to the non-targeted molecule, 
particularly at low concentrations, as relevant factor for targeting effects in vitro. However, a 
beneficial impact of the antibody moiety on the in vivo therapeutic activity remains to be 
confirmed. 
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3.4 Generation and analysis of dual-targeting scTRAIL fusion proteins 
As a strategy to further improve scTRAIL-based therapeutics, a format was developed that 
allows dimeric assembly combined with simultaneous targeting of two different tumor-
associated antigens in one molecule. Using a bispecific single-chain diabody (scDb) that is built 
up of the variable domains of the heavy and light chain of two antibodies of different 
specificity, scDb-EHD2-scTRAIL molecules were generated by replacing the scFv of the scFv-
EHD2-scTRAIL fusion protein by a scDb (Figure 3.43). Based on the targeting moieties 
described before, four different scDb-EHD2-scTRAIL fusion proteins directed against 
EGFRxHER3, EpCAMxEGFR, HER2xEGFR, and HER2xHER3 were produced by combining 
hu225x3M6, 323/A3hu3xhu225, 4D5xhu225, and 4D5x3M6, respectively. According to the 
other scTRAIL constructs, scDb-EHD2-scTRAIL fusion proteins were expressed in stably 
transfected HEK293T cells comprising a FLAG-tag at the N-terminus for purification via FLAG 
affinity chromatography from the cell culture supernatant. 
 
Figure 3.43: Schematic representation and generation of scDb-EHD2-scTRAIL molecules. A) Composition and 
B) schematic assembly of scDb-EHD2-scTRAIL molecules targeting two tumor-associated antigens A and B. L, Igκ 
chain leader sequence. L1, GGGGSGT linker. L2, GGGGS linker. L3, GGGGSGGRASGGGGS linker. L4, AAAGGSGG 
linker. L5, GGSGGASSGG linker. TRAIL subunits consist of aa 118-281 and are connected by a glycine residue. 
 
3.4.1 Biochemical characterization 
The scDb-EHD2-scTRAIL molecules were produced with yields ranging from 1.2 to 3.3 mg 
protein per liter cell culture supernatant (Table 3.17). Purity and integrity of the proteins was 
verified in SDS-PAGE, but revealed considerable amounts of the monomeric form of 
scDbhu225x3M6-EHD2-scTRAIL, scDb323/A3hu3xhu225-EHD2-scTRAIL, and scDb4D5x3M6-
EHD2-scTRAIL under non-reducing conditions (Figure 3.44A). Size exclusion HPLC identified 
inhomogeneous preparations for all proteins under native conditions (Figure 3.44B) 
confirming large fractions of the monomeric form for the hu225x3M6, 323/A3hu3xhu225, and 
  RESULTS   
  119   
4D5x3M6 constructs. In contrast, high molecular weight species were detected for 
scDb4D5xhu225-EHD2-scTRAIL. The hydrodynamic radii of the desired dimeric form of the 
molecules varied from 6.2 nm to 7.0 nm (Table 3.17). Analysis of the thermal stability by 
dynamic light scattering demonstrated similar melting points for all proteins of 56 °C and 57 °C 
(Table 3.17). 
 
Figure 3.44: Biochemical characterization of scDb-EHD2-scTRAIL molecules. A) SDS-PAGE (8 % PAA) of scDb-
EHD2-scTRAIL fusion proteins comprising the targeting moieties hu225x3M6 (1), 323/A3hu3xhu225 (2), 
4D5xhu225 (3), and 4D5x3M6 (4) was performed under reducing (R) and non-reducing conditions (NR). 2 µg 
protein were loaded per lane and proteins were stained with Coomassie Brilliant Blue. M, protein marker. 
B) Proteins were analyzed by size exclusion HPLC. Elution times of standard proteins and their respective 
molecular masses [kDa] are indicated. 
 
3.4.2 Evaluation of binding properties 
To fully characterize the binding properties of the scDb-EHD2-scTRAIL molecules, binding to 
both antigens, human TRAIL-R2, and Colo205 cells was investigated (Figure 3.45). Consistent 
with the binding properties of the hu225 targeting moiety (Table 3.1), the hu225x3M6 and 
323/A3hu3xhu225 constructs showed strong binding to EGFR with EC50 values in the 
subnanomolar range (Table 3.17), whereas a significantly higher concentration of 5.1 nM 
(P<0.001) was necessary to reach half-maximal binding of scDb4D5xhu225-EHD2-scTRAIL. 
Binding of scDb4D5x3M6-EHD2-scTRAIL to HER2 was similar to that detected for the 4D5 
targeting moiety (Table 3.2). Again, the 4D5xhu225 molecule exhibited reduced binding 
(P<0.001) indicating an impaired binding activity of both targeting moieties of this protein. 
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Binding analysis to HER3 revealed an EC50 value of 2.3 nM for scDbhu225x3M6-EHD2-scTRAIL, 
which resembles values determined for 3M6 fusion proteins before (Table 3.11), and weaker 
binding for the 4D5x3M6 molecule (P<0.001). Half-maximal binding of 
scDb323/A3hu3xhu225-EHD2-scTRAIL to EpCAM reflected the binding properties of the 
323/A3hu3 targeting moiety (Table 3.4). In agreement with the data of the other scTRAIL 
fusion proteins, all molecules bound to human TRAIL-R2 with similar EC50 values of 2.3 nM to 
4.4 nM (P>0.05). Although strong antigen binding of both targeting moieties of the 
hu225x3M6 and 323/A3hu3xhu225 constructs was detected in ELISA, these properties only 
translated into effective binding to Colo205 cells for scDbhu225x3M6-EHD2-scTRAIL, while all 
other proteins showed similar (P>0.05) and significantly weaker binding activities than the 
hu225x3M6 construct (P<0.001). Thus, all molecules bound to their designated target 
proteins, albeit in some cases with a lower binding strength than the respective recombinant 
antibody. Superior binding to Colo205 cells was identified for the hu225x3M6 construct and 
only marginal differences were found for the other proteins. 
 
Figure 3.45: Binding studies of scDb-EHD2-scTRAIL molecules. Binding to EGFR-Fc (300 ng/well), HER2-Fc 
(300 ng/well), HER3-Fc (300 ng/well), sEpCAM (200 ng/well), and huTRAIL-R2-Fc (200 ng/well) was analyzed by 
ELISA. Bound proteins were detected with an anti-FLAG-HRP or anti-human IgG (Fc specific)-POD. OD measured 
at 450 nm was normalized to the value determined for the highest concentration. Flow cytometry was performed 
to investigate binding to Colo205 cells detecting bound molecules using a PE-conjugated anti-FLAG antibody. 
Binding of scDb323/A3hu3xhu225-EHD2-scTRAIL to Colo205 cells is plotted on the right Y axis. Concentrations 
refer to scTRAIL units. 
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Table 3.17: Biochemical and binding properties of scDb-EHD2-scTRAIL molecules. Molecular masses (M) were 
calculated based on the amino acid sequence. Yields are expressed as mg protein per liter cell culture 
supernatant. Stokes radii (Sr) and melting points (TM) were determined by size exclusion HPLC and dynamic light 
scattering, respectively. Half-maximal binding was analyzed by ELISA (AgA, AgB, huTRAIL-R2-Fc) and flow 
cytometry (Colo205 cells) and is represented as nM scTRAIL units. AgA and AgB refer to antigens (Ag) of scDbAxB. 
Protein M 
[kDa] 
Yield 
[mg/l] 
Sr 
[nm] 
TM 
[°C] 
EC50 AgA 
[nM] 
EC50 AgB 
[nM] 
EC50 
huTRAIL-
R2 [nM] 
EC50 
Colo205 
[nM] 
scDbhu225x3M6-EHD2-
scTRAIL 
244 3.3 6.2 57 0.9 ± 0.1 2.3 ± 0.2 2.8 ± 1.2 1.1 ± 0.1 
scDb323/A3hu3xhu225-
EHD2-scTRAIL 
246 1.2 7.0 56 1.4 ± 0.03 0.8 ± 0.2 4.4 ± 2.2 20.7 ± 1.2 
scDb4D5xhu225-EHD2-
scTRAIL 
245 1.6 6.7 56 12.5 ± 1.8 5.1 ± 1.2 3.1 ± 1.4 26.5 ± 4.4 
scDb4D5x3M6-EHD2-
scTRAIL 
244 2.8 6.8 57 3.3 ± 0.3 11.4 ± 1.5 2.3 ± 1.0 23.7 ± 3.4 
 
3.4.3 Induction of cell death in vitro 
Cell death induction of the dual-targeting scTRAIL fusion proteins was investigated on Colo205 
(Figure 3.46A) and HCT116 cells (Figure 3.46B) in the absence and presence of bortezomib. All 
proteins showed concentration-dependent induction of cell death on both cells lines. On 
Colo205 cells in the absence and presence of bortezomib, lowest EC50 values were determined 
for the construct comprising the 4D5xhu225 targeting moieties, followed by hu225x3M6, 
4D5x3M6, and 323/A3hu3xhu225 (Table 3.18). Differing effects were found on HCT116 cells 
identifying highest activity for the hu225x3M6 protein, followed by 323/A3hu3xhu225, 
4D5xhu225, and 4D5x3M6. Although the heterogeneities detected in the protein preparations 
do not allow clear conclusions about the activities of the different molecules, comparison of 
the results of Colo205 and HCT116 cells highlights cell line-specific differences and common 
properties. On the one hand, the construct directed against HER2 and EGFR exerted despite 
the large amount of high molecular weight species (Figure 3.44B) strongest effects only on 
Colo205 cells, whereas lower activity was measured on HCT116 cells. On the other hand, 
scDbhu225x3M6-EHD2-scTRAIL exhibiting the highest fraction of monomer strongly induced 
cell death on both cell lines, which indicates a favorable impact of combining these targeting 
moieties. To further evaluate the characteristics of combined targeting of two antigens in one 
scTRAIL fusion protein, the activity of scDb4D5xhu225-EHD2-scTRAIL on Colo205 cells in the 
presence of bortezomib was assessed simultaneously to Dbhu225-scTRAIL and Db4D5-scTRAIL 
alone or in combination. Regarding equimolar concentrations of scTRAIL units, the scDb-
EHD2-scTRAIL molecule induced cell death more potently than Db4D5-scTRAIL, but less 
effectively as compared to Dbhu225-scTRAIL, while similar activity was observed for the 
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respective combination of the two Db-scTRAIL molecules (Figure 3.46C). Comparable results 
were obtained on HCT116 cells (Figure 3.46D). 
 
Figure 3.46: Cell death induction of scDb-EHD2-scTRAIL molecules. A) Colo205 (50,000/well) and B) HCT116 cells 
(15,000/well) were treated with serial dilutions of the molecules for 16 h after preincubation with medium or 
BZB (250 ng/ml) for 30 min. Viable cells were stained with crystal violet. C) Effects of scDb4D5xhu225-EHD2-
scTRAIL were compared to Dbhu225-scTRAIL and Db4D5-scTRAIL alone or in combination after pretreatment 
with BZB (250 ng/ml) for Colo205 and D) HCT116 cells. Experiments of C and D were performed once. 
Concentrations refer to scTRAIL units. 
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In summary, these data confirm that using a bispecific scDb as antibody moiety fused to a 
dimeric scTRAIL molecule allows targeting of two different antigens. However, size exclusion 
chromatography data revealed either large fractions of high molecular weight species or 
monomers. Based on the data obtained for the different formats of targeted dimeric scTRAIL 
molecules, these problems in product quality may be improved by using the human IgG1 Fc 
part as dimerization module instead of the EHD2. The binding studies verified binding to the 
corresponding target proteins, although in some cases with decreased activity. Hence, 
generation of dual-targeting dimeric scTRAIL fusion proteins requires further optimization 
steps, i.e. ideal orientation of the variable domains in the scDb and possibly adjustments of 
linker lengths. Despite the heterogeneities of the protein preparations, cell death induction 
analysis on Colo205 and HCT116 cells indicated a cell line-dependent relevance of the 
different combinations of targets and beneficial effects of the hu225x3M6 construct, which 
are probably related to its superior cell binding activity. 
 
Table 3.18: EC50 values of cell death induction of scDb-EHD2-scTRAIL molecules. EC50 values [pM scTRAIL units] 
were determined for Colo205 and HCT116 cells after pretreatment with medium or BZB (250 ng/ml). 
Protein Colo205 HCT116 
without BZB with BZB without BZB with BZB 
scDbhu225x3M6-EHD2-scTRAIL 104.2 ± 25.7 13.5 ± 4.2 68.0 ± 21.9 2.4 ± 0.4 
scDb323/A3hu3xhu225-EHD2-scTRAIL 775.3 ± 525.0 41.5 ± 17.2 87.9 ± 39.6 3.0 ± 1.1 
scDb4D5xhu225-EHD2-scTRAIL 69.1 ± 20.1 11.2 ± 4.1 114.7 ± 49.5 2.9 ± 1.2 
scDb4D5x3M6-EHD2-scTRAIL 314.1 ± 50.8 22.0 ± 3.9 597.7 ± 172.0 4.8 ± 2.3 
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4 Discussion 
Considering the diversity and large number of second generation TRAIL-based therapeutics, 
the need of systematic comparison arises to further guide optimization and therapeutic 
development of those molecules. In this study, four different formats of dimeric antibody-
scTRAIL fusion proteins comprising five distinct targeting moieties have been generated. 
Comprehensive analysis of biochemical and functional properties confirmed the suitability of 
all formats to combine targeting and defined oligomerization of scTRAIL in general and 
revealed the superiority of Fc-based constructs in terms of production, stability, 
pharmacokinetics, and pharmacodynamics. Major differences in the in vitro bioactivity were 
found depending on the incorporated antibody moiety. The factors underlying these 
differences remain to be fully elucidated, but seem to be linked to properties of both the 
antibody and the targeted antigen. While beneficial effects of targeting were confirmed for 
certain antibody moieties in vitro, further improvement of the highly potent activity of non-
targeted Fc-scTRAIL was not observed in vivo. 
 
4.1 Dimeric recombinant antibody formats as fusion partners of scTRAIL 
In order to create a set of different formats of targeted dimeric scTRAIL molecules, the first 
part of this study was dedicated to generating and characterizing dimeric recombinant 
antibodies as potential fusion partners of scTRAIL. In recent decades, a diverse set of dimeric 
recombinant antibody formats has been developed in an attempt to improve e.g. binding 
properties compared to monomeric scFvs (reviewed by Kontermann, 2010; Nun᷉ez-Prado et 
al., 2015). A well-established format is the diabody that has already been successfully used to 
equip various fusion partners, like scTRAIL (Siegemund et al., 2012), IL-2 (Frey et al., 2010), IL-
15 and GM-CSF (Kaspar et al., 2007), or B7.2 (Hornig et al., 2012), with tumor-targeting 
properties. Regarding the non-covalent assembly of the diabody, dissociation of the two 
chains might be possible. In fact, Huang et al. (2005) demonstrated dissociation of a diabody 
into an inactive monomeric form at dilute concentrations. In order to address this possible 
stability issue, structural analysis has been performed and identified positions in the variable 
domains suitable for introduction of cysteine residues to form interchain disulfide bonds 
(reviewed by Reiter et al., 1996). In accordance with previous reports, disulfide-stabilization 
increased the thermal stability of all diabodies analyzed in this study, although with increases 
of 2 °C to 4 °C to a lesser extent than that described for an anti-CEA diabody, showing a melting 
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point improved by 10 °C (FitzGerald et al., 1997). This less pronounced stabilizing effect might 
be related to the already considerably higher melting points of the unmodified diabodies 
investigated in this study. Since diabodies possess a rather compact structure (Holliger et al., 
1993), additional strategies have been developed in order to generate bivalent molecules that 
show an organization and flexibility similar to that of natural immunoglobulins. This has been 
achieved using separate modules for targeting, e.g. scFvs, and dimerization, e.g. the heavy 
chain domain 2 of IgE or the Fc part of human IgG1. The EHD2 has already been applied not 
only to generate bivalent recombinant antibodies, but also scTRAIL fusion proteins, and lacks 
additional effector functions (Seifert et al., 2014a). The Fc part of human IgG1 is an established 
fusion partner of various proteins mediating, besides dimeric assembly, effector functions, like 
recycling via the FcRn (reviewed by Beck and Reichert, 2011; Kontermann, 2010). Employing 
these extensively investigated antibody formats of different structural organization, flexibility, 
size, and effector functions, all targeting moieties were successfully converted into diverse 
types of dimeric recombinant antibodies without loss of binding activity. 
 
Based on these recombinant antibody formats, the respective scTRAIL molecules were 
generated by fusion of scTRAIL to their C-terminus. In its natural configuration, TRAIL is 
expressed as a type II transmembrane protein, thus anchored to the cell membrane via its N-
terminus (Wiley et al., 1995). Linking a fusion partner N-terminally to scTRAIL therefore 
reflects the physiological structure, and most TRAIL fusion proteins utilize this concept (Table 
1.1), although fusion partners have also been attached to the C-terminus of TRAIL yielding 
active proteins (Gieffers et al., 2013; Liu et al., 2014). In terms of production properties, the 
different formats of dimeric antibody-scTRAIL molecules showed major variations. In 
accordance with literature (reviewed by Levin et al., 2015), incorporating the Fc part greatly 
enhanced the product yield. Extensive development and characterization of various kinds of 
Fc fusion proteins have moreover demonstrated its beneficial effects on stability and solubility 
(reviewed by Levin et al., 2015). This is consistent with the results obtained for the scFv-Fc-
scTRAIL molecules of all five antibody moieties exhibiting better thermal stability than the 
other formats. Investigations of the fusion proteins after incubation in human plasma at 
physiological temperatures, however, did not confirm superior stability of the Fc construct. 
Thus, plasma stability may be limited rather by the susceptibility (especially of the linker 
sequences) to proteolytic cleavage than by thermal stability of the dimerization modules, 
although introduction of disulfide bonds into the diabody appeared to have a positive impact. 
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While all formats of the EGFR- and HER2-targeting molecules reliably formed the desired 
dimers, only the Fc part was capable of converting the HER3- and EpCAM-specific proteins 
completely into the dimeric form. Hence, dimer formation seems to be influenced by the 
antibody moiety. Stable association of the diabody chains has been described to depend on 
the interfaces formed by the variable domains and therefore on the antibody sequence 
(reviewed by Todorovska et al., 2001). In contrast, dimer formation via the EHD2 is supposed 
to be unaffected by the respective antibody (Seifert et al., 2014a). Here, the differences in 
dimeric assembly may additionally be caused by protein batch-specific variations. With 
respect to functional properties, all formats of all antibody moieties retained antigen as well 
as TRAIL receptor binding activity, which is in agreement with previous studies, using 
particularly the hu225 targeting moiety in similar scTRAIL molecules (Seifert et al., 2014a; 
Siegemund et al., 2012; Siegemund et al., 2016). Likewise, 323/A3hu3 has recently been 
demonstrated to confer EpCAM-binding properties to (sc)TNFSF members in scFv-TNFSF and 
scFv-scTNFSF molecules (Fellermeier et al., 2016). While proteins combining (sc)TRAIL with 
distinct antibody moieties directed against EGFR, HER2, and EpCAM have already been 
described (Table 1.1), no HER3-targeting scTRAIL fusion protein has been available yet. Since 
in recent years, HER3 has become an attractive target for tumor therapy (reviewed by Hsieh 
and Moasser, 2007; Kol et al., 2014), HER3-targeting scTRAIL molecules might be especially 
promising. Referring to TRAIL receptor binding properties, half-maximal binding of all analyzed 
constructs to human TRAIL-R2 was with values in the sub- to low nanomolar range in line with 
previous studies reporting affinities of 0.76 nM to 2 nM (Lang et al., 2016). Consistent with 
the described specificities of human TRAIL for human and mouse TRAIL receptors (Bossen et 
al., 2006), the scTRAIL fusion proteins were capable of binding to all human and mouse 
TRAIL-R, except for moDcTRAIL-R1. Highlighting differences between the human and mouse 
TRAIL – TRAIL receptor system, modeling studies have revealed the molecular reasons for the 
lacking interaction of moDcTRAIL-R1 and human TRAIL. Binding of moTRAIL to this receptor 
crucially involves a salt bridge that cannot be formed with the human ligand due to an 
uncharged serine at the corresponding position (Schneider et al., 2003). These differences 
have to be considered for the translation of data obtained in mouse models. In addition to the 
lacking interaction with moDcTRAIL-R1, the lower binding activity of human TRAIL for 
moTRAIL-R2 compared to huTRAIL-R2 may contribute to differential activities in mice and 
humans, e.g. altering the risk for toxic effects. 
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The investigated targeted dimeric scTRAIL fusion proteins are supposed to act in trans, i.e. to 
bind simultaneously to target antigens and TRAIL receptors on distinct cells, as well as in cis 
with concomitant binding to both kinds of target structures on the same cell. Recent studies 
by Tatzel et al. (2016) demonstrated the crucial dependence on a long flexible linker 
incorporated between an scFv and a single-chain version of TRAIL for the capability to bend 
over and act in cis. By analyzing the cell population surviving treatment with an scFv-scTRAIL 
variant lacking a spacer sequence, they could show that this format exclusively acted in trans. 
In contrast, the respective spacer-containing version was able to exert effects in cis. 
Accordingly, further experiments are required to reveal whether the investigated targeted 
dimeric scTRAIL fusion proteins act in cis or in trans or both. Especially scFv-EHD2-scTRAIL and 
scFv-Fc-scTRAIL molecules with their central dimerization moiety and flexible linkers on both 
ends connecting the antibody and scTRAIL units are supposed to possess greater flexibility. 
With respect to therapeutic application, there might even be sound scientific rationale to use 
a mixture of trans- and cis-acting formats to effectively target solid tumors (which might profit 
from a bystander effect) and circulating tumor cells, respectively. 
 
4.2 TRAIL valency and active tumor cell targeting as factors influencing in vitro 
bioactivity of scTRAIL fusion proteins 
Previous studies of EHD2-scTRAIL, scTRAIL-RBD-Fc, and hexameric isoleucine zipper-fused 
TRAIL have demonstrated the superior activity obtained by assembly of two (sc)TRAIL units in 
one molecule thereby generating six TRAIL receptor binding sites. The markedly improved 
effects of these molecules rely on the increased TRAIL valency that allows efficient clustering 
and thus activation of death receptors (Gieffers et al., 2013; Han et al., 2016; Seifert et al., 
2014a). In line with these data, dimeric assembly of two scTRAIL units via the EHD2 and an Fc 
part significantly enhanced the cytotoxic activity compared to monomeric scTRAIL. Further 
studies on caspase activities confirmed faster and more pronounced activation of initiator and 
executioner caspases by Fc-scTRAIL compared to scTRAIL. Similarly, increased caspase 
activities have already been observed for tetra- and pentavalent forms of a TRAIL-R2-directed 
nanobody (Huet et al., 2014). Analysis of these and other TRAIL-R2-agonistic scaffold proteins 
and antibody fragments that allow successive extension of single binding sites confirmed the 
requirement of an at least tetravalent format to improve the exerted effects compared to 
homotrimeric TRAIL (Huet et al., 2014; Liu et al., 2015; Swers et al., 2013; Wang et al., 2013). 
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Recent data of Beyrath et al. (2016), however, demonstrated that the required degree of 
oligomerization is cell line-dependent. Even dimeric TRAIL-R2-specific peptides were 
described to be sufficient to induce apoptosis on some cell lines, while having antagonistic 
effects on others. They furthermore showed that the valency of the analyzed peptides is not 
the sole determinant for efficient apoptosis induction. Additionally, an appropriate spatial 
distribution is essential to avoid sterical hindrance of multivalent receptor binding (Beyrath et 
al., 2016). Using a single-chain version of the natural homotrimeric ligand circumvents this 
problem, and obviously, the flexibility provided by the homodimerization modules and linkers 
employed in this study is sufficient to also allow more than trivalent receptor binding. 
 
In accordance with previous reports of scFvhu225-EHD2-scTRAIL and EHD2-scTRAIL fusion 
proteins (Seifert et al., 2014a), all formats of EGFR-targeted dimeric scTRAIL molecules 
showed significantly improved induction of cell death in vitro compared to non-targeted 
dimeric Fc-scTRAIL. Initially, the sets of different dimeric antibody-scTRAIL formats comprising 
several targeting moieties were generated to validate both the suitability of the distinct 
formats and the concept of improving the bioactivity of dimeric scTRAIL fusion proteins by 
combination with an antibody part. However, cell death induction assays did not confirm 
targeting effects for all antibody moieties. Attempting to understand the factors underlying 
these differences, the EC50 values of cell death induction were correlated with the binding 
properties of the respective molecules. A first analysis indicated potent antigen binding by the 
antibody moiety (stronger than binding to TRAIL-R2) as requirement for targeting effects. 
Despite the effective binding activity of the HER3-specific antibody moiety 3-43 to its isolated 
antigen, increased bioactivity of the corresponding scFv-Fc-scTRAIL fusion protein compared 
to Fc-scTRAIL was only obtained for Colo205 cells. Examination of the binding properties for 
the relevant cell lines revealed that scFv-Fc-scTRAIL molecules showing targeting effects in 
cytotoxicity assays exhibited improved binding to the respective cell line compared to Fc-
scTRAIL. While increased binding of scFv3-43-Fc-scTRAIL was seen on Colo205 cells, no 
differences to Fc-scTRAIL were found on HCT116 cells that displayed lower HER3 expression 
levels. These differential HER3 expression profiles were confirmed by a recent quantitative 
study reporting 2,850 receptor molecules on Colo205 cells and 1,520 on HCT116 cells (Schmitt 
et al., in preparation). Thus, active targeting of dimeric scTRAIL molecules seemed to depend 
on enhanced binding properties for the respective cell line that in turn appeared to be 
determined by the antibody affinity and sufficient antigen expression levels. Unlike this 
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observation, active targeting has been demonstrated for all reported scFv-(sc)TRAIL molecules 
(Table 1.1), although KD values of the antibody part as high as 142 nM have been described 
(Stieglmaier et al., 2008). In contrast to scFv-(sc)TRAIL fusion proteins that show an activity 
comparable to soluble TRAIL in the absence of target antigen expression (Wajant et al., 2001), 
dimeric versions of scTRAIL per se exert considerably stronger effects. While scFv-(sc)TRAIL 
molecules require membrane-attachment to signal via TRAIL-R2, dimeric forms intrinsically 
possess this capacity. This explains why dimeric scTRAIL molecules have higher requirements 
to improve their activity by active targeting than non-oligomerized forms of TRAIL. 
 
Consistent with previous studies (Seifert et al., 2014a), inhibition of EGFR or HER3 binding with 
excess amounts of blocking antibodies reduced the cell death-inducing activity of scFvhu225-
Fc-scTRAIL (on Colo205 and HCT116 cells) and scFv3-43-Fc-scTRAIL (on Colo205 cells) to a level 
comparable to that of Fc-scTRAIL. This confirms active targeting by these antibody moieties 
and additionally demonstrates that the beneficial effects observed in these short-term in vitro 
experiments are induced due to mechanistic binding to the receptor, not because of inhibition 
of receptor signaling, which would also occur in the presence of blocking antibody. Especially 
for the analyzed cell lines that both have activating mutations in BRAF (Colo205) or KRAS and 
PIK3CA (HCT116), blocking of the receptors is not supposed to prevent downstream signaling. 
Since the hu225 targeting moiety is derived from cetuximab, it is in general capable of blocking 
EGFR activation and signaling in wild-type KRAS-expressing cells. Indeed, investigations of 
Dbhu225-scTRAIL on Caco-2 cells that exhibit a wild-type status for MAPK and PI3K pathways 
confirmed the ability of this molecule to reduce basal and ligand-induced proliferation. In 
addition, Caco-2 cells surviving treatment with Dbhu225-scTRAIL have been characterized by 
very low EGFR expression levels, further indicating an importance of targeting EGFR for 
efficient elimination of the cells (Möller et al., 2014). Referring to the data of Tatzel et al. 
(2016) that demonstrated an enrichment of target-positive cells for trans-acting molecules, 
survival of cells expressing very low levels of EGFR might indicate that Dbhu225-scTRAIL exerts 
effects in cis. Although KRAS mutation has been associated with a switch of apoptotic to 
oncogenic TRAIL signaling (Hoogwater et al., 2010; von Karstedt et al., 2015), the analyzed 
scTRAIL molecules efficiently induced cell death in both cell lines. In the context of non-
apoptotic signaling, low concentrations of the soluble form of the death ligand FasL have been 
reported to induce migration and proliferation, whereas membrane-attached or soluble 
oligomerized variants trigger apoptosis (reviewed by Wajant, 2015). In the case of TRAIL, 
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evidence that also oligomeric forms are generally able to induce non-apoptotic signaling is 
provided by a study reporting activation of proinflammatory pathways in melanoma cell lines 
by cross-linked FLAG-TNC-TRAIL (Berg et al., 2009). Further rationale for the combination of 
TRAIL with anti-EGFR or also anti-HER2 therapeutics is related to this complex non-apoptotic 
signaling that can be induced by TRAIL. In colorectal cancer cells, cross-talk with EGFR and 
HER2 signaling via SRC family kinases and ADAM-17 has been described, leading to proteolytic 
release of TGF-α that in turn induces autocrine and paracrine EGFR/HER2 pro-survival 
signaling (reviewed by Azijli et al., 2013). Therefore, combining TRAIL and anti-EGFR/HER2 
therapy can overcome this pro-survival signaling loop that might be induced by TRAIL therapy 
alone. In fact, synergistic effects of combinatorial treatment with an anti-HER2 and an anti-
TRAIL-R2 antibody have been confirmed in a mouse model of breast cancer (Stagg et al., 2008). 
Together with the results of this study, depending on cell line- and antibody-specific 
properties, incorporation of a receptor-blocking antibody moiety in dimeric scTRAIL molecules 
can have beneficial effects in terms of targeting the therapeutic to tumor cells and modulating 
signaling pathways to synergize with TRAIL activity. Similarly, targeting of EpCAM with an 
antagonistic antibody additionally provides a means of selectively killing cancer stem cells and 
inhibiting its mitogenic signaling activity (reviewed by Munz et al., 2009). Despite significantly 
improved cell death induction of scFv323/A3hu3-Fc-scTRAIL compared to Fc-scTRAIL, addition 
of the respective blocking antibody did not or only partially reduce or even increase this 
favorable activity. Although scFv323/A3hu3-Fc alone did not show any effects on Colo205 cells 
for concentrations up to 10 nM, further experiments are required to determine whether 
higher doses used for blocking may exert inhibitory activity. In conclusion, selection of an 
appropriate antibody moiety with respect to binding strength, specificity for a sufficiently 
expressed antigen, and interference with a relevant signaling pathway has the potential to 
improve the in vitro bioactivity of the respective dimeric scTRAIL fusion proteins. 
 
4.3 Protein format as factor influencing in vivo pharmacokinetics of scTRAIL 
fusion proteins 
Investigations of the pharmacokinetic properties of the different formats of scTRAIL molecules 
revealed significant differences. According to the expectations, the Fc fusion proteins 
exhibited longest terminal half-lives. Furthermore, both scFvhu225-EHD2-scTRAIL and EHD2-
scTRAIL showed a significantly extended PK profile compared to the diabody constructs and 
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scTRAIL, which is consistent with previous PK analysis of these protein formats (Seifert et al., 
2014a). Since only the targeted, but not the non-targeted EHD2 fusion protein has an 
increased molecular mass and hydrodynamic radius compared to Dbhu225-scTRAIL and 
dsDbhu225-scTRAIL, the prolonged half-lives cannot simply be explained by increases in size. 
Another factor potentially influencing these differences is thermal stability, which was 
demonstrated to be improved for the EHD2-comprising molecules. However, the higher 
melting points did not translate into enhanced stability in human plasma at 37 °C. Therefore, 
it remains unclear, if thermal stability contributes to the differences in half-lives observed for 
diabody and EHD2 constructs or which other factors might be involved. 
 
The half-lives of the Fc fusion proteins of 17.8 h and 14.5 h were in a similar range to that 
reported for a scTRAIL-RBD-Fc construct (Gieffers et al., 2013). Yet these half-lives were 
dramatically shorter than those observed for other Fc fusion proteins (Unverdorben et al., 
2016), and a significant reduction compared to scFvhu225-Fc was found. Similarly, conjugation 
and fusion of TRAIL to HSA have been described to improve its half-life to 6.2 h and 15 h 
(Byeon et al., 2014; Müller et al., 2010), which is again considerably lower than those reported 
for other HSA fusion proteins, reaching values up to almost 50 h (Müller et al., 2007). 
Consistent with these data, fusion of TRAIL to an albumin-binding domain (Li et al., 2016) was 
not as effective as described for e.g. a single-chain diabody (Stork et al., 2007). An even shorter 
half-life of only 100 min has been estimated for a fusion protein of the human IgG1 Fc part 
and homotrimeric TRAIL (Wang et al., 2014), which highlights the importance of incorporating 
a single-chain version of TRAIL. Interestingly, a reduced PK profile has also been demonstrated 
for scFvhu225-EHD2-scTRAIL compared to the respective recombinant antibody scFvhu225-
EHD2, despite the considerable increase in size for the scTRAIL molecule (Seifert et al., 2014a). 
Based on the presence of an additional linker and effector moiety in scFvhu225-Fc-scTRAIL 
compared to scFvhu225-Fc, the serum half-life may be reduced due to decreased stability and 
increased susceptibility for cleavage by proteases. Indeed, the thermal stability of the 
corresponding scTRAIL molecule is 8 °C lower than that of the recombinant antibody. Analysis 
of the stability in human plasma at physiological temperatures revealed that at least 50 % of 
the scTRAIL fusion proteins remain intact after seven days. This level is clearly higher than that 
detected after seven days in vivo, indicating that decreased stability is unlikely the limiting 
factor. 
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Another aspect influencing pharmacokinetic properties is target-mediated clearance 
(reviewed by Wang et al., 2008). Since the investigated scTRAIL molecules were capable of 
binding to all mouse TRAIL receptors, except for moDcTRAIL-R1, TRAIL receptor-mediated 
processes may lead to reduced levels of scTRAIL fusion proteins in the serum. An indicator of 
such target-mediated clearance is the observation of dose-dependent differences in 
elimination leading to increased half-lives for higher doses (reviewed by Wang et al., 2008). A 
prominent example is cetuximab, for which short serum half-lives have been found and 
attributed to receptor-mediated clearance. Consistent with the described observation, 
prolonged half-lives and accumulation have been demonstrated for increased doses and 
multiple application of high doses of cetuximab, respectively (Tan et al., 2006). However, 
application of increased and/or multiple doses of scTRAIL molecules during the 
pharmacodynamic experiments did not lead to saturation effects as indicated by comparable 
PK profiles determined for all settings. Generation and analysis of fusion proteins comprising 
a receptor-dead variant of scTRAIL may provide deeper insight into the role of target-
mediated clearance. Mutations selectively disrupting TRAIL receptor binding sites have been 
described previously (Hymowitz et al., 2000) and can be used to develop a scTRAIL variant that 
lacks the ability to bind to TRAIL receptors. Increased serum half-lives of fusion proteins 
thereof would indicate the relevance of target-mediated processes. A strategy restoring 
improved PK properties of antibodies eliminated due to target binding has been developed 
and successfully applied for an anti-PCSK9 and an anti-IL-6R antibody. Engineering antigen 
binding to occur in a pH-sensitive manner, i.e. binding at physiological pH and dissociation at 
acidic endosomal pH, allowed exploitation of neonatal Fc receptor (FcRn)-mediated recycling 
after antibody release in the endosome (Chaparro-Riggers et al., 2012; Igawa et al., 2010b). A 
corresponding engineering approach might confer prolonged serum half-lives on Fc-
containing scTRAIL fusion proteins, if in fact limited due to target-mediated clearance. Recent 
studies of a scTRAIL molecule largely incapable of binding to TRAIL receptors, though, revealed 
PK properties similar to those of the respective fusion protein comprising fully active scTRAIL 
(Marquardt and Seifert, unpublished data). Therefore, TRAIL receptor-mediated clearance 
does not seem to be the main cause of the significantly reduced serum half-lives of Fc-
containing scTRAIL constructs. 
 
Further factors that may influence the pharmacokinetic behavior of the analyzed fusion 
proteins are FcRn-mediated recycling and non-specific clearance. The exceptionally long half-
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lives of IgGs are linked to their ability to bind to the neonatal Fc receptor in a pH-dependent 
manner (reviewed by Kontermann, 2009). In order to evaluate whether the fusion of scTRAIL 
to the Fc part impairs FcRn-mediated recycling, binding studies of scFvhu225-Fc-scTRAIL, Fc-
scTRAIL, and scFvhu225-Fc to the FcRn similar to those described by Unverdorben et al. (2016) 
are required. By performing quartz crystal microbalance measurements, FcRn binding kinetics 
at pH 6.0 and pH 7.4, as well as the dissociation behavior due to changes of pH from 6.0 to 7.4 
can be determined to unravel potential differences. Modification of the linker connecting the 
Fc part and scTRAIL as well as incorporation of mutations in the Fc part shown to enhance 
FcRn interaction (Datta-Mannan et al., 2012) might provide a strategy to overcome potential 
limitations. Since a reduced pharmacokinetic profile has also been reported for scFvhu225-
EHD2-scTRAIL compared to scFvhu225-EHD2 (Seifert et al., 2014a), other factors seem to 
affect the PK of the analyzed scTRAIL molecules independent of a potential contribution of 
altered FcRn-mediated recycling. Regarding non-specific clearance of antibodies, binding to 
negatively charged structures has been proposed as the main reason underlying this process. 
Previous studies demonstrated a correlation between basic isoelectric points (pI) and atypical 
rapid clearance of monoclonal antibodies. Reducing the pI by at least one unit was shown to 
restore improved PK properties, decreasing the clearance by factors of 2 to 4 (Igawa et al., 
2010a; Li et al., 2014). In order to analyze a potential influence of scTRAIL on the pI of the 
respective fusion protein, isoelectric points were calculated based on the amino acid 
sequences, revealing values of 8.2, 8.0, 8.1, and 8.1 for scFvhu225-Fc-scTRAIL, Fc-scTRAIL, 
scTRAIL, and scFvhu225-Fc, respectively. Thus, the recombinant antibody, scTRAIL, and the 
fusion proteins thereof have similar calculated isoelectric points, thereby indicating the 
importance of other factors in provoking the differences in half-lives. Recent studies 
investigating non-specific clearance based on binding to negatively charged heparin or cell 
membranes demonstrated that instead of the isoelectric point, fast clearance is rather 
mediated by positively charged patches within the protein (Datta-Mannan et al., 2015a; Datta-
Mannan et al., 2015b). Visualization of positively charged amino acids in the crystal structure 
of TRAIL indeed confirmed the existence of positively charged areas (Figure 4.1A). Hence, non-
specific clearance due to binding of positively charged patches of scTRAIL to negatively 
charged structures might at least contribute to the reduced serum half-lives of Fc-containing 
scTRAIL molecules compared to scFvhu225-Fc. 
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Figure 4.1: Visualization of positively charged patches at the surface of TRAIL. Surfaces of the THD of 
homotrimeric TRAIL alone (A) and in complex with three TRAIL-R2 chains (B) are represented. Visualization of 
PDB 1DU3 (Cha et al., 2000) was performed using PyMOL. TRAIL monomers are shown in light gray, gray, and 
dark gray. TRAIL-R2 chains are colored in different shades of green. Positively charged amino acids are highlighted 
in magenta. 
 
Datta-Mannan et al. (2015a) used molecular surface modeling to identify amino acid 
substitutions that disrupt positively charged regions and successfully demonstrated enhanced 
pharmacokinetic properties of the respectively modified antibodies compared to the parental 
forms without affecting the pI. Accordingly, balancing the positively charged areas in scTRAIL 
might provide a strategy to generate fusion proteins with improved half-lives. Since positively 
charged amino acids are partly located at the interface formed by two TRAIL monomers 
(Figure 4.1), disruption of these patches might influence binding to TRAIL receptors and 
therefore activity. Besides careful selection of amino acid substitutions and investigations of 
potential immunogenicity, validation of the activity of the generated variant will be required 
for the development of a potentially PK-optimized scTRAIL version. 
 
4.4 Protein format and targeting as factors influencing pharmacodynamics of 
scTRAIL fusion proteins 
In vivo studies confirmed potent activity of all analyzed formats of EGFR-targeting scTRAIL 
fusion proteins. This is consistent with previous investigations, reporting significantly reduced 
tumor volumes by treatment with Dbhu225-scTRAIL and scFvhu225-EHD2-scTRAIL (Seifert et 
al., 2014; Siegemund et al., 2012; Siegemund et al., 2016). Although direct comparison of 
doses used in those experiments and in the present study might be complicated by tumor 
heterogeneities, the scTRAIL variant and linkers employed here seem to generate proteins 
that are even more active. The single-chain version of TRAIL used in the present study 
comprised the amino acids 118 to 281 and linkers of a single glycine residue. This variant was 
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derived from a previous optimization study and was chosen due to favorable properties 
regarding product quality, thermal stability, and activity. This optimization study additionally 
identified other promising scTRAIL versions containing reduced and modified sequences and 
evaluated one variant as Dbhu225-scTRAIL fusion protein in a Colo205 xenograft model. 
However, application of 0.3 nmol of that Dbhu225-scTRAIL variant in combination with 5 µg 
bortezomib on eight consecutive days induced only marginal effects (Siegemund et al., 2016), 
while six treatments with 0.2 nmol of the Dbhu225-scTRAIL version used in the present study 
significantly reduced tumor growth in the absence of bortezomib. These data clearly illustrate 
the influence of the scTRAIL version and linkers on efficacy. The in vivo experiments were not 
only performed to confirm activity, but also to compare the PD effects induced by the already 
described diabody and EHD2 formats, and the newly established scFv-Fc-scTRAIL. In general, 
pharmacodynamic properties of a therapeutic are driven by a specific pharmacokinetic 
parameter, such as peak concentration (Cmax) or systemic exposure (AUC; reviewed by 
Tuntland et al., 2014). Applying six injections of 0.5 nmol protein in combination with 
bortezomib, the first PD experiment did not reveal any differences between the analyzed 
formats. Initial peak concentrations determined 3 min after injection were similar for all 
molecules, which might suggest a Cmax-driven effect. Since the treatment regimen of this 
experiment induced almost complete tumor remission, another PD study was conducted, 
injecting 0.2 nmol of the EGFR-targeting formats without bortezomib to identify potential 
differences that might have been masked by the high doses applied before. Similar anti-tumor 
activity was determined for Dbhu225-scTRAIL and scFvhu225-EHD2-scTRAIL, whereas 
scFvhu225-Fc-scTRAIL induced considerably stronger effects, indicating that the AUC has an 
influence on the in vivo activity. However, it should be noted that the PD studies were not 
designed to elucidate the pharmacokinetic parameter driving the effects, which would require 
extensive studies, systematically comparing the effect of varying dosing schedules (reviewed 
by Tuntland et al., 2014). The observation that a prolonged serum half-life translates into 
improved anti-tumor activity is in accordance with previous reports of an HSA-TNC-TRAIL and 
an ABD-TRAIL fusion protein that have been shown to exhibit a dramatically improved serum 
half-life and in vivo activity compared to TNC-TRAIL and TRAIL, respectively (Li et al., 2016; 
Müller et al., 2010). 
 
Consistent with data described for a scTRAIL-RBD-Fc construct (Gieffers et al., 2013), also non-
targeted Fc-scTRAIL potently induced tumor regression. In contrast to the in vitro bioactivities 
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and a previous in vivo study of targeted and non-targeted EHD2-scTRAIL molecules, targeting 
did not improve the efficacy of hu225- and 3-43-based scFv-Fc-scTRAIL fusion proteins 
compared to Fc-scTRAIL in vivo and even significantly reduced the anti-tumor activity of 
scFv323/A3hu3-Fc-scTRAIL. Seifert et al. (2014a) reported significantly improved anti-tumor 
activity of scFvhu225-EHD2-scTRAIL in a Colo205 xenograft model compared to non-targeted 
EHD2-scTRAIL. While EHD2-scTRAIL (0.35 nmol protein in combination with bortezomib, 4 
applications) only marginally influenced tumor growth (Seifert et al., 2014a), Fc-scTRAIL 
induced almost complete tumor regression already after four applications of 0.2 nmol protein 
without bortezomib. In line with the observation of increased in vivo activity of scFvhu225-Fc-
scTRAIL compared to scFvhu225-EHD2-scTRAIL, the different effects of EHD2-scTRAIL and Fc-
scTRAIL seem to be related to the significant differences in PK properties. Thus, due to its 
improved serum half-life, Fc-scTRAIL might reach sufficient levels at the tumor site, even 
without targeting. Interestingly, no targeting effects have also been observed for a fusion 
protein of scTRAIL and scFvhu225 in a Colo205 xenograft model, despite of improved activity 
in vitro (Siegemund et al., 2012). The superior in vivo effects of Dbhu225-scTRAIL observed in 
the same study might therefore be mediated rather by dimeric assembly of scTRAIL than by 
targeting. While several in vivo studies of targeted non-oligomerized (sc)TRAIL lacked a 
respective control of untargeted TRAIL (Aronin et al., 2013; de Bruyn et al., 2010; de Bruyn et 
al., 2011; Spitzer et al., 2010), thereby not allowing conclusions about targeting effects, other 
investigations clearly demonstrated improved activity of the targeted versions in mouse 
models (Cao et al., 2008; Kim et al., 2012; Liu et al., 2014; Schneider et al., 2010; Stieglmaier 
et al., 2008). In order to evaluate the reasons for the discrepancy between in vitro and in vivo 
data obtained in this study, further experiments are required. Several hypotheses arise that 
might explain the lack of beneficial targeting effects in vivo: i) Long-circulating dimeric scTRAIL 
fusion proteins already exert maximum anti-tumor effects and cannot be improved by 
targeting. ii) The improved activity of scFv-Fc-scTRAIL compared to Fc-scTRAIL is compensated 
by reduced extravasation and tumor penetration due to increased size. iii) Instead of 
specifically targeting tumor cells, the antibody moiety directs the construct additionally to 
other healthy tissues. iv) The characteristics of the analyzed tumor model are not adequate to 
reveal the full potential of the targeted molecules. A strategy to investigate the influence of 
incorporating an antibody moiety in general is the generation of an scFv-Fc-scTRAIL molecule 
of irrelevant specificity. However, variations in the in vivo effects of this construct compared 
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to Fc-scTRAIL cannot be explicitly attributed to the increase in size, but might also involve non-
specific clearance processes. Addressing especially the observation of decreased activity of 
scFv323/A3hu3-Fc-scTRAIL, experiments treating mice with excess amounts of the respective 
blocking antibody prior to application of the scTRAIL molecule might reveal a potential impact 
of targeting the scTRAIL fusion protein to a specific antigen. To ultimately elucidate differences 
of scFv-Fc-scTRAIL and Fc-scTRAIL molecules in terms of tumor localization and penetration as 
well as uptake in healthy tissues, biodistribution analysis is crucially required. According to 
imaging studies of labeled TRAIL receptor-targeting antibodies (Ciprotti et al., 2015; Oldenhuis 
et al., 2009), such data will help to reveal the differential ability of the constructs to localize 
to tumors. Despite of employing an antibody moiety with high specificity to the respective 
antigen, a fusion partner may strongly influence tumor localization. For example, a fusion 
protein of murine TRAIL and an scFv directed against the alternatively-spliced EDA domain of 
fibronectin showed specific tumor uptake, while molecules comprising most other members 
of the murine TNFSF instead of TRAIL were additionally found in high levels in certain healthy 
tissues (Hemmerle et al., 2014). Likewise, incorporation of different antibody moieties might 
dramatically influence the localization of the molecules. Biodistribution studies of a 
transferrin-PEG-TRAIL conjugate furthermore indicate that tumor uptake is not necessarily 
impaired for large-sized therapeutics. Even though transferrin with a molecular mass of 
80 kDa considerably increased the size of the respective conjugate, transferrin-PEG-TRAIL 
exhibited significantly higher tumor uptake compared to PEG-TRAIL (Kim et al., 2012). 
Accordingly, biodistribution analysis of scFv-Fc-scTRAIL and Fc-scTRAIL molecules will have to 
reveal potential differences in tumor localization. Addressing the last hypothesis mentioned 
above, which refers to characteristics of the tumor model, the in vitro experiments already 
demonstrated that targeting effects depend on properties not only of the antibody moieties, 
but also of the analyzed cell lines. Investigation of the antigen and TRAIL receptor expression 
levels on Colo205 tumors is therefore required to determine potential alterations between 
the in vivo and in vitro situation. Since in vitro studies indicated an importance of sufficient 
antigen expression levels (probably relative to TRAIL receptor levels), tumor models using cell 
lines known to express higher antigen levels are necessary to exclude insufficient antigen 
expression as reason for lacking targeting effects. However, by analyzing different cell lines, 
besides antigen expression levels, also other factors, like mutations in relevant signaling 
pathways, might influence the outcome. Modification of a TRAIL-sensitive cell line to stably 
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express various, but defined levels of the antigen is needed in order to circumvent an impact 
of other aspects and to support antigen expression levels as factor important for targeting 
effects in vitro and potentially in vivo. Thus, further studies are required to understand the 
role of targeting in vivo. 
 
Referring to the in vitro data discussed above (see 4.2), selection of an appropriate antibody 
moiety with respect to tumor characteristics is able to provide additional effects synergizing 
with TRAIL activity. As already outlined, the hu225 targeting moiety is able to inhibit EGFR-
induced proliferation in tumor cells exhibiting a wild-type status for MAPK and PI3K pathways 
(Möller et al., 2014). Since EGFR signaling has been described to contribute to TRAIL resistance 
(reviewed by Azijli et al., 2013), blocking of EGFR is moreover able to sensitize tumor cells for 
TRAIL treatment, and even direct induction of apoptosis by cetuximab has been reported 
(reviewed by Galizia et al., 2007). Furthermore, only scFv3-43-Fc seemed to exert inhibitory 
effects on Colo205 cells in vitro, and the respective scTRAIL fusion protein (together with Fc-
scTRAIL) showed most promising efficacy in vivo. Therefore, antibody moieties offer a great 
potential to equip scTRAIL fusion proteins with additional anti-tumor activity. Further rational 
for the incorporation of targeting moieties is provided by toxicity analysis. Monitoring of body 
weight and determination of ALT and amylase serum levels did not indicate any signs of 
toxicity induced by the investigated scTRAIL molecules. This is consistent with data reported 
for Dbhu225-scTRAIL and scFvhu225-EHD2-scTRAIL, where even doses of 1 nmol protein in 
combination with bortezomib did not induce adverse effects (Seifert et al., 2014a; Siegemund 
et al., 2016). In previous studies, histological and caspase-3 activity analysis of liver tissue of 
treated mice further demonstrated good tolerability of Dbhu225-scTRAIL, which was 
additionally verified treating primary human hepatocytes in the absence as well as in presence 
of bortezomib (Siegemund et al., 2012). More extensive investigations of human liver cells and 
intact liver tissue have been performed for scFvhu225-scTRAIL. These studies confirmed safety 
and revealed a superior toxicity profile of targeted compared to non-targeted scTRAIL on 
inflamed liver tissue (Wahl et al., 2013), indicating favorable effects of targeting with respect 
to safety. Further validation of tolerability of hexavalent TRAIL-R agonists is provided by 
toxicology studies of scTRAIL-RBD-Fc in mice and cynomolgus monkeys (Gieffers et al., 2013). 
These results illustrate promising safety properties of the investigated molecules. Recently, 
Papadopoulos et al. (2015), however, reported partly significant hepatotoxicity of a 
tetravalent TRAIL-R2-agonistic nanobody in a phase I study, despite lacking toxicity in 
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cynomolgus monkeys and on human hepatocytes. The authors suppose a correlation between 
hepatotoxicity and the presence of preexisting anti-drug antibodies, but also indicate that the 
improved activity of multivalent TRAIL-R agonists may limit the maximum tolerated dose due 
to hepatotoxicity (Papadopoulos et al., 2015). Supporting the assumption that hepatotoxicity 
is mediated by anti-drug antibodies, safety studies of recombinant human TRAIL in 
cynomolgus monkeys demonstrated that the observation of hepatotoxic effects is related to 
the formation of anti-drug antibodies that are able to cross-link TRAIL and therefore induce 
increased clustering of TRAIL receptors and apoptosis activation (Zuch de Zafra et al., 2016). 
Hence, further development of the investigated scTRAIL molecules requires careful 
assessment of potential toxicities. 
 
4.5 Combined targeting of two TAAs as improvement strategy for dimeric 
antibody-scTRAIL fusion proteins 
Based on the results of the in vivo experiments that failed to show beneficial effects of 
targeting, the concept of improving dimeric scTRAIL molecules by incorporation of targeting 
moieties is in question. Assuming that the therapeutic potential of the fusion proteins can be 
enhanced by antibody moieties (e.g. by signaling inhibition or increased tolerability, see 4.4), 
further optimization of the developed scDb-EHD2-scTRAIL format is necessary. Regarding the 
EHD2 as dimerization module, the generated data revealed improved performance of the Fc 
part in terms of production, stability, dimer formation, PK, and PD. Especially, the strong 
heterogeneity and low amount of dimer of all scDb-EHD2-scTRAIL preparations suggests the 
replacement of the EHD2 by an Fc part. With respect to the scDb, binding studies 
demonstrated significantly reduced activity of several antibody moieties in certain 
combinations. Since a dramatic influence of the domain order of bispecific diabodies on 
functional properties, like binding and T cell retargeting, has been reported by previous 
studies (Asano et al., 2013; Lu et al., 2004), further development of these molecules requires 
systematic generation and characterization of scDb versions of different orientation. Final 
optimization of the format may be achieved by variation of linkers within the scDb as well as 
linkers connecting scDb, dimerization module, and scTRAIL according to Siegemund et al. 
(2016). By increasing the linker length of Dbhu225 from five to ten amino acids and 
modification of the linker connecting Dbhu225 and scTRAIL, a considerably improved product 
quality has been obtained (Siegemund et al., 2016). Another strategy for further optimization 
  DISCUSSION   
  140   
might be provided by the use of alternative bispecific antibody formats as fusion partner of 
scTRAIL, including small molecules, like tandem scFvs, and IgG-like formats, such as dual 
variable domain immunoglobulins or CrossMabs (reviewed by Kontermann and Brinkmann, 
2015). Concerning the specificities, for example, combination of antagonistic anti-HER2 
and -HER3 antibody moieties has been demonstrated to efficiently inhibit proliferation of 
HER2-amplified tumor cells (McDonagh et al., 2012). Therefore, selection of targeting moieties 
fitting the characteristics of the respective tumor allows generation of highly selective 
therapeutics as well as modulation of relevant receptor signaling. 
 
4.6 Conclusions and Outlook 
By generating and comprehensively characterizing four different targeted dimeric scTRAIL 
formats comprising five distinct antibody moieties, this study is the first to comparatively 
analyze the impact of format and targeting on biochemical and functional properties to 
further guide the development of potent scTRAIL-based therapeutics. In vitro experiments 
identified scFv-Fc-scTRAIL as superior format in terms of production, dimer formation, and 
stability and furthermore indicated factors relevant to improve cell death induction by 
targeting. Namely, these targeting effects seemed to be related to enhanced cell binding of 
scFv-Fc-scTRAIL compared to non-targeted Fc-scTRAIL, which appeared to be determined by 
a potent binding activity of the antibody (relative to scTRAIL) and sufficient antigen expression 
levels (relative to TRAIL receptors). In vivo studies confirmed significantly prolonged serum 
half-lives of Fc fusion proteins that translated into improved anti-tumor activity. Surprisingly, 
no beneficial effects of targeting were observed in the investigated Colo205 xenograft model. 
 
Referring to the lack of targeting effects in vivo, further experiments already suggested above 
(see 4.4) are required to determine the underlying reasons. Assuming that the size increase 
hampers the activity of the targeted molecules, employing smaller ligands, such as single 
domain antibodies (reviewed by Kontermann, 2010), antigen-binding scaffold proteins 
(reviewed by Gebauer and Skerra, 2009) or peptides (Ferrieu-Weisbuch et al., 2006; Liu et al., 
2014), might provide a strategy to incorporate a targeting moiety leading to a more limited 
increase in size. Most likely, targeting and other effects exerted by antibody moieties highly 
depend on tumor properties. Therefore, analysis of biomarkers (Wagner et al., 2007; Soria et 
al., 2011) and gene or protein expression profiles (Chen et al., 2012; O’Reilly et al., 2014; 
Passante et al., 2013; Weyhenmeyer et al., 2016) seems to be crucial to predict TRAIL 
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sensitivity of a certain tumor and to suggest i) an appropriate antibody moiety or alternative 
fusion partner, ii) the incorporation of a receptor-specific TRAIL variant, and iii) a suitable 
sensitizer. Considering the long list of established TRAIL fusion proteins (see Table 1.1), there 
is a large diversity of antibodies and ligands that can be selected as fusion partners explicitly 
fitting the requirements for treatment of a specific tumor. Likewise, tumor cell line-dependent 
incorporation of a TRAIL-R1- or TRAIL-R2-specific TRAIL version might provide a strategy to 
improve cell death induction (reviewed by de Miguel et al., 2016). With respect to selection 
of an optimal sensitizer, significantly improved bioactivity by co-treatment with bortezomib 
was observed for both cell lines in vitro. However, a previous in vivo experiment revealed only 
slightly enhanced efficacy of Dbhu225-scTRAIL in the presence of bortezomib (Siegemund et 
al., 2012). In accordance with the strong sensitizing effect of the SMAC mimetic SM83 
reported e.g. for oncogenic KRAS-expressing cell lines (Möller et al., 2014), significantly 
improved activity of Dbhu225-scTRAIL in combination with SM83 compared to bortezomib 
was found in a Colo205 xenograft model (Hutt, unpublished data), highlighting the influence 
of an appropriately selected sensitizer. Apart from SMAC mimetics, the meanwhile broad 
variety of highly potent sensitizers offers the possibility to adjust the sensitization strategy 
depending on specific tumor characteristics, e.g. inhibiting anti-apoptotic BCL-2 family 
members, histone deacetylases, cyclin-dependent kinase 9, and the molecular chaperone 
Hsp90, as well as inducing ER stress (reviewed by Lemke et al., 2014; Stolfi et al., 2012). As an 
alternative to separate treatments with TRAIL and sensitizer, a concept has been established 
integrating both in one molecule. Fusion of a SMAC-derived peptide to TRAIL via a linker 
including protease cleavage sites and a membrane-penetrating domain has demonstrated 
considerably increased activity on various cell lines (Pieczykolan et al., 2014). Besides analysis 
of the fusion proteins in less artificial systems, like patient-derived xenografts (reviewed by 
Hidalgo et al., 2014), additional experiments might be performed to determine their potential 
in non-cancerous diseases. Positive effects of TRAIL administration have been shown for 
example for certain autoimmune diseases and infections (reviewed by Amarante-Mendes and 
Griffith, 2015). Further development of the molecules for therapeutic application will 
additionally require generation of high producer cell lines, a strategy for purification of tagless 
versions, as well as extensive toxicity analysis. 
 
In conclusion, this study identified scFv-Fc-scTRAIL as superior dimeric antibody-scTRAIL 
format and hu225, 3-43, and 323/A3hu3 as favorable targeting moieties in vitro, whereas in 
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vivo experiments revealed the potent anti-tumor activity of Fc-scTRAIL, which even exceeded 
that of certain targeted counterparts. Therefore, the long-circulating dimeric Fc-scTRAIL 
fusion protein represents a promising version of second generation scTRAIL molecules and 
potentially exerts maximum activity, at least in the investigated tumor model. Allowing the 
combination with various fusion partners, Fc-scTRAIL provides a platform that can be readily 
equipped with additional properties likely to synergize with TRAIL activity in a tumor type-
specific manner, thereby offering the opportunity for tumor-tailored optimization. 
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6 Sequences 
6.1 Single-chain fragments variable 
6.1.1 scFvhu225 (pAB1) 
>pelB leader                                                                            >VHhu225          
|                                                                                       | 
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG GCC ATG GCG GAA GTG CAG CTG GTT GAA AGC GGC   90 
M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A   M   A   E   V   Q   L   V   E   S   G    
 
GGT GGT CTG GTT CAG CCG GGT GGC AGC CTG CGT CTG AGC TGT GCG GCG AGC GGC TTT AGC CTG ACC AAC TAT GGC GTG CAT TGG GTG CGT < 180 
G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   S   L   T   N   Y   G   V   H   W   V   R    
 
CAG GCA CCG GGC AAA GGC CTG GAA TGG CTG GGC GTG ATT TGG AGC GGC GGC AAC ACC GAT TAT AAC ACC CCG TTT ACC AGC CGT TTT ACC < 270 
Q   A   P   G   K   G   L   E   W   L   G   V   I   W   S   G   G   N   T   D   Y   N   T   P   F   T   S   R   F   T    
 
ATT AGC CGT GAT AAC AGC AAA AAC ACC CTG TAT CTG CAG ATG AAC AGC CTG CGT GCG GAA GAT ACC GCG GTG TAT TAT TGC GCG CGT GCG < 360 
I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R   A    
 
                                                                                    >linker          
                                                                                    | 
CTG ACC TAT TAT GAT TAC GAA TTT GCG TAT TGG GGC CAG GGC ACC ACC GTT ACG GTC TCG AGC GGT GGC GGT GGT AGC GGT GGT GGC GGC < 450 
L   T   Y   Y   D   Y   E   F   A   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   G   G   G   G    
 
                        >VLhu225          
                        | 
TCT GGC GGT GGT GGA TCC GAT ATT CAG CTG ACC CAG AGC CCG AGC TTT CTG AGC GCG AGC GTG GGC GAT CGT GTT ACC ATT ACC TGT CGT < 540 
S   G   G   G   G   S   D   I   Q   L   T   Q   S   P   S   F   L   S   A   S   V   G   D   R   V   T   I   T   C   R    
 
GCA AGC CAG AGC ATT GGC ACC AAC ATT CAT TGG TAT CAG CAG AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT AAA TAT GCG AGC GAA AGC < 630 
A   S   Q   S   I   G   T   N   I   H   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   K   Y   A   S   E   S    
 
ATT AGC GGC GTG CCG AGC CGT TTT AGC GGC AGC GGT AGC GGC ACC GAA TTT ACC CTG ACC ATT AGC AGC CTG CAG CCG GAA GAT TTT GCG < 720 
  I   S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F   T   L   T   I   S   S   L   Q   P   E   D   F   A    
 
                                                                                                NotI  
                                                                                                | 
ACC TAT TAT TGC CAG CAG AAC AAC AAC TGG CCG ACC ACC TTT GGT GCG GGC ACC AAA CTG GAA ATT AAA CGT GCG GCC GCA GAA CAA AAA < 810 
T   Y   Y   C   Q   Q   N   N   N   W   P   T   T   F   G   A   G   T   K   L   E   I   K   R   A   A   A   E   Q   K    
 
                                            >His-tag                                   
                                            |                                       
CTC ATC TCA GAA GAG GAT CTG AAT GGG GCC GCA CAT CAC CAT CAT CAC CAT TAA  
L   I   S   E   E   D   L   N   G   A   A   H   H   H   H   H   H   *   
 
6.1.2 scFv4D5 (pAB1) 
>pelB leader                                                                            AgeI    >VH4D5 
|                                                                                       |       | 
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG GCC ATG GCC ACC GGT GAA GTG CAG CTC GTC GAA < 90 
M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A   M   A   T   G   E   V   Q   L   V   E    
 
AGT GGC GGT GGA CTT GTG CAG CCT GGC GGT TCC CTC AGA CTG TCC TGT GCC GCG TCA GGC TTC AAC ATC AAG GAC ACG TAC ATC CAC TGG < 180 
S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   N   I   K   D   T   Y   I   H   W    
 
GTG AGG CAA GCT CCT GGA AAG GGC TTG GAG TGG GTC GCT AGG ATC TAC CCG ACG AAC GGC TAC ACC AGG TAC GCT GAC TCA GTG AAG GGA < 270 
V   R   Q   A   P   G   K   G   L   E   W   V   A   R   I   Y   P   T   N   G   Y   T   R   Y   A   D   S   V   K   G    
 
AGG TTC ACG ATC AGT GCA GAC ACC AGC AAG AAC ACC GCA TAC CTC CAA ATG AAC TCC CTG AGA GCC GAG GAC ACC GCC GTG TAC TAC TGC < 360 
R   F   T   I   S   A   D   T   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C    
 
                                                                                                >linker 
                                                                                                | 
TCT CGT TGG GGT GGA GAT GGC TTC TAC GCT ATG GAC TAC TGG GGT CAA GGC ACA CTG GTG ACC GTG TCC AGT GGT GGC GGA GGC AGT GGC < 450 
S   R   W   G   G   D   G   F   Y   A   M   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   G    
 
                                    >VL4D5       
                                    | 
GGA GGT GGC TCA GGA GGC GGA GGA TCC GAC ATC CAG ATG ACC CAG TCA CCC TCA AGC CTC AGT GCC AGC GTC GGA GAT AGA GTG ACC ATA < 540 
G   G   G   S   G   G   G   G   S   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S   V   G   D   R   V   T   I    
 
ACG TGC CGA GCT TCT CAG GAT GTG AAC ACG GCA GTG GCT TGG TAT CAG CAA AAG CCT GGG AAA GCC CCA AAG CTG CTC ATC TAC TCC GCA < 630 
T   C   R   A   S   Q   D   V   N   T   A   V   A   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   Y   S   A   
 
TCC TTC CTG TAT AGC GGA GTT CCA TCT AGG TTC TCA GGC TCT AGG TCT GGG ACC GAC TTC ACG CTG ACG ATC TCC TCC CTG CAA CCT GAG < 720 
S   F   L   Y   S   G   V   P   S   R   F   S   G   S   R   S   G   T   D   F   T   L   T   I   S   S   L   Q   P   E   
 
                                                                                                            NotI 
                                                                                                            | 
GAC TTC GCC ACG TAC TAC TGC CAG CAG CAC TAC ACG ACT CCT CCA ACC TTC GGT CAG GGA ACG AAG GTC GAG ATC AAG CGT GCG GCC GCA < 810 
D   F   A   T   Y   Y   C   Q   Q   H   Y   T   T   P   P   T   F   G   Q   G   T   K   V   E   I   K   R   A   A   A   
 
                                                        >His-tag        
                                                        | 
GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT GGG GCC GCA CAT CAC CAT CAT CAC CAT TAA 
E   Q   K   L   I   S   E   E   D   L   N   G   A   A   H   H   H   H   H   H   *   
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6.1.3 scFv3M6 (pAB1) 
>pelB leader                                                                            AgeI    >VH3M6 
|                                                                                       |       | 
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG GCC ATG GCC ACC GGT GAA GTG CAG CTG CTG GAA < 90 
M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A   M   A   T   G   E   V   Q   L   L   E    
 
AGC GGA GGC GGC CTG GTG CAG CCT GGC GGC TCT CTG AGA CTG AGC TGT GCC GCC AGC GGC TTC ACC TTC AGC CAC TAC GTG ATG GCC TGG < 180 
S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   T   F   S   H   Y   V   M   A   W    
 
GTC CGA CAG GCC CCT GGC AAG GGA CTG GAA TGG GTG TCC AGC ATC AGC AGC AGC GGC GGC TGG ACC CTG TAC GCC GAT AGC GTG AAG GGC < 270 
V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S   S   S   G   G   W   T   L   Y   A   D   S   V   K   G    
 
CGG TTT ACC ATC AGC CGG GAC AAC AGC AAG AAC ACC CTG TAC CTG CAG ATG AAC AGC CTG CGG GCC GAG GAC ACC GCC GTG TAC TAC TGC < 360 
R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C    
 
                                                                                            >linker         
                                                                                            | 
ACC AGA GGC CTG AAG ATG GCC ACC ATC TTC GAC TAC TGG GGG CAG GGC ACC CTG GTC ACA GTC TCG AGT GGC GGG GGA GGA TCT GGG GGA < 450 
T   R   G   L   K   M   A   T   I   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   G   G    
 
                                >VL3M6          
                                | 
GGT GGA AGT GGC GGC GGT GGA TCC CAG TCT GCC CTG ACA CAG CCT GCC AGC GTG TCC GGC AGC CCT GGC CAG AGC ATC ACA ATC AGC TGC < 540 
G   G   S   G   G   G   G   S   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   G   Q   S   I   T   I   S   C    
 
ACC GGC ACC AGC AGC GAC GTG GGC AGC TAC AAC GTG GTG TCC TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATC ATC TAC GAG < 630 
T   G   T   S   S   D   V   G   S   Y   N   V   V   S   W   Y   Q   Q   H   P   G   K   A   P   K   L   I   I   Y   E    
 
GTG TCC CAG CGG CCC AGC GGC GTG TCC AAC AGA TTC AGC GGC AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC GGG CTG CAG ACC < 720 
V   S   Q   R   P   S   G   V   S   N   R   F   S   G   S   K   S   G   N   T   A   S   L   T   I   S   G   L   Q   T    
 
                                                                                                                    NotI 
                                                                                                                    | 
GAG GAC GAG GCC GAC TAC TAC TGC TCC AGC TAC GCC GGC AGC AGC ATC TTC GTG ATC TTC GGA GGT GGC ACC AAA GTG ACC GTG CTG GCG < 810 
E   D   E   A   D   Y   Y   C   S   S   Y   A   G   S   S   I   F   V   I   F   G   G   G   T   K   V   T   V   L   A    
 
                                                                >His-tag          
                                                                |                 
GCC GCA GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT GGG GCC GCA CAT CAC CAT CAT CAC CAT TAA 
A   A   E   Q   K   L   I   S   E   E   D   L   N   G   A   A   H   H   H   H   H   H   *  
 
6.1.4 scFv3-43 (pSecTagAL1) 
>Igk leader                                                             AgeI    >VH3-43 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT CAA GTG CAG CTG CAG CAG TCT GGC CCT GGC < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   Q   V   Q   L   Q   Q   S   G   P   G    
 
CTC GTG AAG CCT AGC CAG ACC CTG AGC CTG ACC TGT GCC ATC AGC GGC GAT AGC GTG TCC AGC AAC AGA GCC GCC TGG AAC TGG ATC AGA < 180 
L   V   K   P   S   Q   T   L   S   L   T   C   A   I   S   G   D   S   V   S   S   N   R   A   A   W   N   W   I   R    
 
CAG AGC CCC AGC AGA GGC CTG GAA TGG CTG GGC CGG ACC TAC TAC CGC AGC AAG TGG TAC AAC GAC TAC GCC CAG AGC CTG AAG TCC CGG < 270 
Q   S   P   S   R   G   L   E   W   L   G   R   T   Y   Y   R   S   K   W   Y   N   D   Y   A   Q   S   L   K   S   R    
 
ATC ACC ATC AAC CCC GAC ACC CCC AAG AAC CAG TTC TCC CTG CAG CTG AAC AGC GTG ACC CCC GAG GAT ACC GCC GTG TAC TAC TGC GCC < 360 
I   T   I   N   P   D   T   P   K   N   Q   F   S   L   Q   L   N   S   V   T   P   E   D   T   A   V   Y   Y   C   A    
 
                                                                                            >linker         
                                                                                            | 
AGA GAT GGA CAG CTG GGC CTG GAC GCC CTG GAC ATT TGG GGC CAG GGC ACA ATG GTC ACA GTG TCC TCT GGC GGG GGA GGA TCT GGG GGA < 450 
R   D   G   Q   L   G   L   D   A   L   D   I   W   G   Q   G   T   M   V   T   V   S   S   G   G   G   G   S   G   G    
 
                                >VL3-43         
                                | 
GGT GGA AGT GGC GGC GGT GGA TCC CAA GCC GGA CTG ACA CAG CCT CCA GCC GTG TCT GTG GCC CCT GGA CAG ACA GCC AGC ATC ACC TGT < 540 
G   G   S   G   G   G   G   S   Q   A   G   L   T   Q   P   P   A   V   S   V   A   P   G   Q   T   A   S   I   T   C    
 
GGC CGG GAC AAC ATC GGC AGC AGA AGC GTG CAC TGG TAT CAG CAG AAA CCC GGC CAG GCC CCT GTG CTG GTG GTG TAC GAC GAC AGC GAT < 630 
G   R   D   N   I   G   S   R   S   V   H   W   Y   Q   Q   K   P   G   Q   A   P   V   L   V   V   Y   D   D   S   D   
 
AGA CCT GCC GGC ATC CCC GAG AGA TTC AGC GGC AGC AAC TAC GAG AAC ACC GCC ACC CTG ACC ATC AGC AGA GTG GAA GCC GGC GAC GAG < 720 
R   P   A   G   I   P   E   R   F   S   G   S   N   Y   E   N   T   A   T   L   T   I   S   R   V   E   A   G   D   E    
 
                                                                                                        NotI        >His-tag 
                                                                                                        |           | 
GCC GAC TAC TAC TGT CAA GTG TGG GGC ATC ACC AGC GAT CAC GTG GTG TTT GGC GGA GGC ACC AAG CTG ACA GTG CTG GCG GCC GCC CAC < 810 
A   D   Y   Y   C   Q   V   W   G   I   T   S   D   H   V   V   F   G   G   G   T   K   L   T   V   L   A   A   A   H    
 
CAT CAT CAC CAT CAC TAA  
H   H   H   H   H   *    
 
6.1.5 scFv323/A3hu3 (pAB1) 
>pelB leader                                                                            AgeI    >VH323/A3hu3 
|                                                                                       |       | 
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG GCC ATG GCC ACC GGT CAA GTG CAG CTG GTG CAG < 90 
M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A   M   A   T   G   Q   V   Q   L   V   Q   
 
TCT GGC GCC GAA GTG AAG AAA CCA GGC GCC AGC GTG AAG GTG TCC TGC AAG GCC AGC GGC TAC ACC TTT ACC AAC TAC GGC ATG AAC TGG < 180 
S   G   A   E   V   K   K   P   G   A   S   V   K   V   S   C   K   A   S   G   Y   T   F   T   N   Y   G   M   N   W   
 
GTG CGC CAG GCC CCT GGC CAG AGA CTG GAA TGG ATG GGC TGG ATC AAC ACC TAC ACC GGC GAG CCC ACC TAC GGC GAG GAC TTC AAG GGC < 270 
V   R   Q   A   P   G   Q   R   L   E   W   M   G   W   I   N   T   Y   T   G   E   P   T   Y   G   E   D   F   K   G   
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AGA GTG ACC ATC ACC CTG GAC ACC AGC GCC AGC ACC GCC TAC ATG GAA CTG AGC AGC CTG CGG AGC GAG GAC ACC GCC GTG TAC TAC TGC < 360 
R   V   T   I   T   L   D   T   S   A   S   T   A   Y   M   E   L   S   S   L   R   S   E   D   T   A   V   Y   Y   C   
 
                                                                                >Linker       
                                                                                | 
GCC AGA TTC GGC AAC TAC GTG GAC TAC TGG GGC CAG GGC ACC CTC GTG ACA GTC TCG AGT GGC GGC GGA GGA TCT GGC GGA GGC GGA AGT < 450 
A   R   F   G   N   Y   V   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   
 
                    >VL323/A3hu3       
                    | 
GGG GGA GGC GGA TCT GAG ATC GTG CTG ACA CAG AGC CCT GGC ACC CTG AGC CTG TCT CCA GGC GAA AGA GCC ACC CTG TCC TGC AGA AGC < 540 
G   G   G   G   S   E   I   V   L   T   Q   S   P   G   T   L   S   L   S   P   G   E   R   A   T   L   S   C   R   S   
 
AGC AAG AAC CTG CTG CAC AGC AAC GGC ATC ACC TAC CTG TAC TGG TAT CAG CAG AAG CCC GGC CAG GCC CCC AGA CTG CTG ATC TAC CAG < 630 
S   K   N   L   L   H   S   N   G   I   T   Y   L   Y   W   Y   Q   Q   K   P   G   Q   A   P   R   L   L   I   Y   Q   
 
ATG AGC AAC CTG GCC AGC GGC ATC CCC GAC AGA TTT TCT GGC AGC GGC TCC GGC ACC GAC TTC ACC CTG ACA ATC AGC AGA CTG GAA CCC < 720 
M   S   N   L   A   S   G   I   P   D   R   F   S   G   S   G   S   G   T   D   F   T   L   T   I   S   R   L   E   P   
 
                                                                                                                NotI 
                                                                                                                | 
GAG GAC TTC GCC GTG TAC TAC TGC GCC CAG AAC CTG GAA ATC CCC CGG ACC TTT GGC CAG GGC ACC AAG CTG GAA ATC AAG AGA GCG GCC < 810 
E   D   F   A   V   Y   Y   C   A   Q   N   L   E   I   P   R   T   F   G   Q   G   T   K   L   E   I   K   R   A   A   
 
                                                            >His-tag      
                                                            | 
GCA GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT GGG GCC GCA CAT CAC CAT CAT CAC CAT TAA  
A   E   Q   K   L   I   S   E   E   D   L   N   G   A   A   H   H   H   H   H   H   *    
 
6.2 Diabodies and disulfide-stabilized diabodies 
6.2.1 (ds)Dbhu225 (pSecTagAL1) 
Sequence of Dbhu225 is represented. Mutation of underlined codons GGC to TGT and GCG to 
TGC replaces G and A with cysteines, respectively, and generates sequence of dsDbhu225. 
>Igk leader                                                             AgeI    VHhu225 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAA GTG CAG CTG GTT GAA AGC GGC GGT GGT < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   E   V   Q   L   V   E   S   G   G   G   
 
CTG GTT CAG CCG GGT GGC AGC CTG CGT CTG AGC TGT GCG GCG AGC GGC TTT AGC CTG ACC AAC TAT GGC GTG CAT TGG GTG CGT CAG GCA < 180 
L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   S   L   T   N   Y   G   V   H   W   V   R   Q   A   
 
CCG GGC AAA GGC CTG GAA TGG CTG GGC GTG ATT TGG AGC GGC GGC AAC ACC GAT TAT AAC ACC CCG TTT ACC AGC CGT TTT ACC ATT AGC < 270 
P   G   K   G   L   E   W   L   G   V   I   W   S   G   G   N   T   D   Y   N   T   P   F   T   S   R   F   T   I   S   
 
CGT GAT AAC AGC AAA AAC ACC CTG TAT CTG CAG ATG AAC AGC CTG CGT GCG GAA GAT ACC GCG GTG TAT TAT TGC GCG CGT GCG CTG ACC < 360 
R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R   A   L   T   
 
                                                                            >linker             >VLhu225 
                                                                            |                   | 
TAT TAT GAT TAC GAA TTT GCG TAT TGG GGC CAG GGC ACC ACC GTT ACG GTC TCG AGC GGT GGC GGT GGA TCC GAT ATT CAG CTG ACC CAG < 450 
Y   Y   D   Y   E   F   A   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   D   I   Q   L   T   Q   
 
AGC CCG AGC TTT CTG AGC GCG AGC GTG GGC GAT CGT GTT ACC ATT ACC TGT CGT GCA AGC CAG AGC ATT GGC ACC AAC ATT CAT TGG TAT < 540 
S   P   S   F   L   S   A   S   V   G   D   R   V   T   I   T   C   R   A   S   Q   S   I   G   T   N   I   H   W   Y   
 
CAG CAG AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT AAA TAT GCG AGC GAA AGC ATT AGC GGC GTG CCG AGC CGT TTT AGC GGC AGC GGT < 630 
Q   Q   K   P   G   K   A   P   K   L   L   I   K   Y   A   S   E   S   I   S   G   V   P   S   R   F   S   G   S   G   
 
AGC GGC ACC GAA TTT ACC CTG ACC ATT AGC AGC CTG CAG CCG GAA GAT TTT GCG ACC TAT TAT TGC CAG CAG AAC AAC AAC TGG CCG ACC < 720 
S   G   T   E   F   T   L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y   C   Q   Q   N   N   N   W   P   T   
 
                                                NotI        >His-tag         
                                                |           | 
ACC TTT GGT GCG GGC ACC AAA CTG GAA ATT AAA CGT GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
T   F   G   A   G   T   K   L   E   I   K   R   A   A   A   H   H   H   H   H   H   *    
 
6.2.2 (ds)Db4D5 (pSecTagAL1) 
Sequence of Db4D5 is represented. Mutation of underlined codons GGC to TGT and CAG to 
TGC replaces G and Q with cysteines, respectively, and generates sequence of dsDb4D5. 
>Igk leader                                                             AgeI    VH4D5 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAA GTG CAG CTC GTC GAA AGT GGC GGT GGA < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   E   V   Q   L   V   E   S   G   G   G    
 
CTT GTG CAG CCT GGC GGT TCC CTC AGA CTG TCC TGT GCC GCG TCA GGC TTC AAC ATC AAG GAC ACG TAC ATC CAC TGG GTG AGG CAA GCT < 180 
L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   N   I   K   D   T   Y   I   H   W   V   R   Q   A   
 
CCT GGA AAG GGC TTG GAG TGG GTC GCT AGG ATC TAC CCG ACG AAC GGC TAC ACC AGG TAC GCT GAC TCA GTG AAG GGA AGG TTC ACG ATC < 270 
P   G   K   G   L   E   W   V   A   R   I   Y   P   T   N   G   Y   T   R   Y   A   D   S   V   K   G   R   F   T   I   
 
AGT GCA GAC ACC AGC AAG AAC ACC GCA TAC CTC CAA ATG AAC TCC CTG AGA GCC GAG GAC ACC GCC GTG TAC TAC TGC TCT CGT TGG GGT < 360 
S   A   D   T   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   S   R   W   G   
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                                                                                >linker             >VL4D5 
                                                                                |                   | 
GGA GAT GGC TTC TAC GCT ATG GAC TAC TGG GGT CAA GGC ACA CTG GTG ACC GTC AGT TCC GGA GGA GGG GGT AGT GAC ATC CAG ATG ACC < 450 
G   D   G   F   Y   A   M   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   D   I   Q   M   T   
 
CAG TCA CCC TCA AGC CTC AGT GCC AGC GTC GGA GAT AGA GTG ACC ATA ACG TGC CGA GCT TCT CAG GAT GTG AAC ACG GCA GTG GCT TGG < 540 
Q   S   P   S   S   L   S   A   S   V   G   D   R   V   T   I   T   C   R   A   S   Q   D   V   N   T   A   V   A   W   
 
TAT CAG CAA AAG CCT GGG AAA GCC CCA AAG CTG CTC ATC TAC TCC GCA TCC TTC CTG TAT AGC GGA GTT CCA TCT AGG TTC TCA GGC TCT < 630 
Y   Q   Q   K   P   G   K   A   P   K   L   L   I   Y   S   A   S   F   L   Y   S   G   V   P   S   R   F   S   G   S   
 
AGG TCT GGG ACC GAC TTC ACG CTG ACG ATC TCC TCC CTG CAA CCT GAG GAC TTC GCC ACG TAC TAC TGC CAG CAG CAC TAC ACG ACT CCT < 720 
R   S   G   T   D   F   T   L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y   C   Q   Q   H   Y   T   T   P   
 
                                                    NotI        >His-tag         
                                                    |           | 
CCA ACC TTC GGT CAG GGA ACG AAG GTC GAG ATC AAG CGT GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
P   T   F   G   Q   G   T   K   V   E   I   K   R   A   A   A   H   H   H   H   H   H   *    
 
6.2.3 (ds)Db3M6 (pSecTagAL1) 
Sequence of Db3M6 is represented. Mutation of underlined codons GGA to TGT and GGT to 
TGC replaces G and G with cysteines, respectively, and generates sequence of dsDb3M6. 
>Igk leader                                                             AgeI    >VH3M6 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAA GTG CAG CTG CTG GAA AGC GGA GGC GGC < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   E   V   Q   L   L   E   S   G   G   G   
 
CTG GTG CAG CCT GGC GGC TCT CTG AGA CTG AGC TGT GCC GCC AGC GGC TTC ACC TTC AGC CAC TAC GTG ATG GCC TGG GTC CGA CAG GCC < 180 
L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   T   F   S   H   Y   V   M   A   W   V   R   Q   A   
 
CCT GGC AAG GGA CTG GAA TGG GTG TCC AGC ATC AGC AGC AGC GGC GGC TGG ACC CTG TAC GCC GAT AGC GTG AAG GGC CGG TTT ACC ATC < 270 
P   G   K   G   L   E   W   V   S   S   I   S   S   S   G   G   W   T   L   Y   A   D   S   V   K   G   R   F   T   I   
 
AGC CGG GAC AAC AGC AAG AAC ACC CTG TAC CTG CAG ATG AAC AGC CTG CGG GCC GAG GAC ACC GCC GTG TAC TAC TGC ACC AGA GGC CTG < 360 
S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   T   R   G   L   
 
                                                                            >linker             >VL3M6 
                                                                            |                   | 
AAG ATG GCC ACC ATC TTC GAC TAC TGG GGG CAG GGC ACC CTG GTC ACA GTC TCG AGT GGG GGA GGC GGA TCC CAG TCT GCC CTG ACA CAG < 450 
K   M   A   T   I   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   Q   S   A   L   T   Q   
 
CCT GCC AGC GTG TCC GGC AGC CCT GGC CAG AGC ATC ACA ATC AGC TGC ACC GGC ACC AGC AGC GAC GTG GGC AGC TAC AAC GTG GTG TCC < 540 
P   A   S   V   S   G   S   P   G   Q   S   I   T   I   S   C   T   G   T   S   S   D   V   G   S   Y   N   V   V   S   
 
TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATC ATC TAC GAG GTG TCC CAG CGG CCC AGC GGC GTG TCC AAC AGA TTC AGC GGC < 630 
W   Y   Q   Q   H   P   G   K   A   P   K   L   I   I   Y   E   V   S   Q   R   P   S   G   V   S   N   R   F   S   G   
 
AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC GGG CTG CAG ACC GAG GAC GAG GCC GAC TAC TAC TGC TCC AGC TAC GCC GGC AGC < 720 
S   K   S   G   N   T   A   S   L   T   I   S   G   L   Q   T   E   D   E   A   D   Y   Y   C   S   S   Y   A   G   S   
 
                                                            NotI        >His-tag         
                                                            |           | 
AGC ATC TTC GTG ATC TTC GGA GGT GGC ACC AAA GTG ACC GTG CTG GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
S   I   F   V   I   F   G   G   G   T   K   V   T   V   L   A   A   A   H   H   H   H   H   H   *    
 
6.2.4 Db3-43 (pSecTagAL1) 
>Igk leader                                                             AgeI    >VH3-43 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT CAA GTG CAG CTG CAG CAG TCT GGC CCT GGC < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   Q   V   Q   L   Q   Q   S   G   P   G    
 
CTC GTG AAG CCT AGC CAG ACC CTG AGC CTG ACC TGT GCC ATC AGC GGC GAT AGC GTG TCC AGC AAC AGA GCC GCC TGG AAC TGG ATC AGA < 180 
L   V   K   P   S   Q   T   L   S   L   T   C   A   I   S   G   D   S   V   S   S   N   R   A   A   W   N   W   I   R   
 
CAG AGC CCC AGC AGA GGC CTG GAA TGG CTG GGC CGG ACC TAC TAC CGC AGC AAG TGG TAC AAC GAC TAC GCC CAG AGC CTG AAG TCC CGG < 270 
Q   S   P   S   R   G   L   E   W   L   G   R   T   Y   Y   R   S   K   W   Y   N   D   Y   A   Q   S   L   K   S   R   
 
ATC ACC ATC AAC CCC GAC ACC CCC AAG AAC CAG TTC TCC CTG CAG CTG AAC AGC GTG ACC CCC GAG GAT ACC GCC GTG TAC TAC TGC GCC < 360 
I   T   I   N   P   D   T   P   K   N   Q   F   S   L   Q   L   N   S   V   T   P   E   D   T   A   V   Y   Y   C   A   
 
                                                                                            >linker             >VL3-43 
                                                                                            |                   | 
AGA GAT GGA CAG CTG GGC CTG GAC GCC CTG GAC ATT TGG GGC CAG GGC ACA ATG GTC ACA GTG TCC TCT GGG GGA GGC GGA TCC CAA GCC < 450 
R   D   G   Q   L   G   L   D   A   L   D   I   W   G   Q   G   T   M   V   T   V   S   S   G   G   G   G   S   Q   A   
 
GGA CTG ACA CAG CCT CCA GCC GTG TCT GTG GCC CCT GGA CAG ACA GCC AGC ATC ACC TGT GGC CGG GAC AAC ATC GGC AGC AGA AGC GTG < 540 
G   L   T   Q   P   P   A   V   S   V   A   P   G   Q   T   A   S   I   T   C   G   R   D   N   I   G   S   R   S   V   
 
CAC TGG TAT CAG CAG AAA CCC GGC CAG GCC CCT GTG CTG GTG GTG TAC GAC GAC AGC GAT AGA CCT GCC GGC ATC CCC GAG AGA TTC AGC < 630 
H   W   Y   Q   Q   K   P   G   Q   A   P   V   L   V   V   Y   D   D   S   D   R   P   A   G   I   P   E   R   F   S   
 
GGC AGC AAC TAC GAG AAC ACC GCC ACC CTG ACC ATC AGC AGA GTG GAA GCC GGC GAC GAG GCC GAC TAC TAC TGT CAA GTG TGG GGC ATC < 720 
G   S   N   Y   E   N   T   A   T   L   T   I   S   R   V   E   A   G   D   E   A   D   Y   Y   C   Q   V   W   G   I   
 
                                                                NotI        >His-tag         
                                                                |           | 
ACC AGC GAT CAC GTG GTG TTT GGC GGA GGC ACC AAG CTG ACA GTG CTG GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
T   S   D   H   V   V   F   G   G   G   T   K   L   T   V   L   A   A   A   H   H   H   H   H   H   *    
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6.2.5 Db323/A3hu3 (pSecTagAL1) 
>Igk leader                                                             AgeI    >VH323/A3hu3 
|                                                                       |       | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT CAA GTG CAG CTG GTG CAG TCT GGC GCC GAA < 90 
  M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   Q   V   Q   L   V   Q   S   G   A   E   
 
GTG AAG AAA CCA GGC GCC AGC GTG AAG GTG TCC TGC AAG GCC AGC GGC TAC ACC TTT ACC AAC TAC GGC ATG AAC TGG GTG CGC CAG GCC < 180 
V   K   K   P   G   A   S   V   K   V   S   C   K   A   S   G   Y   T   F   T   N   Y   G   M   N   W   V   R   Q   A   
 
CCT GGC CAG AGA CTG GAA TGG ATG GGC TGG ATC AAC ACC TAC ACC GGC GAG CCC ACC TAC GGC GAG GAC TTC AAG GGC AGA GTG ACC ATC < 270 
P   G   Q   R   L   E   W   M   G   W   I   N   T   Y   T   G   E   P   T   Y   G   E   D   F   K   G   R   V   T   I   
 
ACC CTG GAC ACC AGC GCC AGC ACC GCC TAC ATG GAA CTG AGC AGC CTG CGG AGC GAG GAC ACC GCC GTG TAC TAC TGC GCC AGA TTC GGC < 360 
T   L   D   T   S   A   S   T   A   Y   M   E   L   S   S   L   R   S   E   D   T   A   V   Y   Y   C   A   R   F   G    
 
                                                                >linker             >VL323/A3hu3 
                                                                |                   | 
AAC TAC GTG GAC TAC TGG GGC CAG GGC ACC CTC GTG ACA GTC TCG AGC GGT GGC GGT GGA TCC GAG ATC GTG CTG ACA CAG AGC CCT GGC < 450 
N   Y   V   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   E   I   V   L   T   Q   S   P   G   
 
ACC CTG AGC CTG TCT CCA GGC GAA AGA GCC ACC CTG TCC TGC AGA AGC AGC AAG AAC CTG CTG CAC AGC AAC GGC ATC ACC TAC CTG TAC < 540 
T   L   S   L   S   P   G   E   R   A   T   L   S   C   R   S   S   K   N   L   L   H   S   N   G   I   T   Y   L   Y   
 
TGG TAT CAG CAG AAG CCC GGC CAG GCC CCC AGA CTG CTG ATC TAC CAG ATG AGC AAC CTG GCC AGC GGC ATC CCA GAC AGA TTT TCT GGC < 630 
W   Y   Q   Q   K   P   G   Q   A   P   R   L   L   I   Y   Q   M   S   N   L   A   S   G   I   P   D   R   F   S   G   
 
AGC GGC TCC GGC ACC GAC TTC ACC CTG ACA ATC AGC AGA CTG GAA CCC GAG GAC TTC GCC GTG TAC TAC TGC GCC CAG AAC CTG GAA ATC < 720 
S   G   S   G   T   D   F   T   L   T   I   S   R   L   E   P   E   D   F   A   V   Y   Y   C   A   Q   N   L   E   I   
 
                                                        NotI        >His-tag         
                                                        |           | 
CCC CGG ACC TTT GGC CAG GGC ACC AAG CTG GAA ATC AAG AGA GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
P   R   T   F   G   Q   G   T   K   L   E   I   K   R   A   A   A   H   H   H   H   H   H   *    
 
6.3 scFv-EHD2 (pSecTagAL1) 
ScFv-EHD2 constructs were generated by insertion of the respective scFv sequences (see 6.1) 
as AgeI-NotI fragments into the sequence represented below (after AgeI-NotI digestion). 
>Igk leader                                                             AgeI            
|                                                                       |               
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT ... ... ... ... ... ... ... ... ... ... < 90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G    
 
                    NotI>linker                     >EHD2 
                    |                               | 
... ... ... ... ... GCG GCC GCC GGG GGA AGC GGC GGT GAT TTC ACC CCC CCC ACA GTG AAG ATC CTC CAG AGC AGC TGT GAC GGC GGA < 180 
                    A   A   A   G   G   S   G   G   D   F   T   P   P   T   V   K   I   L   Q   S   S   C   D   G   G   
 
GGC CAC TTC CCA CCT ACC ATC CAG CTG CTG TGT CTG GTG TCC GGC TAC ACC CCC GGC ACC ATC AAC ATC ACC TGG CTG GAA GAT GGA CAA < 270 
G   H   F   P   P   T   I   Q   L   L   C   L   V   S   G   Y   T   P   G   T   I   N   I   T   W   L   E   D   G   Q    
 
GTG ATG GAC GTG GAC CTG AGC ACC GCC AGC ACC ACA CAG GAA GGC GAG CTG GCC TCT ACC CAG AGC GAG CTG ACA CTG AGC CAG AAG CAC < 360 
V   M   D   V   D   L   S   T   A   S   T   T   Q   E   G   E   L   A   S   T   Q   S   E   L   T   L   S   Q   K   H   
 
                                                                                                                    >linker  
                                                                                                                    |  
TGG CTG AGC GAC CGG ACC TAC ACC TGT CAA GTG ACC TAC CAG GGC CAC ACC TTC GAG GAC AGC ACC AAG AAG TGC GCC GAC AGC AAC GGA < 450 
W   L   S   D   R   T   Y   T   C   Q   V   T   Y   Q   G   H   T   F   E   D   S   T   K   K   C   A   D   S   N   G   
 
                            >His-tag        
                            | 
GGT TCA GGG GGC GCC TCG AGC CAC CAT CAT CAC CAT CAC TAA  
G   S   G   G   A   S   S   H   H   H   H   H   H   *    
 
6.4 scFv-Fc (pSecTagAL1) 
ScFv-Fc constructs were generated by insertion of the respective scFv sequences (see 6.1) as 
AgeI-NotI fragments into the sequence represented below (after AgeI-NotI digestion). 
>Igk leader                                                             AgeI                NotI>linker 
|                                                                       |                   | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT ... ... ... GCG GCC GCA GGG GGA AGC GGC < 180 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G               A   A   A   G   G   S   G   
 
    >hinge                                  CH2 
    |                                       | 
GGT GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC < 270 
G   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   
 
ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG < 360 
T   L   M   I   S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   
 
GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG < 450 
D   G   V   E   V   H   N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   
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CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC < 540 
H   Q   D   W   L   N   G   K   E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A    
 
    >CH3       
    | 
AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC < 630 
K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R   D   E   L   T   K   N   Q   V   S   L   T   C   L   V    
 
AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC < 720 
K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E   N   N   Y   K   T   T   P   P   V   L   D    
 
TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT < 810 
S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N   V   F   S   C   S   V   M   H    
 
GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA TGA 
E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   K   *   
 
6.5 Bispecific single-chain diabodies 
6.5.1 scDbhu225x3M6 (pSecTagAHis) 
>Igk leader                                                                                                     >VHhu225 
|                                                                                                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCG GAA GTG <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   E   V    
 
CAG CTG GTT GAA AGC GGC GGT GGT CTG GTT CAG CCG GGT GGC AGC CTG CGT CTG AGC TGT GCG GCG AGC GGC TTT AGC CTG ACC AAC TAT <180 
Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   S   L   T   N   Y    
 
GGC GTG CAT TGG GTG CGT CAG GCA CCG GGC AAA GGC CTG GAA TGG CTG GGC GTG ATT TGG AGC GGC GGC AAC ACC GAT TAT AAC ACC CCG <270 
G   V   H   W   V   R   Q   A   P   G   K   G   L   E   W   L   G   V   I   W   S   G   G   N   T   D   Y   N   T   P    
 
TTT ACC AGC CGT TTT ACC ATT AGC CGT GAT AAC AGC AAA AAC ACC CTG TAT CTG CAG ATG AAC AGC CTG CGT GCG GAA GAT ACC GCG GTG <360 
F   T   S   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E   D   T   A   V    
 
                                                                                                            >linker 
                                                                                                            | 
TAT TAT TGC GCG CGT GCG CTG ACC TAT TAT GAT TAC GAA TTT GCG TAT TGG GGC CAG GGC ACC ACC GTT ACG GTC TCG AGT GGC GGT GGC <450 
Y   Y   C   A   R   A   L   T   Y   Y   D   Y   E   F   A   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G    
 
        >VL3M6 
        | 
GGA TCG CAG TCT GCC CTG ACA CAG CCT GCC AGC GTG TCC GGC AGC CCT GGC CAG AGC ATC ACA ATC AGC TGC ACC GGC ACC AGC AGC GAC <540 
G   S   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   G   Q   S   I   T   I   S   C   T   G   T   S   S   D    
 
GTG GGC AGC TAC AAC GTG GTG TCC TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATC ATC TAC GAG GTG TCC CAG CGG CCC AGC <630 
V   G   S   Y   N   V   V   S   W   Y   Q   Q   H   P   G   K   A   P   K   L   I   I   Y   E   V   S   Q   R   P   S    
 
GGC GTG TCC AAC AGA TTC AGC GGC AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC GGG CTG CAG ACC GAG GAC GAG GCC GAC TAC <720 
G   V   S   N   R   F   S   G   S   K   S   G   N   T   A   S   L   T   I   S   G   L   Q   T   E   D   E   A   D   Y    
 
                                                                                            >linker 
                                                                                            | 
TAC TGC TCC AGC TAC GCC GGC AGC AGC ATC TTC GTG ATC TTC GGA GGT GGC ACC AAA GTG ACC GTG CTG GGA GGC GGT GGC AGC GGT GGG <810 
Y   C   S   S   Y   A   G   S   S   I   F   V   I   F   G   G   G   T   K   V   T   V   L   G   G   G   G   S   G   G    
 
                                >VH3M6 
                                | 
CGC GCC TCG GGC GGA GGT GGC TCA GAA GTG CAG CTG CTG GAA AGC GGA GGC GGC CTG GTG CAG CCT GGC GGC TCT CTG AGA CTG AGC TGT <900 
R   A   S   G   G   G   G   S   E   V   Q   L   L   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C    
 
GCC GCC AGC GGC TTC ACC TTC AGC CAC TAC GTG ATG GCC TGG GTC CGA CAG GCC CCT GGC AAG GGA CTG GAA TGG GTG TCC AGC ATC AGC <990 
A   A   S   G   F   T   F   S   H   Y   V   M   A   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S    
 
AGC AGC GGC GGC TGG ACC CTG TAC GCC GAT AGC GTG AAG GGC CGG TTT ACC ATC AGC CGG GAC AAC AGC AAG AAC ACC CTG TAC CTG CAG <1080 
S   S   G   G   W   T   L   Y   A   D   S   V   K   G   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q    
 
ATG AAC AGC CTG CGG GCC GAG GAC ACC GCC GTG TAC TAC TGC ACC AGA GGC CTG AAG ATG GCC ACC ATC TTC GAC TAC TGG GGG CAG GGC <1170 
M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   T   R   G   L   K   M   A   T   I   F   D   Y   W   G   Q   G    
 
                            >linker             >VLhu225 
                            |                   | 
ACC CTG GTC ACA GTC TCG AGT GGA GGC GGG GGA TCC GAT ATT CAG CTG ACC CAG AGC CCG AGC TTT CTG AGC GCG AGC GTG GGC GAT CGT <1260 
T   L   V   T   V   S   S   G   G   G   G   S   D   I   Q   L   T   Q   S   P   S   F   L   S   A   S   V   G   D   R    
 
GTT ACC ATT ACC TGT CGT GCA AGC CAG AGC ATT GGC ACC AAC ATT CAT TGG TAT CAG CAG AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT <1350 
V   T   I   T   C   R   A   S   Q   S   I   G   T   N   I   H   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I    
 
AAA TAT GCG AGC GAA AGC ATT AGC GGC GTG CCG AGC CGT TTT AGC GGC AGC GGT AGC GGC ACC GAA TTT ACC CTG ACC ATT AGC AGC CTG <1440 
K   Y   A   S   E   S   I   S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F   T   L   T   I   S   S   L    
 
CAG CCG GAA GAT TTT GCG ACC TAT TAT TGC CAG CAG AAC AAC AAC TGG CCG ACC ACC TTT GGT GCG GGC ACC AAA CTG GAA ATT AAA CGT <1530 
Q   P   E   D   F   A   T   Y   Y   C   Q   Q   N   N   N   W   P   T   T   F   G   A   G   T   K   L   E   I   K   R    
 
NotI        >His-tag     
|           |            
GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
A   A   A   H   H   H   H   H   H   *    
 
6.5.2 scDb323/A3hu3xhu225 (pSecTagAHis) 
>Igk leader 
| 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC ACC GGT <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   T   G    
  SEQUENCES   
  166   
>VH323/A3hu3 
| 
CAA GTG CAG CTG GTG CAG TCT GGC GCC GAA GTG AAG AAA CCA GGC GCC AGC GTG AAG GTG TCC TGC AAG GCC AGC GGC TAC ACC TTT ACC <180 
Q   V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   A   S   V   K   V   S   C   K   A   S   G   Y   T   F   T    
 
AAC TAC GGC ATG AAC TGG GTG CGC CAG GCC CCT GGC CAG AGA CTG GAA TGG ATG GGC TGG ATC AAC ACC TAC ACC GGC GAG CCC ACC TAC <270 
N   Y   G   M   N   W   V   R   Q   A   P   G   Q   R   L   E   W   M   G   W   I   N   T   Y   T   G   E   P   T   Y    
 
GGC GAG GAC TTC AAG GGC AGA GTG ACC ATC ACC CTG GAC ACC AGC GCC AGC ACC GCC TAC ATG GAA CTG AGC AGC CTG CGG AGC GAG GAC <360 
G   E   D   F   K   G   R   V   T   I   T   L   D   T   S   A   S   T   A   Y   M   E   L   S   S   L   R   S   E   D    
 
                                                                                                        >linker 
                                                                                                        | 
ACC GCC GTG TAC TAC TGC GCC AGA TTC GGC AAC TAC GTG GAC TAC TGG GGC CAG GGC ACC CTC GTG ACA GTC TCG AGT GGC GGT GGC GGA <450 
T   A   V   Y   Y   C   A   R   F   G   N   Y   V   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G    
 
    >VLhu225 
    | 
TCG GAT ATT CAG CTG ACC CAG AGC CCG AGC TTT CTG AGC GCG AGC GTG GGC GAT CGT GTT ACC ATT ACC TGT CGT GCA AGC CAG AGC ATT <540 
S   D   I   Q   L   T   Q   S   P   S   F   L   S   A   S   V   G   D   R   V   T   I   T   C   R   A   S   Q   S   I    
 
GGC ACC AAC ATT CAT TGG TAT CAG CAG AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT AAA TAT GCG AGC GAA AGC ATT AGC GGC GTG CCG <630 
G   T   N   I   H   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   K   Y   A   S   E   S   I   S   G   V   P    
 
AGC CGT TTT AGC GGC AGC GGT AGC GGC ACC GAA TTT ACC CTG ACC ATT AGC AGC CTG CAG CCG GAA GAT TTT GCG ACC TAT TAT TGC CAG <720 
S   R   F   S   G   S   G   S   G   T   E   F   T   L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y   C   Q    
 
                                                                            >linker 
                                                                            | 
CAG AAC AAC AAC TGG CCG ACC ACC TTT GGT GCG GGC ACC AAA CTG GAA ATT AAA CGT GGA GGC GGT GGC AGC GGT GGG CGC GCC TCG GGC <810 
Q   N   N   N   W   P   T   T   F   G   A   G   T   K   L   E   I   K   R   G   G   G   G   S   G   G   R   A   S   G    
 
                >VHhu225 
                | 
GGA GGT GGC TCA GAA GTG CAG CTG GTT GAA AGC GGC GGT GGT CTG GTT CAG CCG GGT GGC AGC CTG CGT CTG AGC TGT GCG GCG AGC GGC <900 
G   G   G   S   E   V   Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G    
 
TTT AGC CTG ACC AAC TAT GGC GTG CAT TGG GTG CGT CAG GCA CCG GGC AAA GGC CTG GAA TGG CTG GGC GTG ATT TGG AGC GGC GGC AAC <990 
F   S   L   T   N   Y   G   V   H   W   V   R   Q   A   P   G   K   G   L   E   W   L   G   V   I   W   S   G   G   N    
 
ACC GAT TAT AAC ACC CCG TTT ACC AGC CGT TTT ACC ATT AGC CGT GAT AAC AGC AAA AAC ACC CTG TAT CTG CAG ATG AAC AGC CTG CGT <1080 
T   D   Y   N   T   P   F   T   S   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R    
 
GCG GAA GAT ACC GCG GTG TAT TAT TGC GCG CGT GCG CTG ACC TAT TAT GAT TAC GAA TTT GCG TAT TGG GGC CAG GGC ACC ACC GTT ACG <1170 
A   E   D   T   A   V   Y   Y   C   A   R   A   L   T   Y   Y   D   Y   E   F   A   Y   W   G   Q   G   T   T   V   T    
 
            >linker             >VL323/A3hu3 
            |                   | 
GTC TCT AGC GGA GGC GGG GGA TCC GAG ATC GTG CTG ACA CAG AGC CCT GGC ACC CTG AGC CTG TCT CCA GGC GAA AGA GCC ACC CTG TCC <1260 
V   S   S   G   G   G   G   S   E   I   V   L   T   Q   S   P   G   T   L   S   L   S   P   G   E   R   A   T   L   S    
 
TGC AGA AGC AGC AAG AAC CTG CTG CAC AGC AAC GGC ATC ACC TAC CTG TAC TGG TAT CAG CAG AAG CCC GGC CAG GCC CCC AGA CTG CTG <1350 
C   R   S   S   K   N   L   L   H   S   N   G   I   T   Y   L   Y   W   Y   Q   Q   K   P   G   Q   A   P   R   L   L    
 
ATC TAC CAG ATG AGC AAC CTG GCC AGC GGC ATC CCC GAC AGA TTT TCT GGC AGC GGC TCC GGC ACC GAC TTC ACC CTG ACA ATC AGC AGA <1440 
I   Y   Q   M   S   N   L   A   S   G   I   P   D   R   F   S   G   S   G   S   G   T   D   F   T   L   T   I   S   R    
 
CTG GAA CCC GAG GAC TTC GCC GTG TAC TAC TGC GCC CAG AAC CTG GAA ATC CCC CGG ACC TTT GGC CAG GGC ACC AAG CTG GAA ATC AAG <1530 
L   E   P   E   D   F   A   V   Y   Y   C   A   Q   N   L   E   I   P   R   T   F   G   Q   G   T   K   L   E   I   K    
 
    NotI        >His-tag              
    |           |                  
AGA GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
R   A   A   A   H   H   H   H   H   H   *    
 
6.5.3 scDb4D5xhu225 (pSecTagAHis) 
>Igk leader                                                                                                     >VH4D5 
|                                                                                                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC GAA GTG <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   E   V    
 
CAG CTC GTC GAA AGT GGC GGT GGA CTT GTG CAG CCT GGC GGT TCC CTC AGA CTG TCC TGT GCC GCG TCA GGC TTC AAC ATC AAG GAC ACG <180 
Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   N   I   K   D   T    
 
TAC ATC CAC TGG GTG AGG CAA GCT CCT GGA AAG GGC TTG GAG TGG GTC GCT AGG ATC TAC CCG ACG AAC GGC TAC ACC AGG TAC GCT GAC <270 
Y   I   H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   R   I   Y   P   T   N   G   Y   T   R   Y   A   D    
 
TCA GTG AAG GGA AGG TTC ACG ATC AGT GCA GAC ACC AGC AAG AAC ACC GCA TAC CTC CAA ATG AAC TCC CTG AGA GCC GAG GAC ACC GCC <360 
S   V   K   G   R   F   T   I   S   A   D   T   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T   A    
 
                                                                                                                >linker 
                                                                                                                | 
GTG TAC TAC TGC TCT CGT TGG GGT GGA GAT GGC TTC TAC GCT ATG GAC TAC TGG GGT CAA GGC ACA CTG GTG ACC GTC TCG AGT GGC GGT <450 
V   Y   Y   C   S   R   W   G   G   D   G   F   Y   A   M   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G    
 
            >VLhu225 
            | 
GGC GGA TCG GAT ATT CAG CTG ACC CAG AGC CCG AGC TTT CTG AGC GCG AGC GTG GGC GAT CGT GTT ACC ATT ACC TGT CGT GCA AGC CAG <540 
G   G   S   D   I   Q   L   T   Q   S   P   S   F   L   S   A   S   V   G   D   R   V   T   I   T   C   R   A   S   Q    
 
AGC ATT GGC ACC AAC ATT CAT TGG TAT CAG CAG AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT AAA TAT GCG AGC GAA AGC ATT AGC GGC <630 
S   I   G   T   N   I   H   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   K   Y   A   S   E   S   I   S   G    
 
GTG CCG AGC CGT TTT AGC GGC AGC GGT AGC GGC ACC GAA TTT ACC CTG ACC ATT AGC AGC CTG CAG CCG GAA GAT TTT GCG ACC TAT TAT <720 
V   P   S   R   F   S   G   S   G   S   G   T   E   F   T   L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y    
 
                                                                                    >linker 
                                                                                    | 
TGC CAG CAG AAC AAC AAC TGG CCG ACC ACC TTT GGT GCG GGC ACC AAA CTG GAA ATT AAA CGT GGA GGC GGT GGC AGC GGT GGG CGC GCC <810 
C   Q   Q   N   N   N   W   P   T   T   F   G   A   G   T   K   L   E   I   K   R   G   G   G   G   S   G   G   R   A    
  SEQUENCES   
  167   
                        >VHhu225 
                        | 
TCG GGC GGA GGT GGC TCA GAA GTG CAG CTG GTT GAA AGC GGC GGT GGT CTG GTT CAG CCG GGT GGC AGC CTG CGT CTG AGC TGT GCG GCG <900 
S   G   G   G   G   S   E   V   Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A    
 
AGC GGC TTT AGC CTG ACC AAC TAT GGC GTG CAT TGG GTG CGT CAG GCA CCG GGC AAA GGC CTG GAA TGG CTG GGC GTG ATT TGG AGC GGC <990 
S   G   F   S   L   T   N   Y   G   V   H   W   V   R   Q   A   P   G   K   G   L   E   W   L   G   V   I   W   S   G    
 
GGC AAC ACC GAT TAT AAC ACC CCG TTT ACC AGC CGT TTT ACC ATT AGC CGT GAT AAC AGC AAA AAC ACC CTG TAT CTG CAG ATG AAC AGC <1080 
G   N   T   D   Y   N   T   P   F   T   S   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S    
 
CTG CGT GCG GAA GAT ACC GCG GTG TAT TAT TGC GCG CGT GCG CTG ACC TAT TAT GAT TAC GAA TTT GCG TAT TGG GGC CAG GGC ACC ACC <1170 
L   R   A   E   D   T   A   V   Y   Y   C   A   R   A   L   T   Y   Y   D   Y   E   F   A   Y   W   G   Q   G   T   T    
 
                    >linker             >VL4D5 
                    |                   | 
GTT ACG GTC TCT AGC GGA GGC GGG GGA TCC GAC ATC CAG ATG ACC CAG TCA CCC TCA AGC CTC AGT GCC AGC GTC GGA GAT AGA GTG ACC <1260 
V   T   V   S   S   G   G   G   G   S   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S   V   G   D   R   V   T    
 
ATA ACG TGC CGA GCT TCT CAG GAT GTG AAC ACG GCA GTG GCT TGG TAT CAG CAA AAG CCT GGG AAA GCC CCA AAG CTG CTC ATC TAC TCC <1350 
I   T   C   R   A   S   Q   D   V   N   T   A   V   A   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   Y   S    
 
GCA TCC TTC CTG TAT AGC GGA GTT CCA TCT AGG TTC TCA GGC TCT AGG TCT GGG ACC GAC TTC ACG CTG ACG ATC TCC TCC CTG CAA CCT <1440 
A   S   F   L   Y   S   G   V   P   S   R   F   S   G   S   R   S   G   T   D   F   T   L   T   I   S   S   L   Q   P    
 
                                                                                                                NOTI 
                                                                                                                | 
GAG GAC TTC GCC ACG TAC TAC TGC CAG CAG CAC TAC ACG ACT CCT CCA ACC TTC GGT CAG GGA ACG AAG GTC GAG ATC AAG CGT GCG GCC <1530 
E   D   F   A   T   Y   Y   C   Q   Q   H   Y   T   T   P   P   T   F   G   Q   G   T   K   V   E   I   K   R   A   A    
 
    >His-tag              
    |                  
GCC CAC CAT CAT CAC CAT CAC TAA  
A   H   H   H   H   H   H   *    
 
6.5.4 scDb4D5x3M6 (pSecTagAHis) 
>Igk leader                                                                                                     >VH4D5 
|                                                                                                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC GAA GTG <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   E   V    
 
CAG CTC GTC GAA AGT GGC GGT GGA CTT GTG CAG CCT GGC GGT TCC CTC AGA CTG TCC TGT GCC GCG TCA GGC TTC AAC ATC AAG GAC ACG <180 
Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   N   I   K   D   T    
 
TAC ATC CAC TGG GTG AGG CAA GCT CCT GGA AAG GGC TTG GAG TGG GTC GCT AGG ATC TAC CCG ACG AAC GGC TAC ACC AGG TAC GCT GAC <270 
Y   I   H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   R   I   Y   P   T   N   G   Y   T   R   Y   A   D    
 
TCA GTG AAG GGA AGG TTC ACG ATC AGT GCA GAC ACC AGC AAG AAC ACC GCA TAC CTC CAA ATG AAC TCC CTG AGA GCC GAG GAC ACC GCC <360 
S   V   K   G   R   F   T   I   S   A   D   T   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T   A    
 
                                                                                                                >linker 
                                                                                                                | 
GTG TAC TAC TGC TCT CGT TGG GGT GGA GAT GGC TTC TAC GCT ATG GAC TAC TGG GGT CAA GGC ACA CTG GTG ACC GTC TCG AGT GGC GGT <450 
V   Y   Y   C   S   R   W   G   G   D   G   F   Y   A   M   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G    
 
            >VL3M6 
            | 
GGC GGA TCG CAG TCT GCC CTG ACA CAG CCT GCC AGC GTG TCC GGC AGC CCT GGC CAG AGC ATC ACA ATC AGC TGC ACC GGC ACC AGC AGC <540 
G   G   S   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   G   Q   S   I   T   I   S   C   T   G   T   S   S    
 
GAC GTG GGC AGC TAC AAC GTG GTG TCC TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATC ATC TAC GAG GTG TCC CAG CGG CCC <630 
D   V   G   S   Y   N   V   V   S   W   Y   Q   Q   H   P   G   K   A   P   K   L   I   I   Y   E   V   S   Q   R   P    
 
AGC GGC GTG TCC AAC AGA TTC AGC GGC AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC GGG CTG CAG ACC GAG GAC GAG GCC GAC <720 
S   G   V   S   N   R   F   S   G   S   K   S   G   N   T   A   S   L   T   I   S   G   L   Q   T   E   D   E   A   D   
 
                                                                                                >linker 
                                                                                                | 
TAC TAC TGC TCC AGC TAC GCC GGC AGC AGC ATC TTC GTG ATC TTC GGA GGT GGC ACC AAA GTG ACC GTG CTG GGA GGC GGT GGC AGC GGT <810 
Y   Y   C   S   S   Y   A   G   S   S   I   F   V   I   F   G   G   G   T   K   V   T   V   L   G   G   G   G   S   G    
 
                                    >VH3M6 
                                    | 
GGG CGC GCC TCG GGC GGA GGT GGC TCA GAA GTG CAG CTG CTG GAA AGC GGA GGC GGC CTG GTG CAG CCT GGC GGC TCT CTG AGA CTG AGC <900 
G   R   A   S   G   G   G   G   S   E   V   Q   L   L   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S    
 
TGT GCC GCC AGC GGC TTC ACC TTC AGC CAC TAC GTG ATG GCC TGG GTC CGA CAG GCC CCT GGC AAG GGA CTG GAA TGG GTG TCC AGC ATC <990 
C   A   A   S   G   F   T   F   S   H   Y   V   M   A   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I    
 
AGC AGC AGC GGC GGC TGG ACC CTG TAC GCC GAT AGC GTG AAG GGC CGG TTT ACC ATC AGC CGG GAC AAC AGC AAG AAC ACC CTG TAC CTG <1080 
S   S   S   G   G   W   T   L   Y   A   D   S   V   K   G   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L    
 
CAG ATG AAC AGC CTG CGG GCC GAG GAC ACC GCC GTG TAC TAC TGC ACC AGA GGC CTG AAG ATG GCC ACC ATC TTC GAC TAC TGG GGG CAG <1170 
Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   T   R   G   L   K   M   A   T   I   F   D   Y   W   G   Q    
 
                                >linker             >VL4D5 
                                |                   | 
GGC ACC CTG GTC ACA GTC TCG AGT GGA GGC GGG GGA TCC GAC ATC CAG ATG ACC CAG TCA CCC TCA AGC CTC AGT GCC AGC GTC GGA GAT <1260 
G   T   L   V   T   V   S   S   G   G   G   G   S   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S   V   G   D    
 
AGA GTG ACC ATA ACG TGC CGA GCT TCT CAG GAT GTG AAC ACG GCA GTG GCT TGG TAT CAG CAA AAG CCT GGG AAA GCC CCA AAG CTG CTC <1350 
R   V   T   I   T   C   R   A   S   Q   D   V   N   T   A   V   A   W   Y   Q   Q   K   P   G   K   A   P   K   L   L    
 
ATC TAC TCC GCA TCC TTC CTG TAT AGC GGA GTT CCA TCT AGG TTC TCA GGC TCT AGG TCT GGG ACC GAC TTC ACG CTG ACG ATC TCC TCC <1440 
I   Y   S   A   S   F   L   Y   S   G   V   P   S   R   F   S   G   S   R   S   G   T   D   F   T   L   T   I   S   S    
 
CTG CAA CCT GAG GAC TTC GCC ACG TAC TAC TGC CAG CAG CAC TAC ACG ACT CCT CCA ACC TTC GGT CAG GGA ACG AAG GTC GAG ATC AAG <1530 
L   Q   P   E   D   F   A   T   Y   Y   C   Q   Q   H   Y   T   T   P   P   T   F   G   Q   G   T   K   V   E   I   K    
 
 
  SEQUENCES   
  168   
    NotI        >His-tag              
    |           |                  
CGT GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA  
R   A   A   A   H   H   H   H   H   H   *    
 
6.6 scTRAIL (pIRESpuro) 
>VH leader                                                                          >Flag-tag                       >linker 
|                                                                                   |                               | 
ATG GAC TGG ACC TGG CGC GTG TTT TGC CTG CTC GCC GTG GCT CCT GGG GCC CAC AGC CTC GAC GAT TAC AAA GAC GAT GAC GAT AAA GAA <90 
M   D   W   T   W   R   V   F   C   L   L   A   V   A   P   G   A   H   S   L   D   D   Y   K   D   D   D   D   K   E    
 
            >TRAIL 1 
            | 
TTC GGC GGA GGC CCC CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC ACC CTG AGC AGC CCC AAC AGC AAG AAC GAG <180 
F   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   
 
AAG GCC CTG GGC CGG AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG AGC AAC CTG CAC CTG CGG AAC GGC GAG CTG <270 
K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L    
 
GTC ATC CAC GAG AAG GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA GAG ATC AAA GAG AAC ACC AAG AAC GAC AAG <360 
V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K    
 
CAG ATG GTG CAG TAC ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG TCC GCC CGG AAC AGC TGC TGG TCC AAG GAC <450 
Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D    
 
GCC GAG TAC GGC CTG TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC CGG ATC TTC GTG AGC GTG ACC AAC GAG CAC <540 
A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H    
 
                                                                    >G  >TRAIL 2 
                                                                    |   | 
CTG ATC GAC ATG GAC CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT CAG CGG GTG GCC GCC CAT ATT ACA GGC ACA <630 
L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T    
 
AGA GGC CGG TCC AAC ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA AAG ATC AAC TCC TGG GAG TCC AGC CGC TCC <720 
R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S    
 
GGC CAC TCC TTT CTG TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG GGG TTT TAC TAT ATC TAC TCT CAG ACA TAC <810 
G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y    
 
TTT AGG TTT CAG GAA GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT ATC TAT AAA TAC ACT TCC TAC CCT GAT CCT <900 
F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P    
 
ATT CTG CTG ATG AAA AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC TAC TCT ATC TAC CAG GGG GGG ATT TTT GAA <990 
I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E    
 
CTT AAG GAG AAT GAC AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT CAC GAA GCC TCA TTC TTT GGA GCC TTT CTT <1080 
L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L    
 
        >G  >TRAIL 3 
        |   | 
GTG GGA GGG GGC CCA CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT ACC CTG TCC AGC CCG AAC TCC AAA AAT GAG <1170 
V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E    
 
AAA GCG CTG GGG CGG AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC AGC AAT CTG CAT CTG CGC AAC GGG GAA CTC <1260 
K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L    
 
GTG ATT CAT GAG AAG GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG GAA ATT AAA GAG AAC ACT AAA AAC GAT AAA <1350 
V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K    
 
CAA ATG GTT CAA TAC ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG AGT GCC AGA AAC TCC TGC TGG TCT AAG GAT <1440 
Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D    
 
GCG GAA TAC GGA TTG TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT CGC ATT TTC GTG TCC GTC ACG AAT GAG CAC <1530 
A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H    
 
CTC ATA GAC ATG GAT CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   *    
 
6.7 EHD2-scTRAIL (pSecTagFLAG) 
>Igk leader                                                                     >FLAG-tag                       >linker 
|                                                                               |                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAC TAC AAA GAC GAT GAC GAT AAA GCG GCC <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   Y   K   D   D   D   D   K   A   A    
 
                        >EHD2 
                        | 
GCC GGG GGA AGC GGC GGT GAT TTC ACC CCC CCC ACA GTG AAG ATC CTC CAG AGC AGC TGT GAC GGC GGA GGC CAC TTC CCA CCT ACC ATC <180 
A   G   G   S   G   G   D   F   T   P   P   T   V   K   I   L   Q   S   S   C   D   G   G   G   H   F   P   P   T   I    
 
CAG CTG CTG TGT CTG GTG TCC GGC TAC ACC CCC GGC ACC ATC AAC ATC ACC TGG CTG GAA GAT GGA CAA GTG ATG GAC GTG GAC CTG AGC <270 
Q   L   L   C   L   V   S   G   Y   T   P   G   T   I   N   I   T   W   L   E   D   G   Q   V   M   D   V   D   L   S    
 
ACC GCC AGC ACC ACA CAG GAA GGC GAG CTG GCC TCT ACC CAG AGC GAG CTG ACA CTG AGC CAG AAG CAC TGG CTG AGC GAC CGG ACC TAC <360 
T   A   S   T   T   Q   E   G   E   L   A   S   T   Q   S   E   L   T   L   S   Q   K   H   W   L   S   D   R   T   Y    
 
                                                                                        >linker       
                                                                                        | 
ACC TGT CAA GTG ACC TAC CAG GGC CAC ACC TTC GAG GAC AGC ACC AAG AAG TGC GCC GAC AGC AAC GGA GGT TCA GGG GGC GCC TCG AGC <450 
T   C   Q   V   T   Y   Q   G   H   T   F   E   D   S   T   K   K   C   A   D   S   N   G   G   S   G   G   A   S   S    
 
        >TRAIL 1 
        | 
GGC GGC GGC CCC CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC ACC CTG AGC AGC CCC AAC AGC AAG AAC GAG AAG <540 
G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K    
 
  SEQUENCES   
  169   
GCC CTG GGC CGG AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG AGC AAC CTG CAC CTG CGG AAC GGC GAG CTG GTC <630 
A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V    
 
ATC CAC GAG AAG GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA GAG ATC AAA GAG AAC ACC AAG AAC GAC AAG CAG <720 
I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q    
 
ATG GTG CAG TAC ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG TCC GCC CGG AAC AGC TGC TGG TCC AAG GAC GCC <810 
M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A    
 
GAG TAC GGC CTG TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC CGG ATC TTC GTG AGC GTG ACC AAC GAG CAC CTG <900 
E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L    
 
                                                                >G  >TRAIL 2 
                                                                |   | 
ATC GAC ATG GAC CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT CAG CGG GTG GCC GCC CAT ATT ACA GGC ACA AGA <990 
I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R    
 
GGC CGG TCC AAC ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA AAG ATC AAC TCC TGG GAG TCC AGC CGC TCC GGC <1080 
G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G    
 
CAC TCC TTT CTG TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG GGG TTT TAC TAT ATC TAC TCT CAG ACA TAC TTT <1170 
H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F    
 
AGG TTT CAG GAA GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT ATC TAT AAA TAC ACT TCC TAC CCT GAT CCT ATT <1260 
R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I    
 
CTG CTG ATG AAA AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC TAC TCT ATC TAC CAG GGG GGG ATT TTT GAA CTT <1350 
L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L    
 
AAG GAG AAT GAC AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT CAC GAA GCC TCA TTC TTT GGA GCC TTT CTT GTG <1440 
K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V    
 
    >G  >TRAIL 3 
    |   | 
GGA GGG GGC CCA CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT ACC CTG TCC AGC CCG AAC TCC AAA AAT GAG AAA <1530 
G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K    
 
GCG CTG GGG CGG AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC AGC AAT CTG CAT CTG CGC AAC GGG GAA CTC GTG <1620 
A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V    
 
ATT CAT GAG AAG GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG GAA ATT AAA GAG AAC ACT AAA AAC GAT AAA CAA <1710 
I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q    
 
ATG GTT CAA TAC ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG AGT GCC AGA AAC TCC TGC TGG TCT AAG GAT GCG <1800 
M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A    
 
GAA TAC GGA TTG TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT CGC ATT TTC GTG TCC GTC ACG AAT GAG CAC CTC <1890 
E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L    
 
ATA GAC ATG GAT CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   *    
 
6.8 Fc-scTRAIL (pSecTagFLAG) 
>Igk leader                                                                     >FLAG-tag                       >linker 
|                                                                               |                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAC TAC AAA GAC GAT GAC GAT AAA GGC GGT <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   Y   K   D   D   D   D   K   G   G    
 
            >hinge                                          >CH2 
            |                                               | 
GGC GGA TCA GGT ACC GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA <180 
G   G   S   G   T   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P    
 
AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC <270 
K   P   K   D   T   L   M   I   S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F    
 
AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC <360 
N   W   Y   V   D   G   V   E   V   H   N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V    
 
CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC <450 
L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E   K   T    
 
                    >CH3 
                    | 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG <540 
I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R   D   E   L   T   K   N   Q   V   S   L    
 
ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT <630 
T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E   N   N   Y   K   T   T   P    
 
CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC <720 
P   V   L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N   V   F   S   C    
 
                                                                                        >linker 
                                                                                        | 
TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT CAG GGG GGA AGC GGC GGT GGC TCG AGC <810 
S   V   M   H   E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   Q   G   G   S   G   G   G   S   S    
 
        >TRAIL 1 
        | 
GGC GGC GGC CCC CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC ACC CTG AGC AGC CCC AAC AGC AAG AAC GAG AAG <900 
G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K    
 
GCC CTG GGC CGG AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG AGC AAC CTG CAC CTG CGG AAC GGC GAG CTG GTC <990 
A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V    
 
ATC CAC GAG AAG GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA GAG ATC AAA GAG AAC ACC AAG AAC GAC AAG CAG <1080 
I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q    
 
 
  SEQUENCES   
  170   
ATG GTG CAG TAC ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG TCC GCC CGG AAC AGC TGC TGG TCC AAG GAC GCC <1170 
M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A    
 
GAG TAC GGC CTG TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC CGG ATC TTC GTG AGC GTG ACC AAC GAG CAC CTG <1260 
E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L    
 
                                                                >G  >TRAIL 2 
                                                                |   | 
ATC GAC ATG GAC CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT CAG CGG GTG GCC GCC CAT ATT ACA GGC ACA AGA <1350 
I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R    
 
GGC CGG TCC AAC ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA AAG ATC AAC TCC TGG GAG TCC AGC CGC TCC GGC <1440 
G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G    
 
CAC TCC TTT CTG TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG GGG TTT TAC TAT ATC TAC TCT CAG ACA TAC TTT <1530 
H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F    
 
AGG TTT CAG GAA GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT ATC TAT AAA TAC ACT TCC TAC CCT GAT CCT ATT <1620 
R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I    
 
CTG CTG ATG AAA AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC TAC TCT ATC TAC CAG GGG GGG ATT TTT GAA CTT <1710 
L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L    
 
AAG GAG AAT GAC AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT CAC GAA GCC TCA TTC TTT GGA GCC TTT CTT GTG <1800 
K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V    
 
    >G  >TRAIL 3 
    |   | 
GGA GGG GGC CCA CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT ACC CTG TCC AGC CCG AAC TCC AAA AAT GAG AAA <1890 
G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K    
 
GCG CTG GGG CGG AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC AGC AAT CTG CAT CTG CGC AAC GGG GAA CTC GTG <1980 
A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V    
 
ATT CAT GAG AAG GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG GAA ATT AAA GAG AAC ACT AAA AAC GAT AAA CAA <2070 
I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q    
 
ATG GTT CAA TAC ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG AGT GCC AGA AAC TCC TGC TGG TCT AAG GAT GCG <2160 
M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A    
 
GAA TAC GGA TTG TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT CGC ATT TTC GTG TCC GTC ACG AAT GAG CAC CTC <2250 
E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L    
 
ATA GAC ATG GAT CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
  I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   *  
 
6.9 (ds)Db-scTRAIL (pSecTagFLAG) 
(Ds)Db-scTRAIL constructs were generated by insertion of the respective (ds)Db sequences 
(see 6.2) as KpnI-NotI fragments into the sequence represented below (after KpnI-NotI 
digestion). 
>Igk leader                                                                     >FLAG-tag                       >linker 
|                                                                               |                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC Acc ggT GAC TAC AAA GAC GAT GAC GAT AAA GGC GGT <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   Y   K   D   D   D   D   K   G   G    
 
            KpnI    NotI>linker                     >TRAIL 1 
            |       |                               | 
GGC GGA TCA GGT ACC GCg gcc GCC GGG GGA AGC GGC GGC GGC CCC CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC <180 
G   G   S   G   T   A   A   A   G   G   S   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   
 
ACC CTG AGC AGC CCC AAC AGC AAG AAC GAG AAG GCC CTG GGC CGG AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG <270 
T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   
 
AGC AAC CTG CAC CTG CGG AAC GGC GAG CTG GTC ATC CAC GAG AAG GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA <360 
S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   
 
GAG ATC AAA GAG AAC ACC AAG AAC GAC AAG CAG ATG GTG CAG TAC ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG <450 
E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   
 
TCC GCC CGG AAC AGC TGC TGG TCC AAG GAC GCC GAG TAC GGC CTG TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC <540 
S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D    
 
                                                                                                            >G  >TRAIL 2       
                                                                                                            |   | 
CGG ATC TTC GTG AGC GTG ACC AAC GAG CAC CTG ATC GAC ATG GAC CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT <630 
R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   
 
CAG CGG GTG GCC GCC CAT ATT ACA GGC ACA AGA GGC CGG TCC AAC ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA <720 
Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   
 
AAG ATC AAC TCC TGG GAG TCC AGC CGC TCC GGC CAC TCC TTT CTG TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG <810 
K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   
 
GGG TTT TAC TAT ATC TAC TCT CAG ACA TAC TTT AGG TTT CAG GAA GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT <900 
G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   
 
ATC TAT AAA TAC ACT TCC TAC CCT GAT CCT ATT CTG CTG ATG AAA AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC <990 
I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   
 
TAC TCT ATC TAC CAG GGG GGG ATT TTT GAA CTT AAG GAG AAT GAC AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT <1080 
Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   
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                                                >G  >TRAIL 3       
                                                |   | 
CAC GAA GCC TCA TTC TTT GGA GCC TTT CTT GTG GGA GGG GGC CCA CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT <1170 
H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N    
 
ACC CTG TCC AGC CCG AAC TCC AAA AAT GAG AAA GCG CTG GGG CGG AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC <1260 
T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   
 
AGC AAT CTG CAT CTG CGC AAC GGG GAA CTC GTG ATT CAT GAG AAG GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG <1350 
S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   
 
GAA ATT AAA GAG AAC ACT AAA AAC GAT AAA CAA ATG GTT CAA TAC ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG <1440 
E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   
 
AGT GCC AGA AAC TCC TGC TGG TCT AAG GAT GCG GAA TAC GGA TTG TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT <1530 
S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   
 
CGC ATT TTC GTG TCC GTC ACG AAT GAG CAC CTC ATA GAC ATG GAT CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   *    
 
6.10 scFv-EHD2-scTRAIL (pSecTagFLAG) 
ScFv-EHD2-scTRAIL constructs were generated by insertion of the respective scFv sequences 
(see 6.1) as KpnI-NotI fragments into the sequence represented below (after KpnI-NotI 
digestion). 
>Igk leader                                                             AgeI    >FLAG-tag                       >linker 
|                                                                       |       |                               | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAC TAC AAA GAC GAT GAC GAT AAA GGC GGT <90 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   Y   K   D   D   D   D   K   G   G   
 
            KpnI    NotI>linker                     >EHD2 
            |       |                               | 
GGC GGA TCA GGT ACC GCG GCC GCC GGG GGA AGC GGC GGT GAT TTC ACC CCC CCC ACA GTG AAG ATC CTC CAG AGC AGC TGT GAC GGC GGA <180 
G   G   S   G   T   A   A   A   G   G   S   G   G   D   F   T   P   P   T   V   K   I   L   Q   S   S   C   D   G   G   
 
GGC CAC TTC CCA CCT ACC ATC CAG CTG CTG TGT CTG GTG TCC GGC TAC ACC CCC GGC ACC ATC AAC ATC ACC TGG CTG GAA GAT GGA CAA <270 
G   H   F   P   P   T   I   Q   L   L   C   L   V   S   G   Y   T   P   G   T   I   N   I   T   W   L   E   D   G   Q   
 
GTG ATG GAC GTG GAC CTG AGC ACC GCC AGC ACC ACA CAG GAA GGC GAG CTG GCC TCT ACC CAG AGC GAG CTG ACA CTG AGC CAG AAG CAC <360 
V   M   D   V   D   L   S   T   A   S   T   T   Q   E   G   E   L   A   S   T   Q   S   E   L   T   L   S   Q   K   H   
 
                                                                                                                    >linker  
                                                                                                                    | 
TGG CTG AGC GAC CGG ACC TAC ACC TGT CAA GTG ACC TAC CAG GGC CAC ACC TTC GAG GAC AGC ACC AAG AAG TGC GCC GAC AGC AAC GGA <450 
W   L   S   D   R   T   Y   T   C   Q   V   T   Y   Q   G   H   T   F   E   D   S   T   K   K   C   A   D   S   N   G   
 
                                    >TRAIL 1       
                                    | 
GGT TCA GGG GGC GCC TCG AGC GGC GGC GGC CCC CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC ACC CTG AGC AGC <540 
G   S   G   G   A   S   S   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   
 
CCC AAC AGC AAG AAC GAG AAG GCC CTG GGC CGG AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG AGC AAC CTG CAC <630 
P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   
 
CTG CGG AAC GGC GAG CTG GTC ATC CAC GAG AAG GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA GAG ATC AAA GAG <720 
L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   
 
AAC ACC AAG AAC GAC AAG CAG ATG GTG CAG TAC ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG TCC GCC CGG AAC <810 
N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   
 
AGC TGC TGG TCC AAG GAC GCC GAG TAC GGC CTG TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC CGG ATC TTC GTG <900 
S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   
 
                                                                                            >G   >TRAIL 2       
                                                                                            |   | 
AGC GTG ACC AAC GAG CAC CTG ATC GAC ATG GAC CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT CAG CGG GTG GCC <990 
S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A    
 
GCC CAT ATT ACA GGC ACA AGA GGC CGG TCC AAC ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA AAG ATC AAC TCC <1080 
A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   
 
TGG GAG TCC AGC CGC TCC GGC CAC TCC TTT CTG TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG GGG TTT TAC TAT <1170 
W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   
 
ATC TAC TCT CAG ACA TAC TTT AGG TTT CAG GAA GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT ATC TAT AAA TAC <1260 
I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   
 
ACT TCC TAC CCT GAT CCT ATT CTG CTG ATG AAA AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC TAC TCT ATC TAC <1350 
T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y    
 
CAG GGG GGG ATT TTT GAA CTT AAG GAG AAT GAC AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT CAC GAA GCC TCA <1440 
Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S    
 
                                >G  >TRAIL 3       
                                |   | 
TTC TTT GGA GCC TTT CTT GTG GGA GGG GGC CCA CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT ACC CTG TCC AGC <1530 
F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S    
 
CCG AAC TCC AAA AAT GAG AAA GCG CTG GGG CGG AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC AGC AAT CTG CAT <1620 
P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H    
 
CTG CGC AAC GGG GAA CTC GTG ATT CAT GAG AAG GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG GAA ATT AAA GAG <1710 
L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   
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AAC ACT AAA AAC GAT AAA CAA ATG GTT CAA TAC ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG AGT GCC AGA AAC <1800 
N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   
 
TCC TGC TGG TCT AAG GAT GCG GAA TAC GGA TTG TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT CGC ATT TTC GTG <1890 
S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   
 
TCC GTC ACG AAT GAG CAC CTC ATA GAC ATG GAT CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   *    
 
6.11 scFv-Fc-scTRAIL (pSecTagFLAG) 
ScFv-Fc-scTRAIL constructs were generated by insertion of the respective FLAG-scFv 
sequences from previously cloned pSecTagFLAG-scFv-EHD2-scTRAIL (see 6.10) as AgeI-NotI 
fragments into the sequence represented below (after AgeI-NotI digestion). 
>Igk leader                                                             AgeI                NotI>linker 
|                                                                       |                   | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT ... ... ... GCG GCC GCA GGG GGA AGC GGC <180 
M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G               A   A   A   G   G   S   G   
 
    >hinge                                  CH2 
    |                                       | 
GGT GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC <270 
G   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   
 
ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG <360 
T   L   M   I   S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   
 
GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG <450 
D   G   V   E   V   H   N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   
 
CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC <540 
H   Q   D   W   L   N   G   K   E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A    
 
    >CH3 
    | 
AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC <630 
K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R   D   E   L   T   K   N   Q   V   S   L   T   C   L   V    
 
AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC <720 
K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E   N   N   Y   K   T   T   P   P   V   L   D    
 
TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT <810 
S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N   V   F   S   C   S   V   M   H    
 
                                                                        >linker                                 >TRAIL 1 
                                                                        |                                       | 
GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT CAG GGG GGA AGC GGC GGT GGC TCG AGC GGC GGC GGC CCC <900 
E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   Q   G   G   S   G   G   G   S   S   G   G   G   P    
 
CAG AGA GTC GCC GCC CAC ATC ACC GGC ACC CGG GGC AGA AGC AAC ACC CTG AGC AGC CCC AAC AGC AAG AAC GAG AAG GCC CTG GGC CGG <990 
Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R    
 
AAG ATC AAC AGC TGG GAG AGC AGC AGA AGC GGC CAC AGC TTT CTG AGC AAC CTG CAC CTG CGG AAC GGC GAG CTG GTC ATC CAC GAG AAG <1080 
K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K    
 
GGC TTC TAC TAC ATC TAC AGC CAG ACC TAC TTC AGA TTC CAA GAA GAG ATC AAA GAG AAC ACC AAG AAC GAC AAG CAG ATG GTG CAG TAC <1170 
G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y    
 
ATC TAC AAG TAC ACC AGC TAC CCC GAC CCC ATC CTG CTG ATG AAG TCC GCC CGG AAC AGC TGC TGG TCC AAG GAC GCC GAG TAC GGC CTG <1260 
I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   
 
TAC AGC ATC TAC CAG GGC GGC ATC TTC GAG CTG AAA GAG AAC GAC CGG ATC TTC GTG AGC GTG ACC AAC GAG CAC CTG ATC GAC ATG GAC <1350 
Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D    
 
                                                >G  >TRAIL 2 
                                                |   | 
CAC GAG GCC AGC TTT TTC GGC GCA TTC CTG GTC GGC GGC GGA CCT CAG CGG GTG GCC GCC CAT ATT ACA GGC ACA AGA GGC CGG TCC AAC <1440 
H   E   A   S   F   F   G   A   F   L   V   G   G   G   P   Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N    
 
ACC CTG TCC TCC CCC AAC TCT AAG AAT GAA AAG GCC CTC GGG AGA AAG ATC AAC TCC TGG GAG TCC AGC CGC TCC GGC CAC TCC TTT CTG <1530 
T   L   S   S   P   N   S   K   N   E   K   A   L   G   R   K   I   N   S   W   E   S   S   R   S   G   H   S   F   L    
 
TCC AAT CTG CAC CTG AGA AAT GGG GAG CTG GTC ATT CAC GAA AAG GGG TTT TAC TAT ATC TAC TCT CAG ACA TAC TTT AGG TTT CAG GAA <1620 
S   N   L   H   L   R   N   G   E   L   V   I   H   E   K   G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E    
 
GAA ATT AAA GAA AAT ACA AAG AAT GAT AAA CAG ATG GTC CAG TAT ATC TAT AAA TAC ACT TCC TAC CCT GAT CCT ATT CTG CTG ATG AAA <1710 
E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y   I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K    
 
AGC GCC AGA AAC AGC TGT TGG AGC AAG GAT GCC GAA TAT GGG CTC TAC TCT ATC TAC CAG GGG GGG ATT TTT GAA CTT AAG GAG AAT GAC <1800 
S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L   Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D    
 
                                                                                                            >G  >TRAIL 3     
                                                                                                            |   | 
AGA ATC TTT GTG TCT GTG ACA AAT GAG CAT CTG ATT GAT ATG GAT CAC GAA GCC TCA TTC TTT GGA GCC TTT CTT GTG GGA GGG GGC CCA <1890 
R   I   F   V   S   V   T   N   E   H   L   I   D   M   D   H   E   A   S   F   F   G   A   F   L   V   G   G   G   P    
 
CAG AGG GTC GCC GCT CAC ATT ACA GGG ACC AGG GGC CGC AGC AAT ACC CTG TCC AGC CCG AAC TCC AAA AAT GAG AAA GCG CTG GGG CGG <1980 
Q   R   V   A   A   H   I   T   G   T   R   G   R   S   N   T   L   S   S   P   N   S   K   N   E   K   A   L   G   R    
 
AAG ATT AAT TCC TGG GAA AGC TCC AGA AGC GGG CAC TCC TTC CTC AGC AAT CTG CAT CTG CGC AAC GGG GAA CTC GTG ATT CAT GAG AAG <2070 
K   I   N   S   W   E   S   S   R   S   G   H   S   F   L   S   N   L   H   L   R   N   G   E   L   V   I   H   E   K    
 
GGA TTC TAT TAT ATC TAT TCC CAG ACA TAC TTC CGC TTC CAA GAG GAA ATT AAA GAG AAC ACT AAA AAC GAT AAA CAA ATG GTT CAA TAC <2160 
G   F   Y   Y   I   Y   S   Q   T   Y   F   R   F   Q   E   E   I   K   E   N   T   K   N   D   K   Q   M   V   Q   Y    
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ATC TAC AAA TAT ACC TCT TAC CCA GAT CCC ATC CTC CTC ATG AAG AGT GCC AGA AAC TCC TGC TGG TCT AAG GAT GCG GAA TAC GGA TTG <2250 
I   Y   K   Y   T   S   Y   P   D   P   I   L   L   M   K   S   A   R   N   S   C   W   S   K   D   A   E   Y   G   L    
 
TAC TCC ATC TAT CAA GGG GGA ATC TTT GAG TTG AAA GAA AAT GAT CGC ATT TTC GTG TCC GTC ACG AAT GAG CAC CTC ATA GAC ATG GAT <2340 
Y   S   I   Y   Q   G   G   I   F   E   L   K   E   N   D   R   I   F   V   S   V   T   N   E   H   L   I   D   M   D    
 
CAT GAA GCG AGT TTC TTC GGG GCT TTC CTC GTG GGT TGA  
H   E   A   S   F   F   G   A   F   L   V   G   *    
 
6.12 scDb-EHD2-scTRAIL (pSecTagFLAG) 
ScDb-EHD2-scTRAIL constructs were generated by insertion of the respective scDb sequences 
(see 6.5) as KpnI-NotI fragments into the sequence represented in 6.10 (after KpnI-NotI 
digestion). 
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